{| class="wikitable" style="text-align:center; width:50%;"
!colspan="2" align="center" style="color:white; font-size:125%; background-color:#08519c"|'''Section editor'''
|-
|style="background-color:#F0F0F0"|[[File:TravisOsterman.jpg|frameless|upright=0.3|center]]
|<big>[[User:Travisosterman|Travis Osterman, DO, MS]]<br>Nashville, TN</big><br>Twitter: [https://twitter.com/TravisOsterman TravisOsterman]<br>[https://www.linkedin.com/in/travis-osterman-1850b236/ LinkedIn]
|-
|}
''Are you looking for a regimen but can't find it here? It is possible that we've moved it to the [[Non-small cell lung cancer_-_historical|historical regimens page]]. If you still can't find it, please let us know so we can add it!''.
<br>There are several related dedicated pages:
*'''[[CNS carcinoma]]
*'''[[Non-small_cell_lung_cancer,_ALK-positive|NSCLC, ALK-positive]]
*'''[[Non-small_cell_lung_cancer,_BRAF-mutated|NSCLC, BRAF-mutated]]
*'''[[Non-small cell lung cancer, EGFR-mutated|NSCLC, EGFR-mutated]]'''
*'''[[Non-small_cell_lung_cancer,_ROS1-positive|NSCLC, ROS1-positive]]

{| class="wikitable" style="float:right; margin-right: 5px;"
|-
|<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div>
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
|}
{{TOC limit|limit=3}}

=Guidelines=
==[https://www.asco.org/ ASCO]==
*'''2017:''' Hanna et al. [http://ascopubs.org/doi/full/10.1200/JCO.2017.74.6065 Systemic therapy for stage IV non–small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update] [https://www.ncbi.nlm.nih.gov/pubmed/28806116 PubMed]
===Older===
*'''2015:''' Masters et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5019421/ Systemic therapy for stage IV non–small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update]

==ASCO/CCO==
===Current===
*'''2017:''' [http://ascopubs.org/doi/full/10.1200/JCO.2017.72.4401 Adjuvant systemic therapy and adjuvant radiation therapy for stage I to IIIA completely resected non–small-cell lung cancers: American Society of Clinical Oncology/Cancer Care Ontario clinical practice guideline update] [https://www.ncbi.nlm.nih.gov/pubmed/28437162 PubMed]
===Former===
*'''2007:''' [http://ascopubs.org/doi/full/10.1200/JCO.2007.14.1226 Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline] [https://www.ncbi.nlm.nih.gov/pubmed/17954710 PubMed]

==[http://www.esmo.org/ ESMO]==
*'''2018:''' Planchard et al. [https://www.esmo.org/Guidelines/Lung-and-Chest-Tumours/Metastatic-Non-Small-Cell-Lung-Cancer Metastatic Non-Small-Cell Lung Cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up]
*'''2016:''' Novello et al. [http://annonc.oxfordjournals.org/content/27/suppl_5/v1.full.pdf+html Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.] [https://www.ncbi.nlm.nih.gov/pubmed/27664245 PubMed]
*'''2015:''' Eberhardt et al. [http://annonc.oxfordjournals.org/content/26/8/1573.full.pdf+html 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer.] [https://www.ncbi.nlm.nih.gov/pubmed/25897013 PubMed]
===Older===
*'''2014:''' Vansteenkiste et al. [http://annonc.oxfordjournals.org/content/25/8/1462.full.pdf+html 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up.] [https://www.ncbi.nlm.nih.gov/pubmed/24562446 PubMed]
*'''2014:''' Besse et al. [http://annonc.oxfordjournals.org/content/25/8/1475.full.pdf+html 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease.] [https://www.ncbi.nlm.nih.gov/pubmed/24669016 PubMed]
*'''2014:''' Kerr et al. [http://annonc.oxfordjournals.org/content/25/9/1681.full.pdf+html Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer.] [https://www.ncbi.nlm.nih.gov/pubmed/24718890 PubMed]

==[https://www.nccn.org/ NCCN]==
*[https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf NCCN Guidelines - Non-Small Cell Lung Cancer]
=Neoadjuvant therapy=
==Cisplatin & Docetaxel {{#subobject:cab6b8|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:e8cc0c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)60294-X/fulltext Pless et al. 2015 (SAKK 16/00)]
|style="background-color:#1a9851"|Phase III (C)
|Cisplatin & Docetaxel, then RT
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''This trial included patients with Stage IIIA or N2 NSCLC.''
====Chemotherapy====
*[[Cisplatin (Platinol)]]
*[[Docetaxel (Taxotere)]]

====Subsequent treatment====
*Complete [[Surgery|resection]]
===References===
# '''SAKK 16/00:''' Pless M, Stupp R, Ris HB, Stahel RA, Weder W, Thierstein S, Gerard MA, Xyrafas A, Früh M, Cathomas R, Zippelius A, Roth A, Bijelovic M, Ochsenbein A, Meier UR, Mamot C, Rauch D, Gautschi O, Betticher DC, Mirimanoff RO, Peters S; SAKK Lung Cancer Project Group. Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial. Lancet. 2015 Sep 12;386(9998):1049-56. Epub 2015 Aug 11. Erratum in: Lancet. 2015 Sep 12;386(9998):1040. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)60294-X/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26275735 PubMed]

==Cisplatin & Gemcitabine {{#subobject:c567c5|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:b0097e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2010.33.7089 Scagliotti et al. 2011]
|style="background-color:#1a9851"|Phase III (E)
|[[#No_neoadjuvant_therapy|Surgery alone]]
|style="background-color:#91cf60"|Seems to have superior OS
|-
|}
''This trial included patients with Stage IB to IIIA NSCLC.''
====Chemotherapy====
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV once on day 1, '''given at least 4 hours after gemcitabine'''
*[[Gemcitabine (Gemzar)]] 1250 mg/m<sup>2</sup> IV once per day on days 1 & 8

'''21-day cycle for 3 cycles'''
====Subsequent treatment====
*Complete [[Surgery|resection]], 2 to 6 weeks after last dose of chemotherapy
===References===
# Scagliotti GV, Pastorino U, Vansteenkiste JF, Spaggiari L, Facciolo F, Orlowski TM, Maiorino L, Hetzel M, Leschinger M, Visseren-Grul C, Torri V. Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non-small-cell lung cancer. J Clin Oncol. 2012 Jan 10;30(2):172-8. Epub 2011 Nov 28. [http://ascopubs.org/doi/full/10.1200/JCO.2010.33.7089 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22124104 PubMed]

==No neoadjuvant therapy==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://academic.oup.com/annonc/article/14/1/116/130211 Mattson et al. 2003]
|style="background-color:#1a9851"|Phase III (C)
|Docetaxel
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(07)60714-4/fulltext Gilligan et al. 2007 (MRC LU22/NVALT 2/EORTC 08012)]
|style="background-color:#1a9851"|Phase III (C)
|Platinum doublet
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2860367/ Pisters et al. 2010 (SWOG S9900)]
|style="background-color:#1a9851"|Phase III (C)
|Carboplatin & Paclitaxel
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2010.33.7089 Scagliotti et al. 2011]
|style="background-color:#1a9851"|Phase III (C)
|[[#Cisplatin_.26_Gemcitabine|Cisplatin & Gemcitabine]]
|style="background-color:#fc8d59"|Seems to have inferior OS
|-
|}
''These trials included patients with Stage IB to IIIA NSCLC. No preoperative therapy is given.''
====Subsequent treatment====
*Complete [[Surgery|resection]]
===References===
# Mattson KV, Abratt RP, ten Velde G, Krofta K. Docetaxel as neoadjuvant therapy for radically treatable stage III non-small-cell lung cancer: a multinational randomised phase III study. Ann Oncol. 2003 Jan;14(1):116-22. [https://academic.oup.com/annonc/article/14/1/116/130211 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/12488303 PubMed]
# '''MRC LU22/NVALT 2/EORTC 08012:''' Gilligan D, Nicolson M, Smith I, Groen H, Dalesio O, Goldstraw P, Hatton M, Hopwood P, Manegold C, Schramel F, Smit H, van Meerbeeck J, Nankivell M, Parmar M, Pugh C, Stephens R. Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review. Lancet. 2007 Jun 9;369(9577):1929-37. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(07)60714-4/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/17544497 PubMed]
# '''SWOG S9900:''' Pisters KM, Vallières E, Crowley JJ, Franklin WA, Bunn PA Jr, Ginsberg RJ, Putnam JB Jr, Chansky K, Gandara D. Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial. J Clin Oncol. 2010 Apr 10;28(11):1843-9. Epub 2010 Mar 15. [http://ascopubs.org/doi/full/10.1200/JCO.2009.26.1685 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2860367/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/20231678 PubMed]
# Scagliotti GV, Pastorino U, Vansteenkiste JF, Spaggiari L, Facciolo F, Orlowski TM, Maiorino L, Hetzel M, Leschinger M, Visseren-Grul C, Torri V. Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non-small-cell lung cancer. J Clin Oncol. 2012 Jan 10;30(2):172-8. Epub 2011 Nov 28. [http://ascopubs.org/doi/full/10.1200/JCO.2010.33.7089 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22124104 PubMed]

=Adjuvant therapy=
==Carboplatin & Paclitaxel {{#subobject:3a6ad9|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:59db47|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2652093/ Strauss et al. 2008 (CALGB 9633)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Observation|Observation]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Preceding treatment====
*[[Surgery#Lobectomy|Lobectomy]] or [[Surgery#Pneumonectomy|pneumonectomy]], within 4 to 8 weeks
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 6 IV over 45 to 60 minutes once on day 1
*[[Paclitaxel (Taxol)]] 200 mg/m<sup>2</sup> IV over 3 hours once on day 1

'''21-day cycle for 4 cycles'''

===References===
<!-- Presented in part at the 40th Annual Meeting of the American Society of Clinical Oncology, June 5-8, 2004, New Orleans, LA, and at the 42nd Annual Meeting of the American Society of Clinical Oncology, June 2-6, 2006, Atlanta, GA. -->
# '''CALGB 9633:''' Strauss GM, Herndon JE 2nd, Maddaus MA, Johnstone DW, Johnson EA, Harpole DH, Gillenwater HH, Watson DM, Sugarbaker DJ, Schilsky RL, Vokes EE, Green MR. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol. 2008 Nov 1;26(31):5043-51. Epub 2008 Sep 22. [http://jco.ascopubs.org/content/26/31/5043.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2652093/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/18809614 PubMed]

==Cisplatin & Docetaxel {{#subobject:211cca|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
DC: '''<u>D</u>'''ocetaxel & '''<u>C</u>'''isplatin
===Regimen {{#subobject:bc45d4|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://icvts.oxfordjournals.org/content/20/6/783.long Barlesi et al. 2015]
|style="background-color:#1a9851"|Phase III (E)
|[[#Cisplatin_.26_Gemcitabine_2|Cisplatin & Gemcitabine]]
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30691-5/fulltext Wakelee et al. 2017 (ECOG-ACRIN E1505)]
|style="background-color:#1a9851"|Phase III (C)
|1. Cisplatin, Docetaxel, Bevacizumab<br> 2. Cisplatin, Gemcitabine, Bevacizumab<br> 3. Cisplatin, Pemetrexed, Bevacizumab<br> 4. Cisplatin, Vinorelbine, Bevacizumab
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Preceding treatment====
*Barlesi et al. 2015: Complete R0 [[Surgery#Lung_cancer_surgery|resection]], within 8 weeks
*ECOG-ACRIN E1505: Complete [[Surgery#Lung_cancer_surgery|surgical resection]], within 6 to 12 weeks
====Chemotherapy====
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV once on day 1
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 3 cycles (Barlesi et al. 2015) or 4 cycles (ECOG-ACRIN E1505)'''

===References===
# Barlesi F, Chouaid C, Crequit J, Le Caer H, Pujol JL, Legodec J, Vergnenegre A, Le Treut J, Fabre-Guillevin E, Loundou A, Auquier P, Simeoni MC, Thomas PA. A randomized trial comparing adjuvant chemotherapy with gemcitabine plus cisplatin with docetaxel plus cisplatin in patients with completely resected non-small-cell lung cancer with quality of life as the primary objective. Interact Cardiovasc Thorac Surg. 2015 Jun;20(6):783-90. Epub 2015 Mar 11. [http://icvts.oxfordjournals.org/content/20/6/783.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25765952 PubMed]
# '''ECOG-ACRIN E1505:''' Wakelee HA, Dahlberg SE, Keller SM, Tester WJ, Gandara DR, Graziano SL, Adjei AA, Leighl NB, Aisner SC, Rothman JM, Patel JD, Sborov MD, McDermott SR, Perez-Soler R, Traynor AM, Butts C, Evans T, Shafqat A, Chapman AE, Kasbari SS, Horn L, Ramalingam SS, Schiller JH; ECOG-ACRIN. Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2017 Dec;18(12):1610-1623. Epub 2017 Nov 9. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30691-5/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29129443 PubMed]

==Cisplatin & Etoposide {{#subobject:dbad67|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:a211c5|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa031644 Arriagada et al. 2004 (IALT)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Observation|Observation]]
|style="background-color:#91cf60"|Seems to have superior OS
|-
|}
====Preceding treatment====
*Complete [[Surgery#Lung_cancer_surgery|surgical resection]], within 60 days
====Chemotherapy====
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV once on day 1
*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV once per day on days 1 to 3

'''28-day cycle for 4 cycles'''

===References===
# '''IALT:''' Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J; International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004 Jan 22;350(4):351-60. [https://www.nejm.org/doi/full/10.1056/NEJMoa031644 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/14736927 PubMed]
## '''Update:''' Arriagada R, Dunant A, Pignon JP, Bergman B, Chabowski M, Grunenwald D, Kozlowski M, Le Péchoux C, Pirker R, Pinel MI, Tarayre M, Le Chevalier T. Long-term results of the international adjuvant lung cancer trial evaluating adjuvant cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol. 2010 Jan 1;28(1):35-42. Epub 2009 Nov 23. [http://ascopubs.org/doi/10.1200/JCO.2009.23.2272 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/19933916 PubMed]

==Cisplatin & Gemcitabine {{#subobject:289ea6|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
GC: '''<u>G</u>'''emcitabine & '''<u>C</u>'''isplatin
===Variant #1, 75/1200 x 4 {{#subobject:4cd112|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30691-5/fulltext Wakelee et al. 2017 (ECOG-ACRIN E1505)]
|style="background-color:#1a9851"|Phase III (C)
|1. Cisplatin, Docetaxel, Bevacizumab<br> 2. Cisplatin, Gemcitabine, Bevacizumab<br> 3. Cisplatin, Pemetrexed, Bevacizumab<br> 4. Cisplatin, Vinorelbine, Bevacizumab
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Preceding treatment====
*Complete [[Surgery#Lung_cancer_surgery|surgical resection]], within 6 to 12 weeks
====Chemotherapy====
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV once on day 1
*[[Gemcitabine (Gemzar)]] 1200 mg/m<sup>2</sup> IV once per day on days 1 & 8

'''21-day cycle for 4 cycles'''

===Variant #2, 75/1250 x 3 {{#subobject:22cb4c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://icvts.oxfordjournals.org/content/20/6/783.long Barlesi et al. 2015]
|style="background-color:#1a9851"|Phase III (E)
|[[#Cisplatin_.26_Docetaxel_2|Cisplatin & Docetaxel]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''This trial included patients with Stage IB–III NSCLC.''
====Preceding treatment====
*Complete R0 [[Surgery#Lung_cancer_surgery|resection]], within 8 weeks
====Chemotherapy====
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV once on day 1
*[[Gemcitabine (Gemzar)]] 1250 mg/m<sup>2</sup> IV once per day on days 1 & 8

'''21-day cycle for 3 cycles'''

===References===
# Barlesi F, Chouaid C, Crequit J, Le Caer H, Pujol JL, Legodec J, Vergnenegre A, Le Treut J, Fabre-Guillevin E, Loundou A, Auquier P, Simeoni MC, Thomas PA. A randomized trial comparing adjuvant chemotherapy with gemcitabine plus cisplatin with docetaxel plus cisplatin in patients with completely resected non-small-cell lung cancer with quality of life as the primary objective. Interact Cardiovasc Thorac Surg. 2015 Jun;20(6):783-90. Epub 2015 Mar 11. [http://icvts.oxfordjournals.org/content/20/6/783.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25765952 PubMed]
# '''ECOG-ACRIN E1505:''' Wakelee HA, Dahlberg SE, Keller SM, Tester WJ, Gandara DR, Graziano SL, Adjei AA, Leighl NB, Aisner SC, Rothman JM, Patel JD, Sborov MD, McDermott SR, Perez-Soler R, Traynor AM, Butts C, Evans T, Shafqat A, Chapman AE, Kasbari SS, Horn L, Ramalingam SS, Schiller JH; ECOG-ACRIN. Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2017 Dec;18(12):1610-1623. Epub 2017 Nov 9. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30691-5/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29129443 PubMed]

==Cisplatin & Pemetrexed {{#subobject:1caad6|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CPx: '''<u>C</u>'''isplatin & '''<u>P</u>'''emetre'''<u>x</u>'''ed
===Regimen {{#subobject:73f03b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://annonc.oxfordjournals.org/content/24/4/986.long Kreuter et al. 2013 (TREAT)]
|style="background-color:#1a9851"|Randomized Phase II (E)
|[[#Cisplatin_.26_Vinorelbine|Cisplatin & Vinorelbine]]
|style="background-color:#ffffbf"|Seems not superior (*)
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30691-5/fulltext Wakelee et al. 2017 (ECOG-ACRIN E1505)]
|style="background-color:#1a9851"|Phase III (C)
|1. Cisplatin, Docetaxel, Bevacizumab<br> 2. Cisplatin, Gemcitabine, Bevacizumab<br> 3. Cisplatin, Pemetrexed, Bevacizumab<br> 4. Cisplatin, Vinorelbine, Bevacizumab
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''In '''TREAT''', intended for pathologically confirmed NSCLC stages (according to the TNM staging system version 6) IB, IIA, IIB or T3N1. Efficacy reported for '''TREAT''' based on 2016 update.''
====Preceding treatment====
*TREAT: Complete [[Surgery#Lung_cancer_surgery|surgical resection]], within 4 to 6 weeks
*ECOG-ACRIN E1505: Complete [[Surgery#Lung_cancer_surgery|surgical resection]], within 6 to 12 weeks
====Chemotherapy====
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV once on day 1
*[[Pemetrexed (Alimta)]] 500 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 4 cycles'''

===References===
# '''TREAT:''' Kreuter M, Vansteenkiste J, Fischer JR, Eberhardt W, Zabeck H, Kollmeier J, Serke M, Frickhofen N, Reck M, Engel-Riedel W, Neumann S, Thomeer M, Schumann C, De Leyn P, Graeter T, Stamatis G, Zuna I, Griesinger F, Thomas M; TREAT investigators. Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study. Ann Oncol. 2013 Apr;24(4):986-92. Epub 2012 Nov 15. [http://annonc.oxfordjournals.org/content/24/4/986.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23161898 PubMed]
## '''Update:''' Kreuter M, Vansteenkiste J, Fischer JR, Eberhardt WE, Zabeck H, Kollmeier J, Serke M, Frickhofen N, Reck M, Engel-Riedel W, Neumann S, Thomeer M, Schumann C, De Leyn P, Graeter T, Stamatis G, Griesinger F, Thomas M; TREAT investigators. Three-year follow-up of a randomized phase II trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine (the TREAT study). J Thorac Oncol. 2016 Jan;11(1):85-93. [http://www.jto.org/article/S1556-0864(15)00023-4/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26762743 PubMed]
# '''ECOG-ACRIN E1505:''' Wakelee HA, Dahlberg SE, Keller SM, Tester WJ, Gandara DR, Graziano SL, Adjei AA, Leighl NB, Aisner SC, Rothman JM, Patel JD, Sborov MD, McDermott SR, Perez-Soler R, Traynor AM, Butts C, Evans T, Shafqat A, Chapman AE, Kasbari SS, Horn L, Ramalingam SS, Schiller JH; ECOG-ACRIN. Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2017 Dec;18(12):1610-1623. Epub 2017 Nov 9. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30691-5/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29129443 PubMed]

==Cisplatin & Vinblastine {{#subobject:af5cc1|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:1d592|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa031644 Arriagada et al. 2004 (IALT)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Observation|Observation]]
|style="background-color:#91cf60"|Seems to have superior OS
|-
|}
''Note: Exact days for parts of the regimen were not specified by Arriagada et al. 2004. This vinblastine schedule is extrapolated from regimen information in Table 1 in which vinblastine is said to be given "weekly from days 1 to 29" and "then every 2 weeks after day 43 until last cisplatin administration.''
====Preceding treatment====
*Complete [[Surgery#Lung_cancer_surgery|surgical resection]], within 60 days
====Chemotherapy====
*[[Cisplatin (Platinol)]] 80 mg/m<sup>2</sup> IV once per day on days 1, 22, 43, 64
*[[Vinblastine (Velban)]] 4 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22, 29, 43, 57

'''12-week course'''

===References===
# '''IALT:''' Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J; International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004 Jan 22;350(4):351-60. [https://www.nejm.org/doi/full/10.1056/NEJMoa031644 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/14736927 PubMed]
## '''Update:''' Arriagada R, Dunant A, Pignon JP, Bergman B, Chabowski M, Grunenwald D, Kozlowski M, Le Péchoux C, Pirker R, Pinel MI, Tarayre M, Le Chevalier T. Long-term results of the international adjuvant lung cancer trial evaluating adjuvant cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol. 2010 Jan 1;28(1):35-42. Epub 2009 Nov 23. [http://ascopubs.org/doi/10.1200/JCO.2009.23.2272 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/19933916 PubMed]

==Cisplatin & Vindesine {{#subobject:80fe2|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:2d16cd|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa031644 Arriagada et al. 2004 (IALT)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Observation|Observation]]
|style="background-color:#91cf60"|Seems to have superior OS
|-
|}
''Note: Exact days for parts of the regimen were not specified by Arriagada et al. 2004. This vindesine schedule is extrapolated from regimen information in Table 1 in which vindesine is said to be given "weekly from days 1 to 29" and "then every 2 weeks after day 43 until last cisplatin administration.''
====Preceding treatment====
*Complete [[Surgery#Lung_cancer_surgery|surgical resection]], within 60 days
====Chemotherapy====
*[[Cisplatin (Platinol)]] 80 mg/m<sup>2</sup> IV once per day on days 1, 22, 43, 64
*[[Vindesine (Eldisine)]] 3 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22, 29, 43, 57

'''12-week course'''

===References===
# '''IALT:''' Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J; International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004 Jan 22;350(4):351-60. [https://www.nejm.org/doi/full/10.1056/NEJMoa031644 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/14736927 PubMed]
## '''Update:''' Arriagada R, Dunant A, Pignon JP, Bergman B, Chabowski M, Grunenwald D, Kozlowski M, Le Péchoux C, Pirker R, Pinel MI, Tarayre M, Le Chevalier T. Long-term results of the international adjuvant lung cancer trial evaluating adjuvant cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol. 2010 Jan 1;28(1):35-42. Epub 2009 Nov 23. [http://ascopubs.org/doi/10.1200/JCO.2009.23.2272 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/19933916 PubMed]

==Cisplatin & Vinorelbine {{#subobject:ab1b88|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CVb: '''<u>C</u>'''isplatin & '''<u>V</u>'''inorel'''<u>b</u>'''ine
===Variant #1, cisplatin 50 mg/m<sup>2</sup>, 2 weeks out of 4 {{#subobject:c1a368|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa043623 Winton et al. 2005 (JBR.10)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Observation|Observation]]
|style="background-color:#91cf60"|Seems to have superior OS
|-
|[http://annonc.oxfordjournals.org/content/24/4/986.long Kreuter et al. 2013 (TREAT)]
|style="background-color:#1a9851"|Randomized Phase II (C)
|[[#Cisplatin_.26_Pemetrexed|Cisplatin & Pemetrexed]]
|style="background-color:#ffffbf"|Seems not superior (*)
|-
|}
''Efficacy for '''TREAT''' based on 2016 update.''
====Preceding treatment====
*JBR.10: Complete [[Surgery#Lung_cancer_surgery|surgical resection]], within 6 weeks
*TREAT: Complete [[Surgery#Lung_cancer_surgery|surgical resection]], within 4 to 6 weeks
====Chemotherapy====
*[[Cisplatin (Platinol)]] 50 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Vinorelbine (Navelbine)]] 25 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22

'''28-day cycle for 4 cycles'''
===Variant #2, cisplatin 75 mg/m<sup>2</sup>, q3wk {{#subobject:04b3e6|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30691-5/fulltext Wakelee et al. 2017 (ECOG-ACRIN E1505)]
|style="background-color:#1a9851"|Phase III (C)
|1. Cisplatin, Docetaxel, Bevacizumab<br> 2. Cisplatin, Gemcitabine, Bevacizumab<br> 3. Cisplatin, Pemetrexed, Bevacizumab<br> 4. Cisplatin, Vinorelbine, Bevacizumab
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30729-5/fulltext Zhong et al. 2017 (ADJUVANT/CTONG1104)]
|style="background-color:#1a9851"|Phase III (C)
|[[Non-small_cell_lung_cancer,_EGFR-mutated#Gefitinib_monotherapy|Gefinitib]]
|style="background-color:#d73027"|Inferior DFS
|-
|}
''Patients enrolled in '''ADJUVANT/CTONG1104''' had EGFR-mutated lung cancer.''
====Preceding treatment====
*Complete [[Surgery#Lung_cancer_surgery|surgical resection]], within 6 to 12 weeks
====Chemotherapy====
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV once on day 1
*[[Vinorelbine (Navelbine)]] 30 mg/m<sup>2</sup> IV once per day on days 1 & 8

'''21-day cycle for 4 cycles'''

===Variant #3, cisplatin 100 mg/m<sup>2</sup>, q4wk {{#subobject:6edee|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa031644 Arriagada et al. 2004 (IALT)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Observation|Observation]]
|style="background-color:#91cf60"|Seems to have superior OS
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(06)70804-X/fulltext Douillard et al. 2006 (ANITA)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Observation|Observation]]
|style="background-color:#91cf60"|Seems to have superior OS
|-
|}
====Preceding treatment====
*IALT: Complete [[Surgery#Lung_cancer_surgery|surgical resection]], within 60 days
*ANITA: Complete [[Surgery#Lung_cancer_surgery|surgical resection]]
====Chemotherapy====
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV once on day 1
*[[Vinorelbine (Navelbine)]] 30 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22

'''28-day cycle for 4 cycles'''

===References===
# '''IALT:''' Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J; International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004 Jan 22;350(4):351-60. [https://www.nejm.org/doi/full/10.1056/NEJMoa031644 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/14736927 PubMed]
## '''Update:''' Arriagada R, Dunant A, Pignon JP, Bergman B, Chabowski M, Grunenwald D, Kozlowski M, Le Péchoux C, Pirker R, Pinel MI, Tarayre M, Le Chevalier T. Long-term results of the international adjuvant lung cancer trial evaluating adjuvant cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol. 2010 Jan 1;28(1):35-42. Epub 2009 Nov 23. [http://ascopubs.org/doi/10.1200/JCO.2009.23.2272 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/19933916 PubMed]
# '''JBR.10:''' Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, Cormier Y, Goss G, Inculet R, Vallieres E, Fry W, Bethune D, Ayoub J, Ding K, Seymour L, Graham B, Tsao MS, Gandara D, Kesler K, Demmy T, Shepherd F; National Cancer Institute of Canada Clinical Trials Group; National Cancer Institute of the United States Intergroup JBR.10 Trial Investigators. Vinorelbine plus cisplatin vs observation in resected non-small-cell lung cancer. N Engl J Med. 2005 Jun 23;352(25):2589-97. [https://www.nejm.org/doi/full/10.1056/NEJMoa043623 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15972865 PubMed]
## '''Update:''' Butts CA, Ding K, Seymour L, Twumasi-Ankrah P, Graham B, Gandara D, Johnson DH, Kesler KA, Green M, Vincent M, Cormier Y, Goss G, Findlay B, Johnston M, Tsao MS, Shepherd FA. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. J Clin Oncol. 2010 Jan 1;28(1):29-34. Epub 2009 Nov 23. [http://ascopubs.org/doi/10.1200/JCO.2009.24.0333 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2799232/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/19933915 PubMed]
# '''ANITA:''' Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzáles-Larriba JL, Grodzki T, Rodrigues Pereira J, Le Groumellec A, Lorusso V, Clary C, Torres AJ, Dahabreh J, Souquet PJ, Astudillo J, Fournel P, Artal-Cortes A, Jassem J, Koubkova L, His P, Riggi M, Hurteloup P. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006 Sep;7(9):719-27. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(06)70804-X/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16945766 PubMed]
# '''TREAT:''' Kreuter M, Vansteenkiste J, Fischer JR, Eberhardt W, Zabeck H, Kollmeier J, Serke M, Frickhofen N, Reck M, Engel-Riedel W, Neumann S, Thomeer M, Schumann C, De Leyn P, Graeter T, Stamatis G, Zuna I, Griesinger F, Thomas M; TREAT investigators. Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study. Ann Oncol. 2013 Apr;24(4):986-92. Epub 2012 Nov 15. [http://annonc.oxfordjournals.org/content/24/4/986.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23161898 PubMed]
## '''Update:''' Kreuter M, Vansteenkiste J, Fischer JR, Eberhardt WE, Zabeck H, Kollmeier J, Serke M, Frickhofen N, Reck M, Engel-Riedel W, Neumann S, Thomeer M, Schumann C, De Leyn P, Graeter T, Stamatis G, Griesinger F, Thomas M; TREAT investigators. Three-year follow-up of a randomized phase II trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine (the TREAT study). J Thorac Oncol. 2016 Jan;11(1):85-93. [http://www.jto.org/article/S1556-0864(15)00023-4/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26762743 PubMed]
# '''ECOG-ACRIN E1505:''' Wakelee HA, Dahlberg SE, Keller SM, Tester WJ, Gandara DR, Graziano SL, Adjei AA, Leighl NB, Aisner SC, Rothman JM, Patel JD, Sborov MD, McDermott SR, Perez-Soler R, Traynor AM, Butts C, Evans T, Shafqat A, Chapman AE, Kasbari SS, Horn L, Ramalingam SS, Schiller JH; ECOG-ACRIN. Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2017 Dec;18(12):1610-1623. Epub 2017 Nov 9. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30691-5/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29129443 PubMed]
# '''ADJUVANT/CTONG1104:''' Zhong WZ, Wang Q, Mao WM, Xu ST, Wu L, Shen Y, Liu YY, Chen C, Cheng Y, Xu L, Wang J, Fei K, Li XF, Li J, Huang C, Liu ZD, Xu S, Chen KN, Xu SD, Liu LX, Yu P, Wang BH, Ma HT, Yan HH, Yang XN, Zhou Q, Wu YL; ADJUVANT investigators. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. Lancet Oncol. 2018 Jan;19(1):139-148. Epub 2017 Nov 21. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30729-5/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29174310 PubMed]

==Observation==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(76)90212-9/fulltext McKneally et al. 1976]
|style="background-color:#1a9851"|Phase III (C)
|Intrapleural BCG
| style="background-color:#d73027" |Inferior OS
|-
|[https://academic.oup.com/jnci/article-abstract/85/4/299/884633 Feld et al. 1993 (LCSG 801)]
|style="background-color:#1a9851"|Phase III (C)
|CAP
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.ncbi.nlm.nih.gov/pubmed/8412266 Ohta et al. 1993 (JCOG8601)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Cisplatin_.26_Vindesine|Cisplatin & Vindesine]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://academic.oup.com/jnci/article/95/19/1453/2520466 Scagliotti et al. 2003 (ALPI)]
|style="background-color:#1a9851"|Phase III (C)
|MVP
| style="background-color:#ffffbf" |Seems not superior
|-
|rowspan=4|[https://www.nejm.org/doi/full/10.1056/NEJMoa031644 Arriagada et al. 2004 (IALT)]
|rowspan=4 style="background-color:#1a9851"|Phase III (C)
|1. [[#Cisplatin_.26_Etoposide|Cisplatin & Etoposide]]
|style="background-color:#fc8d59"|Seems to have inferior OS
|-
|2. [[#Cisplatin_.26_Vinblastine|Cisplatin & Vinblastine]]
|style="background-color:#fc8d59"|Seems to have inferior OS
|-
|3. [[#Cisplatin_.26_Vindesine|Cisplatin & Vindesine]]
|style="background-color:#fc8d59"|Seems to have inferior OS
|-
|4. [[#Cisplatin_.26_Vinorelbine|Cisplatin & Vinorelbine]]
|style="background-color:#fc8d59"|Seems to have inferior OS
|-
|[https://www.lungcancerjournal.info/article/S0169-5002(03)00450-1/fulltext Tada et al. 2004 (JCOG9304)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Cisplatin_.26_Vindesine|Cisplatin & Vindesine]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa032792 Kato et al. 2004]
|style="background-color:#1a9851"|Phase III (C)
|[[#Tegafur_.26_Uracil|Tegafur & Uracil]]
|style="background-color:#fc8d59"|Seems to have inferior OS
|-
|[https://academic.oup.com/annonc/article/16/1/75/180265 Nakagawa et al. 2005 (WJSG4)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Tegafur_.26_Uracil|Tegafur & Uracil]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa043623 Winton et al. 2005 (JBR.10)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Cisplatin_.26_Vinorelbine|Cisplatin & Vinorelbine]]
|style="background-color:#fc8d59"|Seems to have inferior OS
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(06)70804-X/fulltext Douillard et al. 2006 (ANITA)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Cisplatin_.26_Vinorelbine|Cisplatin & Vinorelbine]]
|style="background-color:#fc8d59"|Seems to have inferior OS
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2652093/ Strauss et al. 2008 (CALGB 9633)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Carboplatin_.26_Paclitaxel|Carboplatin & Paclitaxel]]
|style="background-color:#ffffbf"|Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2009.27.6204 Felip et al. 2010]
|style="background-color:#1a9851"|Phase III (C)
|1. Adjuvant [[#Carboplatin_.26_Paclitaxel|Carboplatin & Paclitaxel]]<br> 2. Neoadjuvant Carboplatin & Paclitaxel
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''No systemic treatment after surgery. Placed here because one or more randomized clinical trials included a placebo or observation arm in this disease context.''
====Preceding treatment====
*[[Surgery#Lung_cancer_surgery|Surgery]]
===References===
# McKneally MF, Maver C, Kausel HW. Regional immunotherapy of lung cancer with intrapleural BCG. Lancet. 1976 Feb 21;1(7956):377-9. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(76)90212-9/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/55646 PubMed]
# '''LCSG 801:''' Feld R, Rubinstein L, Thomas PA; The Lung Cancer Study Group. Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage I non-small-cell lung cancer. J Natl Cancer Inst. 1993 Feb 17;85(4):299-306. [https://academic.oup.com/jnci/article-abstract/85/4/299/884633 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/8381187 PubMed]
# '''JCOG8601:''' Ohta M, Tsuchiya R, Shimoyama M, Sawamura K, Mori T, Miyazawa N, Suemasu K, Watanabe Y, Tomita M, Terashima M; The Japan Clinical Oncology Group. Adjuvant chemotherapy for completely resected stage III non-small-cell lung cancer: results of a randomized prospective study. J Thorac Cardiovasc Surg. 1993 Oct;106(4):703-8. [https://www.ncbi.nlm.nih.gov/pubmed/8412266 PubMed]
# '''ALPI:''' Scagliotti GV, Fossati R, Torri V, Crinò L, Giaccone G, Silvano G, Martelli M, Clerici M, Cognetti F, Tonato M; Adjuvant Lung Project Italy/European Organisation for Research Treatment of Cancer-Lung Cancer Cooperative Group Investigators. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. J Natl Cancer Inst. 2003 Oct 1;95(19):1453-61. [https://academic.oup.com/jnci/article/95/19/1453/2520466 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/14519751 PubMed]
# '''IALT:''' Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J; International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004 Jan 22;350(4):351-60. [https://www.nejm.org/doi/full/10.1056/NEJMoa031644 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/14736927 PubMed]
## '''Update:''' Arriagada R, Dunant A, Pignon JP, Bergman B, Chabowski M, Grunenwald D, Kozlowski M, Le Péchoux C, Pirker R, Pinel MI, Tarayre M, Le Chevalier T. Long-term results of the international adjuvant lung cancer trial evaluating adjuvant cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol. 2010 Jan 1;28(1):35-42. Epub 2009 Nov 23. [http://ascopubs.org/doi/10.1200/JCO.2009.23.2272 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/19933916 PubMed]
# '''JCOG9304:''' Tada H, Tsuchiya R, Ichinose Y, Koike T, Nishizawa N, Nagai K, Kato H. A randomized trial comparing adjuvant chemotherapy versus surgery alone for completely resected pN2 non-small cell lung cancer (JCOG9304). Lung Cancer. 2004 Feb;43(2):167-73. [https://www.lungcancerjournal.info/article/S0169-5002(03)00450-1/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/14739037 PubMed]
# Kato H, Ichinose Y, Ohta M, Hata E, Tsubota N, Tada H, Watanabe Y, Wada H, Tsuboi M, Hamajima N, Ohta M; Japan Lung Cancer Research Group on Postsurgical Adjuvant Chemotherapy. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med. 2004 Apr 22;350(17):1713-21. [https://www.nejm.org/doi/full/10.1056/NEJMoa032792 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15102997 PubMed]
# '''WJSG4:''' Nakagawa M, Tanaka F, Tsubota N, Ohta M, Takao M, Wada H; West Japan Study Group for Lung Cancer Surgery. A randomized phase III trial of adjuvant chemotherapy with UFT for completely resected pathological stage I non-small-cell lung cancer: the West Japan Study Group for Lung Cancer Surgery (WJSG)--the 4th study. Ann Oncol. 2005 Jan;16(1):75-80. [https://academic.oup.com/annonc/article/16/1/75/180265 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15598942 PubMed]
# '''JBR.10:''' Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, Cormier Y, Goss G, Inculet R, Vallieres E, Fry W, Bethune D, Ayoub J, Ding K, Seymour L, Graham B, Tsao MS, Gandara D, Kesler K, Demmy T, Shepherd F; National Cancer Institute of Canada Clinical Trials Group; National Cancer Institute of the United States Intergroup JBR.10 Trial Investigators. Vinorelbine plus cisplatin vs observation in resected non-small-cell lung cancer. N Engl J Med. 2005 Jun 23;352(25):2589-97. [https://www.nejm.org/doi/full/10.1056/NEJMoa043623 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15972865 PubMed]
## '''Update:''' Butts CA, Ding K, Seymour L, Twumasi-Ankrah P, Graham B, Gandara D, Johnson DH, Kesler KA, Green M, Vincent M, Cormier Y, Goss G, Findlay B, Johnston M, Tsao MS, Shepherd FA. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. J Clin Oncol. 2010 Jan 1;28(1):29-34. Epub 2009 Nov 23. [http://ascopubs.org/doi/10.1200/JCO.2009.24.0333 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2799232/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/19933915 PubMed]
# '''ANITA:''' Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzáles-Larriba JL, Grodzki T, Rodrigues Pereira J, Le Groumellec A, Lorusso V, Clary C, Torres AJ, Dahabreh J, Souquet PJ, Astudillo J, Fournel P, Artal-Cortes A, Jassem J, Koubkova L, His P, Riggi M, Hurteloup P. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006 Sep;7(9):719-27. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(06)70804-X/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16945766 PubMed]
<!-- Presented in part at the 40th Annual Meeting of the American Society of Clinical Oncology, June 5-8, 2004, New Orleans, LA, and at the 42nd Annual Meeting of the American Society of Clinical Oncology, June 2-6, 2006, Atlanta, GA. -->
# '''CALGB 9633:''' Strauss GM, Herndon JE 2nd, Maddaus MA, Johnstone DW, Johnson EA, Harpole DH, Gillenwater HH, Watson DM, Sugarbaker DJ, Schilsky RL, Vokes EE, Green MR. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol. 2008 Nov 1;26(31):5043-51. Epub 2008 Sep 22. [http://jco.ascopubs.org/content/26/31/5043.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2652093/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/18809614 PubMed]
# Felip E, Rosell R, Maestre JA, Rodríguez-Paniagua JM, Morán T, Astudillo J, Alonso G, Borro JM, González-Larriba JL, Torres A, Camps C, Guijarro R, Isla D, Aguiló R, Alberola V, Padilla J, Sánchez-Palencia A, Sánchez JJ, Hermosilla E, Massuti B; Spanish Lung Cancer Group. Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer. J Clin Oncol. 2010 Jul 1;28(19):3138-45. Epub 2010 Jun 1. [http://ascopubs.org/doi/full/10.1200/JCO.2009.27.6204 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/20516435 PubMed]

==Tegafur & Uracil {{#subobject:ac88ea|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:b0fe3f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa032792 Kato et al. 2004]
|style="background-color:#1a9851"|Phase III (E)
|[[#Observation|Observation]]
| style="background-color:#91cf60" |Seems to have superior OS
|-
|}
====Preceding treatment====
*[[Surgery#Lung_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Tegafur and uracil (UFT)]] 250 mg PO once per day

'''2-year course'''

===References===
# Kato H, Ichinose Y, Ohta M, Hata E, Tsubota N, Tada H, Watanabe Y, Wada H, Tsuboi M, Hamajima N, Ohta M; Japan Lung Cancer Research Group on Postsurgical Adjuvant Chemotherapy. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med. 2004 Apr 22;350(17):1713-21. [https://www.nejm.org/doi/full/10.1056/NEJMoa032792 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15102997 PubMed]

=Induction chemotherapy for locally advanced disease=
==Carboplatin & Paclitaxel {{#subobject:b2de53|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
PC: '''<u>P</u>'''aclitaxel & '''<u>C</u>'''arboplatin
===Variant #1, 6/200 {{#subobject:4d4e46|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/23/25/5883.long Belani et al. 2005 (LAMP)]
|style="background-color:#91cf61"|Phase II
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2005.05.4163 Huber et al. 2006 (CTRT99/97)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2006.07.3569 Vokes et al. 2007 (CALGB 39801)]
|style="background-color:#1a9851"|Phase III (E)
|[[#No_induction|No induction]]
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 6 IV over 30 minutes once on day 1, '''given second'''
*[[Paclitaxel (Taxol)]] 200 mg/m<sup>2</sup> IV over 3 hours once on day 1, '''given first'''

'''21-day cycle for 2 cycles'''

====Subsequent treatment====
*LAMP: [[#Radiation_therapy|RT]] x 63 Gy
*CTRT99/97: Paclitaxel & RT versus [[#Radiation_therapy|RT]]
*CALGB 39801: [[#Carboplatin.2C_Paclitaxel.2C_RT|Carboplatin, Paclitaxel, RT]]

===Variant #2, 6/225 {{#subobject:1ec13b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3295560/ Hoang et al. 2012 (ECOG 3598)]
|style="background-color:#1a9851"|Phase III (C)
|[[Complex_multipart_regimens#ECOG_3598|See link]]
| style="background-color:#ffffbf" |[[Complex_multipart_regimens#ECOG_3598|See link]]
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 6 IV once on day 1
*[[Paclitaxel (Taxol)]] 225 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 2 cycles'''

====Subsequent treatment====
*[[#Carboplatin.2C_Paclitaxel.2C_RT|Carboplatin, Paclitaxel, RT]]
===References===
# '''LAMP:''' Belani CP, Choy H, Bonomi P, Scott C, Travis P, Haluschak J, Curran WJ Jr. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol. 2005 Sep 1;23(25):5883-91. [http://jco.ascopubs.org/content/23/25/5883.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16087941 PubMed]
# '''CTRT99/97:''' Huber RM, Flentje M, Schmidt M, Pöllinger B, Gosse H, Willner J, Ulm K; Bronchial Carcinoma Therapy Group. Simultaneous chemoradiotherapy compared with radiotherapy alone after induction chemotherapy in inoperable stage IIIA or IIIB non-small-cell lung cancer: study CTRT99/97 by the Bronchial Carcinoma Therapy Group. J Clin Oncol. 2006 Sep 20;24(27):4397-404. [http://ascopubs.org/doi/full/10.1200/JCO.2005.05.4163 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16983107 PubMed]
# '''CALGB 39801:''' Vokes EE, Herndon JE 2nd, Kelley MJ, Cicchetti MG, Ramnath N, Neill H, Atkins JN, Watson DM, Akerley W, Green MR; Cancer and Leukemia Group B. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol. 2007 May 1;25(13):1698-704. Epub 2007 Apr 2. [http://ascopubs.org/doi/full/10.1200/JCO.2006.07.3569 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17404369 PubMed]
# '''ECOG 3598:''' Hoang T, Dahlberg SE, Schiller JH, Mehta MP, Fitzgerald TJ, Belinsky SA, Johnson DH. Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: the ECOG 3598 study. J Clin Oncol. 2012 Feb 20;30(6):616-22. Epub 2012 Jan 23. [http://ascopubs.org/doi/full/10.1200/JCO.2011.36.9116 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3295560/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22271472 PubMed]

==Cisplatin & Vinblastine {{#subobject:6b4fa8|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:2433e7|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJM199010043231403 Dillman et al. 1990 (CALGB 8433)]
|style="background-color:#1a9851"|Phase III (E)
|[[#No_induction|No induction]]
| style="background-color:#91cf60" |Seems to have superior OS (*)
|-
|[https://academic.oup.com/jnci/article-abstract/87/3/198/932006 Sause et al. 1995 (RTOG 88-08)]
|style="background-color:#1a9851"|Phase III (E)
|[[#No_induction|No induction]]
| style="background-color:#91cf60" |Seems to have superior OS
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3186782/ Curran et al. 2011 (RTOG 9410)]
|style="background-color:#1a9851"|Phase III (C)
|[[Complex_multipart_regimens#RTOG_9410|See link]]
| style="background-color:#fc8d59" |[[Complex_multipart_regimens#RTOG_9410|See link]]
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment. Reported efficacy for CALGB 8433 is based on the 1996 update.''
====Chemotherapy====
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV once per day on days 1 & 29
*[[Vinblastine (Velban)]] 5 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22, 29

'''5-week course'''

====Subsequent treatment====
*[[#Radiation_therapy|RT]] x 60 to 63 Gy

===References===
# '''CALGB 8433:''' Dillman RO, Seagren SL, Propert KJ, Guerra J, Eaton WL, Perry MC, Carey RW, Frei EF 3rd, Green MR. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med. 1990 Oct 4;323(14):940-5. [https://www.nejm.org/doi/full/10.1056/NEJM199010043231403 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/2169587 PubMed]
## '''Update:''' Dillman RO, Herndon J, Seagren SL, Eaton WL Jr, Green MR. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial. J Natl Cancer Inst. 1996 Sep 4;88(17):1210-5. [https://academic.oup.com/jnci/article/88/17/1210/911128 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/8780630 PubMed]
# '''RTOG 88-08:''' Sause WT, Scott C, Taylor S, Johnson D, Livingston R, Komaki R, Emami B, Curran WJ, Byhardt RW, Turrisi AT, et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst. 1995 Feb 1;87(3):198-205. [https://academic.oup.com/jnci/article-abstract/87/3/198/932006 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/7707407 PubMed]
# '''RTOG 9410:''' Curran WJ Jr, Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S, Movsas B, Wasserman T, Rosenthal SA, Gore E, Machtay M, Sause W, Cox JD. Sequential vs concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst. 2011 Oct 5;103(19):1452-60. Epub 2011 Sep 8. Erratum in: J Natl Cancer Inst. 2012;104(1):79. [http://jnci.oxfordjournals.org/content/103/19/1452.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3186782/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21903745 PubMed]

==No induction==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2006.07.3569 Vokes et al. 2007 (CALGB 39801)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Carboplatin_.26_Paclitaxel_2|Carboplatin & Paclitaxel]]
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''No treatment given prior to definitive therapy.''
====Subsequent treatment====
*[[#Carboplatin.2C_Paclitaxel.2C_RT|Carboplatin, Paclitaxel, RT]]
===References===
# '''CALGB 39801:''' Vokes EE, Herndon JE 2nd, Kelley MJ, Cicchetti MG, Ramnath N, Neill H, Atkins JN, Watson DM, Akerley W, Green MR; Cancer and Leukemia Group B. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol. 2007 May 1;25(13):1698-704. Epub 2007 Apr 2. [http://ascopubs.org/doi/full/10.1200/JCO.2006.07.3569 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17404369 PubMed]

=Definitive therapy for locally advanced disease=
==Carboplatin, Paclitaxel, RT {{#subobject:899399|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
PC & RT: '''<u>P</u>'''aclitaxel, '''<u>C</u>'''arboplatin, '''<u>R</u>'''adiation '''<u>T</u>'''herapy
===Variant #1, 2/40/60 {{#subobject:5d3a16|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2009.24.5050 Yamamoto et al. 2010 (WJTOG0105)]
|style="background-color:#1a9851"|Phase III (E)
|1. MVP & RT<br> 2. Carboplatin, Irinotecan, RT
|style="background-color:#ffffbf"|Inconclusive whether non-inferior
|-
|}
====Chemoradiotherapy====
*[[Carboplatin (Paraplatin)]] AUC 2 IV once per week
*[[Paclitaxel (Taxol)]] 40 mg/m<sup>2</sup> IV once per week
*Concurrent [[External_beam_radiotherapy|radiation therapy]], 60 Gy

'''6-week course'''

===Variant #2, 2/45/60 {{#subobject:5d4d16|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2902826/ Lu et al. 2010]
|style="background-color:#1a9851"|Phase III (C)
|PC, AE-941, RT
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3295560/ Hoang et al. 2012 (ECOG 3598)]
|style="background-color:#1a9851"|Phase III (C)
|[[Complex_multipart_regimens#ECOG_3598|See link]]
|[[Complex_multipart_regimens#ECOG_3598|See link]] 
|-
|rowspan=2|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4419359/ Bradley et al. 2015 (RTOG 0617)]
|rowspan=2 style="background-color:#1a9851"|Phase III (C)
|1. Carboplatin, Paclitaxel, Cetuximab, concurrent RT
|style="background-color:#ffffbf"|Seems not superior
|-
|2. Carboplatin, Paclitaxel, high-dose RT<br> 3. Carboplatin, Paclitaxel, Cetuximab, high-dose RT
|style="background-color:#1a9850"|Superior OS
|-
|[https://academic.oup.com/annonc/article-lookup/doi/10.1093/annonc/mdx009 Liang et al. 2017]
|style="background-color:#1a9851"|Phase III (C)
|[[#Cisplatin.2C_Etoposide.2C_RT|EP & RT]]
|style="background-color:#fee08b"|Might have inferior OS
|-
|}
''Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm.''
====Preceding treatment====
*ECOG 3598: [[#Carboplatin_.26_Paclitaxel_2|PC]] induction x 2
====Chemoradiotherapy====
*[[Carboplatin (Paraplatin)]] AUC 2 IV over 30 minutes once per day on days 1, 8, 15, '''given second'''
*[[Paclitaxel (Taxol)]] 45 mg/m<sup>2</sup> IV over 1 to 3 hours once per day on days 1, 8, 15, '''given first'''
*Concurrent [[External_beam_radiotherapy|radiation therapy]]: 2 Gy fractions x 30 fractions given 5 days per week, over a 6 week course of treatment

'''21-day cycle for 2 cycles'''
====Subsequent treatment====
*RTOG 0617: [[#Carboplatin_.26_Paclitaxel_3|PC]] consolidation x 2

===Variant #3, 2/45/63 {{#subobject:59d765|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/23/25/5883.long Belani et al. 2005 (LAMP)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Preceding treatment====
*[[#Carboplatin_.26_Paclitaxel_2|PC induction]]
====Chemoradiotherapy====
*[[Carboplatin (Paraplatin)]] AUC 2 IV over 30 minutes once per day on days 1, 8, 15, '''given second'''
*[[Paclitaxel (Taxol)]] 45 mg/m<sup>2</sup> IV over 1 to 3 hours once per day on days 1, 8, 15, '''given first'''
*Concurrent [[External_beam_radiotherapy|radiation therapy]]: 1.8 Gy fractions x 25 fractions given 5 days per week, then 2 Gy fractions x 9 fractions given 5 days per week, over a 7 week course of treatment

'''21-day cycle for 2 cycles'''
====Subsequent treatment====
*[[#Carboplatin_.26_Paclitaxel_3|PC]] consolidation x 2

===Variant #4, 2/50/66 {{#subobject:c54de8|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2006.07.3569 Vokes et al. 2007 (CALGB 39801)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|}
====Preceding treatment====
*[[#Carboplatin_.26_Paclitaxel_2|PC]] x 2 versus [[#No_induction|no induction]]
====Chemoradiotherapy====
*[[Carboplatin (Paraplatin)]] AUC 2 IV once per week
*[[Paclitaxel (Taxol)]] 50 mg/m<sup>2</sup> IV once per week
*Concurrent [[External_beam_radiotherapy|radiation therapy]], 66 Gy

'''One course'''
===References===
# '''LAMP:''' Belani CP, Choy H, Bonomi P, Scott C, Travis P, Haluschak J, Curran WJ Jr. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol. 2005 Sep 1;23(25):5883-91. [http://jco.ascopubs.org/content/23/25/5883.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16087941 PubMed]
# '''CALGB 39801:''' Vokes EE, Herndon JE 2nd, Kelley MJ, Cicchetti MG, Ramnath N, Neill H, Atkins JN, Watson DM, Akerley W, Green MR; Cancer and Leukemia Group B. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol. 2007 May 1;25(13):1698-704. Epub 2007 Apr 2. [http://ascopubs.org/doi/full/10.1200/JCO.2006.07.3569 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17404369 PubMed]
# Lu C, Lee JJ, Komaki R, Herbst RS, Feng L, Evans WK, Choy H, Desjardins P, Esparaz BT, Truong MT, Saxman S, Kelaghan J, Bleyer A, Fisch MJ. Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial. J Natl Cancer Inst. 2010 Jun 16;102(12):859-65. Epub 2010 May 26. [https://academic.oup.com/jnci/article/102/12/859/2568981 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2902826/ link to PMC article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20505152 PubMed]
# '''WJTOG0105:''' Yamamoto N, Nakagawa K, Nishimura Y, Tsujino K, Satouchi M, Kudo S, Hida T, Kawahara M, Takeda K, Katakami N, Sawa T, Yokota S, Seto T, Imamura F, Saka H, Iwamoto Y, Semba H, Chiba Y, Uejima H, Fukuoka M. Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105. J Clin Oncol. 2010 Aug 10;28(23):3739-45. Epub 2010 Jul 12. [http://ascopubs.org/doi/full/10.1200/JCO.2009.24.5050 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20625120 PubMed]
# '''ECOG 3598:''' Hoang T, Dahlberg SE, Schiller JH, Mehta MP, Fitzgerald TJ, Belinsky SA, Johnson DH. Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: the ECOG 3598 study. J Clin Oncol. 2012 Feb 20;30(6):616-22. Epub 2012 Jan 23. [http://ascopubs.org/doi/full/10.1200/JCO.2011.36.9116 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3295560/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22271472 PubMed]
# '''RTOG 0617:''' Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, Bogart J, Hu C, Forster K, Magliocco A, Kavadi V, Garces YI, Narayan S, Iyengar P, Robinson C, Wynn RB, Koprowski C, Meng J, Beitler J, Gaur R, Curran W Jr, Choy H. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015 Feb;16(2):187-99. Epub 2015 Jan 16. '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4419359/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25601342 PubMed]
## '''Dataset:''' [https://www.projectdatasphere.org/projectdatasphere/html/content/236 Project Data Sphere]
<!-- Note: This study was previously oral presented as: 15th World Conference on Lung Cancer, Sydney, 27–30 October 2013. -->
# Liang J, Bi N, Wu S, Chen M, Lv C, Zhao L, Shi A, Jiang W, Xu Y, Zhou Z, Wang W, Chen D, Hui Z, Lv J, Zhang H, Feng Q, Xiao Z, Wang X, Liu L, Zhang T, Du L, Chen W, Shyr Y, Yin W, Li J, He J, Wang L. Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial. Ann Oncol. 2017 Apr 1;28(4):777-783. [https://academic.oup.com/annonc/article-lookup/doi/10.1093/annonc/mdx009 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28137739 PubMed]

==Carboplatin, Vinorelbine, RT {{#subobject:c9edfa|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:a0fcb6|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3776981/ Strøm et al. 2013]
|style="background-color:#1a9851"|Phase III (E)
|[[#Carboplatin_.26_Vinorelbine|Carboplatin & Vinorelbine]]
| style="background-color:#1a9850" |Superior OS
|-
|}
====Chemoradiotherapy====
*[[Carboplatin (Paraplatin)]]
*[[Vinorelbine (Navelbine)]]
*Concurrent [[External_beam_radiotherapy|radiation therapy]]

===References===
# Strøm HH, Bremnes RM, Sundstrøm SH, Helbekkmo N, Fløtten O, Aasebø U. Concurrent palliative chemoradiation leads to survival and quality of life benefits in poor prognosis stage III non-small-cell lung cancer: a randomised trial by the Norwegian Lung Cancer Study Group. Br J Cancer. 2013 Sep 17;109(6):1467-75. Epub 2013 Aug 20. [https://www.nature.com/articles/bjc2013466 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3776981/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23963145 PubMed]

==Carboplatin & RT {{#subobject:f563a8|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
RT: '''<u>R</u>'''adiation '''<u>T</u>'''herapy
===Regimen {{#subobject:6b0bae|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70139-0/fulltext Atagi et al. 2012 (JCOG0301)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Radiation_therapy|RT]]
|style="background-color:#91cf60"|Seems to have superior OS
|-
|}
====Chemoradiotherapy====
*[[Carboplatin (Paraplatin)]] 30 mg/m<sup>2</sup> IV once per day on days 1 to 5, 8 to 12, 15 to 19, 22 to 26
*Concurrent [[External_beam_radiotherapy|radiation therapy]]: 60 Gy, details not available in abstract

===References===
# '''JCOG0301:''' Atagi S, Kawahara M, Yokoyama A, Okamoto H, Yamamoto N, Ohe Y, Sawa T, Ishikura S, Shibata T, Fukuda H, Saijo N, Tamura T; Japan Clinical Oncology Group Lung Cancer Study Group. Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301). Lancet Oncol. 2012 Jul;13(7):671-8. Epub 2012 May 22. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70139-0/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22622008 PubMed]

==Cisplatin & RT {{#subobject:e6b41e|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
RT: '''<u>R</u>'''adiation '''<u>T</u>'''herapy
===Regimen {{#subobject:6b0bae|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[https://www.nejm.org/doi/full/10.1056/NEJM199202203260805 Schaake-Koning et al. 1992]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. Cisplatin & RT (weekly dosing)
| style="background-color:#ffffbf" |Seems not superior
|-
|2. [[#Radiation_therapy|RT]]
| style="background-color:#1a9850" |Superior OS
|-
|}
====Chemoradiotherapy====
*[[Cisplatin (Platinol)]] 6 mg/m<sup>2</sup> IV once per day on days of radiation
*Concurrent [[External_beam_radiotherapy|radiation therapy]] as follows:
**Weeks 1 & 2: 3 Gy fractions, five fractions per week
**Weeks 3 to 5: no radiation
**Weeks 6 & 7: 2.5 Gy fractions, five fractions per week

'''7-week course'''
===References===
# Schaake-Koning C, van den Bogaert W, Dalesio O, Festen J, Hoogenhout J, van Houtte P, Kirkpatrick A, Koolen M, Maat B, Nijs A, Renaud A, Rodrigus P, Schuster-Uitterhoeve L, Sculier JP, van Zandwijk N, Bartelink H. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med. 1992 Feb 20;326(8):524-30. [https://www.nejm.org/doi/full/10.1056/NEJM199202203260805 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/1310160 PubMed]

==Cisplatin, Docetaxel, RT {{#subobject:6d901b|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
RT: '''<u>R</u>'''adiation '''<u>T</u>'''herapy
===Variant #1, 20/20 {{#subobject:fdef61|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2014.60.0130 Ahn et al. 2015 (KCSG-LU05-04)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
|-
|}
''In this trial, no benefit was observed to giving post-definitive consolidation.''
====Chemoradiotherapy====
*[[Cisplatin (Platinol)]] 20 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22, 29, 36
*[[Docetaxel (Taxotere)]] 20 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22, 29, 36
*Concurrent [[External_beam_radiotherapy|radiation therapy]], 2.00 Gy fractions x 33 fractions (total dose: 66 Gy), given 5 days per week, started on day 1

'''One course'''
====Subsequent treatment====
*Cisplatin & Docetaxel consolidation versus no further treatment

===Variant #2, 40/40 {{#subobject:6a7064|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2009.24.7577 Segawa et al. 2010 (OLCSG 0007)]
| style="background-color:#1a9851" |Phase III (E)
|MVP & RT
| style="background-color:#d9ef8b" |Might have superior OS
|-
|}
====Chemoradiotherapy====
*[[Cisplatin (Platinol)]] 40 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Docetaxel (Taxotere)]] 40 mg/m<sup>2</sup> IV once per day on days 1 & 8
*Concurrent [[External_beam_radiotherapy|radiation therapy]]

'''28-day cycle for 2 cycles'''
===References===
# '''OLCSG 0007:''' Segawa Y, Kiura K, Takigawa N, Kamei H, Harita S, Hiraki S, Watanabe Y, Sugimoto K, Shibayama T, Yonei T, Ueoka H, Takemoto M, Kanazawa S, Takata I, Nogami N, Hotta K, Hiraki A, Tabata M, Matsuo K, Tanimoto M. Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007. J Clin Oncol. 2010 Jul 10;28(20):3299-306. Epub 2010 Jun 7. [http://ascopubs.org/doi/full/10.1200/JCO.2009.24.7577 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20530281 PubMed]
# '''KCSG-LU05-04:''' Ahn JS, Ahn YC, Kim JH, Lee CG, Cho EK, Lee KC, Chen M, Kim DW, Kim HK, Min YJ, Kang JH, Choi JH, Kim SW, Zhu G, Wu YL, Kim SR, Lee KH, Song HS, Choi YL, Sun JM, Jung SH, Ahn MJ, Park K. Multinational randomized phase III trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage III non-small-cell lung cancer: KCSG-LU05-04. J Clin Oncol. 2015 Aug 20;33(24):2660-6. Epub 2015 Jul 6. [http://ascopubs.org/doi/full/10.1200/JCO.2014.60.0130 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26150444 PubMed]

==Cisplatin, Etoposide, RT {{#subobject:743aa8|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
EP & RT: '''<u>E</u>'''toposide, '''<u>P</u>'''latinol (Cisplatin), '''<u>R</u>'''adiation '''<u>T</u>'''herapy
===Variant #1, 45 Gy with response-adapted treatment {{#subobject:dcb6c1|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/20/16/3454.long Albain et al. 2002 (SWOG 9019)]
|style="background-color:#91cf61"|Phase II
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407808/ Albain et al. 2009 (RTOG 93-09)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|}
====Chemoradiotherapy====
*[[Cisplatin (Platinol)]] 50 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Etoposide (Vepesid)]] 50 mg/m<sup>2</sup> IV once per day on days 1 to 5
*Concurrent [[External_beam_radiotherapy|radiation therapy]], 1.80 Gy fractions x 25 fractions (total dose: 45 Gy), given 5 days per week, to start within 24 hours of cycle 1 day 1

'''28-day cycle for 2 cycles''' 
====Subsequent treatment====
*SWOG 9019: Patients were re-imaged with CT scan (bone scan and head imaging were only done if patients had new symptoms), and those without progression or new metastatic disease received an additional 2.00 Gy per day x 8 fractions for a total of 61 Gy administered overall
*RTOG 93-09: Additional radiation to 61 Gy, then [[#Cisplatin_.26_Etoposide_2|cisplatin & etoposide consolidation]] versus surgery, then [[#Cisplatin_.26_Etoposide_2|cisplatin & etoposide consolidation]]

===Variant #2, 60 to 66 Gy {{#subobject:426dfc|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2007.14.4824 Kelly et al. 2008 (SWOG S0023)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2008.17.7840 Hanna et al. 2008 (HOG Lun 01-24)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2015.64.8824 Senan et al. 2016 (PROCLAIM)]
|style="background-color:#1a9851"|Phase III (C)
|Cisplatin, Pemetrexed, RT, then Pemetrexed consolidation
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://academic.oup.com/annonc/article-lookup/doi/10.1093/annonc/mdx009 Liang et al. 2017]
|style="background-color:#1a9851"|Phase III (C)
|[[#Carboplatin.2C_Paclitaxel.2C_RT|PC & RT]]
|style="background-color:#d9ef8b"|Might have superior OS
|-
|}
====Chemoradiotherapy====
*[[Cisplatin (Platinol)]] 50 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Etoposide (Vepesid)]] 50 mg/m<sup>2</sup> IV once per day on days 1 to 5
*Concurrent [[External_beam_radiotherapy|radiation therapy]], 1.80 to 2.00 Gy fractions x 30 to 33 fractions (total dose: 60 to 66 Gy), given 5 days per week, started on cycle 1 day 1

'''28-day cycle for 2 cycles'''
====Subsequent treatment====
*SWOG S0023: Docetaxel x 3, then gefitinib versus [[#Placebo|placebo]]
*HOG Lun 01-24: Docetexal consolidation versus [[#Observation_2|observation]]
*PROCLAIM: Investigator's choice of: [[#Carboplatin_.26_Paclitaxel|Carboplatin & Paclitaxel]] or [[#Cisplatin_.26_Etoposide_2|Cisplatin & Etoposide]] or [[#Cisplatin_.26_Vinorelbine_2|Cisplatin & Vinorelbine]] consolidation
*Liang et al. 2017: Optional consolidation chemotherapy

===Variant #3, 66 Gy, split cisplatin {{#subobject:f35aaa|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2005.03.070 Fournel et al. 2005 (NPC 95-01)]
|style="background-color:#1a9851"|Phase III (E)
|Cisplatin & Vinorelbine, then [[#Radiation_therapy|RT]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''Note: this is an experimental arm that did not meet its primary endpoint; included here because it was eventually used to establish this regimen as a standard comparator.''
====Chemoradiotherapy====
*[[Cisplatin (Platinol)]] 20 mg/m<sup>2</sup> IV once per day on days 1 to 5
*[[Etoposide (Vepesid)]] 50 mg/m<sup>2</sup> IV once per day on days 1 to 5
*Concurrent [[External_beam_radiotherapy|radiation therapy]], 2.00 Gy fractions x 33 fractions (total dose: 66 Gy), given 5 days per week, started on cycle 1 day 1

'''28-day cycle for 2 cycles'''
====Subsequent treatment====
*[[#Cisplatin_.26_Vinorelbine_2|Cisplatin & Vinorelbine consolidation]]

===Variant #4, 69.6 Gy (hyperfractionated) {{#subobject:3ea5c6|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3186782/ Curran et al. 2011 (RTOG 9410)]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. [[#Cisplatin.2C_Vinblastine.2C_RT|Cisplatin, Vinblastine, RT]]
|style="background-color:#ffffbf"|Seems not superior
|-
|2. [[#Cisplatin_.26_Vinblastine_2|Cisplatin & Vinblastine]], then [[#Radiation_therapy|RT]]
|style="background-color:#d9ef8b"|Might have superior OS
|-
|}
====Chemoradiotherapy====
*[[Cisplatin (Platinol)]] 50 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Etoposide (Vepesid)]] 50 mg PO twice per day on days 1 to 5, 8 to 12
*Concurrent [[External_beam_radiotherapy|radiation therapy]], 1.20 Gy fractions (total dose: 69.6 Gy), given twice per day for 5 days per week, starting on cycle 1 day 1

'''28-day cycle for 2 cycles'''
===References===
# '''SWOG 9019:''' Albain KS, Crowley JJ, Turrisi AT 3rd, Gandara DR, Farrar WB, Clark JI, Beasley KR, Livingston RB. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. J Clin Oncol. 2002 Aug 15;20(16):3454-60. [http://jco.ascopubs.org/content/20/16/3454.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12177106 PubMed]
# '''NPC 95-01:''' Fournel P, Robinet G, Thomas P, Souquet PJ, Léna H, Vergnenégre A, Delhoume JY, Le Treut J, Silvani JA, Dansin E, Bozonnat MC, Daurés JP, Mornex F, Pérol M; Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Français de Pneumo-Cancérologie. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Français de Pneumo-Cancérologie NPC 95-01 Study. J Clin Oncol. 2005 Sep 1;23(25):5910-7. Epub 2005 Aug 8. [http://ascopubs.org/doi/full/10.1200/JCO.2005.03.070 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16087956/ PubMed]
# '''SWOG S0023:''' Kelly K, Chansky K, Gaspar LE, Albain KS, Jett J, Ung YC, Lau DH, Crowley JJ, Gandara DR. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol. 2008 May 20;26(15):2450-6. Epub 2008 Mar 31. [http://ascopubs.org/doi/full/10.1200/JCO.2007.14.4824 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18378568 PubMed]
# '''HOG Lun 01-24:''' Hanna N, Neubauer M, Yiannoutsos C, McGarry R, Arseneau J, Ansari R, Reynolds C, Govindan R, Melnyk A, Fisher W, Richards D, Bruetman D, Anderson T, Chowhan N, Nattam S, Mantravadi P, Johnson C, Breen T, White A, Einhorn L; Hoosier Oncology Group; US Oncology. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol. 2008 Dec 10;26(35):5755-60. Epub 2008 Nov 10. [http://ascopubs.org/doi/full/10.1200/JCO.2008.17.7840 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19001323 PubMed]
# '''RTOG 93-09:''' Albain KS, Swann RS, Rusch VW, Turrisi AT 3rd, Shepherd FA, Smith C, Chen Y, Livingston RB, Feins RH, Gandara DR, Fry WA, Darling G, Johnson DH, Green MR, Miller RC, Ley J, Sause WT, Cox JD. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet. 2009 Aug 1;374(9687):379-86. Epub 2009 Jul 24. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)60737-6/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407808/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/19632716 PubMed]
# '''RTOG 9410:''' Curran WJ Jr, Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S, Movsas B, Wasserman T, Rosenthal SA, Gore E, Machtay M, Sause W, Cox JD. Sequential vs concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst. 2011 Oct 5;103(19):1452-60. Epub 2011 Sep 8. Erratum in: J Natl Cancer Inst. 2012;104(1):79. [http://jnci.oxfordjournals.org/content/103/19/1452.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3186782/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21903745 PubMed]
# '''PROCLAIM:''' Senan S, Brade A, Wang LH, Vansteenkiste J, Dakhil S, Biesma B, Martinez Aguillo M, Aerts J, Govindan R, Rubio-Viqueira B, Lewanski C, Gandara D, Choy H, Mok T, Hossain A, Iscoe N, Treat J, Koustenis A, San Antonio B, Chouaki N, Vokes E. PROCLAIM: randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2016 Mar 20;34(9):953-62. Epub 2016 Jan 25. [http://ascopubs.org/doi/full/10.1200/JCO.2015.64.8824 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26811519 PubMed]
## '''Dataset:''' [https://www.projectdatasphere.org/projectdatasphere/html/content/148 Project Data Sphere]
# Liang J, Bi N, Wu S, Chen M, Lv C, Zhao L, Shi A, Jiang W, Xu Y, Zhou Z, Wang W, Chen D, Hui Z, Lv J, Zhang H, Feng Q, Xiao Z, Wang X, Liu L, Zhang T, Du L, Chen W, Shyr Y, Yin W, Li J, He J, Wang L. Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial. Ann Oncol. 2017 Apr 1;28(4):777-783. [https://academic.oup.com/annonc/article-lookup/doi/10.1093/annonc/mdx009 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28137739 PubMed]

==Cisplatin, Vinblastine, RT {{#subobject:54c5c4|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:c057fe|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3186782/ Curran et al. 2011 (RTOG 9410)]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. [[#Cisplatin.2C_Etoposide.2C_RT|Cisplatin, Etoposide, RT]]
|style="background-color:#ffffbf"|Seems not superior
|-
|2. [[#Cisplatin_.26_Vinblastine_2|Cisplatin & Vinblastine]], then [[#Radiation_therapy|RT]]
|style="background-color:#91cf60"|Seems to have superior OS
|-
|}
====Chemoradiotherapy====
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV once per day on days 1 & 29
*[[Vinblastine (Velban)]] 5 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22, 29
*Concurrent [[External_beam_radiotherapy|radiation therapy]]

'''5-week course of chemotherapy'''

===References===
# '''RTOG 9410:''' Curran WJ Jr, Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S, Movsas B, Wasserman T, Rosenthal SA, Gore E, Machtay M, Sause W, Cox JD. Sequential vs concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst. 2011 Oct 5;103(19):1452-60. Epub 2011 Sep 8. Erratum in: J Natl Cancer Inst. 2012;104(1):79. [http://jnci.oxfordjournals.org/content/103/19/1452.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3186782/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21903745 PubMed]

==Radiation therapy {{#subobject:6a90fb|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
RT:  '''<u>R</u>'''adiation '''<u>T</u>'''herapy
===Variant #1, 45 Gy + 18 Gy boost (63 Gy total) {{#subobject:5d7861|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/23/25/5883.long Belani et al. 2005 (LAMP)]
|style="background-color:#91cf61"|Phase II
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3186782/ Curran et al. 2011 (RTOG 9410)]
|style="background-color:#1a9851"|Phase III (C)
|[[Complex_multipart_regimens#RTOG_9410|See link]]
|[[Complex_multipart_regimens#RTOG_9410|See link]]
|-
|}
====Preceding treatment====
*LAMP: [[#Carboplatin_.26_Paclitaxel_2|Carboplatin & Paclitaxel]] x 2
*RTOG 9410: [[#Cisplatin_.26_Vinblastine_2|Cisplatin & Vinblastine]] x 5 wk
====Radiotherapy====
*[[External beam radiotherapy]] 45 Gy in 1.80 Gy fractions x 25 fractions, given once per day 5 days per week, then 18 Gy boost in 2.00 Gy fractions x 9 fractions, given once per day 5 days per week. 

'''7-week course'''

===Variant #2, 60 Gy {{#subobject:12f326|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.1999.17.1.4 Clamon et al. 1999]
|style="background-color:#1a9851"|Phase III (C)
|[[#Carboplatin_.26_RT|Carboplatin & RT]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.redjournal.org/article/S0360-3016(01)02797-3/fulltext Bradley et al. 2002 (RTOG 93-04)]
|style="background-color:#1a9851"|Phase III (C)
|Beta-interferon & RT
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://academic.oup.com/annonc/article/15/3/427/211654 Groen et al. 2004]
|style="background-color:#1a9851"|Phase III (C)
|[[#Carboplatin_.26_RT|Carboplatin & RT]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70139-0/fulltext Atagi et al. 2012 (JCOG0301)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Carboplatin_.26_RT|Carboplatin & RT]]
|style="background-color:#fc8d59"|Seems to have inferior OS
|-
|}
====Preceding treatment====
*Clamon et al. 1999: [[#Cisplatin_.26_Vinblastine_2|Cisplatin & Vinblastine]] x 5 wk
====Radiotherapy====
*[[External beam radiotherapy]] 60 Gy

'''One course'''
===References===
# Clamon G, Herndon J, Cooper R, Chang AY, Rosenman J, Green MR. Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group. J Clin Oncol. 1999 Jan;17(1):4-11. [http://ascopubs.org/doi/full/10.1200/JCO.1999.17.1.4 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/10458211 PubMed]
# '''RTOG 93-04:''' Bradley JD, Scott CB, Paris KJ, Demas WF, Machtay M, Komaki R, Movsas B, Rubin P, Sause WT. A phase III comparison of radiation therapy with or without recombinant beta-interferon for poor-risk patients with locally advanced non-small-cell lung cancer (RTOG 93-04). Int J Radiat Oncol Biol Phys. 2002 Apr 1;52(5):1173-9. [https://www.redjournal.org/article/S0360-3016(01)02797-3/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11955727 PubMed]
# Groen HJ, van der Leest AH, Fokkema E, Timmer PR, Nossent GD, Smit WJ, Nabers J, Hoekstra HJ, Hermans J, Otter R, van Putten JW, de Vries EG, Mulder NH. Continuously infused carboplatin used as radiosensitizer in locally unresectable non-small-cell lung cancer: a multicenter phase III study. Ann Oncol. 2004 Mar;15(3):427-32. [https://academic.oup.com/annonc/article/15/3/427/211654 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/14998844 PubMed]
# '''LAMP:''' Belani CP, Choy H, Bonomi P, Scott C, Travis P, Haluschak J, Curran WJ Jr. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol. 2005 Sep 1;23(25):5883-91. [http://jco.ascopubs.org/content/23/25/5883.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16087941 PubMed]
# '''RTOG 9410:''' Curran WJ Jr, Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S, Movsas B, Wasserman T, Rosenthal SA, Gore E, Machtay M, Sause W, Cox JD. Sequential vs concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst. 2011 Oct 5;103(19):1452-60. Epub 2011 Sep 8. Erratum in: J Natl Cancer Inst. 2012;104(1):79. [http://jnci.oxfordjournals.org/content/103/19/1452.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3186782/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21903745 PubMed]
# '''JCOG0301:''' Atagi S, Kawahara M, Yokoyama A, Okamoto H, Yamamoto N, Ohe Y, Sawa T, Ishikura S, Shibata T, Fukuda H, Saijo N, Tamura T; Japan Clinical Oncology Group Lung Cancer Study Group. Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301). Lancet Oncol. 2012 Jul;13(7):671-8. Epub 2012 May 22. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70139-0/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22622008 PubMed]

=Consolidation or maintenance after definitive therapy for inoperable disease=

==Carboplatin & Paclitaxel {{#subobject:81d5a7|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:d729a8|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/23/25/5883.long Belani et al. 2005 (LAMP)]
|style="background-color:#91cf61"|Phase II
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4419359/ Bradley et al. 2015 (RTOG 0617)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2015.64.8824 Senan et al. 2016 (PROCLAIM)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|}
====Preceding treatment====
*LAMP and RTOG 0617: [[#Carboplatin.2C_Paclitaxel.2C_RT|Carboplatin, Paclitaxel, RT]]
*PROCLAIM: [[#Cisplatin.2C_Etoposide.2C_RT|Cisplatin, Etoposide, RT]]
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 6 IV over 30 minutes once on day 1, '''given second'''
*[[Paclitaxel (Taxol)]] 200 mg/m<sup>2</sup> IV over 3 hours once on day 1, '''given first'''

'''21-day cycle for 2 cycles'''

===References===
# '''LAMP:''' Belani CP, Choy H, Bonomi P, Scott C, Travis P, Haluschak J, Curran WJ Jr. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol. 2005 Sep 1;23(25):5883-91. [http://jco.ascopubs.org/content/23/25/5883.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16087941 PubMed]
# '''RTOG 0617:''' Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, Bogart J, Hu C, Forster K, Magliocco A, Kavadi V, Garces YI, Narayan S, Iyengar P, Robinson C, Wynn RB, Koprowski C, Meng J, Beitler J, Gaur R, Curran W Jr, Choy H. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015 Feb;16(2):187-99. Epub 2015 Jan 16. '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4419359/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25601342 PubMed]
## '''Dataset:''' [https://www.projectdatasphere.org/projectdatasphere/html/content/272 Project Data Sphere]
# '''PROCLAIM:''' Senan S, Brade A, Wang LH, Vansteenkiste J, Dakhil S, Biesma B, Martinez Aguillo M, Aerts J, Govindan R, Rubio-Viqueira B, Lewanski C, Gandara D, Choy H, Mok T, Hossain A, Iscoe N, Treat J, Koustenis A, San Antonio B, Chouaki N, Vokes E. PROCLAIM: randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2016 Mar 20;34(9):953-62. Epub 2016 Jan 25. [http://ascopubs.org/doi/full/10.1200/JCO.2015.64.8824 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26811519 PubMed]
## '''Dataset:''' [https://www.projectdatasphere.org/projectdatasphere/html/content/148 Project Data Sphere]

==Cisplatin & Etoposide {{#subobject:816959|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:f4cbd2|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2015.64.8824 Senan et al. 2016 (PROCLAIM)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|}
====Preceding treatment====
*[[#Cisplatin.2C_Etoposide.2C_RT|Cisplatin, Etoposide, RT]]
====Chemotherapy====
*[[Cisplatin (Platinol)]] 50 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Etoposide (Vepesid)]] 50 mg/m<sup>2</sup> IV once per day on days 1 to 5

'''28-day cycle for 2 cycles'''

===References===
# '''PROCLAIM:''' Senan S, Brade A, Wang LH, Vansteenkiste J, Dakhil S, Biesma B, Martinez Aguillo M, Aerts J, Govindan R, Rubio-Viqueira B, Lewanski C, Gandara D, Choy H, Mok T, Hossain A, Iscoe N, Treat J, Koustenis A, San Antonio B, Chouaki N, Vokes E. PROCLAIM: randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2016 Mar 20;34(9):953-62. Epub 2016 Jan 25. [http://ascopubs.org/doi/full/10.1200/JCO.2015.64.8824 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26811519 PubMed]
## '''Dataset:''' [https://www.projectdatasphere.org/projectdatasphere/html/content/148 Project Data Sphere]

==Cisplatin & Vinorelbine {{#subobject:ea6875|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:56f466|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2015.64.8824 Senan et al. 2016 (PROCLAIM)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|}
====Preceding treatment====
*[[#Cisplatin.2C_Etoposide.2C_RT|Cisplatin, Etoposide, RT]]
====Chemotherapy====
*[[Cisplatin (Platinol)]] (dose not specified) mg/m<sup>2</sup> IV once on day 1
*[[Vinorelbine (Navelbine)]] 30 mg/m<sup>2</sup> IV once per day on days 1 & 8

'''21-day cycle for 2 cycles'''

===References===
# '''PROCLAIM:''' Senan S, Brade A, Wang LH, Vansteenkiste J, Dakhil S, Biesma B, Martinez Aguillo M, Aerts J, Govindan R, Rubio-Viqueira B, Lewanski C, Gandara D, Choy H, Mok T, Hossain A, Iscoe N, Treat J, Koustenis A, San Antonio B, Chouaki N, Vokes E. PROCLAIM: randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2016 Mar 20;34(9):953-62. Epub 2016 Jan 25. [http://ascopubs.org/doi/full/10.1200/JCO.2015.64.8824 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26811519 PubMed]
## '''Dataset:''' [https://www.projectdatasphere.org/projectdatasphere/html/content/148 Project Data Sphere]

==Durvalumab monotherapy {{#subobject:6f72e5|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:04242b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1709937 Antonia et al. 2017 (PACIFIC)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Placebo|Placebo]]
|style="background-color:#1a9850"|Superior OS (*)
|-
|}
''Note: reported efficacy is based on the 2018 update.''
====Preceding treatment====
*"Two or more cycles (defined according to local practice) of platinum-based chemotherapy (containing etoposide, vinblastine, vinorelbine, a taxane [paclitaxel or docetaxel], or pemetrexed) concurrently with definitive radiation therapy (54 to 66 Gy), in which the mean dose to the lung was less than 20 Gy, the V20 (the volume of lung parenchyma that received 20 Gy or more) was less than 35%, or both."
====Immunotherapy====
*[[Durvalumab (Imfinzi)]] 10 mg/kg IV once every 2 weeks

'''Up to 12-month course'''
===References===
# '''PACIFIC:''' Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Wadsworth C, Melillo G, Jiang H, Huang Y, Dennis PA, Özgüroğlu M; PACIFIC Investigators. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017 Nov 16;377(20):1919-1929. Epub 2017 Sep 8. [https://www.nejm.org/doi/full/10.1056/NEJMoa1709937 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28885881 PubMed]
## '''Update:''' Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Faivre-Finn C, Reck M, Vansteenkiste J, Spigel DR, Wadsworth C, Melillo G, Taboada M, Dennis PA, Özgüroğlu M; PACIFIC Investigators. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018 Sep 25. [Epub ahead of print] [https://www.nejm.org/doi/full/10.1056/NEJMoa1709937 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/30280658 PubMed]

==Placebo==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2007.14.4824 Kelly et al. 2008 (SWOG S0023)]
|style="background-color:#1a9851"|Phase III (C)
|Gefitinib
| style="background-color:#91cf60" |Seems to have superior OS
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70510-2/fulltext Butts et al. 2013 (START)]
|style="background-color:#1a9851"|Phase III (C)
|Tecemotide
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1709937 Antonia et al. 2017 (PACIFIC)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Durvalumab_monotherapy|Durvalumab]]
|style="background-color:#d73027"|Inferior OS (*)
|-
|}
''Note: reported efficacy for PACIFIC is based on the 2018 update. No further antineoplastic treatment.''
====Preceding treatment====
*SWOG S0023: [[#Cisplatin.2C_Etoposide.2C_RT|Cisplatin, Etoposide, RT]], then Docetaxel x 3
*START: Chemoradiotherapy (type not specified in protocol)
*PACIFIC: "Two or more cycles (defined according to local practice) of platinum-based chemotherapy (containing etoposide, vinblastine, vinorelbine, a taxane [paclitaxel or docetaxel], or pemetrexed) concurrently with definitive radiation therapy (54 to 66 Gy), in which the mean dose to the lung was less than 20 Gy, the V20 (the volume of lung parenchyma that received 20 Gy or more) was less than 35%, or both."

===References===
# '''SWOG S0023:''' Kelly K, Chansky K, Gaspar LE, Albain KS, Jett J, Ung YC, Lau DH, Crowley JJ, Gandara DR. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol. 2008 May 20;26(15):2450-6. Epub 2008 Mar 31. [http://ascopubs.org/doi/full/10.1200/JCO.2007.14.4824 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18378568 PubMed]
# '''START:''' Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, Nawrocki S, Ciuleanu TE, Bosquée L, Trigo JM, Spira A, Tremblay L, Nyman J, Ramlau R, Wickart-Johansson G, Ellis P, Gladkov O, Rodrigues Pereira J, Eberhardt WE, Helwig C, Schröder A, Shepherd FA; START trial team. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2014 Jan;15(1):59-68. Epub 2013 Dec 9. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70510-2/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/24331154 PubMed]
## '''Update:''' Mitchell P, Thatcher N, Socinski MA, Wasilewska-Tesluk E, Horwood K, Szczesna A, Martín C, Ragulin Y, Zukin M, Helwig C, Falk M, Butts C, Shepherd FA. Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses. Ann Oncol. 2015 Jun;26(6):1134-42. Epub 2015 Feb 26. [https://academic.oup.com/annonc/article/26/6/1134/161561 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25722382 PubMed]
## '''Dataset:''' [https://www.projectdatasphere.org/projectdatasphere/html/content/145 Project Data Sphere]
# '''PACIFIC:''' Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Wadsworth C, Melillo G, Jiang H, Huang Y, Dennis PA, Özgüroğlu M; PACIFIC Investigators. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017 Nov 16;377(20):1919-1929. Epub 2017 Sep 8. [https://www.nejm.org/doi/full/10.1056/NEJMoa1709937 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28885881 PubMed]
## '''Update:''' Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Faivre-Finn C, Reck M, Vansteenkiste J, Spigel DR, Wadsworth C, Melillo G, Taboada M, Dennis PA, Özgüroğlu M; PACIFIC Investigators. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018 Sep 25. [Epub ahead of print] [https://www.nejm.org/doi/full/10.1056/NEJMoa1709937 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/30280658 PubMed]

==Observation==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(76)90213-0/fulltext Pines 1976]
|style="background-color:#1a9851"|Randomized (C)
|BCG
| style="background-color:#fc8d59" |Seems to have inferior OS
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2008.17.7840 Hanna et al. 2008 (HOG Lun 01-24)]
|style="background-color:#1a9851"|Phase III (C)
|Docetaxel
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3056462/ Gore et al. 2010 (RTOG 0214)]
|style="background-color:#1a9851"|Phase III (C)
|Prophylactic cranial irradiation
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.clinical-lung-cancer.com/article/S1525-7304(11)00247-6/fulltext Carter et al. 2011]
|style="background-color:#1a9851"|Phase III (C)
|Paclitaxel
| style="background-color:#d9ef8b" |Might have superior OS
|-
|[https://academic.oup.com/annonc/article/26/3/504/223363 Li et al. 2014]
|style="background-color:#1a9851"|Phase III (C)
|Prophylactic cranial irradiation
| style="background-color:#fc8d59" |Seems to have inferior DFS
|-
|[https://link.springer.com/article/10.1007%2Fs00066-016-0941-8 Flentje et al. 2016 (GILT)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Cisplatin_.26_Vinorelbine_2|Cisplatin & Vinorelbine]]
|style="background-color:#ffffbf"|Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2017.77.5817 de Ruysscher et al. 2018 (NVALT-11/DLCRG-02)]
|style="background-color:#1a9851"|Phase III (C)
|Prophylactic cranial irradiation
| style="background-color:#d73027" |Inferior time to symptomatic CNS metastases
|-
|}
''No further treatment.''
====Preceding treatment====
*HOG Lun 01-24: [[#Cisplatin.2C_Etoposide.2C_RT|EP & RT]]
*GILT: Cisplatin, Vinorelbine, RT
*NVALT-11/DLCRG-02: Definitive therapy
===References===
# Pines A. A 5-year controlled study of BCG and radiotherapy inoperable lung cancer. Lancet. 1976 Feb 21;1(7956):380-1. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(76)90213-0/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/55647 PubMed]
# '''HOG Lun 01-24:''' Hanna N, Neubauer M, Yiannoutsos C, McGarry R, Arseneau J, Ansari R, Reynolds C, Govindan R, Melnyk A, Fisher W, Richards D, Bruetman D, Anderson T, Chowhan N, Nattam S, Mantravadi P, Johnson C, Breen T, White A, Einhorn L; Hoosier Oncology Group; US Oncology. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol. 2008 Dec 10;26(35):5755-60. Epub 2008 Nov 10. [http://ascopubs.org/doi/full/10.1200/JCO.2008.17.7840 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19001323 PubMed]
# '''RTOG 0214:''' Gore EM, Bae K, Wong SJ, Sun A, Bonner JA, Schild SE, Gaspar LE, Bogart JA, Werner-Wasik M, Choy H. Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small-cell lung cancer: primary analysis of radiation therapy oncology group study RTOG 0214. J Clin Oncol. 2011 Jan 20;29(3):272-8. Epub 2010 Dec 6. Erratum in: J Clin Oncol. 2011 Aug 10;29(23):3204. [http://ascopubs.org/doi/full/10.1200/JCO.2010.29.1609 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3056462/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21135270 PubMed]
# Carter DL, Garfield D, Hathorn J, Mundis R, Boehm KA, Ilegbodu D, Asmar L, Reynolds C. A randomized phase III trial of combined paclitaxel, carboplatin, and radiation therapy followed by weekly paclitaxel or observation for patients with locally advanced inoperable non-small-cell lung cancer. Clin Lung Cancer. 2012 May;13(3):205-13. Epub 2011 Dec 3. [https://www.clinical-lung-cancer.com/article/S1525-7304(11)00247-6/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22138037 PubMed]
# Li N, Zeng ZF, Wang SY, Ou W, Ye X, Li J, He XH, Zhang BB, Yang H, Sun HB, Fang Q, Wang BX. Randomized phase III trial of prophylactic cranial irradiation versus observation in patients with fully resected stage IIIA-N2 nonsmall-cell lung cancer and high risk of cerebral metastases after adjuvant chemotherapy. Ann Oncol. 2015 Mar;26(3):504-9. Epub 2014 Dec 15. [https://academic.oup.com/annonc/article/26/3/504/223363 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25515658 PubMed]
# '''GILT:''' Flentje M, Huber RM, Engel-Riedel W, Andreas S, Kollmeier J, Staar S, Dickgreber N, Vaissiere N, De Almeida C, Edlich B, Fietkau R. GILT--A randomised phase III study of oral vinorelbine and cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral vinorelbine and cisplatin or best supportive care alone in stage III non-small cell lung cancer. Strahlenther Onkol. 2016 Apr;192(4):216-22. Epub 2016 Jan 25. [https://link.springer.com/article/10.1007%2Fs00066-016-0941-8 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26809652 PubMed]
# '''NVALT-11/DLCRG-02:''' De Ruysscher D, Dingemans AC, Praag J, Belderbos J, Tissing-Tan C, Herder J, Haitjema T, Ubbels F, Lagerwaard F, El Sharouni SY, Stigt JA, Smit E, van Tinteren H, van der Noort V, Groen HJM. Prophylactic cranial irradiation versus observation in radically treated stage III non-small-cell lung cancer: a randomized phase III NVALT-11/DLCRG-02 study. J Clin Oncol. 2018 Aug 10;36(23):2366-2377. Epub 2018 May 22. [http://ascopubs.org/doi/full/10.1200/JCO.2017.77.5817 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/29787357 PubMed]

=Advanced or metastatic disease, first-line=

==Carboplatin & Docetaxel {{#subobject:bdce59|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
DCb: '''<u>D</u>'''ocetaxel & '''<u>C</u>'''ar'''<u>b</u>'''oplatin
===Regimen {{#subobject:bce236|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[http://jco.ascopubs.org/content/21/16/3016.long Fossella et al. 2003 (TAX 326)]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. [[#Cisplatin_.26_Docetaxel_3|Cisplatin & Docetaxel]]
|style="background-color:#d3d3d3"|Not reported
|-
|2. [[#Cisplatin_.26_Vinorelbine_3|Cisplatin & Vinorelbine]]
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://academic.oup.com/annonc/article/17/7/1111/212924 Booton et al. 2006 (BTOG1)]
|style="background-color:#1a9851"|Phase III (E)
|1. [[Non-small_cell_lung_cancer_-_historical#MIC_3|MIC]]<br> 2. [[Non-small_cell_lung_cancer_-_historical#MVP_.28Vinblastine.29|MVP]]
|style="background-color:#ffffbf"|Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2009.21.9618 Lynch et al. 2010 (BMS099)]
|style="background-color:#1a9851"|Phase III (C)
|Carboplatin, Docetaxel, Cetuximab
|style="background-color:#ffffbf"|Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2011.35.5214 Groen et al. 2011 (NVALT-4)]
|style="background-color:#1a9851"|Phase III (C)
|Carboplatin, Docetaxel, Celecoxib
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70393-X/fulltext Rossell et al. 2012 (EURTAC)]
|style="background-color:#1a9851"|Phase III (C)
|[[Non-small_cell_lung_cancer,_EGFR-mutated#Erlotinib_monotherapy|Erlotinib]]
|style="background-color:#d73027"|Inferior PFS
|-
|}
''Note: Patients in EURTAC had EGFR exon 19 deletion or p.L858R mutation in exon 21.''
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 6 IV once on day 1
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for up to 5 cycles (NVALT-4), 6 cycles (BMS099), or indefinitely'''

===References===
<!-- Previously presented in part at the Annual Meeting of the American Society of Clinical Oncology (ASCO), San Francisco, CA, May 12–15, 2001; the Annual Meeting of ASCO, Orlando, FL, May 18–21, 2002; and the Congress of the European Society for Medical Oncology, Nice, France, October 18–22, 2002. -->
# '''TAX 326:''' Fossella F, Rodrigues Pereira J, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, Mattson KV, Ramlau R, Szczesna A, Fidias P, Millward M, Belani CP. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol. 2003 Aug 15;21(16):3016-24. Epub 2003 Jul 1. [http://jco.ascopubs.org/content/21/16/3016.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12837811 PubMed]
# '''BTOG1:''' Booton R, Lorigan P, Anderson H, Baka S, Ashcroft L, Nicolson M, O'Brien M, Dunlop D, O'Byrne K, Laurence V, Snee M, Dark G, Thatcher N. A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1). Ann Oncol. 2006 Jul;17(7):1111-9. Epub 2006 Apr 7. [https://academic.oup.com/annonc/article/17/7/1111/212924 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16603599 PubMed]
# '''BMS099:''' Lynch TJ, Patel T, Dreisbach L, McCleod M, Heim WJ, Hermann RC, Paschold E, Iannotti NO, Dakhil S, Gorton S, Pautret V, Weber MR, Woytowitz D. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol. 2010 Feb 20;28(6):911-7. Epub 2010 Jan 25. [http://ascopubs.org/doi/full/10.1200/JCO.2009.21.9618 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20100966 PubMed]
<!-- Presented in part at the 45th Annual Meeting of the American Society of Clinical Oncology, May 29-June 2, 2009, Orlando, FL. -->
# '''NVALT-4:''' Groen HJ, Sietsma H, Vincent A, Hochstenbag MM, van Putten JW, van den Berg A, Dalesio O, Biesma B, Smit HJ, Termeer A, Hiltermann TJ, van den Borne BE, Schramel FM. Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study. J Clin Oncol. 2011 Nov 10;29(32):4320-6. Epub 2011 Oct 11. [http://ascopubs.org/doi/full/10.1200/JCO.2011.35.5214 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/21990410 PubMed]
# '''EURTAC:''' Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012 Mar;13(3):239-46. Epub 2012 Jan 26. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70393-X/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22285168 PubMed]

==Carboplatin & Etoposide {{#subobject:4c2ff5|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:f920ac|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.1990.8.9.1556 Klastersky et al. 1990 (EORTC 07861)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Cisplatin_.26_Etoposide_3|Cisplatin & Etoposide]]
|style="background-color:#fee08b"|Might have inferior ORR
|-
|}
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] 325 mg/m<sup>2</sup> IV over 60 minutes once on day 1
*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV once per day on days 1 to 3

'''3- to 4-week cycles'''

===References===
# '''EORTC 07861:''' Klastersky J, Sculier JP, Lacroix H, Dabouis G, Bureau G, Libert P, Richez M, Ravez P, Vandermoten G, Thiriaux J, Cordier R, Finet C, Berchier MC, Sergysels R, Mommen P, Paesmans M. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861. J Clin Oncol. 1990 Sep;8(9):1556-62. [http://ascopubs.org/doi/full/10.1200/JCO.1990.8.9.1556 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/2167953 PubMed]

==Carboplatin & Gemcitabine {{#subobject:8669e|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
GC: '''<u>G</u>'''emcitabine & '''<u>C</u>'''arboplatin
<br>GCa: '''<u>G</u>'''emcitabine & '''<u>Ca</u>'''rboplatin
<br>GCb: '''<u>G</u>'''emcitabine & '''<u>C</u>'''ar'''<u>b</u>'''oplatin
===Variant #1, 4/1000 {{#subobject:fa3601|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360329/ Helbekkmo et al. 2007]
|style="background-color:#1a9851"|Phase III (E)
|[[#Carboplatin_.26_Vinorelbine|VC]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''Note: AUC was calculated using the Chatelut formula.''
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 4 IV once on day 1
*[[Gemcitabine (Gemzar)]] 1000 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1 & 8

'''21-day cycle for 3 cycles'''

===Variant #2, 5/1000 q3wk {{#subobject:cfb199|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/27/19/3217.long Grønberg et al. 2009]
|style="background-color:#1a9851"|Phase III (C)
|[[#Carboplatin_.26_Pemetrexed|Carboplatin & Pemetrexed]]
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70184-X/fulltext Zhou et al. 2011 (OPTIMAL)]
|style="background-color:#1a9851"|Phase III (C)
|[[Non-small_cell_lung_cancer,_EGFR-mutated#Erlotinib_monotherapy|Erlotinib]]
|style="background-color:#d73027"|Inferior PFS
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70393-X/fulltext Rossell et al. 2012 (EURTAC)]
|style="background-color:#1a9851"|Phase III (C)
|[[Non-small_cell_lung_cancer,_EGFR-mutated#Erlotinib_monotherapy|Erlotinib]]
|style="background-color:#d73027"|Inferior PFS
|-
|}
''Patients in OPTIMAL were EGFR mutation positive; patients in EURTAC had EGFR exon 19 deletion or p.L858R mutation in exon 21. It is unclear from the abstract how many cycles of therapy were given in EURTAC.''
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 5 IV once on day 1
*[[Gemcitabine (Gemzar)]] 1000 mg/m<sup>2</sup> IV once per day on days 1 & 8

'''21-day cycle for up to 4 cycles'''

===Variant #3, 5/1000 q4wk {{#subobject:82e4e7|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1002/cncr.11535/abstract Danson et al. 2003]
|style="background-color:#1a9851"|Phase III (E)
|1. [[Non-small_cell_lung_cancer_-_historical#MIC_3|MIC]]<br> 2. [[Non-small_cell_lung_cancer_-_historical#MVP_.28Vinblastine.29|MVP]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''Note: this is an experimental arm that did not meet its primary endpoint; included here because other variants of this regimen have demonstrated comparative superiority.''
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 5 IV once on day 1
*[[Gemcitabine (Gemzar)]] 1000 mg/m<sup>2</sup> IV once per day on days 1, 8, 15

'''28-day cycle for 4 cycles'''

===Variant #4, 5/1200 {{#subobject:58b47e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.lungcancerjournal.info/article/S0169-5002(03)00233-2/fulltext Zatloukal et al. 2003]
|style="background-color:#1a9851"|Phase III (E)
|[[#Cisplatin_.26_Gemcitabine_3|Cisplatin & Gemcitabine]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2005.03.037 Rudd et al. 2005]
|style="background-color:#1a9851"|Phase III (E)
|[[Non-small_cell_lung_cancer_-_historical#MIC_3|MIC]]
| style="background-color:#1a9850" |Superior OS
|-
|}
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 5 IV once on day 1
*[[Gemcitabine (Gemzar)]] 1200 mg/m<sup>2</sup> IV once per day on days 1 & 8

'''21-day cycle for up to 6 cycles'''

===Variant #5, 5/1250 q3wk {{#subobject:4bca29|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 20%"|Study
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 20%"|Comparator
!style="width: 20%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
!style="width: 20%"|[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[http://jco.ascopubs.org/content/23/33/8380.full Sederholm et al. 2005]
|style="background-color:#1a9851"|Phase III (C)
|Gemcitabine
|style="background-color:#91cf60"|Seems to have superior OS
|
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1606774 Reck et al. 2016 (KEYNOTE-024)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Pembrolizumab_monotherapy|Pembrolizumab]]
|style="background-color:#d73027"|Inferior OS
|style="background-color:#d73027"|Inferior HRQoL
|-
|}
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 5 IV once on day 1
*[[Gemcitabine (Gemzar)]] 1250 mg/m<sup>2</sup> IV once per day on days 1 & 8

'''21-day cycle for 4 to 6 cycles'''

===Variant #6, 5/1250 q4wk {{#subobject:7e79d9|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70254-7/fulltext Wu et al. 2013 (FASTACT-2)]
|style="background-color:#1a9851"|Phase III (C)
|[[Non-small_cell_lung_cancer,_EGFR-mutated#Carboplatin_.26_Gemcitabine.2FErlotinib|Carboplatin & Gemcitabine/Erlotinib]]
|style="background-color:#fc8d59"|Seems to have inferior OS
|-
|}
''Note: this cohort was enriched for EGFR mutations and only those patients with an activating EGFR gene mutation were noted to have a treatment benefit in favor of the experimental arm.'' 
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 5 IV once on day 1
*[[Gemcitabine (Gemzar)]] 1250 mg/m<sup>2</sup> IV once per day on days 1 & 8

'''28-day cycle for 4 cycles'''

===Variant #7, 6/1000 {{#subobject:c7aefa|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://academic.oup.com/annonc/article/19/1/115/180390 Kosmidis et al. 2007]
|style="background-color:#1a9851"|Phase III (C)
|Gemcitabine & Paclitaxel
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 6 IV once on day 1
*[[Gemcitabine (Gemzar)]] 1000 mg/m<sup>2</sup> IV once per day on days 1 & 8

'''21-day cycles'''

===Variant #8, 6/1250 ("GCb6") {{#subobject:afcfd9|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 20%"|Study
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 20%"|Comparator
!style="width: 20%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
!style="width: 20%"|[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1606774 Reck et al. 2016 (KEYNOTE-024)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Pembrolizumab_monotherapy|Pembrolizumab]]
|style="background-color:#d73027"|Inferior OS
|style="background-color:#d73027"|Inferior HRQoL
|-
|rowspan=2|[https://www.ejcancer.com/article/S0959-8049(17)31001-8/fulltext Ferry et al. 2017 (BTOG2)]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. GC50
|style="background-color:#91cf60"|Seems to have superior OS
|
|-
|2. [[#Cisplatin_.26_Gemcitabine_3|GC80]]
|style="background-color:#eeee01"|Non-inferior OS
|
|-
|}
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 6 IV once on day 1
*[[Gemcitabine (Gemzar)]] 1250 mg/m<sup>2</sup> IV once per day on days 1 & 8

'''21-day cycle for 4 to 6 cycles'''

===Variant #9, 300/1000 {{#subobject:9c94c9|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.lungcancerjournal.info/article/S0169-5002(01)00493-7/fulltext Grigorescu et al. 2002]
|style="background-color:#1a9851"|Phase III (E)
|[[Non-small_cell_lung_cancer_-_historical#Cisplatin_.26_Vinblastine|Cisplatin & Vinblastine]]
| style="background-color:#1a9850" |Superior OS
|-
|}
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] 300 mg/m<sup>2</sup> IV once on day 1
*[[Gemcitabine (Gemzar)]] 1000 mg/m<sup>2</sup> IV once per day on days 1 & 8

'''21-day cycles'''

===References===
# Grigorescu AC, Draghici IN, Nitipir C, Gutulescu N, Corlan E. Gemcitabine (GEM) and carboplatin (CBDCA) versus cisplatin (CDDP) and vinblastine (VLB) in advanced non-small-cell lung cancer (NSCLC) stages III and IV: a phase III randomised trial. Lung Cancer. 2002 Jul;37(1):9-14. [https://www.lungcancerjournal.info/article/S0169-5002(01)00493-7/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12057861 PubMed]
# Danson S, Middleton MR, O'Byrne KJ, Clemons M, Ranson M, Hassan J, Anderson H, Burt PA, Fairve-Finn C, Stout R, Dowd I, Ashcroft L, Beresford C, Thatcher N. Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma. Cancer. 2003 Aug 1;98(3):542-53. [https://onlinelibrary.wiley.com/doi/10.1002/cncr.11535/abstract link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12879472 PubMed]
# Zatloukal P, Petruzelka L, Zemanová M, Kolek V, Skricková J, Pesek M, Fojtů H, Grygárková I, Sixtová D, Roubec J, Horenková E, Havel L, Průsa P, Nováková L, Skácel T, Kůta M. Gemcitabine plus cisplatin vs gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial. Lung Cancer. 2003 Sep;41(3):321-31. [https://www.lungcancerjournal.info/article/S0169-5002(03)00233-2/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12928123 PubMed]
# Rudd RM, Gower NH, Spiro SG, Eisen TG, Harper PG, Littler JA, Hatton M, Johnson PW, Martin WM, Rankin EM, James LE, Gregory WM, Qian W, Lee SM. Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group. J Clin Oncol. 2005 Jan 1;23(1):142-53. [http://ascopubs.org/doi/full/10.1200/JCO.2005.03.037 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15625369 PubMed]
# Sederholm C, Hillerdal G, Lamberg K, Kölbeck K, Dufmats M, Westberg R, Gawande SR. Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group. J Clin Oncol. 2005 Nov 20;23(33):8380-8. [http://jco.ascopubs.org/content/23/33/8380.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16293868 PubMed]
# Helbekkmo N, Sundstrøm SH, Aasebø U, Brunsvig PF, von Plessen C, Hjelde HH, Garpestad OK, Bailey A, Bremnes RM; Norwegian Lung Cancer Study Group. Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity. Br J Cancer. 2007 Aug 6;97(3):283-9. Epub 2007 Jun 26. [https://www.nature.com/articles/6603869 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360329/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17595658 PubMed]
# Kosmidis PA, Kalofonos HP, Christodoulou C, Syrigos K, Makatsoris T, Skarlos D, Bakogiannis C, Nicolaides C, Bafaloukos D, Bamias A, Samantas E, Xiros N, Boukovinas I, Fountzilas G, Dimopoulos MA. Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer: a phase III study of the Hellenic Cooperative Oncology Group. Ann Oncol. 2008 Jan;19(1):115-22. Epub 2007 Oct 15. [https://academic.oup.com/annonc/article/19/1/115/180390 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17938425 PubMed]
<!-- Presented in part at the 43rd Annual Meeting of the American Society of Clinical Oncology, June 1-5, 2007, Chicago, IL; and the International Association for the Study of Lung Cancer 12th World Conference on Lung Cancer, September 2-6, 2007, Seoul, Korea. -->
# Grønberg BH, Bremnes RM, Fløtten O, Amundsen T, Brunsvig PF, Hjelde HH, Kaasa S, von Plessen C, Stornes F, Tollåli T, Wammer F, Aasebø U, Sundstrøm S. Phase III study by the Norwegian Lung Cancer Study Group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2009 Jul 1;27(19):3217-24. Epub 2009 May 11. [http://jco.ascopubs.org/content/27/19/3217.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19433683 PubMed]
# '''ALPHA A1-99002L:''' Treat JA, Gonin R, Socinski MA, Edelman MJ, Catalano RB, Marinucci DM, Ansari R, Gillenwater HH, Rowland KM, Comis RL, Obasaju CK, Belani CP; Alpha Oncology Research Network. A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer. Ann Oncol. 2010 Mar;21(3):540-7. Epub 2009 Oct 15. [https://academic.oup.com/annonc/article/21/3/540/166861 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19833819 PubMed]
# '''OPTIMAL:''' Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L, You C. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011 Aug;12(8):735-42. Epub 2011 Jul 23. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70184-X/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/21783417 PubMed]
## '''Update:''' Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L, You C. Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802). Ann Oncol. 2015 Sep;26(9):1877-83. Epub 2015 Jul 3. [https://academic.oup.com/annonc/article-lookup/doi/10.1093/annonc/mdv276 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26141208 PubMed]
# '''EURTAC:''' Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012 Mar;13(3):239-46. Epub 2012 Jan 26. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70393-X/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22285168 PubMed]
# '''FASTACT-2:''' Wu YL, Lee JS, Thongprasert S, Yu CJ, Zhang L, Ladrera G, Srimuninnimit V, Sriuranpong V, Sandoval-Tan J, Zhu Y, Liao M, Zhou C, Pan H, Lee V, Chen YM, Sun Y, Margono B, Fuerte F, Chang GC, Seetalarom K, Wang J, Cheng A, Syahruddin E, Qian X, Ho J, Kurnianda J, Liu HE, Jin K, Truman M, Bara I, Mok T. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial. Lancet Oncol. 2013 Jul;14(8):777-86. Epub 2013 Jun 17. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70254-7/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23782814 PubMed]
# '''KEYNOTE-024:''' Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Leiby MA, Lubiniecki GM, Shentu Y, Rangwala R, Brahmer JR; KEYNOTE-024 Investigators. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016 Nov 10;375(19):1823-1833. Epub 2016 Oct 8. [https://www.nejm.org/doi/full/10.1056/NEJMoa1606774 link to original article] [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1606774/suppl_file/nejmoa1606774_appendix.pdf link to supplementary appendix] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27718847 PubMed]
## '''HRQoL analysis:''' Brahmer JR, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Zhang J, Lubiniecki GM, Deitz AC, Rangwala R, Reck M. Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. Lancet Oncol. 2017 Dec;18(12):1600-1609. Epub 2017 Nov 9. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30690-3/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/29129441 PubMed]
# Ferry D, Billingham L, Jarrett H, Dunlop D, Woll PJ, Nicolson M, Shah R, Thompson J, Spicer J, Muthukumar D, Skailes G, Leonard P, Chetiyawardana AD, Wells P, Lewanski C, Crosse B, Hill M, Gaunt P, O'Byrne K. Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: Results from a British Thoracic Oncology Group randomised phase III trial. Eur J Cancer. 2017 Sep;83:302-312. Epub 2017 Aug 4. [https://www.ejcancer.com/article/S0959-8049(17)31001-8/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28780466 PubMed]

==Carboplatin & Paclitaxel {{#subobject:c5fbdf|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CP: '''<u>C</u>'''arboplatin & '''<u>P</u>'''aclitaxel
<br>PC: '''<u>P</u>'''aclitaxel & '''<u>C</u>'''arboplatin
<br>TC: '''<u>T</u>'''axol (Paclitaxel) & '''<u>C</u>'''arboplatin
===Variant #1, 5/200 {{#subobject:5g4ff1|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 20%"|Study
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 20%"|Comparator
!style="width: 20%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
!style="width: 20%"|[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa0810699 Mok et al. 2009 (IPASS)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Gefitinib_monotherapy|Gefitinib]]
|style="background-color:#d73027"|Inferior PFS
|
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1606774 Reck et al. 2016 (KEYNOTE-024)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Pembrolizumab_monotherapy|Pembrolizumab]]
|style="background-color:#d73027"|Inferior OS
|style="background-color:#d73027"|Inferior HRQoL
|-
|}
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 5 IV over 15 to 60 minutes once on day 1, '''given second'''
*[[Paclitaxel (Taxol)]] 200 mg/m<sup>2</sup> IV over 3 hours once on day 1, '''given first'''

'''21-day cycle for 4 to 6 cycles'''
====Subsequent treatment====
*KEYNOTE-024: Patients with nonsquamous histology could optionally proceed to [[#Pemetrexed_monotherapy_2|pemetrexed switch maintenance]]

===Variant #2, 6/175 {{#subobject:e3545d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://academic.oup.com/annonc/article/15/7/1048/244873 Stathopoulos et al. 2004]
|style="background-color:#1a9851"|Phase III (C)
|Paclitaxel & Vinorelbine
|style="background-color:#ffffbf"|Seems not superior
|-
|[http://jco.ascopubs.org/content/30/17/2046.long Lynch et al. 2012]
|style="background-color:#1a9851"|Randomized Phase II (C)
|[[#Carboplatin.2C_Paclitaxel.2C_Ipilimumab|CP & Ipilimumab]]
|style="background-color:#fc8d59"|Seems to have inferior PFS
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2016.71.7629 Govindan et al. 2017 (CA184-104)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Carboplatin.2C_Paclitaxel.2C_Ipilimumab|CP & Ipilimumab]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 6 IV once on day 1
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV once on day 1 

====Supportive medications====
*[[:Category:Steroids|Corticosteroids]] could be used as premedication for [[Paclitaxel (Taxol)]] infusion.

'''21-day cycle for up to 6 cycles'''

===Variant #3, 6/200 {{#subobject:5f5ff1|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 20%"|Study
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 20%"|Comparator
!style="width: 20%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
!style="width: 20%"|[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2002.20.5.1335 Socinski et al. 2002]
|style="background-color:#1a9851"|Phase III (E)
|Indefinite CP
|style="background-color:#ffffbf"|Seems not superior
|
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2002.12.112 Kosmidis et al. 2002]
|style="background-color:#1a9851"|Phase III (E)
|Gemcitabine & Paclitaxel
|style="background-color:#ffffbf"|Seems not superior
|
|-
|[https://academic.oup.com/annonc/article/13/10/1539/168019 Rosell et al. 2002]
|style="background-color:#1a9851"|Phase III (E)
|[[#Cisplatin_.26_Paclitaxel|Cisplatin & Paclitaxel]]
| style="background-color:#fc8d59" |Seems to have inferior OS
|
|-
|[http://jco.ascopubs.org/content/22/11/2184.full Johnson et al. 2004]
|style="background-color:#1a9851"|Randomized Phase II (C)
|[[#Carboplatin.2C_Paclitaxel.2C_Bevacizumab|PacCBev]]
|style="background-color:#fc8d59"|Seems to have inferior TTP
|
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2005.04.044 Leighl et al. 2005 (NCIC CTG BR.18)]
|style="background-color:#1a9851"|Phase III (C)
|CP & BMS-275291
|style="background-color:#ffffbf"|Seems not superior
| style="background-color:#1a9850" |Less toxic
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2005.02.840 Herbst et al. 2005 (TRIBUTE)]
|style="background-color:#1a9851"|Phase III (C)
|CP & Erlotinib
|style="background-color:#ffffbf"|Seems not superior
|
|-
|[https://www.clinical-lung-cancer.com/article/S1525-7304(11)70705-7/pdf Schuette et al. 2006]
|style="background-color:#1a9851"|Phase III (C)
|Weekly CP
|style="background-color:#ffffbf"|Seems not superior
|style="background-color:#ffffbf"|Mixed toxicity
|-
|rowspan=3|[https://academic.oup.com/annonc/article-lookup/doi/10.1093/annonc/mdl377 Ohe et al. 2006]
|rowspan=3 style="background-color:#1a9851"|Phase III (E)
|1. [[#Cisplatin_.26_Gemcitabine_3|Cisplatin & Gemcitabine]]
|style="background-color:#ffffbf"|Seems not superior
|
|-
|2. [[#Cisplatin_.26_Irinotecan|Cisplatin & Irinotecan]]
|style="background-color:#ffffbf"|Seems not superior
|
|-
|3. [[#Cisplatin_.26_Vinorelbine_3|Cisplatin & Vinorelbine]]
|style="background-color:#ffffbf"|Seems not superior
|
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2007.12.2689 Blumenschein et al. 2008 (SPIRIT II)]
|style="background-color:#1a9851"|Phase III (C)
|CP & Bexarotene
|style="background-color:#ffffbf"|Seems not superior
|
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2009.26.1321 Scagliotti et al. 2010 (ESCAPE)]
|style="background-color:#1a9851"|Phase III (C)
|CP & Sorafenib
|style="background-color:#ffffbf"|Seems not superior
|
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa0909530 Maemondo et al. 2010 (NEJ002)]
|style="background-color:#1a9851"|Phase III (C)
|[[Non-small_cell_lung_cancer,_EGFR-mutated#Gefitinib_monotherapy_2|Gefitinib]]
|style="background-color:#d73027"|Inferior PFS
|
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2010.31.0326 Okamoto et al. 2010 (LETS)]
|style="background-color:#1a9851"|Phase III (C)
|Carboplatin & S-1
| style="background-color:#eeee01" |Non-inferior OS
|
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2010.32.8971 Hirsh et al. 2011]
|style="background-color:#1a9851"|Phase III (C)
|CP & Agatolimod
|style="background-color:#ffffbf"|Seems not superior
|
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2011.35.0660 Lara et al. 2011]
|style="background-color:#1a9851"|Phase III (C)
|CP & Vadimezan
|style="background-color:#ffffbf"|Seems not superior
|
|-
|[http://jco.ascopubs.org/content/30/17/2055.long Socinski et al. 2012 (CA031)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Carboplatin_.26_nab-Paclitaxel|Carboplatin & nab-Paclitaxel]]
|style="background-color:#d73027"|Inferior ORR
|
|-
|[https://www.ejcancer.com/article/S0959-8049(13)01028-9/fulltext Laurie et al. 2013 (NCIC CTG BR.29)]
|style="background-color:#1a9851"|Phase III (C)
|CP & Cediranib
|style="background-color:#ffffbf"|Seems not superior
| style="background-color:#1a9850" |Less toxic
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4067944/ Langer et al. 2014]
|style="background-color:#1a9851"|Phase III (C)
|CP & Figitumumab
|style="background-color:#d9ef8b"|Might have superior OS
|
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1606774 Reck et al. 2016 (KEYNOTE-024)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Pembrolizumab_monotherapy|Pembrolizumab]]
|style="background-color:#d73027"|Inferior OS
|style="background-color:#d73027"|Inferior HRQoL
|-
|[http://clincancerres.aacrjournals.org/content/23/8/1937.full Ramalingam et al. 2016]
|style="background-color:#1a9851"|Randomized Phase II (C)
|CP & Veliparib
|style="background-color:#ffffbf"|Seems not superior
|
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30694-0/fulltext Herbst et al. 2017 (SWOG S0819)]
|style="background-color:#1a9851"|Phase III (C)
|CP & Cetuximab
|style="background-color:#ffffbf"|Seems not superior
|
|-
|}
''Note: Patients in TRIBUTE received a maximum of 6 cycles. Patients in SWOG S0819 were EGFR FISH positive.''
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 6 IV over 15 to 60 minutes once on day 1, '''given second'''
*[[Paclitaxel (Taxol)]] 200 mg/m<sup>2</sup> IV over 3 hours once on day 1, '''given first'''

'''21-day cycle for 3 or more cycles'''
====Subsequent treatment====
*Socinski et al. 2002, upon progression: Paclitaxel
*KEYNOTE-024: Patients with nonsquamous histology could optionally proceed, after 4 to 6 cycles, to [[#Pemetrexed_monotherapy_2|pemetrexed switch maintenance]]

===Variant #4, 6/225 {{#subobject:847441|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2001.19.13.3210 Kelly et al. 2001 (SWOG 9509)]
|style="background-color:#1a9851"|Phase III (E)
|Cisplatin & Vinorelbine
|style="background-color:#ffffbf"|Seems not superior
|-
|rowspan=3|[https://www.nejm.org/doi/full/10.1056/NEJMoa011954 Schiller et al. 2002 (ECOG E1594)]
|rowspan=3 style="background-color:#1a9851"|Phase III (E)
|1. [[#Cisplatin_.26_Docetaxel_3|Cisplatin & Docetaxel]]
|style="background-color:#ffffbf"|Seems not superior
|-
|2. [[#Cisplatin_.26_Gemcitabine_3|Cisplatin & Gemcitabine]]
|style="background-color:#ffffbf"|Seems not superior
|-
|3. [[#Cisplatin_.26_Paclitaxel|Cisplatin & Paclitaxel]]
|style="background-color:#ffffbf"|Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2004.07.215 Herbst et al. 2004 (INTACT 2)]
|style="background-color:#1a9851"|Phase III (C)
|CP & Gefitinib
|style="background-color:#ffffbf"|Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2005.07.172 Lilenbaum et al. 2005 (CALGB 9730)]
|style="background-color:#1a9851"|Phase III (E)
|Paclitaxel
|style="background-color:#1a9850"|Superior FFS
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2005.01.3771 Williamson et al. 2005 (SWOG S0003)]
|style="background-color:#1a9851"|Phase III (C)
|CP & Tirapazamine
|style="background-color:#ffffbf"|Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2007.13.1912 Belani et al. 2008]
|style="background-color:#1a9851"|Phase III (C)
|CP, weekly paclitaxel
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(08)70261-4/fulltext Kubota et al. 2008 (JMTO LC00-03)]
|style="background-color:#1a9851"|Phase III (C)
|Gemcitabine & Vinorelbine, then Docetaxel
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://academic.oup.com/annonc/article/21/3/540/166861 Treat et al. 2009 (ALPHA A1-99002L)]
|style="background-color:#1a9851"|Phase III (C)
|1. [[#Carboplatin_.26_Gemcitabine|Carboplatin & Gemcitabine]]<br> 2. Gemcitabine & Paclitaxel
|style="background-color:#ffffbf"|Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2009.21.9618 Lynch et al. 2010 (BMS099)]
|style="background-color:#1a9851"|Phase III (C)
|CP & Cetuximab
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.jto.org/article/S1556-0864(15)31941-9/fulltext Weissman et al. 2011]
|style="background-color:#1a9851"|Phase III (C)
|GEMOX
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 6 IV once on day 1, '''given second'''
*[[Paclitaxel (Taxol)]] 225 mg/m<sup>2</sup> IV over 3 hours once on day 1, '''given first'''

'''21-day cycle for up to 4 cycles (Belani et al. 2008), 6 cycles (Weissman et al. 2011), 10 cycles (SWOG 9509), or indefinitely (ECOG E1594)'''
====Subsequent treatment====
*Belani et al. 2008: Paclitaxel maintenance

===References===
# '''SWOG 9509:''' Kelly K, Crowley J, Bunn PA Jr, Presant CA, Grevstad PK, Moinpour CM, Ramsey SD, Wozniak AJ, Weiss GR, Moore DF, Israel VK, Livingston RB, Gandara DR. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol. 2001 Jul 1;19(13):3210-8. [http://ascopubs.org/doi/full/10.1200/JCO.2001.19.13.3210 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11432888 PubMed]
# '''ECOG E1594:''' Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002 Jan 10;346(2):92-8. [https://www.nejm.org/doi/full/10.1056/NEJMoa011954 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11784875 PubMed]
# Socinski MA, Schell MJ, Peterman A, Bakri K, Yates S, Gitten R, Unger P, Lee J, Lee JH, Tynan M, Moore M, Kies MS. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol. 2002 Mar 1;20(5):1335-43. [http://ascopubs.org/doi/full/10.1200/JCO.2002.20.5.1335 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11870177 PubMed]
# Kosmidis P, Mylonakis N, Nicolaides C, Kalophonos C, Samantas E, Boukovinas J, Fountzilas G, Skarlos D, Economopoulos T, Tsavdaridis D, Papakostas P, Bacoyiannis C, Dimopoulos M. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol. 2002 Sep 1;20(17):3578-85. [http://ascopubs.org/doi/full/10.1200/JCO.2002.12.112 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12202657 PubMed]
# Rosell R, Gatzemeier U, Betticher DC, Keppler U, Macha HN, Pirker R, Berthet P, Breau JL, Lianes P, Nicholson M, Ardizzoni A, Chemaissani A, Bogaerts J, Gallant G. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol. 2002 Oct;13(10):1539-49. [https://academic.oup.com/annonc/article/13/10/1539/168019 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12377641 PubMed]
# '''INTACT 2:''' Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, Wolf MK, Krebs AD, Averbuch SD, Ochs JS, Grous J, Fandi A, Johnson DH. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. J Clin Oncol. 2004 Mar 1;22(5):785-94. [http://ascopubs.org/doi/full/10.1200/JCO.2004.07.215 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/14990633 PubMed]
# Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF 3rd, Gaudreault J, Damico LA, Holmgren E, Kabbinavar F. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004 Jun 1;22(11):2184-91. [http://jco.ascopubs.org/content/22/11/2184.full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15169807 PubMed]
# Stathopoulos GP, Veslemes M, Georgatou N, Antoniou D, Giamboudakis P, Katis K, Tsavdaridis D, Rigatos SK, Dimitroulis I, Bastani S, Loukides S, Vergos K, Marossis K, Grigoratou T, Kalatzi E, Charalambatou M, Paspalli A, Michalopoulou P, Stoka M, Gerogianni A. Front-line paclitaxel-vinorelbine versus paclitaxel-carboplatin in patients with advanced non-small-cell lung cancer: a randomized phase III trial. Ann Oncol. 2004 Jul;15(7):1048-55. [https://academic.oup.com/annonc/article/15/7/1048/244873 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15205198 PubMed]
# '''CALGB 9730:''' Lilenbaum RC, Herndon JE 2nd, List MA, Desch C, Watson DM, Miller AA, Graziano SL, Perry MC, Saville W, Chahinian P, Weeks JC, Holland JC, Green MR. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the Cancer and Leukemia Group B (study 9730). J Clin Oncol. 2005 Jan 1;23(1):190-6. [http://ascopubs.org/doi/full/10.1200/JCO.2005.07.172 link to original article]'''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15625373 PubMed]
# '''NCIC CTG BR.18:''' Leighl NB, Paz-Ares L, Douillard JY, Peschel C, Arnold A, Depierre A, Santoro A, Betticher DC, Gatzemeier U, Jassem J, Crawford J, Tu D, Bezjak A, Humphrey JS, Voi M, Galbraith S, Hann K, Seymour L, Shepherd FA. Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR18. J Clin Oncol. 2005 Apr 20;23(12):2831-9. [http://ascopubs.org/doi/full/10.1200/JCO.2005.04.044 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15837997 PubMed]
# '''TRIBUTE:''' Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, Kris MG, Tran HT, Klein P, Li X, Ramies D, Johnson DH, Miller VA; TRIBUTE Investigator Group. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2005 Sep 1;23(25):5892-9. Epub 2005 Jul 25. [http://ascopubs.org/doi/full/10.1200/JCO.2005.02.840 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16043829 PubMed]
# '''SWOG S0003:''' Williamson SK, Crowley JJ, Lara PN Jr, McCoy J, Lau DH, Tucker RW, Mills GM, Gandara DR; Southwest Oncology Group Trial S0003. Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003. J Clin Oncol. 2005 Dec 20;23(36):9097-104. [http://ascopubs.org/doi/full/10.1200/JCO.2005.01.3771 link to original article] '''contains protocol'''  [https://www.ncbi.nlm.nih.gov/pubmed/16361616 PubMed]
# Schuette W, Blankenburg T, Guschall W, Dittrich I, Schroeder M, Schweisfurth H, Chemaissani A, Schumann C, Dickgreber N, Appel T, Ukena D. Multicenter randomized trial for stage IIIB/IV non-small-cell lung cancer using every-3-week versus weekly paclitaxel/carboplatin. Clin Lung Cancer. 2006 Mar;7(5):338-43. [https://www.clinical-lung-cancer.com/article/S1525-7304(11)70705-7/pdf link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16640806 PubMed]
# Ohe Y, Ohashi Y, Kubota K, Tamura T, Nakagawa K, Negoro S, Nishiwaki Y, Saijo N, Ariyoshi Y, Fukuoka M. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol. 2007 Feb;18(2):317-23. Epub 2006 Nov 1. [https://academic.oup.com/annonc/article-lookup/doi/10.1093/annonc/mdl377 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17079694 PubMed]
# Belani CP, Ramalingam S, Perry MC, LaRocca RV, Rinaldi D, Gable PS, Tester WJ. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer. J Clin Oncol. 2008 Jan 20;26(3):468-73. [http://ascopubs.org/doi/full/10.1200/JCO.2007.13.1912 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18202422 PubMed]
# '''SPIRIT II:''' Blumenschein GR Jr, Khuri FR, von Pawel J, Gatzemeier U, Miller WH Jr, Jotte RM, Le Treut J, Sun SL, Zhang JK, Dziewanowska ZE, Negro-Vilar A. Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II. J Clin Oncol. 2008 Apr 10;26(11):1879-85. [http://ascopubs.org/doi/full/10.1200/JCO.2007.12.2689 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18398153 PubMed]
# '''JMTO LC00-03:''' Kubota K, Kawahara M, Ogawara M, Nishiwaki Y, Komuta K, Minato K, Fujita Y, Teramukai S, Fukushima M, Furuse K; Japan Multi-National Trial Organisation. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study. Lancet Oncol. 2008 Dec;9(12):1135-42. Epub 2008 Nov 13. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(08)70261-4/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19013107 PubMed]
# '''ALPHA A1-99002L:''' Treat JA, Gonin R, Socinski MA, Edelman MJ, Catalano RB, Marinucci DM, Ansari R, Gillenwater HH, Rowland KM, Comis RL, Obasaju CK, Belani CP; Alpha Oncology Research Network. A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer. Ann Oncol. 2010 Mar;21(3):540-7. Epub 2009 Oct 15. [https://academic.oup.com/annonc/article/21/3/540/166861 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19833819 PubMed]
# '''BMS099:''' Lynch TJ, Patel T, Dreisbach L, McCleod M, Heim WJ, Hermann RC, Paschold E, Iannotti NO, Dakhil S, Gorton S, Pautret V, Weber MR, Woytowitz D. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol. 2010 Feb 20;28(6):911-7. Epub 2010 Jan 25. [http://ascopubs.org/doi/full/10.1200/JCO.2009.21.9618 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20100966 PubMed]
# '''ESCAPE:''' Scagliotti G, Novello S, von Pawel J, Reck M, Rodrigues Pereira J, Thomas M, Abrão Miziara JE, Balint B, De Marinis F, Keller A, Arén O, Csollak M, Albert I, Barrios CH, Grossi F, Krzakowski M, Cupit L, Cihon F, Dimatteo S, Hanna N. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol. 2010 Apr 10;28(11):1835-42. Epub 2010 Mar 8. [http://ascopubs.org/doi/full/10.1200/JCO.2009.26.1321 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20212250 PubMed]
## '''Dataset:''' [https://www.projectdatasphere.org/projectdatasphere/html/content/274 Project Data Sphere]
# '''NEJ002:''' Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T; North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010 Jun 24;362(25):2380-8. [https://www.nejm.org/doi/full/10.1056/NEJMoa0909530 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20573926 PubMed]
## '''HRQoL analysis:''' Oizumi S, Kobayashi K, Inoue A, Maemondo M, Sugawara S, Yoshizawa H, Isobe H, Harada M, Kinoshita I, Okinaga S, Kato T, Harada T, Gemma A, Saijo Y, Yokomizo Y, Morita S, Hagiwara K, Nukiwa T. Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial. Oncologist. 2012;17(6):863-70. Epub 2012 May 11. [http://theoncologist.alphamedpress.org/content/17/6/863.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3380886/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22581822 PubMed]
## '''Update:''' Inoue A, Kobayashi K, Maemondo M, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Saijo Y, Hagiwara K, Morita S, Nukiwa T; North-East Japan Study Group. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol. 2013 Jan;24(1):54-9. Epub 2012 Sep 11. [https://academic.oup.com/annonc/article/24/1/54/1745637 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22967997 PubMed]
# '''LETS:''' Okamoto I, Yoshioka H, Morita S, Ando M, Takeda K, Seto T, Yamamoto N, Saka H, Asami K, Hirashima T, Kudoh S, Satouchi M, Ikeda N, Iwamoto Y, Sawa T, Miyazaki M, Tamura K, Kurata T, Fukuoka M, Nakagawa K. Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: results of a West Japan Oncology Group study. J Clin Oncol. 2010 Dec 20;28(36):5240-6. Epub 2010 Nov 15. [http://ascopubs.org/doi/full/10.1200/JCO.2010.31.0326 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21079147 PubMed]
# Weissman CH, Reynolds CH, Neubauer MA, Pritchard S, Kobina S, Asmar L. A phase III randomized trial of gemcitabine-oxaliplatin versus carboplatin-paclitaxel as first-line therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2011 Feb;6(2):358-64. [https://www.jto.org/article/S1556-0864(15)31941-9/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21206386 PubMed]
<!-- Presented in part at the 44th Annual Meeting of the American Society of Clinical Oncology, May 30-June 3, 2008, Chicago, IL. -->
# Hirsh V, Paz-Ares L, Boyer M, Rosell R, Middleton G, Eberhardt WE, Szczesna A, Reiterer P, Saleh M, Arrieta O, Bajetta E, Webb RT, Raats J, Benner RJ, Fowst C, Meech SJ, Readett D, Schiller JH. Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (Toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol. 2011 Jul 1;29(19):2667-74. Epub 2011 May 31. [http://ascopubs.org/doi/full/10.1200/JCO.2010.32.8971 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21632509 PubMed]
# Lara PN Jr, Douillard JY, Nakagawa K, von Pawel J, McKeage MJ, Albert I, Losonczy G, Reck M, Heo DS, Fan X, Fandi A, Scagliotti G. Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. J Clin Oncol. 2011 Aug 1;29(22):2965-71. Epub 2011 Jun 27. [http://ascopubs.org/doi/full/10.1200/JCO.2011.35.0660 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21709202 PubMed]
<!-- Presented in part at The Chicago Multidisciplinary Symposium in Thoracic Oncology, Chicago, IL, December 9-11, 2010, and the 14th World Congress on Lung Cancer, Amsterdam, the Netherlands, July 3-7, 2011. -->
# Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, Sebastian M, Neal J, Lu H, Cuillerot JM, Reck M. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol. 2012 Jun 10;30(17):2046-54. Epub 2012 Apr 30. [http://jco.ascopubs.org/content/30/17/2046.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22547592 PubMed]
<!-- Presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, IL, June 4-8, 2010; the 47th Annual Meeting of ASCO, Chicago, IL, June 2-7, 2011, and 14th World Conference on Lung Cancer, Amsterdam Rai, the Netherlands, July 3-7, 2011. -->
# '''CA031:''' Socinski MA, Bondarenko I, Karaseva NA, Makhson AM, Vynnychenko I, Okamoto I, Hon JK, Hirsh V, Bhar P, Zhang H, Iglesias JL, Renschler MF. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol. 2012 Jun 10;30(17):2055-62. Epub 2012 Apr 30. [http://jco.ascopubs.org/content/30/17/2055.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22547591 PubMed]
## '''Dataset:''' [https://www.projectdatasphere.org/projectdatasphere/html/content/108 Project Data Sphere]
# '''NCIC CTG BR.29:''' Laurie SA, Solomon BJ, Seymour L, Ellis PM, Goss GD, Shepherd FA, Boyer MJ, Arnold AM, Clingan P, Laberge F, Fenton D, Hirsh V, Zukin M, Stockler MR, Lee CW, Chen EX, Montenegro A, Ding K, Bradbury PA. Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29. Eur J Cancer. 2014 Mar;50(4):706-12. Epub 2013 Dec 17. [https://www.ejcancer.com/article/S0959-8049(13)01028-9/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24360368 PubMed]
<!-- Presented in part at the 46th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 4-8, 2010. -->
# Langer CJ, Novello S, Park K, Krzakowski M, Karp DD, Mok T, Benner RJ, Scranton JR, Olszanski AJ, Jassem J. Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2014 Jul 1;32(19):2059-66. Epub 2014 Jun 2. [http://jco.ascopubs.org/content/32/19/2059.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4067944/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24888810 PubMed]
# '''KEYNOTE-024:''' Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Leiby MA, Lubiniecki GM, Shentu Y, Rangwala R, Brahmer JR; KEYNOTE-024 Investigators. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016 Nov 10;375(19):1823-1833. Epub 2016 Oct 8. [https://www.nejm.org/doi/full/10.1056/NEJMoa1606774 link to original article] [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1606774/suppl_file/nejmoa1606774_appendix.pdf link to supplementary appendix] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27718847 PubMed]
## '''HRQoL analysis:''' Brahmer JR, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Zhang J, Lubiniecki GM, Deitz AC, Rangwala R, Reck M. Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. Lancet Oncol. 2017 Dec;18(12):1600-1609. Epub 2017 Nov 9. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30690-3/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/29129441 PubMed]
# Ramalingam SS, Blais N, Mazieres J, Reck M, Jones CM, Juhasz E, Urban L, Orlov S, Barlesi F, Kio E, Keiholz U, Qin Q, Qian J, Nickner C, Dziubinski J, Xiong H, Ansell P, McKee M, Giranda V, Gorbunova V. Randomized, placebo-controlled, phase II study of veliparib in combination with carboplatin and paclitaxel for advanced/metastatic non-small cell lung cancer. Clin Cancer Res. 2017 Apr 15;23(8):1937-1944. Epub 2016 Oct 10. [http://clincancerres.aacrjournals.org/content/23/8/1937.full link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27803064 PubMed]
# '''SWOG S0819:''' Herbst RS, Redman MW, Kim ES, Semrad TJ, Bazhenova L, Masters G, Oettel K, Guaglianone P, Reynolds C, Karnad A, Arnold SM, Varella-Garcia M, Moon J, Mack PC, Blanke CD, Hirsch FR, Kelly K, Gandara DR. Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study. Lancet Oncol. 2018 Jan;19(1):101-114. Epub 2017 Nov 20. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30694-0/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29169877 PubMed]

==Carboplatin & nab-Paclitaxel {{#subobject:413b7d|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:bcb4af|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/30/17/2055.long Socinski et al. 2012 (CA031)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Carboplatin_.26_Paclitaxel_4|Carboplatin & Paclitaxel]]
|style="background-color:#1a9850"|Superior ORR
|-
|}
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 6 mg/mL/min (per Calvert formula) IV once on day 1, '''given second'''
*[[Paclitaxel, nanoparticle albumin-bound (Abraxane)]] 100 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1, 8, 15, '''given first'''

'''21-day cycle for 6 cycles'''; treatment could continue at physician's discretion if there was no progressive disease or unacceptable toxicity

===References===
# '''CA031:''' Socinski MA, Bondarenko I, Karaseva NA, Makhson AM, Vynnychenko I, Okamoto I, Hon JK, Hirsh V, Bhar P, Zhang H, Iglesias JL, Renschler MF. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol. 2012 Jun 10;30(17):2055-62. Epub 2012 Apr 30. [http://jco.ascopubs.org/content/30/17/2055.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22547591 PubMed]
## '''Dataset:''' [https://www.projectdatasphere.org/projectdatasphere/html/content/108 Project Data Sphere]

==Carboplatin, Paclitaxel, Bevacizumab {{#subobject:1c2c25|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
PacCBev: '''<u>Pac</u>'''litaxel, '''<u>C</u>'''arboplatin, '''<u>Bev</u>'''acizumab 
<br>B+CP: '''<u>B</u>'''evacizumab, '''<u>C</u>'''arboplatin, '''<u>Pac</u>'''litaxel
<br>BCP: '''<u>B</u>'''evacizumab, '''<u>C</u>'''arboplatin, '''<u>Pac</u>'''litaxel
===Regimen {{#subobject:7df5c3|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/22/11/2184.full Johnson et al. 2004]
|style="background-color:#1a9851"|Randomized Phase II (E)
|[[#Carboplatin_.26_Paclitaxel_4|Carboplatin & Paclitaxel]]
|style="background-color:#91cf60"|Seems to have superior TTP
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30694-0/fulltext Herbst et al. 2017 (SWOG S0819)]
|style="background-color:#1a9851"|Phase III (C)
|Carboplatin, Paclitaxel, Bevacizumab, Cetuximab
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''Note: Patients in SWOG S0819 were EGFR FISH positive.''
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 6 IV over 15 to 30 minutes once on day 1, '''given second, starting 60 minutes after the completion of paclitaxel'''
*[[Paclitaxel (Taxol)]] 200 mg/m<sup>2</sup> IV over 3 hours once on day 1, '''given first'''
*[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1, '''given third, starting 60 minutes after the completion of carboplatin'''
**Infusion time per Johnson, et al. 2004 was over 90 minutes for cycle 1; if tolerated, given over 30 to 60 minutes for cycles 2 and later 

'''21-day cycle for up to 6 cycles'''

===References===
# Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF 3rd, Gaudreault J, Damico LA, Holmgren E, Kabbinavar F. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004 Jun 1;22(11):2184-91. [http://jco.ascopubs.org/content/22/11/2184.full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15169807 PubMed]
# '''SWOG S0819:''' Herbst RS, Redman MW, Kim ES, Semrad TJ, Bazhenova L, Masters G, Oettel K, Guaglianone P, Reynolds C, Karnad A, Arnold SM, Varella-Garcia M, Moon J, Mack PC, Blanke CD, Hirsch FR, Kelly K, Gandara DR. Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study. Lancet Oncol. 2018 Jan;19(1):101-114. Epub 2017 Nov 20. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30694-0/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29169877 PubMed]

==Carboplatin, Paclitaxel, Ipilimumab {{#subobject:e8ba81|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:f70cfc|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/30/17/2046.long Lynch et al. 2012]
|style="background-color:#1a9851"|Randomized Phase II (E)
|[[#Carboplatin_.26_Paclitaxel_4|Carboplatin & Paclitaxel]]
|style="background-color:#91cf60"|Seems to have superior PFS
|-
|}
''Note: this is the "phased" approach to this regimen.''
====Chemoimmunotherapy====
*[[Carboplatin (Paraplatin)]] AUC 6 IV once on day 1
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV once on day 1 
*[[Ipilimumab (Yervoy)]] as follows:
**Cycles 3 to 6: 10 mg/kg IV once on day 1

====Supportive medications====
*[[:Category:Steroids|Corticosteroids]] could be used as premedication for [[Paclitaxel (Taxol)]] infusion or for toxicity management.

'''21-day cycle for up to 6 cycles''' 
====Subsequent treatment====
*[[#Ipilimumab_monotherapy|Maintenance ipilimumab]]

===References===
<!-- Presented in part at The Chicago Multidisciplinary Symposium in Thoracic Oncology, Chicago, IL, December 9-11, 2010, and the 14th World Congress on Lung Cancer, Amsterdam, the Netherlands, July 3-7, 2011. -->
# Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, Sebastian M, Neal J, Lu H, Cuillerot JM, Reck M. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol. 2012 Jun 10;30(17):2046-54. Epub 2012 Apr 30. [http://jco.ascopubs.org/content/30/17/2046.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22547592 PubMed]

==Carboplatin & Pemetrexed {{#subobject:920f46|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CP: '''<u>C</u>'''arboplatin & '''<u>P</u>'''emetrexed
<br>Carbo-Pem: '''<u>Carbo</u>'''platin & '''<u>Pem</u>'''etrexed
===Example orders===
*[[Example orders for Carboplatin (Paraplatin) and Pemetrexed (Alimta) in non-small cell lung cancer]]

===Variant #1, 5/500 x 6 {{#subobject:f0cdea|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 20%"|Study
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 20%"|Comparator
!style="width: 20%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
!style="width: 20%"|[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1606774 Reck et al. 2016 (KEYNOTE-024)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Pembrolizumab_monotherapy|Pembrolizumab]]
|style="background-color:#d73027"|Inferior OS
|style="background-color:#d73027"|Inferior HRQoL
|-
|}
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 5 IV over 15 to 60 minutes once on day 1, '''given second'''
*[[Pemetrexed (Alimta)]] 500 mg/m<sup>2</sup> IV over 10 minutes once on day 1, '''given first'''

====Supportive medications====
*(Ardizzoni et al. 2012 contained more details):
*[[Dexamethasone (Decadron)]] 4 mg or [[steroid conversions|equivalent corticosteroid]] PO twice per day on the day before, the day of, and day after each dose of pemetrexed
*Folic acid 350 to 600 mcg PO once per day, starting 1 to 2 weeks before the first dose of pemetrexed, to be taken throughout pemetrexed therapy.
*[[Cyanocobalamin (Vitamin B12)]] 1000 mcg IM once every 9 weeks, first dose 1 to 2 weeks before the first dose of pemetrexed, to be given throughout pemetrexed therapy

'''21-day cycle for up to 6 cycles'''
====Subsequent treatment====
*Optional [[#Pemetrexed_monotherapy_2|pemetrexed maintenance]]

===Variant #2, 6/500 x 4 {{#subobject:ecc998|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/27/19/3217.long Grønberg et al. 2009]
|style="background-color:#1a9851"|Phase III (E)
|[[#Carboplatin_.26_Gemcitabine|Carboplatin & Gemcitabine]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 6 IV over 15 to 60 minutes once on day 1, '''given second'''
*[[Pemetrexed (Alimta)]] 500 mg/m<sup>2</sup> IV over 10 minutes once on day 1, '''given first'''

====Supportive medications====
*(Ardizzoni et al. 2012 contained more details):
*[[Dexamethasone (Decadron)]] 4 mg or [[steroid conversions|equivalent corticosteroid]] PO twice per day on the day before, the day of, and day after each dose of pemetrexed
*Folic acid 350 to 600 mcg PO once per day, starting 1 to 2 weeks before the first dose of pemetrexed, to be taken throughout pemetrexed therapy.
*[[Cyanocobalamin (Vitamin B12)]] 1000 mcg IM once every 9 weeks, first dose 1 to 2 weeks before the first dose of pemetrexed, to be given throughout pemetrexed therapy

'''21-day cycle for up to 4 cycles'''

===Variant #3, 6/500 x 6 {{#subobject:8aad39|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 20%"|Study
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 20%"|Comparator
!style="width: 20%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
!style="width: 20%"|[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1606774 Reck et al. 2016 (KEYNOTE-024)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Pembrolizumab_monotherapy|Pembrolizumab]]
|style="background-color:#d73027"|Inferior OS
|style="background-color:#d73027"|Inferior HRQoL
|-
|}
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 6 IV once on day 1
*[[Pemetrexed (Alimta)]] 500 mg/m<sup>2</sup> IV once on day 1

====Supportive medications====
*[[Cyanocobalamin (Vitamin B12)]] 1000 mcg IM once every 9 weeks, first dose prior to [[Pemetrexed (Alimta)]]
*Folic acid 1 mg PO once per day

'''21-day cycle for up to 6 cycles'''
====Subsequent treatment====
*Optional [[#Pemetrexed_monotherapy_2|pemetrexed maintenance]]

===References===
<!-- Presented in part at the 43rd Annual Meeting of the American Society of Clinical Oncology, June 1-5, 2007, Chicago, IL; and the International Association for the Study of Lung Cancer 12th World Conference on Lung Cancer, September 2-6, 2007, Seoul, Korea. -->
# Grønberg BH, Bremnes RM, Fløtten O, Amundsen T, Brunsvig PF, Hjelde HH, Kaasa S, von Plessen C, Stornes F, Tollåli T, Wammer F, Aasebø U, Sundstrøm S. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2009 Jul 1;27(19):3217-24. Epub 2009 May 11. [http://jco.ascopubs.org/content/27/19/3217.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19433683 PubMed]
# '''KEYNOTE-024:''' Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Leiby MA, Lubiniecki GM, Shentu Y, Rangwala R, Brahmer JR; KEYNOTE-024 Investigators. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016 Nov 10;375(19):1823-1833. Epub 2016 Oct 8. [https://www.nejm.org/doi/full/10.1056/NEJMoa1606774 link to original article] [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1606774/suppl_file/nejmoa1606774_appendix.pdf link to supplementary appendix] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27718847 PubMed]
## '''HRQoL analysis:''' Brahmer JR, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Zhang J, Lubiniecki GM, Deitz AC, Rangwala R, Reck M. Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. Lancet Oncol. 2017 Dec;18(12):1600-1609. Epub 2017 Nov 9. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30690-3/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/29129441 PubMed]

==Carboplatin, Pemetrexed, Pembrolizumab {{#subobject:a3c8c5|Regimen=1}}==
{{#subobject:04328c|Variant=1}}
{{:Carboplatin, Pemetrexed, Pembrolizumab in advanced or metastatic non-small cell lung cancer}}

==Carboplatin & Vinorelbine {{#subobject:e7a434|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
VC: '''<u>V</u>'''inorelbine & '''<u>C</u>'''arboplatin
===Variant #1, IV vinorelbine {{#subobject:a9c41c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://www.lungcancerjournal.info/article/S0169-5002(05)00119-4/fulltext Tan et al. 2005 (GLOB 2)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Gemcitabine_.26_Vinorelbine|Gemcitabine & Vinorelbine]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm.''
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 5 IV once on day 1
*[[Vinorelbine (Navelbine)]] 30 mg/m<sup>2</sup> IV once per day on days 1 & 8 

'''21-day cycle for up to 6 cycles'''

===Variant #2, PO vinorelbine {{#subobject:bd4ba1|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3405221/ Fløtten et al. 2012]
|style="background-color:#1a9851"|Phase III (C)
|[[#Gemcitabine_.26_Vinorelbine|Gemcitabine & Vinorelbine]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm.''
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 5 IV once on day 1
*[[Vinorelbine (Navelbine)]] 60 mg/m<sup>2</sup> PO once per day on days 1 & 8 

'''21-day cycle for 3 cycles'''

===References===
# '''GLOB 2:''' Tan EH, Szczesna A, Krzakowski M, Macha HN, Gatzemeier U, Mattson K, Wernli M, Reiterer P, Hui R, Pawel JV, Bertetto O, Pouget JC, Burillon JP, Parlier Y, Abratt R; GLOB 2 group. Randomized study of vinorelbine--gemcitabine versus vinorelbine--carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer. 2005 Aug;49(2):233-40. [http://www.lungcancerjournal.info/article/S0169-5002(05)00119-4/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16022917 PubMed]
# Fløtten Ø, Grønberg BH, Bremnes R, Amundsen T, Sundstrøm S, Rolke H, Hornslien K, Wentzel-Larsen T, Aasebø U, von Plessen C. Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC: a phase III randomised controlled trial by the Norwegian Lung Cancer Study Group. Br J Cancer. 2012 Jul 24;107(3):442-7. Epub 2012 Jul 3. [https://www.nature.com/articles/bjc2012284 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3405221/ link to PMC article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22759880 PubMed]

==Cisplatin & Docetaxel {{#subobject:179d86|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
DC: '''<u>D</u>'''ocetaxel & '''<u>C</u>'''isplatin
<br>DP: '''<u>D</u>'''ocetaxel & '''<u>P</u>'''latinol (Cisplatin)
<br>Doc-Cis: '''<u>Doc</u>'''etaxel & '''<u>Cis</u>'''platin
===Variant #1, 50/75 {{#subobject:c60a4e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ar.iiarjournals.org/content/33/12/5477.long Berghmans et al. 2013 (ELCWP-01041)]
|style="background-color:#1a9851"|Phase III (C)
|1. [[Non-small_cell_lung_cancer_-_historical#GIP|GIP]]<br> 2. [[Non-small_cell_lung_cancer_-_historical#Ifosfamide_.26_Gemcitabine|IG]]
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV once on day 1

'''21-day cycles'''

===Variant #2, 75/75 {{#subobject:154c29|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=3|[https://www.nejm.org/doi/full/10.1056/NEJMoa011954 Schiller et al. 2002 (ECOG E1594)]
|rowspan=3 style="background-color:#1a9851"|Phase III (E)
|1. [[#Carboplatin_.26_Paclitaxel_4|Carboplatin & Paclitaxel]]
|style="background-color:#ffffbf"|Seems not superior
|-
|2. [[#Cisplatin_.26_Gemcitabine_3|Cisplatin & Gemcitabine]]
|style="background-color:#ffffbf"|Seems not superior
|-
|3. [[#Cisplatin_.26_Paclitaxel|Cisplatin & Paclitaxel]]
|style="background-color:#ffffbf"|Seems not superior
|-
|rowspan=2|[http://jco.ascopubs.org/content/21/16/3016.long Fossella et al. 2003 (TAX 326)]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. [[#Carboplatin_.26_Paclitaxel_4|Carboplatin & Docetaxel]]
|style="background-color:#d3d3d3"|Not reported
|-
|2. [[#Cisplatin_.26_Vinorelbine_3|Cisplatin & Vinorelbine]]
|style="background-color:#91cf60"|Seems to have superior OS
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2006.09.7915 Cobo et al. 2007]
|style="background-color:#1a9851"|Phase III (C)
|ERCC1 mRNA-guided therapy
| style="background-color:#fc8d59" |Seems to have inferior ORR
|-
|[https://academic.oup.com/annonc/article/20/7/1249/344411 Tan et al. 2009 (GLOB3)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Cisplatin_.26_Vinorelbine_3|Cisplatin & Vinorelbine]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70393-X/fulltext Rossell et al. 2012 (EURTAC)]
|style="background-color:#1a9851"|Phase III (C)
|[[Non-small_cell_lung_cancer,_EGFR-mutated#Erlotinib_monotherapy|Erlotinib]]
|style="background-color:#d73027"|Inferior PFS
|-
|}
''Patients in '''EURTAC''' had EGFR exon 19 deletion or p.L858R mutation.''
====Chemotherapy====
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV once on day 1
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for up to 4 cycles (EURTAC), 6 cycles (GLOB3), or indefinitely (E1594, TAX326)'''

===Variant #3, 80/60 {{#subobject:5a7d3b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2004.06.114 Kubota et al. 2004]
|style="background-color:#1a9851"|Phase III (E)
|[[Non-small_cell_lung_cancer_-_historical#Cisplatin_.26_Vindesine|Cisplatin & Vindesine]]
| style="background-color:#91cf60" |Seems to have superior OS
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(09)70364-X/fulltext Mitsudomi et al. 2009 (WJTOG3405)]
|style="background-color:#1a9851"|Phase III (C)
|[[Non-small_cell_lung_cancer,_EGFR-mutated#Gefitinib_monotherapy_2|Gefitinib]]
|style="background-color:#d73027"|Inferior PFS
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2009.23.3445 Takeda et al. 2009 (WJTOG0203)]
|style="background-color:#1a9851"|Phase III (C)
|Platinum doublet x 3, then Gefitinib
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4478975/ Kubota et al. 2015 (TCOG0701 CATS)]
|style="background-color:#1a9851"|Phase III (C)
|Cisplatin & S-1
| style="background-color:#eeee01" |Non-inferior OS
|-
|}
''Patients in WJTOG3405 had EGFR exon 19 deletion or p.L858R mutation.''
====Chemotherapy====
*[[Cisplatin (Platinol)]] 80 mg/m<sup>2</sup> IV over 90 minutes once on day 1, '''given second'''
*[[Docetaxel (Taxotere)]] 60 mg/m<sup>2</sup> IV over 60 minutes once on day 1, '''given first'''

'''21-day cycle for 3 to 6 cycles'''

===Variant #4, 80/100 {{#subobject:b1a602|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(00)04644-4/fulltext Georgoulias et al. 2001]
|style="background-color:#1a9851"|Phase III (C)
|[[Non-small_cell_lung_cancer_-_historical#Docetaxel_.26_Gemcitabine|Docetaxel & Gemcitabine]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://ascopubs.org/doi/10.1200/JCO.2004.11.004 Georgoulias et al. 2004]
|style="background-color:#1a9851"|Phase III (C)
|Docetaxel
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 80 mg/m<sup>2</sup> IV once on day 2
*[[Docetaxel (Taxotere)]] 100 mg/m<sup>2</sup> IV once on day 1

'''21-day cycles'''
===References===
# Georgoulias V, Papadakis E, Alexopoulos A, Tsiafaki X, Rapti A, Veslemes M, Palamidas P, Vlachonikolis I; Greek Oncology Cooperative Group (GOCG) for Lung Cancer. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet. 2001 May 12;357(9267):1478-84. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(00)04644-4/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/11377599 PubMed]
# '''ECOG E1594:''' Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002 Jan 10;346(2):92-8. [https://www.nejm.org/doi/full/10.1056/NEJMoa011954 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11784875 PubMed]
<!-- Previously presented in part at the Annual Meeting of the American Society of Clinical Oncology (ASCO), San Francisco, CA, May 12–15, 2001; the Annual Meeting of ASCO, Orlando, FL, May 18–21, 2002; and the Congress of the European Society for Medical Oncology, Nice, France, October 18–22, 2002. -->
# '''TAX 326:''' Fossella F, Rodrigues Pereira J, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, Mattson KV, Ramlau R, Szczesna A, Fidias P, Millward M, Belani CP. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol. 2003 Aug 15;21(16):3016-24. Epub 2003 Jul 1. [http://jco.ascopubs.org/content/21/16/3016.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12837811 PubMed]
# Kubota K, Watanabe K, Kunitoh H, Noda K, Ichinose Y, Katakami N, Sugiura T, Kawahara M, Yokoyama A, Yokota S, Yoneda S, Matsui K, Kudo S, Shibuya M, Isobe T, Segawa Y, Nishiwaki Y, Ohashi Y, Niitani H; Japanese Taxotere Lung Cancer Study Group. Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. J Clin Oncol. 2004 Jan 15;22(2):254-61. [http://ascopubs.org/doi/full/10.1200/JCO.2004.06.114 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/14722033 PubMed]
# Georgoulias V, Ardavanis A, Agelidou A, Agelidou M, Chandrinos V, Tsaroucha E, Toumbis M, Kouroussis C, Syrigos K, Polyzos A, Samaras N, Papakotoulas P, Christofilakis C, Ziras N, Alegakis A. Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer: a randomized, multicenter phase III trial. J Clin Oncol. 2004 Jul 1;22(13):2602-9. [http://ascopubs.org/doi/10.1200/JCO.2004.11.004 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15226327 PubMed]
# Cobo M, Isla D, Massuti B, Montes A, Sanchez JM, Provencio M, Viñolas N, Paz-Ares L, Lopez-Vivanco G, Muñoz MA, Felip E, Alberola V, Camps C, Domine M, Sanchez JJ, Sanchez-Ronco M, Danenberg K, Taron M, Gandara D, Rosell R. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol. 2007 Jul 1;25(19):2747-54. [http://ascopubs.org/doi/full/10.1200/JCO.2006.09.7915 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17602080 PubMed]
# Park JO, Kim SW, Ahn JS, Suh C, Lee JS, Jang JS, Cho EK, Yang SH, Choi JH, Heo DS, Park SY, Shin SW, Ahn MJ, Lee JS, Yun YH, Lee JW, Park K. Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer. J Clin Oncol. 2007 Nov 20;25(33):5233-9. [http://ascopubs.org/doi/full/10.1200/JCO.2007.10.8134 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18024869 PubMed]
# '''GLOB3:''' Tan EH, Rolski J, Grodzki T, Schneider CP, Gatzemeier U, Zatloukal P, Aitini E, Carteni G, Riska H, Tsai YH, Abratt R. Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and iv vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer. Ann Oncol. 2009 Jul;20(7):1249-56. Epub 2009 Mar 10. [https://academic.oup.com/annonc/article/20/7/1249/344411 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19276396 PubMed]
# '''WJTOG3405:''' Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, Toyooka S, Nakagawa K, Fukuoka M; West Japan Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010 Feb;11(2):121-8. Epub 2009 Dec 18. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(09)70364-X/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20022809 PubMed]
# '''WJTOG0203:''' Takeda K, Hida T, Sato T, Ando M, Seto T, Satouchi M, Ichinose Y, Katakami N, Yamamoto N, Kudoh S, Sasaki J, Matsui K, Takayama K, Kashii T, Iwamoto Y, Sawa T, Okamoto I, Kurata T, Nakagawa K, Fukuoka M. Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (WJTOG0203). J Clin Oncol. 2010 Feb 10;28(5):753-60. Epub 2009 Dec 28. [http://ascopubs.org/doi/full/10.1200/JCO.2009.23.3445 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20038730 PubMed]
# '''EURTAC:''' Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012 Mar;13(3):239-46. Epub 2012 Jan 26. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70393-X/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22285168 PubMed]
# '''ELCWP-01041:''' Berghmans T, Lafitte JJ, Scherpereel A, Paesmans M, Lecomte J, Marco VG, Meert AP, Leclercq N, Sculier JP; European Lung Cancer Working Party. An ELCWP phase III trial comparing ifosfamide and cisplatin regimens in advanced NSCLC. Anticancer Res. 2013 Dec;33(12):5477-82. [http://ar.iiarjournals.org/content/33/12/5477.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24324084 PubMed]
# '''TCOG0701 CATS:''' Kubota K, Sakai H, Katakami N, Nishio M, Inoue A, Okamoto H, Isobe H, Kunitoh H, Takiguchi Y, Kobayashi K, Nakamura Y, Ohmatsu H, Sugawara S, Minato K, Fukuda M, Yokoyama A, Takeuchi M, Michimae H, Gemma A, Kudoh S; Tokyo Cooperative Oncology Group. A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial. Ann Oncol. 2015 Jul;26(7):1401-8. Epub 2015 Apr 23. [https://academic.oup.com/annonc/article/26/7/1401/165322 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4478975/ link to PMC article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25908605 PubMed]

==Cisplatin & Etoposide {{#subobject:0d191d|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
EC: '''<u>E</u>'''toposide & '''<u>C</u>'''isplatin
===Variant #1, 60/360 {{#subobject:2888e6|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/abs/10.1200/JCO.1986.4.1.14 Ruckdeschel et al. 1986 (ECOG E1581)]
|style="background-color:#1a9851"|Phase III (E)
|1. CAMP<br> 2. [[Non-small_cell_lung_cancer_-_historical#Cisplatin_.26_Vindesine|Cisplatin & Vindesine]]<br> 3. [[Non-small_cell_lung_cancer_-_historical#MVP_.28Vinblastine.29|MVP]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''Note: this is an experimental arm that did not meet its primary endpoint; included here because it was eventually used to establish this regimen as a standard comparator.''
====Chemotherapy====
*[[Cisplatin (Platinol)]] 60 mg/m<sup>2</sup> IV once on day 1
*[[Etoposide (Vepesid)]] 120 mg/m<sup>2</sup> IV once per day on days 4, 6, 8

'''21-day cycles'''

===Variant #2, 75/300 {{#subobject:5151cf|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2000.18.3.623 Bonomi et al. 2000 (ECOG E5592)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Cisplatin_.26_Paclitaxel|Cisplatin & Paclitaxel]]
| style="background-color:#fc8d59" |Seems to have inferior OS
|-
|[https://academic.oup.com/annonc/article/16/7/1069/167072 Belani et al. 2005]
|style="background-color:#1a9851"|Phase III (C)
|[[#Carboplatin_.26_Paclitaxel_4|Carboplatin & Paclitaxel]]
| style="background-color:#d9ef8b" |Might have superior OS
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV over 60 minutes once on day 1
*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV over 45 minutes once per day on days 1 to 3

'''21-day cycles'''

===Variant #3, 100/300 {{#subobject:5281cf|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.1999.17.1.12 Cardenal et al. 1999]
|style="background-color:#1a9851"|Phase III (C)
|[[#Cisplatin_.26_Gemcitabine_3|Cisplatin & Gemcitabine]]
|style="background-color:#d73027"|Inferior TTP
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV once on day 1
*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV once per day on days 1 to 3

'''21-day cycles'''

===Variant #4, 120/300 {{#subobject:d94e47|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.1990.8.9.1556 Klastersky et al. 1990 (EORTC 07861)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Carboplatin_.26_Etoposide|Carboplatin & Etoposide]]
|style="background-color:#d9ef8b"|Might have superior ORR
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2077209/ Comella et al. 1996]
|style="background-color:#1a9851"|Phase III (C)
|Carboplatin, Cisplatin, Etoposide, Vinorelbine
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 120 mg/m<sup>2</sup> IV once on day 1
**Comella et al. 1996 gave 40 mg/m<sup>2</sup> IV once per day on days 1 to 3
*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV once per day on days 1 to 3

'''3- to 4-week cycles'''

===References===
# '''ECOG E1581:''' Ruckdeschel JC, Finkelstein DM, Ettinger DS, Creech RH, Mason BA, Joss RA, Vogl S. A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer. J Clin Oncol. 1986 Jan;4(1):14-22. [http://ascopubs.org/doi/abs/10.1200/JCO.1986.4.1.14 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/3510278 PubMed]
# '''EORTC 07861:''' Klastersky J, Sculier JP, Lacroix H, Dabouis G, Bureau G, Libert P, Richez M, Ravez P, Vandermoten G, Thiriaux J, Cordier R, Finet C, Berchier MC, Sergysels R, Mommen P, Paesmans M. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861. J Clin Oncol. 1990 Sep;8(9):1556-62. [http://ascopubs.org/doi/full/10.1200/JCO.1990.8.9.1556 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/2167953 PubMed]
# Comella P, Frasci G, De Cataldis G, Panza N, Cioffi R, Curcio C, Belli M, Bianco A, Ianniello G, Maiorino L, Della Vittoria M, Perchard J, Comella G; Gruppo Oncologico Campano. Cisplatin/carboplatin + etoposide + vinorelbine in advanced non-small-cell lung cancer: a multicentre randomised trial. Br J Cancer. 1996 Dec;74(11):1805-11. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2077209/ link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/8956797 PubMed]
# Cardenal F, López-Cabrerizo MP, Antón A, Alberola V, Massuti B, Carrato A, Barneto I, Lomas M, García M, Lianes P, Montalar J, Vadell C, González-Larriba JL, Nguyen B, Artal A, Rosell R. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 1999 Jan;17(1):12-8. [http://ascopubs.org/doi/full/10.1200/JCO.1999.17.1.12 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10458212 PubMed]
# '''ECOG E5592:''' Bonomi P, Kim K, Fairclough D, Cella D, Kugler J, Rowinsky E, Jiroutek M, Johnson D. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2000 Feb;18(3):623-31. [http://ascopubs.org/doi/full/10.1200/JCO.2000.18.3.623 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10653877 PubMed]
# Belani CP, Lee JS, Socinski MA, Robert F, Waterhouse D, Rowland K, Ansari R, Lilenbaum R, Natale RB. Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer. Ann Oncol. 2005 Jul;16(7):1069-75. Epub 2005 Apr 28. [https://academic.oup.com/annonc/article/16/7/1069/167072 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15860487 PubMed]

==Cisplatin & Gemcitabine {{#subobject:fb3ee0|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
GC: '''<u>G</u>'''emcitabine & '''<u>C</u>'''isplatin
<br>GP: '''<u>G</u>'''emcitabine & '''<u>P</u>'''latinol (Cisplatin)
===Variant #1, 70/1000 {{#subobject:b0126d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2007.10.8134 Park et al. 2007]
|style="background-color:#1a9851"|Phase III (E)
|Cisplatin & Gemcitabine x 6
| style="background-color:#eeee01" |Non-inferior OS
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 70 mg/m<sup>2</sup> IV once on day 1
*[[Gemcitabine (Gemzar)]] 1000 mg/m<sup>2</sup> IV once per day on days 1 & 8

'''21-day cycle for 4 cycles'''

===Variant #2, 75/1250 q3wk {{#subobject:0e126e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 20%"|Study
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 20%"|Comparator
!style="width: 20%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
!style="width: 20%"|[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2005.03.170 Bissett et al. 2005]
|style="background-color:#1a9851"|Phase III (C)
|GC & Prinomastat
|style="background-color:#ffffbf"|Seems not superior
|
|-
|[https://academic.oup.com/annonc/article/18/5/903/218601 Novello et al. 2007]
|style="background-color:#1a9851"|Phase III (C)
|GC x 2, then gemcitabine x 3
|style="background-color:#ffffbf"|Inconclusive whether non-inferior
|
|-
|[https://academic.oup.com/annonc/article/23/1/72/161342 Manegold et al. 2011]
|style="background-color:#1a9851"|Phase III (C)
|GC & PF-3512676
|style="background-color:#ffffbf"|Seems not superior
|
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70393-X/fulltext Rossell et al. 2012 (EURTAC)]
|style="background-color:#1a9851"|Phase III (C)
|[[Non-small_cell_lung_cancer,_EGFR-mutated#Erlotinib_monotherapy|Erlotinib]]
|style="background-color:#d73027"|Inferior PFS
|
|-
|[https://academic.oup.com/annonc/article-lookup/doi/10.1093/annonc/mdv270 Wu et al. 2015 (ENSURE)]
|style="background-color:#1a9851"|Phase III (C)
|[[Non-small_cell_lung_cancer,_EGFR-mutated#Erlotinib_monotherapy|Erlotinib]]
|style="background-color:#d73027"|Inferior PFS
|
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1606774 Reck et al. 2016 (KEYNOTE-024)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Pembrolizumab_monotherapy|Pembrolizumab]]
|style="background-color:#d73027"|Inferior OS
|style="background-color:#d73027"|Inferior HRQoL
|-
|}
''Note: Patients in Novello et al. 2007 received 5 cycles. Patients in ENSURE received up to 4 cycles. Patients in KEYNOTE-024 received 4 to 6 cycles. Patients in EURTAC had EGFR exon 19 deletion or p.L858R mutation in exon 21.''
====Chemotherapy====
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV over 30 minutes once on day 1
*[[Gemcitabine (Gemzar)]] 1250 mg/m<sup>2</sup> IV over 2 hours once per day on days 1 & 8

'''21-day cycle for up to 6 cycles (see note)'''

===Variant #3, 75/1250 q4wk {{#subobject:64837d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70254-7/fulltext Wu et al. 2013 (FASTACT-2)]
|style="background-color:#1a9851"|Phase III (C)
|[[Non-small_cell_lung_cancer,_EGFR-mutated#Cisplatin_.26_Gemcitabine.2FErlotinib|Cisplatin & Gemcitabine/Erlotinib]]
|style="background-color:#91cf60"|Seems to have superior OS
|-
|}
''Note: this cohort was enriched for EGFR mutations and only those patients with an activating EGFR gene mutation were noted to have a treatment benefit in favor of the experimental arm.'' 
====Chemotherapy====
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV once on day 1
*[[Gemcitabine (Gemzar)]] 1250 mg/m<sup>2</sup> IV once per day on days 1 & 8

'''28-day cycle for 4 cycles'''

===Variant #4, 80/1000 {{#subobject:816a83|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=3|[https://academic.oup.com/annonc/article-lookup/doi/10.1093/annonc/mdl377 Ohe et al. 2006]
|rowspan=3 style="background-color:#1a9851"|Phase III (E)
|1. [[#Carboplatin_.26_Paclitaxel_4|Carboplatin & Paclitaxel]]
|style="background-color:#ffffbf"|Seems not superior
|-
|2. [[#Cisplatin_.26_Irinotecan|Cisplatin & Irinotecan]]
|style="background-color:#ffffbf"|Seems not superior
|-
|3. [[#Cisplatin_.26_Vinorelbine_3|Cisplatin & Vinorelbine]]
|style="background-color:#ffffbf"|Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2009.23.3445 Takeda et al. 2009 (WJTOG0203)]
|style="background-color:#1a9851"|Phase III (C)
|Platinum doublet x 3, then Gefitinib
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 80 mg/m<sup>2</sup> IV once on day 1
*[[Gemcitabine (Gemzar)]] 1000 mg/m<sup>2</sup> IV once per day on days 1 & 8

'''21-day cycle for 6 cycles (WJTOG0203) or indefinitely (Ohe et al. 2006)'''

===Variant #5, 80/1125 {{#subobject:10bc56|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394313/ Wachters et al. 2003]
|style="background-color:#1a9851"|Phase III (C)
|Epirubicin & Gemcitabine
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 80 mg/m<sup>2</sup> IV once on day 2
*[[Gemcitabine (Gemzar)]] 1125 mg/m<sup>2</sup> IV once per day on days 1 & 8

'''21-day cycle for up to 5 cycles'''

===Variant #6, 80/1200 x 6 {{#subobject:744a8d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2003.06.099 Gridelli et al. 2003]
|style="background-color:#1a9851"|Phase III (C)
|[[#Gemcitabine_.26_Vinorelbine|Gemcitabine & Vinorelbine]]
| style="background-color:#d9ef8b" |Might have superior OS
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(07)70146-8/fulltext Gridelli et al. 2007 (GECO)]
|style="background-color:#1a9851"|Phase III (C)
|1. Cisplatin, Gemcitabine, Rofecoxib<br> 2. Cisplatin & PCI Gemcitabine<br> 3. Cisplatin, PCI Gemcitabine, Rofecoxib
|style="background-color:#ffffbf"|Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2011.41.2056 Gridelli et al. 2012 (TORCH)]
|style="background-color:#1a9851"|Phase III (C)
|Erlotinib
| style="background-color:#1a9850" |Superior OS
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 80 mg/m<sup>2</sup> IV once on day 1
*[[Gemcitabine (Gemzar)]] 1200 mg/m<sup>2</sup> IV once per day on days 1 & 8

'''21-day cycle for up to 6 cycles'''
====Subsequent treatment====
*TORCH, at progression: [[Non-small_cell_lung_cancer_-_historical#Erlotinib_monotherapy_2|Erlotinib]]

===Variant #7, 80/1250 x 4 {{#subobject:f2149d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2011.39.9782 Pérol et al. 2012]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|rowspan=2|[https://www.ejcancer.com/article/S0959-8049(17)31001-8/fulltext Ferry et al. 2017 (BTOG2)]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. GC50
|style="background-color:#91cf60"|Seems to have superior OS
|-
|2. [[#Carboplatin_.26_Gemcitabine|GCb6]]
|style="background-color:#eeee01"|Non-inferior OS
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 80 mg/m<sup>2</sup> IV once on day 1
*[[Gemcitabine (Gemzar)]] 1250 mg/m<sup>2</sup> IV once per day on days 1 & 8

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*Pérol et al. 2012: [[Non-small_cell_lung_cancer_-_historical#Erlotinib_monotherapy|Erlotinib switch maintenance]] versus [[#Gemcitabine_monotherapy_2|gemcitabine maintenance]] versus [[#Observation_3|observation]]

===Variant #8, 80/1250 x 6 {{#subobject:646326|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2004.08.001 Giaccone et al. 2004 (INTACT 1)]
|style="background-color:#1a9851"|Phase III (C)
|Cisplatin, Gefitinib, Gemcitabine
|style="background-color:#ffffbf"|Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2005.04.3299 Paz-Ares et al. 2006]
|style="background-color:#1a9851"|Phase III (C)
|Aprinocarsen, Cisplatin, Gemcitabine
|style="background-color:#ffffbf"|Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2005.05.1474 Gatzemeier et al. 2007 (TALENT)]
|style="background-color:#1a9851"|Phase III (C)
|Cisplatin, Erlotinib, Gemcitabine
|style="background-color:#ffffbf"|Seems not superior
|-
|rowspan=2|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3322957/ Boni et al. 2012 (FAST)]
|rowspan=2 style="background-color:#1a9851"|Phase III (C)
|1. GIN<br> 2. GN
| style="background-color:#91cf60" |Seems to have superior OS
|-
|3. [[Non-small_cell_lung_cancer_-_historical#GIP|GIP]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 80 mg/m<sup>2</sup> IV once on day 1
*[[Gemcitabine (Gemzar)]] 1250 mg/m<sup>2</sup> IV once per day on days 1 & 8

'''21-day cycle for up to 6 cycles'''

===Variant #9, 100/1000 q3wk {{#subobject:ec88d3|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.spandidos-publications.com/ijo/39/4/1011 Ridolfi et al. 2011]
|style="background-color:#1a9851"|Phase III (C)
|Cisplatin, Gemcitabine, LD IL-2
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV once on day 1
*[[Gemcitabine (Gemzar)]] 1000 mg/m<sup>2</sup> IV once per day on days 1 & 8

'''21-day cycle for up to 6 cycles'''

===Variant #10, 100/1000 q4wk {{#subobject:a352e8|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.1999.17.11.3522 Crinò et al. 1999]
|style="background-color:#1a9851"|Phase III (E)
|[[Non-small_cell_lung_cancer_-_historical#MIC_2|MIC]]
| style="background-color:#91cf60" |Seems to have superior ORR
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2000.18.1.122 Sandler et al. 2000]
|style="background-color:#1a9851"|Phase III (E)
|[[Non-small_cell_lung_cancer_-_historical#Cisplatin_monotherapy|Cisplatin]]
|style="background-color:#1a9850"|Superior OS
|-
|rowspan=3|[https://www.nejm.org/doi/full/10.1056/NEJMoa011954 Schiller et al. 2002 (ECOG E1594)]
|rowspan=3 style="background-color:#1a9851"|Phase III (E)
|1. [[#Carboplatin_.26_Paclitaxel_4|Carboplatin & Paclitaxel]]
|style="background-color:#ffffbf"|Seems not superior
|-
|2. [[#Cisplatin_.26_Docetaxel_3|Cisplatin & Docetaxel]]
|style="background-color:#ffffbf"|Seems not superior
|-
|3. [[#Cisplatin_.26_Paclitaxel|Cisplatin & Paclitaxel]]
|style="background-color:#1a9850"|Superior PFS
|-
|[http://jco.ascopubs.org/content/26/21/3543.full Scagliotti et al. 2008 (JMDB)]
|style="background-color:#1a9851"|Phase III (C)
|[[Non-small_cell_lung_cancer_-_historical#Cisplatin_.26_Pemetrexed|Cisplatin & Pemetrexed]]
|style="background-color:#eeee01"|Seems non-inferior
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV once on day 1
*[[Gemcitabine (Gemzar)]] 1000 mg/m<sup>2</sup> IV once per day on days 1, 8, 15

'''28-day cycles'''

===Variant #11, 100/1250 {{#subobject:8bb0be|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.1999.17.1.12 Cardenal et al. 1999]
|style="background-color:#1a9851"|Phase III (E)
|[[#Cisplatin_.26_Etoposide_3|Cisplatin & Etoposide]]
|style="background-color:#1a9850"|Superior TTP
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2003.12.038 Alberola et al. 2003]
|style="background-color:#1a9851"|Phase III (C)
|1. CGV<br> 2. GV-VI
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV once on day 1
*[[Gemcitabine (Gemzar)]] 1250 mg/m<sup>2</sup> IV once per day on days 1 & 8

'''21-day cycle for 6 cycles (Alberola et al. 2003) or indefinitely (Cardenal et al. 1999)'''

===Variant #12, 100/1400 {{#subobject:b9409e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.lungcancerjournal.info/article/S0169-5002(02)00444-0/fulltext Gebbia et al. 2003]
|style="background-color:#1a9851"|Phase III (E)
|[[#Cisplatin_.26_Vinorelbine_3|Cisplatin & Vinorelbine]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV once on day 1
*[[Gemcitabine (Gemzar)]] 1400 mg/m<sup>2</sup> IV once per day on days 1 & 8

'''28-day cycles'''
===References===
# Cardenal F, López-Cabrerizo MP, Antón A, Alberola V, Massuti B, Carrato A, Barneto I, Lomas M, García M, Lianes P, Montalar J, Vadell C, González-Larriba JL, Nguyen B, Artal A, Rosell R. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 1999 Jan;17(1):12-8. [http://ascopubs.org/doi/full/10.1200/JCO.1999.17.1.12 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10458212 PubMed]
# Crinò L, Scagliotti GV, Ricci S, De Marinis F, Rinaldi M, Gridelli C, Ceribelli A, Bianco R, Marangolo M, Di Costanzo F, Sassi M, Barni S, Ravaioli A, Adamo V, Portalone L, Cruciani G, Masotti A, Ferrara G, Gozzelino F, Tonato M. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol. 1999 Nov;17(11):3522-30. [http://ascopubs.org/doi/full/10.1200/JCO.1999.17.11.3522 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10550150 PubMed]
# Sandler AB, Nemunaitis J, Denham C, von Pawel J, Cormier Y, Gatzemeier U, Mattson K, Manegold C, Palmer MC, Gregor A, Nguyen B, Niyikiza C, Einhorn LH. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2000 Jan;18(1):122-30. [http://ascopubs.org/doi/full/10.1200/JCO.2000.18.1.122 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10623702 PubMed]
# '''ECOG E1594:''' Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002 Jan 10;346(2):92-8. [https://www.nejm.org/doi/full/10.1056/NEJMoa011954 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11784875 PubMed]
# Gebbia V, Galetta D, Caruso M, Verderame F, Pezzella G, Valdesi M, Borsellino N, Pandolfo G, Durini E, Rinaldi M, Loizzi M, Gebbia N, Valenza R, Tirrito ML, Varvara F, Colucci G; Gruppo Ocologico Italia Meridionale. Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB-IV non small cell lung carcinoma: a prospective randomized phase III trial of the Gruppo Oncologico Italia Meridionale. Lung Cancer. 2003 Feb;39(2):179-89. [https://www.lungcancerjournal.info/article/S0169-5002(02)00444-0/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12581571 PubMed]
# Gridelli C, Gallo C, Shepherd FA, Illiano A, Piantedosi F, Robbiati SF, Manzione L, Barbera S, Frontini L, Veltri E, Findlay B, Cigolari S, Myers R, Ianniello GP, Gebbia V, Gasparini G, Fava S, Hirsh V, Bezjak A, Seymour L, Perrone F. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2003 Aug 15;21(16):3025-34. Epub 2003 Jul 1. [http://ascopubs.org/doi/full/10.1200/JCO.2003.06.099 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12837810 PubMed]
# Alberola V, Camps C, Provencio M, Isla D, Rosell R, Vadell C, Bover I, Ruiz-Casado A, Azagra P, Jiménez U, González-Larriba JL, Diz P, Cardenal F, Artal A, Carrato A, Morales S, Sanchez JJ, de las Peñas R, Felip E, López-Vivanco G; Spanish Lung Cancer Group. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial. J Clin Oncol. 2003 Sep 1;21(17):3207-13. [http://ascopubs.org/doi/full/10.1200/JCO.2003.12.038 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12947054 PubMed]
# Zatloukal P, Petruzelka L, Zemanová M, Kolek V, Skricková J, Pesek M, Fojtů H, Grygárková I, Sixtová D, Roubec J, Horenková E, Havel L, Průsa P, Nováková L, Skácel T, Kůta M. Gemcitabine plus cisplatin vs gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial. Lung Cancer. 2003 Sep;41(3):321-31. [https://www.lungcancerjournal.info/article/S0169-5002(03)00233-2/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12928123 PubMed]
# Wachters FM, Van Putten JW, Kramer H, Erjavec Z, Eppinga P, Strijbos JH, de Leede GP, Boezen HM, de Vries EG, Groen HJ. First-line gemcitabine with cisplatin or epirubicin in advanced non-small-cell lung cancer: a phase III trial. Br J Cancer. 2003 Oct 6;89(7):1192-9. [https://www.nature.com/articles/6601283 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394313/ link to PMC article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/14520444 PubMed]
# '''INTACT 1:''' Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, Natale RB, Schiller JH, Von Pawel J, Pluzanska A, Gatzemeier U, Grous J, Ochs JS, Averbuch SD, Wolf MK, Rennie P, Fandi A, Johnson DH. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. J Clin Oncol. 2004 Mar 1;22(5):777-84. [http://ascopubs.org/doi/full/10.1200/JCO.2004.08.001 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/14990632 PubMed]
# Bissett D, O'Byrne KJ, von Pawel J, Gatzemeier U, Price A, Nicolson M, Mercier R, Mazabel E, Penning C, Zhang MH, Collier MA, Shepherd FA. Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer. J Clin Oncol. 2005 Feb 1;23(4):842-9. [http://ascopubs.org/doi/full/10.1200/JCO.2005.03.170 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15681529 PubMed]
# Paz-Ares L, Douillard JY, Koralewski P, Manegold C, Smit EF, Reyes JM, Chang GC, John WJ, Peterson PM, Obasaju CK, Lahn M, Gandara DR. Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2006 Mar 20;24(9):1428-34. [http://ascopubs.org/doi/full/10.1200/JCO.2005.04.3299 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16549837 PubMed]
# Ohe Y, Ohashi Y, Kubota K, Tamura T, Nakagawa K, Negoro S, Nishiwaki Y, Saijo N, Ariyoshi Y, Fukuoka M. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: four-arm cooperative study in Japan. Ann Oncol. 2007 Feb;18(2):317-23. Epub 2006 Nov 1. [https://academic.oup.com/annonc/article-lookup/doi/10.1093/annonc/mdl377 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17079694 PubMed]
# Novello S, Bruzzi P, Barone C, Buosi R, Masotti A, Michetti G, Fioretti M, Barbera S, Spatafora M, Garetto L, Mazzanti P, Dongiovanni V, Selvaggi G, Crinò L, Scagliotti GV. Phase III study in stage IV non-small-cell lung cancer patients treated with two courses of cisplatin/gemcitabine followed by a randomization to three additional courses of the same combination or gemcitabine alone. Ann Oncol. 2007 May;18(5):903-8. Epub 2007 Mar 9. [https://academic.oup.com/annonc/article/18/5/903/218601 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17351253 PubMed]
# '''TALENT:''' Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, De Rosa F, Milanowski J, Karnicka-Mlodkowski H, Pesek M, Serwatowski P, Ramlau R, Janaskova T, Vansteenkiste J, Strausz J, Manikhas GM, Von Pawel J. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol. 2007 Apr 20;25(12):1545-52. [http://ascopubs.org/doi/full/10.1200/JCO.2005.05.1474 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17442998 PubMed]
# '''GECO:''' Gridelli C, Gallo C, Ceribelli A, Gebbia V, Gamucci T, Ciardiello F, Carozza F, Favaretto A, Daniele B, Galetta D, Barbera S, Rosetti F, Rossi A, Maione P, Cognetti F, Testa A, Di Maio M, Morabito A, Perrone F; GECO investigators. Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study. Lancet Oncol. 2007 Jun;8(6):500-12. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(07)70146-8/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17513173 PubMed]
# Park JO, Kim SW, Ahn JS, Suh C, Lee JS, Jang JS, Cho EK, Yang SH, Choi JH, Heo DS, Park SY, Shin SW, Ahn MJ, Lee JS, Yun YH, Lee JW, Park K. Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer. J Clin Oncol. 2007 Nov 20;25(33):5233-9. [http://ascopubs.org/doi/full/10.1200/JCO.2007.10.8134 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18024869 PubMed]
# '''JMDB:''' Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008 Jul 20;26(21):3543-51. Epub 2008 May 27. [http://jco.ascopubs.org/content/26/21/3543.full link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18506025 PubMed]
# '''WJTOG0203:''' Takeda K, Hida T, Sato T, Ando M, Seto T, Satouchi M, Ichinose Y, Katakami N, Yamamoto N, Kudoh S, Sasaki J, Matsui K, Takayama K, Kashii T, Iwamoto Y, Sawa T, Okamoto I, Kurata T, Nakagawa K, Fukuoka M. Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (WJTOG0203). J Clin Oncol. 2010 Feb 10;28(5):753-60. Epub 2009 Dec 28. [http://ascopubs.org/doi/full/10.1200/JCO.2009.23.3445 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20038730 PubMed]
# Manegold C, van Zandwijk N, Szczesna A, Zatloukal P, Au JS, Blasinska-Morawiec M, Serwatowski P, Krzakowski M, Jassem J, Tan EH, Benner RJ, Ingrosso A, Meech SJ, Readett D, Thatcher N. A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer. Ann Oncol. 2012 Jan;23(1):72-7. Epub 2011 Apr 4. [https://academic.oup.com/annonc/article/23/1/72/161342 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21464154 PubMed]
# Ridolfi L, Bertetto O, Santo A, Naglieri E, Lopez M, Recchia F, Lissoni P, Galliano M, Testore F, Porta C, Maglie M, Dall'agata M, Fumagalli L, Ridolfi R. Chemotherapy with or without low-dose interleukin-2 in advanced non-small cell lung cancer: results from a phase III randomized multicentric trial. Int J Oncol. 2011 Oct;39(4):1011-7. Epub 2011 Jun 24. [https://www.spandidos-publications.com/ijo/39/4/1011 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21720704 PubMed]
# '''FAST:''' Boni C, Tiseo M, Boni L, Baldini E, Recchia F, Barone C, Grossi F, Germano D, Matano E, Marini G, Labianca R, Di Costanzo F, Bagnulo A, Pennucci C, Caroti C, Mencoboni M, Zanelli F, Prochilo T, Cafferata MA, Ardizzoni A; Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB-IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST). Br J Cancer. 2012 Feb 14;106(4):658-65. Epub 2012 Jan 12. [https://www.nature.com/articles/bjc2011606 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3322957/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22240782 PubMed]
# '''EURTAC:''' Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012 Mar;13(3):239-46. Epub 2012 Jan 26. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70393-X/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22285168 PubMed]
# '''TORCH:''' Gridelli C, Ciardiello F, Gallo C, Feld R, Butts C, Gebbia V, Maione P, Morgillo F, Genestreti G, Favaretto A, Leighl N, Wierzbicki R, Cinieri S, Alam Y, Siena S, Tortora G, Felletti R, Riccardi F, Mancuso G, Rossi A, Cantile F, Tsao MS, Saieg M, da Cunha Santos G, Piccirillo MC, Di Maio M, Morabito A, Perrone F. First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. J Clin Oncol. 2012 Aug 20;30(24):3002-11. Epub 2012 Jul 9. [http://ascopubs.org/doi/full/10.1200/JCO.2011.41.2056 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22778317 PubMed]
## '''HRQoL analysis:''' Di Maio M, Leighl NB, Gallo C, Feld R, Ciardiello F, Butts C, Maione P, Gebbia V, Morgillo F, Wierzbicki R, Favaretto A, Alam Y, Cinieri S, Siena S, Bianco R, Riccardi F, Spatafora M, Ravaioli A, Felletti R, Fregoni V, Genestreti G, Rossi A, Mancuso G, Fasano M, Morabito A, Tsao MS, Signoriello S, Perrone F, Gridelli C. Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advancednon-small-cell lung cancer. J Thorac Oncol. 2012 Dec;7(12):1830-1844. [https://www.jto.org/article/S1556-0864(15)33167-1/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23154555 PubMed]
# Pérol M, Chouaid C, Pérol D, Barlési F, Gervais R, Westeel V, Crequit J, Léna H, Vergnenègre A, Zalcman G, Monnet I, Le Caer H, Fournel P, Falchero L, Poudenx M, Vaylet F, Ségura-Ferlay C, Devouassoux-Shisheboran M, Taron M, Milleron B. Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2012 Oct 1;30(28):3516-24. Epub 2012 Sep 4. [http://ascopubs.org/doi/full/10.1200/JCO.2011.39.9782 link to original article]'''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22949150 PubMed]
# '''FASTACT-2:''' Wu YL, Lee JS, Thongprasert S, Yu CJ, Zhang L, Ladrera G, Srimuninnimit V, Sriuranpong V, Sandoval-Tan J, Zhu Y, Liao M, Zhou C, Pan H, Lee V, Chen YM, Sun Y, Margono B, Fuerte F, Chang GC, Seetalarom K, Wang J, Cheng A, Syahruddin E, Qian X, Ho J, Kurnianda J, Liu HE, Jin K, Truman M, Bara I, Mok T. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial. Lancet Oncol. 2013 Jul;14(8):777-86. Epub 2013 Jun 17. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70254-7/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23782814 PubMed]
# '''ENSURE:''' Wu YL, Zhou C, Liam CK, Wu G, Liu X, Zhong Z, Lu S, Cheng Y, Han B, Chen L, Huang C, Qin S, Zhu Y, Pan H, Liang H, Li E, Jiang G, How SH, Fernando MC, Zhang Y, Xia F, Zuo Y. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. Ann Oncol. 2015 Sep;26(9):1883-9. Epub 2015 Jun 23. [https://academic.oup.com/annonc/article-lookup/doi/10.1093/annonc/mdv270 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26105600 PubMed]
# '''KEYNOTE-024:''' Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Leiby MA, Lubiniecki GM, Shentu Y, Rangwala R, Brahmer JR; KEYNOTE-024 Investigators. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016 Nov 10;375(19):1823-1833. Epub 2016 Oct 8. [https://www.nejm.org/doi/full/10.1056/NEJMoa1606774 link to original article] [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1606774/suppl_file/nejmoa1606774_appendix.pdf link to supplementary appendix] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27718847 PubMed]
## '''HRQoL analysis:''' Brahmer JR, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Zhang J, Lubiniecki GM, Deitz AC, Rangwala R, Reck M. Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. Lancet Oncol. 2017 Dec;18(12):1600-1609. Epub 2017 Nov 9. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30690-3/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/29129441 PubMed]
# '''BTOG2:''' Ferry D, Billingham L, Jarrett H, Dunlop D, Woll PJ, Nicolson M, Shah R, Thompson J, Spicer J, Muthukumar D, Skailes G, Leonard P, Chetiyawardana AD, Wells P, Lewanski C, Crosse B, Hill M, Gaunt P, O'Byrne K. Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: results from a British Thoracic Oncology Group randomised phase III trial. Eur J Cancer. 2017 Sep;83:302-312. Epub 2017 Aug 4. [https://www.ejcancer.com/article/S0959-8049(17)31001-8/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28780466 PubMed]

==Cisplatin & Irinotecan {{#subobject:c1250d|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
IP: '''<u>I</u>'''rinotecan & '''<u>P</u>'''latinol (Cisplatin)
===Regimen {{#subobject:4cf321|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2747545/ Negoro et al. 2003]
|style="background-color:#1a9851"|Phase III (E)
|[[Non-small_cell_lung_cancer_-_historical#Cisplatin_.26_Vindesine|Cisplatin & Vindesine]]
|style="background-color:#ffffbf"|Seems not superior
|-
|rowspan=3|[https://academic.oup.com/annonc/article-lookup/doi/10.1093/annonc/mdl377 Ohe et al. 2006]
|rowspan=3 style="background-color:#1a9851"|Phase III (C)
|1. [[#Carboplatin_.26_Paclitaxel_4|Carboplatin & Paclitaxel]]
|style="background-color:#ffffbf"|Seems not superior
|-
|2. [[#Cisplatin_.26_Gemcitabine_3|Cisplatin & Gemcitabine]]
|style="background-color:#ffffbf"|Seems not superior
|-
|3. [[#Cisplatin_.26_Vinorelbine_3|Cisplatin & Vinorelbine]]
|style="background-color:#ffffbf"|Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2009.23.3445 Takeda et al. 2009 (WJTOG0203)]
|style="background-color:#1a9851"|Phase III (C)
|Platinum doublet x 3, then Gefitinib
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 80 mg/m<sup>2</sup> IV once on day 1
*[[Irinotecan (Camptosar)]] 60 mg/m<sup>2</sup> IV once per day on days 1, 8, 15

'''28-day cycle for up to 6 cycles (WJTOG0203) or indefinitely (Ohe et al. 2006)'''

===References===
# Negoro S, Masuda N, Takada Y, Sugiura T, Kudoh S, Katakami N, Ariyoshi Y, Ohashi Y, Niitani H, Fukuoka M; CPT-11 Lung Cancer Study Group West. Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer. Br J Cancer. 2003 Feb 10;88(3):335-41. [https://www.nature.com/articles/6600725 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2747545/ link to PMC article] '''contains verified protocol'''  [https://www.ncbi.nlm.nih.gov/pubmed/12569373 PubMed]
# Ohe Y, Ohashi Y, Kubota K, Tamura T, Nakagawa K, Negoro S, Nishiwaki Y, Saijo N, Ariyoshi Y, Fukuoka M. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol. 2007 Feb;18(2):317-23. Epub 2006 Nov 1. [https://academic.oup.com/annonc/article-lookup/doi/10.1093/annonc/mdl377 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17079694 PubMed]
# '''WJTOG0203:''' Takeda K, Hida T, Sato T, Ando M, Seto T, Satouchi M, Ichinose Y, Katakami N, Yamamoto N, Kudoh S, Sasaki J, Matsui K, Takayama K, Kashii T, Iwamoto Y, Sawa T, Okamoto I, Kurata T, Nakagawa K, Fukuoka M. Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (WJTOG0203). J Clin Oncol. 2010 Feb 10;28(5):753-60. Epub 2009 Dec 28. [http://ascopubs.org/doi/full/10.1200/JCO.2009.23.3445 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20038730 PubMed]

==Cisplatin & Paclitaxel {{#subobject:7f19fc|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
PC: '''<u>P</u>'''aclitaxel & '''<u>C</u>'''isplatin
===Variant #1, 70/175 {{#subobject:a142cf|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2007.10.8134 Park et al. 2007]
|style="background-color:#1a9851"|Phase III (E)
|Cisplatin & Paclitaxel x 6
| style="background-color:#eeee01" |Non-inferior OS
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 70 mg/m<sup>2</sup> IV once on day 1
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 4 cycles'''

===Variant #2, 75/135, q2wk {{#subobject:df98d7|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 20%"|Study
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 20%"|Comparator
!style="width: 20%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
!style="width: 20%"|[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2962260/ Stathopoulos et al. 2010]
|style="background-color:#1a9851"|Phase III (C)
|Liposomal Cisplatin & Paclitaxel
| style="background-color:#ffffbf" |Seems not superior
| style="background-color:#d73027" |Inferior toxicity
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV once on day 1, '''given second'''
*[[Paclitaxel (Taxol)]] 135 mg/m<sup>2</sup> IV over 3 hours once on day 1, '''given first'''

'''14-day cycle for up to 9 cycles'''

===Variant #3, 75/135, q3wk {{#subobject:5f385|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2000.18.3.623 Bonomi et al. 2000 (ECOG E5592)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Cisplatin_.26_Etoposide_3|Cisplatin & Etoposide]]
| style="background-color:#d9ef8b" |Might have superior OS
|-
|rowspan=3|[https://www.nejm.org/doi/full/10.1056/NEJMoa011954 Schiller et al. 2002 (ECOG E1594)]
|rowspan=3 style="background-color:#1a9851"|Phase III (C)
|1. [[#Carboplatin_.26_Paclitaxel_4|Carboplatin & Paclitaxel]]
|style="background-color:#ffffbf"|Seems not superior
|-
|2. [[#Cisplatin_.26_Docetaxel_3|Cisplatin & Docetaxel]]
|style="background-color:#ffffbf"|Seems not superior
|-
|3. [[#Cisplatin_.26_Gemcitabine_3|Cisplatin & Gemcitabine]]
|style="background-color:#d73027"|Inferior PFS
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV once on day 2, '''given second'''
*[[Paclitaxel (Taxol)]] 135 mg/m<sup>2</sup> IV continuous infusion over 24 hours, started on day 1, '''given first'''

'''21-day cycles'''

===Variant #4, 80/175 {{#subobject:2730a0|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2000.18.19.3390 Gatzemeier et al. 2000]
|style="background-color:#1a9851"|Phase III (E)
|Cisplatin
| style="background-color:#91cf60" |Seems to have superior TTP
|-
|[http://ascopubs.org/doi/10.1200/JCO.2003.03.195 Smit et al. 2003 (EORTC 08975)]
|style="background-color:#1a9851"|Phase III (C)
|1. [[#Cisplatin_.26_Gemcitabine_3|Cisplatin & Gemcitabine]]<br> 2. Gemcitabine & Paclitaxel
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 80 mg/m<sup>2</sup> IV once on day 1
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV over 3 hours once on day 1

'''21-day cycle for up to 6 cycles'''

===Variant #5, 80/200 {{#subobject:96cd6e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://academic.oup.com/annonc/article/13/10/1539/168019 Rosell et al. 2002]
|style="background-color:#1a9851"|Phase III (E)
|[[#Carboplatin_.26_Paclitaxel_4|Carboplatin & Paclitaxel]]
| style="background-color:#91cf60" |Seems to have superior OS
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 80 mg/m<sup>2</sup> IV once on day 1
*[[Paclitaxel (Taxol)]] 200 mg/m<sup>2</sup> IV over 3 hours once on day 1

'''21-day cycles'''
===References===
# '''ECOG E5592:''' Bonomi P, Kim K, Fairclough D, Cella D, Kugler J, Rowinsky E, Jiroutek M, Johnson D. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2000 Feb;18(3):623-31. [http://ascopubs.org/doi/full/10.1200/JCO.2000.18.3.623 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10653877 PubMed]
# Gatzemeier U, von Pawel J, Gottfried M, ten Velde GP, Mattson K, de Marinis F, Harper P, Salvati F, Robinet G, Lucenti A, Bogaerts J, Gallant G. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2000 Oct 1;18(19):3390-9. [http://ascopubs.org/doi/full/10.1200/JCO.2000.18.19.3390 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11013280 PubMed]
# '''ECOG E1594:''' Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002 Jan 10;346(2):92-8. [https://www.nejm.org/doi/full/10.1056/NEJMoa011954 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11784875 PubMed]
# Rosell R, Gatzemeier U, Betticher DC, Keppler U, Macha HN, Pirker R, Berthet P, Breau JL, Lianes P, Nicholson M, Ardizzoni A, Chemaissani A, Bogaerts J, Gallant G. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol. 2002 Oct;13(10):1539-49. [https://academic.oup.com/annonc/article/13/10/1539/168019 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12377641 PubMed]
# '''EORTC 08975:''' Smit EF, van Meerbeeck JP, Lianes P, Debruyne C, Legrand C, Schramel F, Smit H, Gaafar R, Biesma B, Manegold C, Neymark N, Giaccone G; European Organization for Research and Treatment of Cancer Lung Cancer Group. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975. J Clin Oncol. 2003 Nov 1;21(21):3909-17. [http://ascopubs.org/doi/10.1200/JCO.2003.03.195 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/14581415 PubMed]
# Park JO, Kim SW, Ahn JS, Suh C, Lee JS, Jang JS, Cho EK, Yang SH, Choi JH, Heo DS, Park SY, Shin SW, Ahn MJ, Lee JS, Yun YH, Lee JW, Park K. Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer. J Clin Oncol. 2007 Nov 20;25(33):5233-9. [http://ascopubs.org/doi/full/10.1200/JCO.2007.10.8134 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18024869 PubMed]
# Stathopoulos GP, Antoniou D, Dimitroulis J, Michalopoulou P, Bastas A, Marosis K, Stathopoulos J, Provata A, Yiamboudakis P, Veldekis D, Lolis N, Georgatou N, Toubis M, Pappas Ch, Tsoukalas G. Liposomal cisplatin combined with paclitaxel versus cisplatin and paclitaxel in non-small-cell lung cancer: a randomized phase III multicenter trial. Ann Oncol. 2010 Nov;21(11):2227-32. Epub 2010 May 3. [https://academic.oup.com/annonc/article/21/11/2227/216562 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2962260/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20439345 PubMed]

==Cisplatin & Vinorelbine {{#subobject:bdd6b2|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CV: '''<u>C</u>'''isplatin & '''<u>V</u>'''inorelbine
<br>NP: '''<u>N</u>'''avelbine (Vinorelbine) & '''<u>P</u>'''latinol (Cisplatin)
<br>PV: '''<u>P</u>'''latinol (Cisplatin) & '''<u>V</u>'''inorelbine
<br>VC: '''<u>V</u>'''inorelbine & '''<u>C</u>'''isplatin
===Variant #1, 75/25 {{#subobject:21f9be|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|-
|[https://www.ejcancer.com/article/S0959-8049(04)00772-5/fulltext Martoni et al. 2005]
|style="background-color:#1a9851"|Phase III (E)
|[[#Cisplatin_.26_Gemcitabine_3|Cisplatin & Gemcitabine]]
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV once on day 1
*[[Vinorelbine (Navelbine)]] 25 mg/m<sup>2</sup> IV once per day on days 1 & 8

'''21-day cycle for up to 6 cycles'''
====Subsequent treatment====
*Vinorelbine maintenance

===Variant #2, 80/25 {{#subobject:daeaf6|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=3|[https://academic.oup.com/annonc/article-lookup/doi/10.1093/annonc/mdl377 Ohe et al. 2006]
|rowspan=3 style="background-color:#1a9851"|Phase III (E)
|1. [[#Carboplatin_.26_Paclitaxel_4|Carboplatin & Paclitaxel]]
|style="background-color:#ffffbf"|Seems not superior
|-
|2. [[#Cisplatin_.26_Gemcitabine_3|Cisplatin & Gemcitabine]]
|style="background-color:#ffffbf"|Seems not superior
|-
|3. [[#Cisplatin_.26_Irinotecan|Cisplatin & Irinotecan]]
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)60569-9/fulltext Pirker et al. 2009 (FLEX)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Cisplatin.2C_Vinorelbine.2C_Cetuximab|Cisplatin, Vinorelbine, Cetuximab]]
|style="background-color:#fc8d59"|Seems to have inferior OS
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2009.23.3445 Takeda et al. 2009 (WJTOG0203)]
|style="background-color:#1a9851"|Phase III (C)
|Platinum doublet x 3, then Gefitinib
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 80 mg/m<sup>2</sup> IV once on day 1
*[[Vinorelbine (Navelbine)]] 25 mg/m<sup>2</sup> IV once per day on days 1 & 8

'''21-day cycle for up to 6 cycles (FLEX; WJTOG0203) or indefinitely (Ohe et al. 2006)'''

===Variant #3, 80/30, 2 out of 3 weeks vinorelbine {{#subobject:6c3243|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 20%"|Study
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 20%"|Comparator
!style="width: 20%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
!style="width: 20%"|[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2003.06.099 Gridelli et al. 2003]
|style="background-color:#1a9851"|Phase III (C)
|[[#Gemcitabine_.26_Vinorelbine|Gemcitabine & Vinorelbine]]
| style="background-color:#d9ef8b" |Might have superior OS
|
|-
|[http://ascopubs.org/doi/10.1200/JCO.2005.04.016 Georgoulias et al. 2005]
|style="background-color:#1a9851"|Phase III (C)
|[[Non-small_cell_lung_cancer_-_historical#Docetaxel_.26_Gemcitabine|Docetaxel & Gemcitabine]]
|style="background-color:#ffffbf"|Seems not superior
|
|-
|[https://www.lungcancerjournal.info/article/S0169-5002(08)00009-3/fulltext Gebbia et al. 2008]
|style="background-color:#1a9851"|Phase III (C)
|Cisplatin & Vinorelbine, 3 out of 4 weeks
|style="background-color:#ffffbf"|Seems not superior
| style="background-color:#1a9850" |Less toxic
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 80 mg/m<sup>2</sup> IV once on day 8
*[[Vinorelbine (Navelbine)]] 30 mg/m<sup>2</sup> IV once per day on days 1 & 8

'''21-day cycle for 6 cycles (Gridelli et al. 2003) or up to 9 cycles (Georgoulias et al. 2005)'''

===Variant #4, 80/30, weekly vinorelbine {{#subobject:6c3243|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://academic.oup.com/annonc/article-abstract/5/1/37/226807 Depierre et al. 1994]
|style="background-color:#1a9851"|Phase III (E)
|Vinorelbine
| style="background-color:#1a9850" |Superior TTP
|-
|[https://academic.oup.com/annonc/article/13/12/1853/148662 Souquet et al. 2002 (GLOB-1)]
|style="background-color:#1a9851"|Phase III (C)
|NIP
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 80 mg/m<sup>2</sup> IV once on day 1
*[[Vinorelbine (Navelbine)]] 30 mg/m<sup>2</sup> IV once per day on days 1, 8, 15

'''21-day cycles'''

===Variant #5, 100/25 {{#subobject:45998f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/abs/10.1200/JCO.1998.16.7.2459 Wozniak et al. 1998]
|style="background-color:#1a9851"|Phase III (E)
|[[Non-small_cell_lung_cancer_-_historical#Cisplatin_monotherapy|Cisplatin]]
| style="background-color:#1a9850" |Superior OS
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2001.19.13.3210 Kelly et al. 2001 (SWOG 9509)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Carboplatin_.26_Paclitaxel_4|Carboplatin & Paclitaxel]]
|style="background-color:#ffffbf"|Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2002.02.068 Scagliotti et al. 2002]
|style="background-color:#1a9851"|Phase III (C)
|1. [[#Carboplatin_.26_Paclitaxel_4|Carboplatin & Paclitaxel]]<br> 2. [[#Cisplatin_.26_Gemcitabine_3|Cisplatin & Gemcitabine]]
|style="background-color:#ffffbf"|Seems not superior
|-
|rowspan=2|[http://jco.ascopubs.org/content/21/16/3016.long Fossella et al. 2003 (TAX 326)]
|rowspan=2 style="background-color:#1a9851"|Phase III (C)
|1. [[#Carboplatin_.26_Docetaxel|Carboplatin & Docetaxel]]
|style="background-color:#ffffbf"|Seems not superior
|-
|2. [[#Cisplatin_.26_Docetaxel_3|Cisplatin & Docetaxel]]
|style="background-color:#fc8d59"|Seems to have inferior OS
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2007.12.2614 Ramlau et al. 2008 (SPIRIT I)]
|style="background-color:#1a9851"|Phase III (C)
|CV & Bexarotene
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV once on day 1
*[[Vinorelbine (Navelbine)]] 25 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22

'''28-day cycle for up to 10 cycles (SWOG 9509) or indefinitely (TAX 326, SPIRIT I)'''

===Variant #6, 100/30 {{#subobject:cda93a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://academic.oup.com/annonc/article/12/1/59/207448 Robinet et al. 2001 (GFPC 95-1)]
|style="background-color:#1a9851"|Phase III (C)
|Cisplatin, Vinorelbine, concurrent WBRT
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://academic.oup.com/annonc/article-lookup/doi/10.1093/annonc/mdi126 Pujol et al. 2005]
|style="background-color:#1a9851"|Phase III (C)
|[[Non-small_cell_lung_cancer_-_historical#Docetaxel_.26_Gemcitabine|Docetaxel & Gemcitabine]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''Note: patients in GFPC 95-1 had intracranial metastases.''
====Chemotherapy====
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV over 60 to 120 minutes once on day 1
*[[Vinorelbine (Navelbine)]] 30 mg/m<sup>2</sup> IV over 10 to 20 minutes once per day on days 1, 8, 15, 22

'''28-day cycle for 6 cycles'''
====Subsequent treatment====
*GFPC 95-1: WBRT

===Variant #7, 120/30 {{#subobject:2bf191|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[http://ascopubs.org/doi/10.1200/JCO.1994.12.2.360 Le Chevalier et al. 1994]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. Cisplatin & Vindesine
| style="background-color:#91cf60" |Seems to have superior OS
|-
|2. Vinorelbine
| style="background-color:#1a9850" |Superior OS
|-
|rowspan=2|[http://ascopubs.org/doi/full/10.1200/JCO.2000.18.7.1451 Comella et al. 2000]
|rowspan=2 style="background-color:#1a9851"|Phase III (C)
|1. [[#Cisplatin_.26_Gemcitabine_3|Cisplatin & Gemcitabine]]
| style="background-color:#d3d3d3" |Not reported
|-
|2. PGV
| style="background-color:#d73027" |Inferior OS
|-
|}
''Note: in Comella et al. 2000, vinorelbine was given for a total of 10 weeks.''
====Chemotherapy====
*[[Cisplatin (Platinol)]] 120 mg/m<sup>2</sup> IV once per day on days 1, 29, then every 6 weeks
*[[Vinorelbine (Navelbine)]] 30 mg/m<sup>2</sup> IV once per week

'''Continued indefinitely (see note)'''

===References===
# Depierre A, Chastang C, Quoix E, Lebeau B, Blanchon F, Paillot N, Lemarie E, Milleron B, Moro D, Clavier J, Herman D, Tuchais E, Jacoulet P, Brechot JM, Cordier JF, Solal-Celigny P, Badri N, Besenval M. Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: a randomized trial. Ann Oncol. 1994 Jan;5(1):37-42. [https://academic.oup.com/annonc/article-abstract/5/1/37/226807 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/8172790 PubMed]
# Le Chevalier T, Brisgand D, Douillard JY, Pujol JL, Alberola V, Monnier A, Riviere A, Lianes P, Chomy P, Cigolari S, Gottfried M, Ruffle P, Panizo A, Gaspard MH, Ravaioli A, Besenval M, Besson F, Martinez A, Berthaud P, Tursz T. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol. 1994 Feb;12(2):360-7. [http://ascopubs.org/doi/10.1200/JCO.1994.12.2.360 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/8113844 PubMed]
# Wozniak AJ, Crowley JJ, Balcerzak SP, Weiss GR, Spiridonidis CH, Baker LH, Albain KS, Kelly K, Taylor SA, Gandara DR, Livingston RB. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol. 1998 Jul;16(7):2459-65. [http://ascopubs.org/doi/abs/10.1200/JCO.1998.16.7.2459 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/9667264 PubMed]
# Comella P, Frasci G, Panza N, Manzione L, De Cataldis G, Cioffi R, Maiorino L, Micillo E, Lorusso V, Di Rienzo G, Filippelli G, Lamberti A, Natale M, Bilancia D, Nicolella G, Di Nota A, Comella G. Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: interim analysis of a phase III trial of the Southern Italy Cooperative Oncology Group. J Clin Oncol. 2000 Apr;18(7):1451-7. [http://ascopubs.org/doi/full/10.1200/JCO.2000.18.7.1451 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10735892 PubMed]
# '''GFPC 95-1:''' Robinet G, Thomas P, Breton JL, Léna H, Gouva S, Dabouis G, Bennouna J, Souquet PJ, Balmes P, Thiberville L, Fournel P, Quoix E, Riou R, Rebattu P, Pérol M, Paillotin D, Mornex F. Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Français de Pneumo-Cancérologie (GFPC) Protocol 95-1. Ann Oncol. 2001 Jan;12(1):59-67. [https://academic.oup.com/annonc/article/12/1/59/207448 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11249050 PubMed]
# '''SWOG 9509:''' Kelly K, Crowley J, Bunn PA Jr, Presant CA, Grevstad PK, Moinpour CM, Ramsey SD, Wozniak AJ, Weiss GR, Moore DF, Israel VK, Livingston RB, Gandara DR. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol. 2001 Jul 1;19(13):3210-8. [http://ascopubs.org/doi/full/10.1200/JCO.2001.19.13.3210 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11432888 PubMed]
# Scagliotti GV, De Marinis F, Rinaldi M, Crinò L, Gridelli C, Ricci S, Matano E, Boni C, Marangolo M, Failla G, Altavilla G, Adamo V, Ceribelli A, Clerici M, Di Costanzo F, Frontini L, Tonato M; Italian Lung Cancer Project. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol. 2002 Nov 1;20(21):4285-91. [http://ascopubs.org/doi/full/10.1200/JCO.2002.02.068 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/12409326 PubMed]
# '''GLOB-1:''' Souquet PJ, Tan EH, Rodrigues Pereira J, Van Klaveren R, Price A, Gatzemeier U, Jaworski M, Burillon JP, Aubert D. GLOB-1: a prospective randomised clinical phase III trial comparing vinorelbine-cisplatin with vinorelbine-ifosfamide-cisplatin in metastatic non-small-cell lung cancer patients. Ann Oncol. 2002 Dec;13(12):1853-61. Erratum in: Ann Oncol. 2003 Feb;14(2):347. [https://academic.oup.com/annonc/article/13/12/1853/148662 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12453852 PubMed]
<!-- Previously presented in part at the Annual Meeting of the American Society of Clinical Oncology (ASCO), San Francisco, CA, May 12–15, 2001; the Annual Meeting of ASCO, Orlando, FL, May 18–21, 2002; and the Congress of the European Society for Medical Oncology, Nice, France, October 18–22, 2002. -->
# '''TAX 326:''' Fossella F, Rodrigues Pereira J, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, Mattson KV, Ramlau R, Szczesna A, Fidias P, Millward M, Belani CP. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol. 2003 Aug 15;21(16):3016-24. Epub 2003 Jul 1. [http://jco.ascopubs.org/content/21/16/3016.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12837811 PubMed]
# Gridelli C, Gallo C, Shepherd FA, Illiano A, Piantedosi F, Robbiati SF, Manzione L, Barbera S, Frontini L, Veltri E, Findlay B, Cigolari S, Myers R, Ianniello GP, Gebbia V, Gasparini G, Fava S, Hirsh V, Bezjak A, Seymour L, Perrone F. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2003 Aug 15;21(16):3025-34. Epub 2003 Jul 1. [http://ascopubs.org/doi/full/10.1200/JCO.2003.06.099 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12837810 PubMed]
# Martoni A, Marino A, Sperandi F, Giaquinta S, Di Fabio F, Melotti B, Guaraldi M, Palomba G, Preti P, Petralia A, Artioli F, Picece V, Farris A, Mantovani L. Multicentre randomised phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer. Eur J Cancer. 2005 Jan;41(1):81-92. [https://www.ejcancer.com/article/S0959-8049(04)00772-5/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15617993 PubMed]
# Georgoulias V, Ardavanis A, Tsiafaki X, Agelidou A, Mixalopoulou P, Anagnostopoulou O, Ziotopoulos P, Toubis M, Syrigos K, Samaras N, Polyzos A, Christou A, Kakolyris S, Kouroussis C, Androulakis N, Samonis G, Chatzidaki D. Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol. 2005 May 1;23(13):2937-45. Epub 2005 Feb 22. [http://ascopubs.org/doi/10.1200/JCO.2005.04.016 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15728228 PubMed]
# Pujol JL, Breton JL, Gervais R, Rebattu P, Depierre A, Morère JF, Milleron B, Debieuvre D, Castéra D, Souquet PJ, Moro-Sibilot D, Lemarié E, Kessler R, Janicot H, Braun D, Spaeth D, Quantin X, Clary C. Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin. Ann Oncol. 2005 Apr;16(4):602-10. Epub 2005 Mar 1. [https://academic.oup.com/annonc/article-lookup/doi/10.1093/annonc/mdi126 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15741225 PubMed]
# Ohe Y, Ohashi Y, Kubota K, Tamura T, Nakagawa K, Negoro S, Nishiwaki Y, Saijo N, Ariyoshi Y, Fukuoka M. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol. 2007 Feb;18(2):317-23. Epub 2006 Nov 1. [https://academic.oup.com/annonc/article-lookup/doi/10.1093/annonc/mdl377 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17079694 PubMed]
# Gebbia V, Galetta D, Lorusso V, Caruso M, Verderame F, Pezzella G, Borsellino N, Durini E, Valenza R, Agostara B, Colucci G; Gruppo Oncologico Italia Meridionale. Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the GOIM (Gruppo Oncologico Italia Meridionale). Lung Cancer. 2008 Sep;61(3):369-77. Epub 2008 Mar 4. [https://www.lungcancerjournal.info/article/S0169-5002(08)00009-3/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18308419 PubMed]
# '''SPIRIT I:''' Ramlau R, Zatloukal P, Jassem J, Schwarzenberger P, Orlov SV, Gottfried M, Rodrigues Pereira J, Temperley G, Negro-Vilar R, Rahal S, Zhang JK, Negro-Vilar A, Dziewanowska ZE. Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I. J Clin Oncol. 2008 Apr 10;26(11):1886-92. [http://ascopubs.org/doi/full/10.1200/JCO.2007.12.2614 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18398154 PubMed]
# '''FLEX:''' Pirker R, Rodrigues Pereira J, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, Vynnychenko I, Park K, Yu CT, Ganul V, Roh JK, Bajetta E, O'Byrne K, de Marinis F, Eberhardt W, Goddemeier T, Emig M, Gatzemeier U; FLEX Study Team. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet. 2009 May 2;373(9674):1525-31. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)60569-9/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19410716 PubMed]
# '''WJTOG0203:''' Takeda K, Hida T, Sato T, Ando M, Seto T, Satouchi M, Ichinose Y, Katakami N, Yamamoto N, Kudoh S, Sasaki J, Matsui K, Takayama K, Kashii T, Iwamoto Y, Sawa T, Okamoto I, Kurata T, Nakagawa K, Fukuoka M. Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (WJTOG0203). J Clin Oncol. 2010 Feb 10;28(5):753-60. Epub 2009 Dec 28. [http://ascopubs.org/doi/full/10.1200/JCO.2009.23.3445 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20038730 PubMed]

==Cisplatin, Vinorelbine, Cetuximab {{#subobject:9c28e0|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:b4c5e3|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)60569-9/fulltext Pirker et al. 2009 (FLEX)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Cisplatin_.26_Vinorelbine_3|Cisplatin & Vinorelbine]]
|style="background-color:#91cf60"|Seems to have superior OS
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 80 mg/m<sup>2</sup> IV once on day 1
*[[Vinorelbine (Navelbine)]] 25 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Cetuximab (Erbitux)]] as follows:
**Week 1: 400 mg/m<sup>2</sup> IV over 2 hours once on day 1
**Week 2 onwards: 250 mg/m<sup>2</sup> IV over 60 minutes once per week

'''21-day cycle for up to 6 cycles'''

====Subsequent treatment====
*Cetuximab maintenance

===References===
# '''FLEX:''' Pirker R, Rodrigues Pereira J, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, Vynnychenko I, Park K, Yu CT, Ganul V, Roh JK, Bajetta E, O'Byrne K, de Marinis F, Eberhardt W, Goddemeier T, Emig M, Gatzemeier U; FLEX Study Team. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet. 2009 May 2;373(9674):1525-31. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)60569-9/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19410716 PubMed]

==Gemcitabine & Paclitaxel {{#subobject:29305d|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
GT: '''<u>G</u>'''emcitabine & '''<u>T</u>'''axol (Paclitaxel)
===Regimen {{#subobject:b3708b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://academic.oup.com/annonc/article/18/2/324/251160 Comella et al. 2006 (SICOG 0101)]
|style="background-color:#1a9851"|Phase III (C)
|1. [[#Gemcitabine_.26_Vinorelbine|GV]]<br> 2. PGT<br> 3. PGV
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Gemcitabine (Gemzar)]] 1000 mg/m<sup>2</sup> IV once per day on days 1 & 8 
*[[Paclitaxel (Taxol)]] 125 mg/m<sup>2</sup> IV once per day on days 1 & 8 

'''21-day cycle for up to 6 cycles'''

===References===
# '''SICOG 0101:''' Comella P, Filippelli G, De Cataldis G, Massidda B, Frasci G, Maiorino L, Putzu C, Mancarella S, Palmeri S, Cioffi R, Roselli M, Buzzi F, Milia V, Gambardella A, Natale D, Bianco M, Ghiani M, Masullo P; Southern Italy Cooperative Oncology Group. Efficacy of the combination of cisplatin with either gemcitabine and vinorelbine or gemcitabine and paclitaxel in the treatment of locally advanced or metastatic non-small-cell lung cancer: a phase III randomised trial of the Southern Italy Cooperative Oncology Group (SICOG 0101). Ann Oncol. 2007 Feb;18(2):324-30. Epub 2006 Oct 27. [https://academic.oup.com/annonc/article/18/2/324/251160 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17071935 PubMed]

==Gemcitabine & Vinorelbine {{#subobject:3c6eb0|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
VG: '''<u>V</u>'''inorelbine & '''<u>G</u>'''emcitabine
===Variant #1, 1000/25, 2 weeks out of 3 (IV vinorelbine) {{#subobject:a01f58|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/10.1200/JCO.2004.10.576 Laack et al. 2004]
|style="background-color:#1a9851"|Phase III (E)
|GVP
|style="background-color:#ffffbf"|Seems not superior
|-
|[http://www.lungcancerjournal.info/article/S0169-5002(05)00119-4/fulltext Tan et al. 2005 (GLOB 2)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Carboplatin_.26_Vinorelbine|Carboplatin & Vinorelbine]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Chemotherapy====
*[[Gemcitabine (Gemzar)]] 1000 mg/m<sup>2</sup> IV once per day on days 1 & 8 
*[[Vinorelbine (Navelbine)]] 25 mg/m<sup>2</sup> IV once per day on days 1 & 8 

====Supportive medications====
*"[[:Category:Emesis_prevention|Antiemetic]] agents and other supportive treatments were provided at the discretion of the treating physician."

'''21-day cycles'''

===Variant #2, 1000/25, 3 weeks out of 4 (IV vinorelbine) {{#subobject:2c7f61|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 20%"|Study
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 20%"|Comparator
!style="width: 20%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
!style="width: 20%"|[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[https://www.clinical-lung-cancer.com/article/S1525-7304(11)70825-7/pdf Greco et al. 2007]
|style="background-color:#1a9851"|Phase III (E)
|PCG
|style="background-color:#ffffbf"|Seems not superior
| style="background-color:#1a9850" |Less toxic
|-
|}
====Chemotherapy====
*[[Gemcitabine (Gemzar)]] 1000 mg/m<sup>2</sup> IV once per day on days 1, 8, 15 
*[[Vinorelbine (Navelbine)]] 25 mg/m<sup>2</sup> IV once per day on days 1, 8, 15

'''28-day cycles'''

===Variant #3, 1000/60 (PO vinorelbine) {{#subobject:c8251a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3405221/ Fløtten et al. 2012]
|style="background-color:#1a9851"|Phase III (E)
|[[#Carboplatin_.26_Vinorelbine|Carboplatin & Vinorelbine]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Chemotherapy====
*[[Gemcitabine (Gemzar)]] 1000 mg/m<sup>2</sup> IV once per day on days 1 & 8 
*[[Vinorelbine (Navelbine)]] 60 mg/m<sup>2</sup> PO once per day on days 1 & 8 

'''21-day cycle for 3 cycles'''
===References===
# Gridelli C, Gallo C, Shepherd FA, Illiano A, Piantedosi F, Robbiati SF, Manzione L, Barbera S, Frontini L, Veltri E, Findlay B, Cigolari S, Myers R, Ianniello GP, Gebbia V, Gasparini G, Fava S, Hirsh V, Bezjak A, Seymour L, Perrone F. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2003 Aug 15;21(16):3025-34. Epub 2003 Jul 1. [http://ascopubs.org/doi/full/10.1200/JCO.2003.06.099 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12837810 PubMed]
# Laack E, Dickgreber N, Müller T, Knuth A, Benk J, Lorenz C, Gieseler F, Dürk H, Engel-Riedel W, Dalhoff K, Kortsik C, Graeven U, Burk M, Dierlamm T, Welte T, Burkholder I, Edler L, Hossfeld DK; German and Swiss Lung Cancer Study Group. Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small-cell lung cancer: from the German and Swiss Lung Cancer Study Group. J Clin Oncol. 2004 Jun 15;22(12):2348-56. [http://ascopubs.org/doi/10.1200/JCO.2004.10.576 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15197195 PubMed]
# '''GLOB 2:''' Tan EH, Szczesna A, Krzakowski M, Macha HN, Gatzemeier U, Mattson K, Wernli M, Reiterer P, Hui R, Pawel JV, Bertetto O, Pouget JC, Burillon JP, Parlier Y, Abratt R; GLOB 2 group. Randomized study of vinorelbine--gemcitabine versus vinorelbine--carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer. 2005 Aug;49(2):233-40. [http://www.lungcancerjournal.info/article/S0169-5002(05)00119-4/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16022917 PubMed]
# Greco FA, Spigel DR, Kuzur ME, Shipley D, Gray JR, Thompson DS, Burris HA, Yardley DA, Pati A, Webb CD, Gandhi JG, Hainsworth JD. Paclitaxel/Carboplatin/gemcitabine versus gemcitabine/vinorelbine in advanced non-small-cell lung cancer: a phase II/III study of the Minnie Pearl Cancer Research Network. Clin Lung Cancer. 2007 Sep;8(8):483-7. [https://www.clinical-lung-cancer.com/article/S1525-7304(11)70825-7/pdf link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/17922972 PubMed]
# Fløtten Ø, Grønberg BH, Bremnes R, Amundsen T, Sundstrøm S, Rolke H, Hornslien K, Wentzel-Larsen T, Aasebø U, von Plessen C. Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC: a phase III randomised controlled trial by the Norwegian Lung Cancer Study Group. Br J Cancer. 2012 Jul 24;107(3):442-7. Epub 2012 Jul 3. [https://www.nature.com/articles/bjc2012284 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3405221/ link to PMC article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22759880 PubMed]

==Ipilimumab & Nivolumab {{#subobject:517ff0|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:3a481c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[https://www.nejm.org/doi/full/10.1056/NEJMoa1801946 Hellmann et al. 2018 (CheckMate 227)]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. [[#Nivolumab_monotherapy|Nivolumab]]
|style="background-color:#d3d3d3"|Not reported
|-
|2. Platinum doublet
|style="background-color:#1a9850"|Superior PFS
|-
|}
====Immunotherapy====
*[[Ipilimumab (Yervoy)]] 3 mg/kg IV once on day 1, 15, 29
*[[Nivolumab (Opdivo)]] 1 mg/kg IV once on day 1

'''42-day cycles'''

===References===
# '''CheckMate 227:''' Hellmann MD, Ciuleanu TE, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C, Minenza E, Linardou H, Burgers S, Salman P, Borghaei H, Ramalingam SS, Brahmer J, Reck M, O'Byrne KJ, Geese WJ, Green G, Chang H, Szustakowski J, Bhagavatheeswaran P, Healey D, Fu Y, Nathan F, Paz-Ares L. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med. 2018 May 31;378(22):2093-2104. Epub 2018 Apr 16. [https://www.nejm.org/doi/full/10.1056/NEJMoa1801946 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29658845 PubMed]

==Nivolumab monotherapy {{#subobject:PYR1|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:PYV1|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!Study
![[Levels_of_Evidence#Evidence|Evidence]]
!Comparator
![[Levels_of_Evidence#Efficacy|Efficacy]]
!ORR
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1613493 Carbone et al. 2017 (CheckMate 026)]
|style="background-color:#1a9851"|Phase III (E)
|Platinum doublet (see note)
|style="background-color:#ffffbf"|Seems not superior
|26% (95% CI 20 - 33)
|-
|}
''Note: control arm patients in '''CheckMate 026''' received investigator's choice of platinum doublet; the most commonly used regimen was [[#Carboplatin_.26_Paclitaxel_4|carboplatin & paclitaxel]].''
====Immunotherapy====
*[[Nivolumab (Opdivo)]] 3 mg/kg IV once on day 1
**Notably, on 9/13/16 the [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm520871.htm FDA recommended] that dosing for this indication be changed to 240 mg with the same schedule based on updated pharmacokinetic data.

'''14-day cycles'''

===References===
# '''CheckMate 026:''' Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, Felip E, van den Heuvel MM, Ciuleanu TE, Badin F, Ready N, Hiltermann TJN, Nair S, Juergens R, Peters S, Minenza E, Wrangle JM, Rodriguez-Abreu D, Borghaei H, Blumenschein GR Jr, Villaruz LC, Havel L, Krejci J, Corral Jaime J, Chang H, Geese WJ, Bhagavatheeswaran P, Chen AC, Socinski MA; CheckMate 026 Investigators. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N Engl J Med. 2017 Jun 22;376(25):2415-2426. [https://www.nejm.org/doi/full/10.1056/NEJMoa1613493 link to original article]'''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28636851 PubMed]
# '''CheckMate 227:''' Hellmann MD, Ciuleanu TE, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C, Minenza E, Linardou H, Burgers S, Salman P, Borghaei H, Ramalingam SS, Brahmer J, Reck M, O'Byrne KJ, Geese WJ, Green G, Chang H, Szustakowski J, Bhagavatheeswaran P, Healey D, Fu Y, Nathan F, Paz-Ares L. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med. 2018 May 31;378(22):2093-2104. Epub 2018 Apr 16. [https://www.nejm.org/doi/full/10.1056/NEJMoa1801946 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29658845 PubMed]

==Pembrolizumab monotherapy {{#subobject:430dc7|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:d2e0ab|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 20%"|Study
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 20%"|Comparator
!style="width: 20%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
!style="width: 20%"|[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1501824 Garon et al. 2015 (KEYNOTE-001)]
| style="background-color:#91cf61" |Phase 1, >20 pts in dosing cohort
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1606774 Reck et al. 2016 (KEYNOTE-024)]
|style="background-color:#1a9851"|Phase III (E)
|1. [[#Carboplatin_.26_Gemcitabine | Carboplatin & Gemcitabine]]<br> 2. [[#Carboplatin_.26_Paclitaxel_4 | Carboplatin & Paclitaxel]]<br> 3. [[#Carboplatin_.26_Pemetrexed | Carboplatin & Pemetrexed]]<br> 4. [[#Cisplatin_.26_Gemcitabine_3 | Cisplatin & Gemcitabine]]<br> 5. [[#Cisplatin_.26_Pemetrexed_2 | Cisplatin & Pemetrexed]]
|style="background-color:#1a9850"|Superior OS
|style="background-color:#1a9850"|Superior HRQoL
|-
|[http://ascopubs.org/doi/abs/10.1200/jco.2015.33.15_suppl.tps8105 Mok et al. 2015 (KEYNOTE-042)]
|style="background-color:#1a9851"|Phase III (E)
|1. [[#Carboplatin_.26_Paclitaxel_6 | Carboplatin & Paclitaxel]]<br> 2. [[#Carboplatin_.26_Pemetrexed_2 | Carboplatin & Pemetrexed]]
|style="background-color:#1a9850"|Superior OS
|
|-
|}
'''''KEYNOTE-024''' required PD-L1 to be expressed on at least '''50% of tumor cells''', no EGFR/ALK mutations. Treatment choice for patients in the comparator arm was up to the investigators; most with nonsquamous histology received carboplatin & pemetrexed, whereas most with squamous histology received carboplatin & gemcitabine. Patients could receive a maximum of 35 cycles. ORR was 45% (95% CI: 37-53).''
<br>'''''KEYNOTE-042''' required PD-L1 to be expressed on at least '''1% of tumor cells'''. Treatment choice for patients in the comparator arm was carboplatin & paclitaxel for patients with squamous histology, and carboplatin & pemetrexed for patients with nonsquamous histology.''
====Immunotherapy====
*[[Pembrolizumab (Keytruda)]] 200 IV once on day 1

'''21-day cycles'''

===References===
# '''Phase 1:''' Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J, Lunceford JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, Gandhi L; KEYNOTE-001 Investigators. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015 May 21;372(21):2018-28. Epub 2015 Apr 19. [https://www.nejm.org/doi/full/10.1056/NEJMoa1501824 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25891174 PubMed]
# '''KEYNOTE-024:''' Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Leiby MA, Lubiniecki GM, Shentu Y, Rangwala R, Brahmer JR; KEYNOTE-024 Investigators. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016 Nov 10;375(19):1823-1833. Epub 2016 Oct 8. [https://www.nejm.org/doi/full/10.1056/NEJMoa1606774 link to original article] [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1606774/suppl_file/nejmoa1606774_appendix.pdf link to supplementary appendix] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27718847 PubMed]
## '''HRQoL analysis:''' Brahmer JR, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Zhang J, Lubiniecki GM, Deitz AC, Rangwala R, Reck M. Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. Lancet Oncol. 2017 Dec;18(12):1600-1609. Epub 2017 Nov 9. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30690-3/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/29129441 PubMed]
# '''Abstract:''' Tony Mok, Yi-Long Wu, Patricia A, Watson, Jin Zhang, Reshma A. Rangwala, and Gilberto Lopes. Phase 3 KEYNOTE-042 trial of pembrolizumab (MK-3475) versus platinum doublet chemotherapy in treatment-naive patients (pts) with PD-L1–positive advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology 2015 33:15_suppl, TPS8105-TPS8105 [http://ascopubs.org/doi/abs/10.1200/jco.2015.33.15_suppl.tps8105 link to abstract]

=Advanced or metastatic disease, first-line, nonsquamous=

==ABCP {{#subobject:ee72af|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
ABCP: '''<u>A</u>'''tezolizumab, '''<u>B</u>'''evacizumab, '''<u>C</u>'''arboplatin, '''<u>P</u>'''aclitaxel
===Variant #1, 1200/15/6/175 x 4 {{#subobject:9088c6|Variant=1}}===
{| class="wikitable" style="color:white; background-color:#404040"
|<small>'''FDA-recommended dose'''</small>
|-
|}
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan = 2|[https://www.nejm.org/doi/full/10.1056/NEJMoa1716948 Socinski et al. 2018 (IMpower150)]
|rowspan = 2 style="background-color:#1a9851"|Phase III (E)
|1. ACP
|style="background-color:#d3d3d3"|Not reported
|-
|2. [[#Carboplatin.2C_Paclitaxel.2C_Bevacizumab_2|BCP]]
| style="background-color:#91cf60" |Seems to have superior OS
|-
|}
''Note: the total number of cycles given was determined prior to randomization; this dose was used for Asian patients. This is the FDA-recommended dose for atezolizumab.''
====Chemotherapy====
*[[Atezolizumab (Tecentriq)]] 1200 mg IV over 60 minutes once on day 1
*[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1
*[[Carboplatin (Paraplatin)]] AUC 6 IV once on day 1
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*[[#Atezolizumab_.26_Bevacizumab|Atezolizumab & Bevacizumab maintenance]]

===Variant #2, 1200/15/6/175 x 6 {{#subobject:99ed77|Variant=1}}===
{| class="wikitable" style="color:white; background-color:#404040"
|<small>'''FDA-recommended dose'''</small>
|-
|}
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan = 2|[https://www.nejm.org/doi/full/10.1056/NEJMoa1716948 Socinski et al. 2018 (IMpower150)]
|rowspan = 2 style="background-color:#1a9851"|Phase III (E)
|1. ACP
|style="background-color:#d3d3d3"|Not reported
|-
|2. [[#Carboplatin.2C_Paclitaxel.2C_Bevacizumab_2|BCP]]
| style="background-color:#91cf60" |Seems to have superior OS
|-
|}
''Note: the total number of cycles given was determined prior to randomization; this dose was used for Asian patients. This is the FDA-recommended dose for atezolizumab.''
====Chemotherapy====
*[[Atezolizumab (Tecentriq)]] 1200 mg IV over 60 minutes once on day 1
*[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1
*[[Carboplatin (Paraplatin)]] AUC 6 IV once on day 1
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 6 cycles'''
====Subsequent treatment====
*[[#Atezolizumab_.26_Bevacizumab|Atezolizumab & Bevacizumab maintenance]]

===Variant #3, 1200/15/6/200 x 4 {{#subobject:878885|Variant=1}}===
{| class="wikitable" style="color:white; background-color:#404040"
|<small>'''FDA-recommended dose'''</small>
|-
|}
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan = 2|[https://www.nejm.org/doi/full/10.1056/NEJMoa1716948 Socinski et al. 2018 (IMpower150)]
|rowspan = 2 style="background-color:#1a9851"|Phase III (E)
|1. ACP
|style="background-color:#d3d3d3"|Not reported
|-
|2. [[#Carboplatin.2C_Paclitaxel.2C_Bevacizumab_2|BCP]]
| style="background-color:#91cf60" |Seems to have superior OS
|-
|}
''Note: the total number of cycles given in IMpower150 was determined prior to randomization. This is the FDA-recommended dose for atezolizumab.''
====Chemotherapy====
*[[Atezolizumab (Tecentriq)]] 1200 mg IV over 60 minutes once on day 1
*[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1
*[[Carboplatin (Paraplatin)]] AUC 6 IV once on day 1
*[[Paclitaxel (Taxol)]] 200 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*[[#Atezolizumab_.26_Bevacizumab|Atezolizumab & Bevacizumab maintenance]]

===Variant #4, 1200/15/6/200 x 6 {{#subobject:2b157e|Variant=1}}===
{| class="wikitable" style="color:white; background-color:#404040"
|<small>'''FDA-recommended dose'''</small>
|-
|}
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan = 2|[https://www.nejm.org/doi/full/10.1056/NEJMoa1716948 Socinski et al. 2018 (IMpower150)]
|rowspan = 2 style="background-color:#1a9851"|Phase III (E)
|1. ACP
|style="background-color:#d3d3d3"|Not reported
|-
|2. [[#Carboplatin.2C_Paclitaxel.2C_Bevacizumab_2|BCP]]
| style="background-color:#91cf60" |Seems to have superior OS
|-
|}
''Note: the total number of cycles given in IMpower150 was determined prior to randomization. This is the FDA-recommended dose for atezolizumab.''
====Chemotherapy====
*[[Atezolizumab (Tecentriq)]] 1200 mg IV over 60 minutes once on day 1
*[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1
*[[Carboplatin (Paraplatin)]] AUC 6 IV once on day 1
*[[Paclitaxel (Taxol)]] 200 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 6 cycles'''
====Subsequent treatment====
*[[#Atezolizumab_.26_Bevacizumab|Atezolizumab & Bevacizumab maintenance]]

===References===
# '''IMpower150:''' Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, Finley G, Kelsch C, Lee A, Coleman S, Deng Y, Shen Y, Kowanetz M, Lopez-Chavez A, Sandler A, Reck M; IMpower150 Study Group. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018 Jun 14;378(24):2288-2301. Epub 2018 Jun 4. [https://www.nejm.org/doi/full/10.1056/NEJMoa1716948 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29863955 PubMed]

==Carboplatin & Docetaxel {{#subobject:ba3359|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
DCb: '''<u>D</u>'''ocetaxel & '''<u>C</u>'''ar'''<u>b</u>'''oplatin
===Regimen {{#subobject:0acdc4|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 20%"|Study
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 20%"|Comparator
!style="width: 20%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
!style="width: 20%"|[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[https://www.jto.org/article/S1556-0864(15)32255-3/fulltext Rodrigues-Pereira et al. 2011]
|style="background-color:#1a9851"|Phase III (C)
|[[#Carboplatin_.26_Pemetrexed_2|Carboplatin & Pemetrexed]]
| style="background-color:#ffffbf" |Seems not superior
| style="background-color:#d73027" |Inferior survival without treatment-emergent grade 3/4 toxicity
|-
|}
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 5 IV once on day 1
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for up to 6 cycles'''

===References===
# Rodrigues-Pereira J, Kim JH, Magallanes M, Lee DH, Wang J, Ganju V, Martínez-Barrera L, Barraclough H, van Kooten M, Orlando M. A randomized phase 3 trial comparing pemetrexed/carboplatin and docetaxel/carboplatin as first-line treatment for advanced, nonsquamous non-small cell lung cancer. J Thorac Oncol. 2011 Nov;6(11):1907-14. [https://www.jto.org/article/S1556-0864(15)32255-3/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22005471 PubMed]

==Carboplatin & Paclitaxel {{#subobject:c5fbdf|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
TC: '''<u>T</u>'''axol (Paclitaxel) & '''<u>C</u>'''arboplatin
<br>CP: '''<u>C</u>'''arbolpatin & '''<u>P</u>'''aclitaxel
===Variant #1, 6/175 {{#subobject:e3545d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2014.59.4424 Zhou et al. 2015 (BEYOND)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Carboplatin.2C_Paclitaxel.2C_Bevacizumab_2|Carboplatin, Paclitaxel, Bevacizumab]]
|style="background-color:#fc8d59"|Seems to have inferior OS
|-
|}
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 6 IV once on day 1
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV once on day 1 

====Supportive medications====
*[[:Category:Steroids|Corticosteroids]] could be used as premedication for [[Paclitaxel (Taxol)]] infusion

'''21-day cycle for up to 6 cycles'''

===Variant #2, 6/200 {{#subobject:5f5ff1|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa061884 Sandler et al. 2006 (ECOG E4599)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Carboplatin.2C_Paclitaxel.2C_Bevacizumab_2|PacCBev]], then [[#Bevacizumab_monotherapy|Maintenance Bev]]
|style="background-color:#d73027"|Inferior OS
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa0810699 Mok et al. 2009 (IPASS)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Gefitinib_monotherapy|Gefitinib]]
|style="background-color:#d73027"|Inferior PFS
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2011.41.4987 Scagliotti et al. 2012 (MONET1)]
|style="background-color:#1a9851"|Phase III (C)
|Carboplatin, Motesanib, Paclitaxel
|style="background-color:#ffffbf"|Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2017.72.7297 Kubota et al. 2017 (MONET-A)]
|style="background-color:#1a9851"|Phase III (C)
|Carboplatin, Motesanib, Paclitaxel
| style="background-color:#fee08b" |Might have inferior PFS
|-
|}
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 6 IV over 15 to 60 minutes once on day 1, '''given second'''
*[[Paclitaxel (Taxol)]] 200 mg/m<sup>2</sup> IV over 3 hours once on day 1, '''given first'''

'''21-day cycle for 3 or more cycles'''

===References===
# '''ECOG E4599:''' Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006 Dec 14;355(24):2542-50. [https://www.nejm.org/doi/full/10.1056/NEJMoa061884 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17167137 PubMed]
## '''Subgroup analysis:''' Ramalingam SS, Dahlberg SE, Langer CJ, Gray R, Belani CP, Brahmer JR, Sandler AB, Schiller JH, Johnson DH; Eastern Cooperative Oncology Group. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol. 2008 Jan 1;26(1):60-5. [http://jco.ascopubs.org/content/26/1/60.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18165641 PubMed]
# '''IPASS:''' Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009 Sep 3;361(10):947-57. Epub 2009 Aug 19. [https://www.nejm.org/doi/full/10.1056/NEJMoa0810699 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19692680 PubMed]
## '''Update:''' Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, Chao TY, Nakagawa K, Chu DT, Saijo N, Duffield EL, Rukazenkov Y, Speake G, Jiang H, Armour AA, To KF, Yang JC, Mok TS. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011 Jul 20;29(21):2866-74. Epub 2011 Jun 13. [http://ascopubs.org/doi/full/10.1200/JCO.2010.33.4235 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/21670455 PubMed]
## '''Dataset:''' [https://www.projectdatasphere.org/projectdatasphere/html/content/152 Project Data Sphere]
<!-- Presented in part at 47th Annual Meeting of the American Society of Clinical Oncology, June 3-7, 2011, Chicago, IL. -->
# '''MONET1:''' Scagliotti GV, Vynnychenko I, Park K, Ichinose Y, Kubota K, Blackhall F, Pirker R, Galiulin R, Ciuleanu TE, Sydorenko O, Dediu M, Papai-Szekely Z, Banaclocha NM, McCoy S, Yao B, Hei YJ, Galimi F, Spigel DR. International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1. J Clin Oncol. 2012 Aug 10;30(23):2829-36. Epub 2012 Jul 2. [http://ascopubs.org/doi/full/10.1200/JCO.2011.41.4987 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22753922 PubMed]
# '''BEYOND:''' Zhou C, Wu YL, Chen G, Liu X, Zhu Y, Lu S, Feng J, He J, Han B, Wang J, Jiang G, Hu C, Zhang H, Cheng G, Song X, Lu Y, Pan H, Zheng W, Yin AY. BEYOND: a randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer. J Clin Oncol. 2015 Jul 1;33(19):2197-204. Epub 2015 May 26. [http://ascopubs.org/doi/full/10.1200/JCO.2014.59.4424 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26014294 PubMed]
# '''MONET-A:''' Kubota K, Yoshioka H, Oshita F, Hida T, Yoh K, Hayashi H, Kato T, Kaneda H, Yamada K, Tanaka H, Ichinose Y, Park K, Cho EK, Lee KH, Lin CB, Yang JC, Hara K, Asato T, Nakagawa K. Phase III, randomized, placebo-controlled, double-blind trial of motesanib (AMG-706) in combination with paclitaxel and carboplatin in East Asian patients with advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2017 Nov 10;35(32):3662-3670. Epub 2017 Sep 13. [http://ascopubs.org/doi/full/10.1200/JCO.2017.72.7297 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28902534 PubMed]

==Carboplatin, Paclitaxel, Bevacizumab {{#subobject:1c2c25|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
PacCBev: '''<u>Pac</u>'''litaxel, '''<u>C</u>'''arboplatin, '''<u>Bev</u>'''acizumab 
<br>B+CP: '''<u>B</u>'''evacizumab, '''<u>C</u>'''arboplatin, '''<u>Pac</u>'''litaxel
<br>BCP: '''<u>B</u>'''evacizumab, '''<u>C</u>'''arboplatin, '''<u>Pac</u>'''litaxel
<br>CbTB: '''<u>C</u>'''ar'''<u>b</u>'''oplatin, '''<u>T</u>'''axol (Paclitaxel), '''<u>Bev</u>'''acizumab
===Variant #1, 6/175/15 x 4 {{#subobject:8da6d9|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan = 2|[https://www.nejm.org/doi/full/10.1056/NEJMoa1716948 Socinski et al. 2018 (IMpower150)]
|rowspan = 2 style="background-color:#1a9851"|Phase III (C)
|1. ACP
|style="background-color:#d3d3d3"|Not reported
|-
|2. [[#ABCP|ABCP]]
|style="background-color:#fc8d59"|Seems to have inferior OS
|-
|}
''Note: the total number of cycles given was determined prior to randomization; this dose was used for Asian patients.''
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 6 IV once on day 1
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV once on day 1
*[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*[[#Bevacizumab_monotherapy|Bevacizumab maintenance]]

===Variant #2, 6/175/15 x 6 {{#subobject:3f73b8|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan = 2|[https://www.nejm.org/doi/full/10.1056/NEJMoa1716948 Socinski et al. 2018 (IMpower150)]
|rowspan = 2 style="background-color:#1a9851"|Phase III (C)
|1. ACP
|style="background-color:#d3d3d3"|Not reported
|-
|2. [[#ABCP|ABCP]]
|style="background-color:#fc8d59"|Seems to have inferior OS
|-
|}
''Note: the total number of cycles given was determined prior to randomization; this dose was used for Asian patients.''
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 6 IV once on day 1
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV once on day 1
*[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1

'''21-day cycle for 6 cycles'''
====Subsequent treatment====
*[[#Bevacizumab_monotherapy|Bevacizumab maintenance]]

===Variant #3, 6/200/15 x 4 {{#subobject:8e5de0|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881367/ Patel et al. 2013 (PointBreak)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Carboplatin.2C_Pemetrexed.2C_Bevacizumab|PemCBev]], then [[#Bevacizumab_.26_Pemetrexed|PemBev maint.]]
|style="background-color:#fc8d59"|Seems to have inferior PFS
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881367/ Zinner et al. 2015 (PRONOUNCE)]
|style="background-color:#1a9851"|Phase III (C)
|[[Complex_multipart_regimens#PRONOUNCE|See link]]
|style="background-color:#ffffbf"|[[Complex_multipart_regimens#PRONOUNCE|See link]]
|-
|rowspan = 2|[https://www.nejm.org/doi/full/10.1056/NEJMoa1716948 Socinski et al. 2018 (IMpower150)]
|rowspan = 2 style="background-color:#1a9851"|Phase III (C)
|1. ACP
|style="background-color:#d3d3d3"|Not reported
|-
|2. [[#ABCP|ABCP]]
|style="background-color:#fc8d59"|Seems to have inferior OS
|-
|}
''Note: the total number of cycles given in IMpower150 was determined prior to randomization.''
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 6 IV once on day 1
*[[Paclitaxel (Taxol)]] 200 mg/m<sup>2</sup> IV once on day 1
*[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1

====Supportive medications====
*Premedications per paclitaxel label
*Erythropoietic agents or granulocyte colony-stimulating factors allowed per ASCO & NCCN guidelines

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*[[#Bevacizumab_monotherapy|Bevacizumab maintenance]]

===Variant #4, 6/200/15 x 6 {{#subobject:7df5c3|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa061884 Sandler et al. 2006 (ECOG E4599)]
|style="background-color:#1a9851"|Phase III (E)
|[[Complex_multipart_regimens#ECOG_E4599|See link]]
| style="background-color:#1a9850" |[[Complex_multipart_regimens#ECOG_E4599|See link]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2014.59.4424 Zhou et al. 2015 (BEYOND)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Carboplatin_.26_Paclitaxel_5|Carboplatin & Paclitaxel]]
|style="background-color:#91cf60"|Seems to have superior OS
|-
|rowspan = 2|[https://www.nejm.org/doi/full/10.1056/NEJMoa1716948 Socinski et al. 2018 (IMpower150)]
|rowspan = 2 style="background-color:#1a9851"|Phase III (C)
|1. ACP
|style="background-color:#d3d3d3"|Not reported
|-
|2. [[#ABCP|ABCP]]
|style="background-color:#fc8d59"|Seems to have inferior OS
|-
|}
''Note: the total number of cycles given in IMpower150 was determined prior to randomization. Patients in SWOG S0819 were EGFR FISH positive.''
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 6 IV over 15 to 30 minutes once on day 1, '''given second, starting 60 minutes after the completion of paclitaxel'''
*[[Paclitaxel (Taxol)]] 200 mg/m<sup>2</sup> IV over 3 hours once on day 1, '''given first'''
*[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1, '''given third, starting 60 minutes after the completion of carboplatin'''
**Infusion time per Johnson, et al. 2004 was over 90 minutes for cycle 1; if tolerated, given over 30 to 60 minutes for cycles 2 and later 

'''21-day cycle for up to 6 cycles'''
====Subsequent treatment====
*[[#Bevacizumab_monotherapy|Bevacizumab maintenance]]

===References===
# '''ECOG E4599:''' Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006 Dec 14;355(24):2542-50. [https://www.nejm.org/doi/full/10.1056/NEJMoa061884 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17167137 PubMed]
## '''Subgroup analysis:''' Ramalingam SS, Dahlberg SE, Langer CJ, Gray R, Belani CP, Brahmer JR, Sandler AB, Schiller JH, Johnson DH; Eastern Cooperative Oncology Group. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol. 2008 Jan 1;26(1):60-5. [http://jco.ascopubs.org/content/26/1/60.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18165641 PubMed]
<!-- Presented in part at the Chicago Multidisciplinary Symposium in Thoracic Oncology, Chicago, IL, September 6-8, 2012, and at the American Society of Clinical Oncology's Quality Care Symposium, San Diego, CA, November 30-December 1, 2012. -->
# '''PointBreak:''' Patel JD, Socinski MA, Garon EB, Reynolds CH, Spigel DR, Olsen MR, Hermann RC, Jotte RM, Beck T, Richards DA, Guba SC, Liu J, Frimodt-Moller B, John WJ, Obasaju CK, Pennella EJ, Bonomi P, Govindan R. PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013 Dec 1;31(34):4349-57. [http://jco.ascopubs.org/content/31/34/4349.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881367/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24145346 PubMed]
## '''Dataset:''' [https://www.projectdatasphere.org/projectdatasphere/html/content/141 Project Data Sphere]
# '''PRONOUNCE:''' Zinner RG, Obasaju CK, Spigel DR, Weaver RW, Beck JT, Waterhouse DM, Modiano MR, Hrinczenko B, Nikolinakos PG, Liu J, Koustenis AG, Winfree KB, Melemed SA, Guba SC, Ortuzar WI, Desaiah D, Treat JA, Govindan R, Ross HJ. PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer. J Thorac Oncol. 2015 Jan;10(1):134-42. [http://www.jto.org/article/S1556-0864(15)30782-6/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4276572/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25371077 PubMed]
# '''BEYOND:''' Zhou C, Wu YL, Chen G, Liu X, Zhu Y, Lu S, Feng J, He J, Han B, Wang J, Jiang G, Hu C, Zhang H, Cheng G, Song X, Lu Y, Pan H, Zheng W, Yin AY. BEYOND: a randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer. J Clin Oncol. 2015 Jul 1;33(19):2197-204. Epub 2015 May 26. [http://ascopubs.org/doi/full/10.1200/JCO.2014.59.4424 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26014294 PubMed]
# '''IMpower150:''' Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, Finley G, Kelsch C, Lee A, Coleman S, Deng Y, Shen Y, Kowanetz M, Lopez-Chavez A, Sandler A, Reck M; IMpower150 Study Group. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018 Jun 14;378(24):2288-2301. Epub 2018 Jun 4. [https://www.nejm.org/doi/full/10.1056/NEJMoa1716948 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29863955 PubMed]

==Carboplatin & Pemetrexed {{#subobject:920f46|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CP: '''<u>C</u>'''arboplatin & '''<u>P</u>'''emetrexed
<br>Carbo-Pem: '''<u>Carbo</u>'''platin & '''<u>Pem</u>'''etrexed
===Example orders===
*[[Example orders for Carboplatin (Paraplatin) and Pemetrexed (Alimta) in non-small cell lung cancer]]

===Variant #1, 5/500 x 4 {{#subobject:843af0|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30498-3/fulltext Langer et al. 2016 (KEYNOTE-021)]
|style="background-color:#1a9851"|Randomized Phase II (C)
|[[Complex_multipart_regimens#KEYNOTE-021|See link]]
|style="background-color:#d73027"|[[Complex_multipart_regimens#KEYNOTE-021|See link]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)30123-X/fulltext Soria et al. 2017 (ASCEND-4)]
|style="background-color:#1a9851"|Phase III (C)
|[[Non-small_cell_lung_cancer,_ALK-positive#Ceritinib_monotherapy|Ceritinib]]
|style="background-color:#d73027"|Inferior PFS
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1801005 Gandhi et al. 2018 (KEYNOTE-189)]
|style="background-color:#1a9851"|Phase III (C)
|[[Complex_multipart_regimens#KEYNOTE-189|See link]]
|style="background-color:#d73027"|[[Complex_multipart_regimens#KEYNOTE-189|See link]]
|-
|}
''Patients enrolled in '''ASCEND-4''' had ALK-rearranged NSCLC.''
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 5 IV over 15 to 60 minutes once on day 1, '''given second'''
*[[Pemetrexed (Alimta)]] 500 mg/m<sup>2</sup> IV over 10 minutes once on day 1, '''given first'''

====Supportive medications====
*(Ardizzoni et al. 2012 contained more details):
*[[Dexamethasone (Decadron)]] 4 mg or [[steroid conversions|equivalent corticosteroid]] PO twice per day on the day before, the day of, and day after each dose of pemetrexed
*Folic acid 350 to 600 mcg PO once per day, starting 1 to 2 weeks before the first dose of pemetrexed, to be taken throughout pemetrexed therapy.
*[[Cyanocobalamin (Vitamin B12)]] 1000 mcg IM once every 9 weeks, first dose 1 to 2 weeks before the first dose of pemetrexed, to be given throughout pemetrexed therapy

'''21-day cycle for up to 4 cycles'''
====Subsequent treatment====
*[[#Pemetrexed_monotherapy_2|Pemetrexed maintenance]] (optional in KEYNOTE-021)

===Variant #2, 5/500 x 6 {{#subobject:f0cdea|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 20%"|Study
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 20%"|Comparator
!style="width: 20%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
!style="width: 20%"|[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[https://www.jto.org/article/S1556-0864(15)32255-3/fulltext Rodrigues-Pereira et al. 2011]
|style="background-color:#1a9851"|Phase III (E)
|[[#Carboplatin_.26_Docetaxel_2|Carboplatin & Docetaxel]]
| style="background-color:#ffffbf" |Seems not superior
| style="background-color:#1a9850" |Superior survival without treatment-emergent grade 3/4 toxicity
|-
|[http://ascopubs.org/doi/abs/10.1200/jco.2015.33.15_suppl.tps8105 Mok et al. 2015 (KEYNOTE-042)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Pembrolizumab_monotherapy|Pembrolizumab]]
|style="background-color:#d73027"|Inferior OS
|
|-
|}
''Patients in KEYNOTE-042 receiving this treatment had nonsquamous NSCLC.''
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 5 IV over 15 to 60 minutes once on day 1, '''given second'''
*[[Pemetrexed (Alimta)]] 500 mg/m<sup>2</sup> IV over 10 minutes once on day 1, '''given first'''

====Supportive medications====
*(Ardizzoni et al. 2012 contained more details):
*[[Dexamethasone (Decadron)]] 4 mg or [[steroid conversions|equivalent corticosteroid]] PO twice per day on the day before, the day of, and day after each dose of pemetrexed
*Folic acid 350 to 600 mcg PO once per day, starting 1 to 2 weeks before the first dose of pemetrexed, to be taken throughout pemetrexed therapy.
*[[Cyanocobalamin (Vitamin B12)]] 1000 mcg IM once every 9 weeks, first dose 1 to 2 weeks before the first dose of pemetrexed, to be given throughout pemetrexed therapy

'''21-day cycle for up to 6 cycles'''
====Subsequent treatment====
*Optional [[#Pemetrexed_monotherapy_2|pemetrexed maintenance]]

===Variant #3, 6/500 x 4 {{#subobject:ecc998|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881367/ Zinner et al. 2015 (PRONOUNCE)]
|style="background-color:#1a9851"|Phase III (E)
|[[Complex_multipart_regimens#PRONOUNCE|See link]]
|style="background-color:#ffffbf"|[[Complex_multipart_regimens#PRONOUNCE|See link]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)30123-X/fulltext Soria et al. 2017 (ASCEND-4)]
|style="background-color:#1a9851"|Phase III (C)
|[[Non-small_cell_lung_cancer,_ALK-positive#Ceritinib_monotherapy|Ceritinib]]
|style="background-color:#d73027"|Inferior PFS
|-
|}
''Patients enrolled in '''ASCEND-4''' had ALK-rearranged NSCLC.''
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 6 IV over 15 to 60 minutes once on day 1, '''given second'''
*[[Pemetrexed (Alimta)]] 500 mg/m<sup>2</sup> IV over 10 minutes once on day 1, '''given first'''

====Supportive medications====
*(Ardizzoni et al. 2012 contained more details):
*[[Dexamethasone (Decadron)]] 4 mg or [[steroid conversions|equivalent corticosteroid]] PO twice per day on the day before, the day of, and day after each dose of pemetrexed
*Folic acid 350 to 600 mcg PO once per day, starting 1 to 2 weeks before the first dose of pemetrexed, to be taken throughout pemetrexed therapy.
*[[Cyanocobalamin (Vitamin B12)]] 1000 mcg IM once every 9 weeks, first dose 1 to 2 weeks before the first dose of pemetrexed, to be given throughout pemetrexed therapy

'''21-day cycle for up to 4 cycles'''
====Subsequent treatment====
*[[#Pemetrexed_monotherapy_2|Pemetrexed maintenance]]

===Variant #4, 6/500 x 6 {{#subobject:8aad39|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/abs/10.1200/jco.2015.33.15_suppl.tps8105 Mok et al. 2015 (KEYNOTE-042)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Pembrolizumab_monotherapy|Pembrolizumab]]
|style="background-color:#d73027"|Inferior OS
|-
|}
''Patients in KEYNOTE-042 receiving this treatment had nonsquamous NSCLC.''
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 6 IV once on day 1
*[[Pemetrexed (Alimta)]] 500 mg/m<sup>2</sup> IV once on day 1

====Supportive medications====
*[[Cyanocobalamin (Vitamin B12)]] 1000 mcg IM once every 9 weeks, first dose prior to [[Pemetrexed (Alimta)]]
*Folic acid 1 mg PO once per day

'''21-day cycle for up to 6 cycles'''
====Subsequent treatment====
*Optional [[#Pemetrexed_monotherapy_2|pemetrexed maintenance]]

===References===
# Rodrigues-Pereira J, Kim JH, Magallanes M, Lee DH, Wang J, Ganju V, Martínez-Barrera L, Barraclough H, van Kooten M, Orlando M. A randomized phase 3 trial comparing pemetrexed/carboplatin and docetaxel/carboplatin as first-line treatment for advanced, nonsquamous non-small cell lung cancer. J Thorac Oncol. 2011 Nov;6(11):1907-14. [https://www.jto.org/article/S1556-0864(15)32255-3/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22005471 PubMed]
# '''PRONOUNCE:''' Zinner RG, Obasaju CK, Spigel DR, Weaver RW, Beck JT, Waterhouse DM, Modiano MR, Hrinczenko B, Nikolinakos PG, Liu J, Koustenis AG, Winfree KB, Melemed SA, Guba SC, Ortuzar WI, Desaiah D, Treat JA, Govindan R, Ross HJ. PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer. J Thorac Oncol. 2015 Jan;10(1):134-42. [http://www.jto.org/article/S1556-0864(15)30782-6/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4276572/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25371077 PubMed]
# '''Abstract:''' Tony Mok, Yi-Long Wu, Patricia A, Watson, Jin Zhang, Reshma A. Rangwala, and Gilberto Lopes. Phase 3 KEYNOTE-042 trial of pembrolizumab (MK-3475) versus platinum doublet chemotherapy in treatment-naive patients (pts) with PD-L1–positive advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology 2015 33:15_suppl, TPS8105-TPS8105 [http://ascopubs.org/doi/abs/10.1200/jco.2015.33.15_suppl.tps8105 link to abstract]
# '''KEYNOTE-021:''' Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Jalal SI, Panwalkar A, Yang JC, Gubens M, Sequist LV, Awad MM, Fiore J, Ge Y, Raftopoulos H, Gandhi L; KEYNOTE-021 investigators. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016 Nov;17(11):1497-1508. Epub 2016 Oct 10. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30498-3/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27745820 PubMed]
# '''ASCEND-4:''' Soria JC, Tan DS, Chiari R, Wu YL, Paz-Ares L, Wolf J, Geater SL, Orlov S, Cortinovis D, Yu CJ, Hochmair M, Cortot AB, Tsai CM, Moro-Sibilot D, Campelo RG, McCulloch T, Sen P, Dugan M, Pantano S, Branle F, Massacesi C, de Castro G Jr. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet. 2017 Mar 4;389(10072):917-929. Epub 2017 Jan 24. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)30123-X/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28126333 PubMed]
# '''KEYNOTE-189:''' Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, Cheng SY, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Hui R, Garon EB, Boyer M, Rubio-Viqueira B, Novello S, Kurata T, Gray JE, Vida J, Wei Z, Yang J, Raftopoulos H, Pietanza MC, Garassino MC; KEYNOTE-189 Investigators. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018 May 31;378(22):2078-2092. Epub 2018 Apr 16. [https://www.nejm.org/doi/full/10.1056/NEJMoa1801005 link to original article] [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1801005/suppl_file/nejmoa1801005_protocol.pdf link to protocol] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29658856 PubMed]

==Carboplatin, Pemetrexed, Bevacizumab {{#subobject:a4bca7|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
PemCBev: '''<u>Pem</u>'''etrexed, '''<u>C</u>'''arboplatin, '''<u>Bev</u>'''acizumab 
===Regimen {{#subobject:3db331|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881367/ Patel et al. 2013 (PointBreak)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Carboplatin.2C_Paclitaxel.2C_Bevacizumab_2|PacCBev]], then [[#Bevacizumab_monotherapy|Maintenance Bev]]
|style="background-color:#91cf60"|Seems to have superior PFS
|-
|}
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 6 IV once on day 1
*[[Pemetrexed (Alimta)]] 500 mg/m<sup>2</sup> IV once on day 1
*[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1

====Supportive medications====
*Premedications, folic acid, and vitamin supplementation per pemetrexed label
*Erythropoietic agents or granulocyte colony-stimulating factors allowed per ASCO & NCCN guidelines

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*Patients with complete response, partial response, or stable disease: [[#Pemetrexed_.26_Bevacizumab_2|Pemetrexed & Bevacizumab maintenance]]

===References===
<!-- Presented in part at the Chicago Multidisciplinary Symposium in Thoracic Oncology, Chicago, IL, September 6-8, 2012, and at the American Society of Clinical Oncology's Quality Care Symposium, San Diego, CA, November 30-December 1, 2012. -->
# '''PointBreak:''' Patel JD, Socinski MA, Garon EB, Reynolds CH, Spigel DR, Olsen MR, Hermann RC, Jotte RM, Beck T, Richards DA, Guba SC, Liu J, Frimodt-Moller B, John WJ, Obasaju CK, Pennella EJ, Bonomi P, Govindan R. PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013 Dec 1;31(34):4349-57. [http://jco.ascopubs.org/content/31/34/4349.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881367/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24145346 PubMed]
## '''Dataset:''' [https://www.projectdatasphere.org/projectdatasphere/html/content/141 Project Data Sphere]

==Cisplatin & Docetaxel {{#subobject:179d86|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
DC: '''<u>D</u>'''ocetaxel & '''<u>C</u>'''isplatin
<br>DP: '''<u>D</u>'''ocetaxel & '''<u>P</u>'''latinol (Cisplatin)
<br>Doc-Cis: '''<u>Doc</u>'''etaxel & '''<u>Cis</u>'''platin
===Regimen {{#subobject:b45602|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://www.clinical-lung-cancer.com/article/S1525-7304(17)30002-5/fulltext Park et al. 2017]
|style="background-color:#1a9851"|Phase III (C)
|[[#Cisplatin_.26_Pemetrexed_2|Cisplatin & Pemetrexed]]
| style="background-color:#ffffbf" |Inconclusive whether non-inferior
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 70 mg/m<sup>2</sup> IV once on day 1
*[[Docetaxel (Taxotere)]] 60 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for up to 4 cycles'''

===References===
# Park CK, Oh IJ, Kim KS, Choi YD, Jang TW, Kim YS, Lee KH, Shin KC, Jung CY, Yang SH, Ryu JS, Jang SH, Yoo SS, Yong SJ, Lee KY, In KH, Lee MK, Kim YC. Randomized phase III study of docetaxel plus cisplatin versus pemetrexed plus cisplatin as first-line treatment of nonsquamous non-small-cell lung cancer: a TRAIL trial. Clin Lung Cancer. 2017 Jul;18(4):e289-e296. Epub 2017 Jan 11. [http://www.clinical-lung-cancer.com/article/S1525-7304(17)30002-5/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28185792 PubMed]

==Cisplatin & Gemcitabine {{#subobject:fb3ee0|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
GC: '''<u>G</u>'''emcitabine & '''<u>C</u>'''isplatin
<br>GP: '''<u>G</u>'''emcitabine & '''<u>P</u>'''latinol (Cisplatin)
===Variant #1, 75/1000 {{#subobject:6a4b24|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70604-1/fulltext Wu et al. 2014 (LUX-Lung 6)]
|style="background-color:#1a9851"|Phase III (C)
|[[Non-small_cell_lung_cancer,_EGFR-mutated#Afatinib_monotherapy|Afatinib]]
|style="background-color:#d73027"|Inferior PFS
|-
|}
''Tumor specimen was required to be EGFR mutation-positive.''
====Chemotherapy====
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV once on day 1
*[[Gemcitabine (Gemzar)]] 1000 mg/m<sup>2</sup> IV once per day on days 1 & 8

'''21-day cycle for up to 6 cycles'''

===Variant #2, 75/1250 q3wk {{#subobject:0e126e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2011.39.7646 Paz-Ares et al. 2012 (NExUS)]
|style="background-color:#1a9851"|Phase III (C)
|Cisplatin, Gemcitabine, Sorafenib
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV over 30 minutes once on day 1
*[[Gemcitabine (Gemzar)]] 1250 mg/m<sup>2</sup> IV over 2 hours once per day on days 1 & 8

'''21-day cycle for up to 6 cycles'''

===Variant #3, 80/1250 x 6 {{#subobject:646326|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[http://ascopubs.org/doi/full/10.1200/JCO.2007.14.5466 Reck et al. 2009 (AVAil)]
|rowspan=2 style="background-color:#1a9851"|Phase III (C)
|1. [[#Cisplatin.2C_Gemcitabine.2C_Bevacizumab|Cisplatin, Gemcitabine, low-dose Bevacizumab]]
| style="background-color:#d73027" |Inferior PFS
|-
|2. [[#Cisplatin.2C_Gemcitabine.2C_Bevacizumab|Cisplatin, Gemcitabine, standard-dose Bevacizumab]]
| style="background-color:#fc8d59" |Seems to have inferior PFS
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 80 mg/m<sup>2</sup> IV once on day 1
*[[Gemcitabine (Gemzar)]] 1250 mg/m<sup>2</sup> IV once per day on days 1 & 8

'''21-day cycle for up to 6 cycles'''

===Variant #4, 80/1250 x 9 {{#subobject:946326|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2011.36.8456 Han et al. 2012 (First-SIGNAL)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Gefitinib_monotherapy|Gefitinib]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 80 mg/m<sup>2</sup> IV once on day 1
*[[Gemcitabine (Gemzar)]] 1250 mg/m<sup>2</sup> IV once per day on days 1 & 8

'''21-day cycle for up to 9 cycles'''

===References===
# '''AVAil:''' Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N, Manegold C. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol. 2009 Mar 10;27(8):1227-34. Epub 2009 Feb 2. Erratum in: J Clin Oncol. 2009 May 10;27(14):2415. [http://ascopubs.org/doi/full/10.1200/JCO.2007.14.5466 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19188680 PubMed]
## '''Update:''' Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N, Manegold C; BO17704 Study Group. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol. 2010 Sep;21(9):1804-9. Epub 2010 Feb 11. [https://academic.oup.com/annonc/article/21/9/1804/145254 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2924992/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/20150572 PubMed]
# '''First-SIGNAL:''' Han JY, Park K, Kim SW, Lee DH, Kim HY, Kim HT, Ahn MJ, Yun T, Ahn JS, Suh C, Lee JS, Yoon SJ, Han JH, Lee JW, Jo SJ, Lee JS. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol. 2012 Apr 1;30(10):1122-8. Epub 2012 Feb 27. [http://ascopubs.org/doi/full/10.1200/JCO.2011.36.8456 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22370314 PubMed]
# '''NExUS:''' Paz-Ares LG, Biesma B, Heigener D, von Pawel J, Eisen T, Bennouna J, Zhang L, Liao M, Sun Y, Gans S, Syrigos K, Le Marie E, Gottfried M, Vansteenkiste J, Alberola V, Strauss UP, Montegriffo E, Ong TJ, Santoro A; NSCLC [non–small-cell lung cancer] Research Experience Utilizing Sorafenib (NExUS) Investigators Study Group. Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer. J Clin Oncol. 2012 Sep 1;30(25):3084-92. Epub 2012 Jul 30. [http://ascopubs.org/doi/full/10.1200/JCO.2011.39.7646 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22851564 PubMed]
## '''Dataset:''' [https://www.projectdatasphere.org/projectdatasphere/html/content/275 Project Data Sphere]
# '''LUX-Lung 6:''' Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, Li W, Hou M, Shi JH, Lee KY, Xu CR, Massey D, Kim M, Shi Y, Geater SL. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014 Feb;15(2):213-22. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70604-1/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24439929 PubMed]
## '''Update:''' Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, Zhou C, Hu CP, O'Byrne K, Feng J, Lu S, Huang Y, Geater SL, Lee KY, Tsai CM, Gorbunova V, Hirsh V, Bennouna J, Orlov S, Mok T, Boyer M, Su WC, Lee KH, Kato T, Massey D, Shahidi M, Zazulina V, Sequist LV. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015 Feb;16(2):141-51. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)71173-8/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25589191 PubMed]
## '''Subgroup analysis:''' Schuler M, Wu YL, Hirsh V, O'Byrne K, Yamamoto N, Mok T, Popat S, Sequist LV, Massey D, Zazulina V, Yang JC. First-line afatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases. J Thorac Oncol. 2016 Mar;11(3):380-90. [http://www.jto.org/article/S1556-0864(15)00220-8/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26823294 PubMed]

==Cisplatin, Gemcitabine, Bevacizumab {{#subobject:72d44d|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, low-dose bev {{#subobject:663066|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2007.14.5466 Reck et al. 2009 (AVAil)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Cisplatin_.26_Gemcitabine_4|Cisplatin & Gemcitabine]]
| style="background-color:#1a9850" |Superior PFS
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 80 mg/m<sup>2</sup> IV once on day 1
*[[Gemcitabine (Gemzar)]] 1250 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Bevacizumab (Avastin)]] 7.5 mg/kg IV once on day 1

'''21-day cycle for up to 6 cycles'''
====Subsequent treatment====
*[[#Bevacizumab_monotherapy|Bevacizumab maintenance]]

===Variant #2, standard-dose bev {{#subobject:a671a4|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2007.14.5466 Reck et al. 2009 (AVAil)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Cisplatin_.26_Gemcitabine_4|Cisplatin & Gemcitabine]]
| style="background-color:#91cf60" |Seems to have superior PFS
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 80 mg/m<sup>2</sup> IV once on day 1
*[[Gemcitabine (Gemzar)]] 1250 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1

'''21-day cycle for up to 6 cycles'''
====Subsequent treatment====
*[[#Bevacizumab_monotherapy|Bevacizumab maintenance]]

===References===
# '''AVAil:''' Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N, Manegold C. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol. 2009 Mar 10;27(8):1227-34. Epub 2009 Feb 2. Erratum in: J Clin Oncol. 2009 May 10;27(14):2415. [http://ascopubs.org/doi/full/10.1200/JCO.2007.14.5466 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19188680 PubMed]
## '''Update:''' Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N, Manegold C; BO17704 Study Group. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol. 2010 Sep;21(9):1804-9. Epub 2010 Feb 11. [https://academic.oup.com/annonc/article/21/9/1804/145254 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2924992/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/20150572 PubMed]

==Cisplatin & Pemetrexed {{#subobject:af12b4|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
Pem-Cis: '''<u>Pem</u>'''etrexed & '''<u>Cis</u>'''platin
<br>Cis-Pem: '''<u>Cis</u>'''platin & '''<u>Pem</u>'''etrexed
===Variant #1, 70/500 {{#subobject:b45602|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://www.clinical-lung-cancer.com/article/S1525-7304(17)30002-5/fulltext Park et al. 2017]
|style="background-color:#1a9851"|Phase III (E)
|[[#Cisplatin_.26_Docetaxel_4|Cisplatin & Docetaxel]]
| style="background-color:#ffffbf" |Inconclusive whether non-inferior
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 70 mg/m<sup>2</sup> IV once on day 1
*[[Pemetrexed (Alimta)]] 500 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for up to 4 cycles'''

===Variant #2, 75/500 {{#subobject:8fdaa3|Variant=1}}===
{| class="wikitable" style="color:white; background-color:#404040"
|<small>'''FDA-recommended dose'''</small>
|-
|}
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 20%"|Study
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 20%"|Comparator
!style="width: 20%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
!style="width: 20%"|[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70063-3/fulltext Paz-Ares et al. 2012 (PARAMOUNT)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|
|-
|[http://jco.ascopubs.org/content/31/27/3327.long Sequist et al. 2013 (LUX-Lung 3)]
|style="background-color:#1a9851"|Phase III (C)
|[[Non-small_cell_lung_cancer,_EGFR-mutated#Afatinib_monotherapy|Afatinib]]
|style="background-color:#d73027"|Inferior PFS
|
|-
|[https://www.lungcancerjournal.info/article/S0169-5002(14)00307-9/fulltext Wu et al. 2014 (JMIL)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Cisplatin_.26_Gemcitabine_4|GC]]
|style="background-color:#ffffbf"|Seems not superior
|
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1408440 Solomon et al. 2014 (PROFILE 1014)]
|style="background-color:#1a9851"|Phase III (C)
|[[Non-small_cell_lung_cancer,_ALK-positive#Crizotinib_monotherapy|Crizotinib]]
|style="background-color:#d73027"|Inferior PFS
|
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)70046-X/fulltext Paz-Ares et al. 2015 (INSPIRE)]
|style="background-color:#1a9851"|Phase III (C)
|Cisplatin, Pemetrexed, Necitumumab
|style="background-color:#ffffbf"|Seems not superior
|
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1606774 Reck et al. 2016 (KEYNOTE-024)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Pembrolizumab_monotherapy|Pembrolizumab]]
|style="background-color:#d73027"|Inferior OS
|style="background-color:#d73027"|Inferior HRQoL
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)30123-X/fulltext Soria et al. 2017 (ASCEND-4)]
|style="background-color:#1a9851"|Phase III (C)
|[[Non-small_cell_lung_cancer,_ALK-positive#Ceritinib_monotherapy|Ceritinib]]
|style="background-color:#d73027"|Inferior PFS
|
|-
|[https://academic.oup.com/annonc/article/28/10/2443/4091563 Shi et al. 2017 (CONVINCE)]
|style="background-color:#1a9851"|Phase III (C)
|[[Complex_multipart_regimens#CONVINCE|See link]]
|style="background-color:#d73027"|[[Complex_multipart_regimens#CONVINCE|See link]]
|
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1801005 Gandhi et al. 2018 (KEYNOTE-189)]
|style="background-color:#1a9851"|Phase III (C)
|[[Complex_multipart_regimens#KEYNOTE-189|See link]]
|style="background-color:#d73027"|[[Complex_multipart_regimens#KEYNOTE-189|See link]]
|
|-
|}
''Note: Patients in LUX-Lung 3 had adenocarcinoma with activating mutations in EGFR. Patients in PROFILE 1014 & ASCEND-4 had ALK-rearranged NSCLC. Patients in CONVINCE had stage IIIB/IV lung adenocarcinoma and exon 19/21 EGFR mutations. Selection of platinum agent in KEYNOTE-189 was per investigator choice.''
====Chemotherapy====
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV once on day 1, '''given second'''
*[[Pemetrexed (Alimta)]] 500 mg/m<sup>2</sup> IV over 10 minutes once on day 1, '''given first'''

====Supportive medications====
*(as described in JMDB):
*[[Cyanocobalamin (Vitamin B12)]] 1000 mcg IM every 9 weeks, first dose prior to [[Pemetrexed (Alimta)]]
*Folic acid 1 mg PO once per day
*In Sequist et al. 2013: Patients "received folic acid, vitamin B12, and dexamethasone, as per package recommendations for [[Pemetrexed (Alimta)]]."

'''21-day cycle for 4 to 6 cycles'''
====Subsequent treatment====
*PARAMOUNT: [[#Placebo_4|Placebo]] versus [[#Pemetrexed_monotherapy_2|pemetrexed maintenance]]
*CONVINCE, KEYNOTE-024, ASCEND-4, KEYNOTE-189: [[#Pemetrexed_monotherapy_2|Pemetrexed maintenance]] (optional in CONVINCE & KEYNOTE-024)

===References===
# '''PARAMOUNT:''' Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, Corral J, Melemed S, John W, Chouaki N, Zimmermann AH, Visseren-Grul C, Gridelli C. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol. 2012 Mar;13(3):247-55. Epub 2012 Feb 16. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70063-3/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22341744 PubMed]
## '''HRQoL analaysis:''' Gridelli C, de Marinis F, Pujol JL, Reck M, Ramlau R, Parente B, Pieters T, Middleton G, Corral J, Winfree K, Melemed S, Zimmermann A, John W, Beyrer J, Chouaki N, Visseren-Grul C, Paz-Ares LG. Safety, resource use, and quality of life in paramount: a phase III study of maintenance pemetrexed versus placebo after induction pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Thorac Oncol. 2012 Nov;7(11):1713-21. [https://www.jto.org/article/S1556-0864(15)33143-9/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23059776 PubMed]
## '''Update:''' Paz-Ares LG, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, Corral J, Melemed S, John W, Chouaki N, Zimmermann AH, Visseren-Grul C, Gridelli C. PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013 Aug 10;31(23):2895-902. Epub 2013 Jul 8. [http://jco.ascopubs.org/content/31/23/2870.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23835707 PubMed]
# '''LUX-Lung 3:''' Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, Su WC, Bennouna J, Kato T, Gorbunova V, Lee KH, Shah R, Massey D, Zazulina V, Shahidi M, Schuler M. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013 Sep 20;31(27):3327-34. Epub 2013 Jul 1. [http://jco.ascopubs.org/content/31/27/3327.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23816960 PubMed]
## '''Subgroup analysis:''' Yang JC, Hirsh V, Schuler M, Yamamoto N, O'Byrne KJ, Mok TS, Zazulina V, Shahidi M, Lungershausen J, Massey D, Palmer M, Sequist LV. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013 Sep 20;31(27):3342-50. Epub 2013 Jul 1. [http://jco.ascopubs.org/content/31/27/3342.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23816967 PubMed]
## '''Update:''' Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, Zhou C, Hu CP, O'Byrne K, Feng J, Lu S, Huang Y, Geater SL, Lee KY, Tsai CM, Gorbunova V, Hirsh V, Bennouna J, Orlov S, Mok T, Boyer M, Su WC, Lee KH, Kato T, Massey D, Shahidi M, Zazulina V, Sequist LV. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015 Feb;16(2):141-51. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)71173-8/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25589191 PubMed]
## '''Subgroup analysis:''' Schuler M, Wu YL, Hirsh V, O'Byrne K, Yamamoto N, Mok T, Popat S, Sequist LV, Massey D, Zazulina V, Yang JC. First-line afatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases. J Thorac Oncol. 2016 Mar;11(3):380-90. [http://www.jto.org/article/S1556-0864(15)00220-8/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26823294 PubMed]
# '''JMIL:''' Wu YL, Lu S, Cheng Y, Zhou C, Wang M, Qin S, Lu Y, Zhang Y, Zhu Y, Song X, Wang X, Barraclough H, Zhang X, Chi H, Orlando M. Efficacy and safety of pemetrexed/cisplatin versus gemcitabine/cisplatin as first-line treatment in Chinese patients with advanced nonsquamous non-small cell lung cancer. Lung Cancer. 2014 Sep;85(3):401-7. Epub 2014 Jul 17. [https://www.lungcancerjournal.info/article/S0169-5002(14)00307-9/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25082564 PubMed]
# '''PROFILE 1014:''' Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Iyer S, Reisman A, Wilner KD, Tursi J, Blackhall F; PROFILE 1014 Investigators. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014 Dec 4;371(23):2167-77. Erratum in: N Engl J Med. 2015 Oct 15;373(16):1582. [https://www.nejm.org/doi/full/10.1056/NEJMoa1408440 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25470694 PubMed]
## '''Supgroup analysis:''' Solomon BJ, Cappuzzo F, Felip E, Blackhall FH, Costa DB, Kim DW, Nakagawa K, Wu YL, Mekhail T, Paolini J, Tursi J, Usari T, Wilner KD, Selaru P, Mok TS. Intracranial efficacy of crizotinib versus chemotherapy in patients with advanced ALK-positive non-small-cell lung cancer: results from PROFILE 1014. J Clin Oncol. 2016 Aug 20;34(24):2858-65. Epub 2016 Mar 28. [http://ascopubs.org/doi/full/10.1200/JCO.2015.63.5888 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27022118 PubMed]
## '''Pooled subgroup analysis:''' Nishio M, Kim DW, Wu YL, Nakagawa K, Solomon BJ, Shaw AT, Hashigaki S, Ohki E, Usari T, Paolini J, Polli A, Wilner KD, Mok T. Crizotinib versus chemotherapy in Asian patients with ALK-positive advanced non-small cell lung cancer. Cancer Res Treat. 2018 Jul;50(3):691-700. Epub 2017 Jul 6. [https://www.e-crt.org/journal/view.php?doi=10.4143/crt.2017.280 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6056984/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/28701030 PubMed]
## '''Update:''' Solomon BJ, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Tang Y, Wilner KD, Blackhall F, Mok TS. Final overall survival analysis from a study comparing first-line crizotinib versus chemotherapy in ALK-mutation-positive non-small-cell lung cancer. J Clin Oncol. 2018 Aug 1;36(22):2251-2258. Epub 2018 May 16. [http://ascopubs.org/doi/full/10.1200/JCO.2017.77.4794 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/29768118 PubMed]
# '''INSPIRE:''' Paz-Ares L, Mezger J, Ciuleanu TE, Fischer JR, von Pawel J, Provencio M, Kazarnowicz A, Losonczy G, de Castro G Jr, Szczesna A, Crino L, Reck M, Ramlau R, Ulsperger E, Schumann C, Miziara JE, Lessa ÁE, Dediu M, Bálint B, Depenbrock H, Soldatenkova V, Kurek R, Hirsch FR, Thatcher N, Socinski MA; INSPIRE investigators. Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study. Lancet Oncol. 2015 Mar;16(3):328-37. Epub 2015 Feb 18. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)70046-X/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25701171 PubMed]
# '''KEYNOTE-024:''' Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Leiby MA, Lubiniecki GM, Shentu Y, Rangwala R, Brahmer JR; KEYNOTE-024 Investigators. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016 Nov 10;375(19):1823-1833. Epub 2016 Oct 8. [https://www.nejm.org/doi/full/10.1056/NEJMoa1606774 link to original article] [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1606774/suppl_file/nejmoa1606774_appendix.pdf link to supplementary appendix] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27718847 PubMed]
## '''HRQoL analysis:''' Brahmer JR, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Zhang J, Lubiniecki GM, Deitz AC, Rangwala R, Reck M. Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. Lancet Oncol. 2017 Dec;18(12):1600-1609. Epub 2017 Nov 9. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30690-3/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/29129441 PubMed]
# Park CK, Oh IJ, Kim KS, Choi YD, Jang TW, Kim YS, Lee KH, Shin KC, Jung CY, Yang SH, Ryu JS, Jang SH, Yoo SS, Yong SJ, Lee KY, In KH, Lee MK, Kim YC. Randomized phase III study of docetaxel plus cisplatin versus pemetrexed plus cisplatin as first-line treatment of nonsquamous non-small-cell lung cancer: a TRAIL trial. Clin Lung Cancer. 2017 Jul;18(4):e289-e296. Epub 2017 Jan 11. [http://www.clinical-lung-cancer.com/article/S1525-7304(17)30002-5/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28185792 PubMed]
# '''ASCEND-4:''' Soria JC, Tan DS, Chiari R, Wu YL, Paz-Ares L, Wolf J, Geater SL, Orlov S, Cortinovis D, Yu CJ, Hochmair M, Cortot AB, Tsai CM, Moro-Sibilot D, Campelo RG, McCulloch T, Sen P, Dugan M, Pantano S, Branle F, Massacesi C, de Castro G Jr. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet. 2017 Mar 4;389(10072):917-929. Epub 2017 Jan 24. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)30123-X/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28126333 PubMed]
# '''CONVINCE:''' Shi YK, Wang L, Han BH, Li W, Yu P, Liu YP, Ding CM, Song X, Ma ZY, Ren XL, Feng JF, Zhang HL, Chen GY, Han XH, Wu N, Yao C, Song Y, Zhang SC, Song W, Liu XQ, Zhao SJ, Lin YC, Ye XQ, Li K, Shu YQ, Ding LM, Tan FL, Sun Y. First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study. Ann Oncol. 2017 Oct 1;28(10):2443-2450. [https://academic.oup.com/annonc/article/28/10/2443/4091563 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28945850 PubMed]
# '''KEYNOTE-189:''' Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, Cheng SY, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Hui R, Garon EB, Boyer M, Rubio-Viqueira B, Novello S, Kurata T, Gray JE, Vida J, Wei Z, Yang J, Raftopoulos H, Pietanza MC, Garassino MC; KEYNOTE-189 Investigators. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018 May 31;378(22):2078-2092. Epub 2018 Apr 16. [https://www.nejm.org/doi/full/10.1056/NEJMoa1801005 link to original article] [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1801005/suppl_file/nejmoa1801005_protocol.pdf link to protocol] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29658856 PubMed]

==Cisplatin, Pemetrexed, Bevacizumab {{#subobject:836c3d|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:297507|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/31/24/3004.long Barlesi et al. 2013 (AVAPERL)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV over 2 hours once on day 1
*[[Pemetrexed (Alimta)]] 500 mg/m<sup>2</sup> IV over 10 minutes once on day 1
*[[Bevacizumab (Avastin)]] 7.5 mg/kg IV over 90 minutes once on day 1
**If well tolerated, subsequent infusions were given over 60 minutes, then 30 minutes

====Supportive medications====
*[[Cyanocobalamin (Vitamin B12)]] 1000 mcg IM every 3 cycles (i.e. every 9 weeks), given throughout therapy
*Folic acid 350 to 1000 mcg PO once per day, given throughout therapy
*[[Dexamethasone (Decadron)]] 4 mg PO twice per day on days -1, 1, 2 of each cycle

'''21-day cycle for 4 cycles''' 
====Subsequent treatment====
*Patients with complete response (CR), partial response (PR), or stable disease (SD): [[#Bevacizumab_monotherapy|Bevacizumab]] versus [[#Pemetrexed_.26_Bevacizumab_2|Pemetrexed & Bevacizumab]] maintenance

===References===
# '''AVAPERL:''' Barlesi F, Scherpereel A, Rittmeyer A, Pazzola A, Ferrer Tur N, Kim JH, Ahn MJ, Aerts JG, Gorbunova V, Vikström A, Wong EK, Perez-Moreno P, Mitchell L, Groen HJ. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). J Clin Oncol. 2013 Aug 20;31(24):3004-11. Epub 2013 Jul 8. [http://jco.ascopubs.org/content/31/24/3004.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23835708 PubMed]
## '''Update:''' Barlesi F, Scherpereel A, Gorbunova V, Gervais R, Vikström A, Chouaid C, Chella A, Kim JH, Ahn MJ, Reck M, Pazzola A, Kim HT, Aerts JG, Morando C, Loundou A, Groen HJ, Rittmeyer A. Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial. Ann Oncol. 2014 May;25(5):1044-52. Epub 2014 Feb 27. [https://academic.oup.com/annonc/article/25/5/1044/156906 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/24585722 PubMed]

==Cisplatin, Pemetrexed, Pembrolizumab {{#subobject:236bea|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:e6458c|Variant=1}}===
{| class="wikitable" style="color:white; background-color:#404040"
|<small>'''FDA-recommended dose'''</small>
|-
|}
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1801005 Gandhi et al. 2018 (KEYNOTE-189)]
|style="background-color:#1a9851"|Phase III (E)
|[[Complex_multipart_regimens#KEYNOTE-189|See link]]
|style="background-color:#1a9850"|[[Complex_multipart_regimens#KEYNOTE-189|See link]]
|-
|}
''Note: selection of platinum agent in KEYNOTE-189 was per investigator choice.''
====Chemoimmunotherapy====
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV once on day 1, '''given third'''
*[[Pemetrexed (Alimta)]] 500 mg/m<sup>2</sup> IV over 10 minutes once on day 1, '''given second'''
*[[Pembrolizumab (Keytruda)]] 200 mg IV over 30 minutes once on day 1, '''given first, at least 30 minutes prior to chemotherapy'''

====Supportive medications====
*"Premedication with [[Folic acid (Folate)|folic acid]], [[Cyanocobalamin (Vitamin B12)|vitamin B12]], and [[:Category:Steroids|corticosteroids]] was administered according to local guidelines."

'''21-day cycle for 4 cycles''' 
====Subsequent treatment====
*[[#Pemetrexed_.26_Pembrolizumab|Pemetrexed & Pembrolizumab maintenance]]

===References===
# '''KEYNOTE-189:''' Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, Cheng SY, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Hui R, Garon EB, Boyer M, Rubio-Viqueira B, Novello S, Kurata T, Gray JE, Vida J, Wei Z, Yang J, Raftopoulos H, Pietanza MC, Garassino MC; KEYNOTE-189 Investigators. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018 May 31;378(22):2078-2092. Epub 2018 Apr 16. [https://www.nejm.org/doi/full/10.1056/NEJMoa1801005 link to original article] [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1801005/suppl_file/nejmoa1801005_protocol.pdf link to protocol] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29658856 PubMed]

==Gefitinib monotherapy {{#subobject:fb3998|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:604e4f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa0810699 Mok et al. 2009 (IPASS)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Carboplatin_.26_Paclitaxel_5|Carboplatin & Paclitaxel]]
|style="background-color:#1a9850"|Superior PFS
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2011.36.8456 Han et al. 2012 (First-SIGNAL)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Cisplatin_.26_Gemcitabine_4|Cisplatin & Gemcitabine]]
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.ejcancer.com/article/S0959-8049(14)00661-3/fulltext Yang et al. 2014]
|style="background-color:#1a9851"|Phase III (E)
|[[#Cisplatin_.26_Pemetrexed_2|Cisplatin & Pemetrexed]], then Gefitinib maint.
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Chemotherapy====
*[[Gefitinib (Iressa)]] 250 mg PO once per day

'''Continued indefinitely'''

===References===
# '''IPASS:''' Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009 Sep 3;361(10):947-57. Epub 2009 Aug 19. [https://www.nejm.org/doi/full/10.1056/NEJMoa0810699 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19692680 PubMed]
## '''Update:''' Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, Chao TY, Nakagawa K, Chu DT, Saijo N, Duffield EL, Rukazenkov Y, Speake G, Jiang H, Armour AA, To KF, Yang JC, Mok TS. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011 Jul 20;29(21):2866-74. Epub 2011 Jun 13. [http://ascopubs.org/doi/full/10.1200/JCO.2010.33.4235 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/21670455 PubMed]
## '''Dataset:''' [https://www.projectdatasphere.org/projectdatasphere/html/content/152 Project Data Sphere]
# '''First-SIGNAL:''' Han JY, Park K, Kim SW, Lee DH, Kim HY, Kim HT, Ahn MJ, Yun T, Ahn JS, Suh C, Lee JS, Yoon SJ, Han JH, Lee JW, Jo SJ, Lee JS. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol. 2012 Apr 1;30(10):1122-8. Epub 2012 Feb 27. [http://ascopubs.org/doi/full/10.1200/JCO.2011.36.8456 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22370314 PubMed]
# Yang JC, Kang JH, Mok T, Ahn MJ, Srimuninnimit V, Lin CC, Kim DW, Tsai CM, Barraclough H, Altug S, Orlando M, Park K. First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: a randomised, phase 3 trial. Eur J Cancer. 2014 Sep;50(13):2219-30. Epub 2014 Jun 18. [https://www.ejcancer.com/article/S0959-8049(14)00661-3/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/24953333 PubMed]

=Advanced or metastatic disease, first-line, squamous=
==Carboplatin & nab-Paclitaxel {{#subobject:56c054|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:0988c0|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/10.1056/NEJMoa1810865 Paz-Ares et al. 2018 (KEYNOTE-407)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Carboplatin.2C_nab-Paclitaxel.2C_Pembrolizumab|Carboplatin, nab-Paclitaxel, Pembrolizumab]] x 4, then [[#Pembrolizumab_monotherapy_2|Pembrolizumab maint.]]
|style="background-color:#d73027"|Inferior OS
|-
|}
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 6 IV once on day 1
*[[Paclitaxel, nanoparticle albumin-bound (Abraxane)]] 100 mg/m<sup>2</sup> IV once per day on days 1, 8, 15

'''21-day cycle for 4 cycles'''

===References===
# '''KEYNOTE-407:''' Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, Hermes B, Çay Şenler F, Csőszi T, Fülöp A, Rodríguez-Cid J, Wilson J, Sugawara S, Kato T, Lee KH, Cheng Y, Novello S, Halmos B, Li X, Lubiniecki GM, Piperdi B, Kowalski DM; KEYNOTE-407 Investigators. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018 Nov 22;379(21):2040-2051. Epub 2018 Sep 25. [https://www.nejm.org/doi/10.1056/NEJMoa1810865 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/30280635 PubMed]

==Carboplatin, nab-Paclitaxel, Pembrolizumab {{#subobject:725667|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:6104db|Variant=1}}===
{| class="wikitable" style="color:white; background-color:#404040"
|<small>'''FDA-recommended dose'''</small>
|-
|}
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/10.1056/NEJMoa1810865 Paz-Ares et al. 2018 (KEYNOTE-407)]
|style="background-color:#1a9851"|Phase III (E)
|[[Complex_multipart_regimens#KEYNOTE-407|See link]]
| style="background-color:#1a9850" |[[Complex_multipart_regimens#KEYNOTE-407|See link]]
|-
|}
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 6 IV once on day 1
*[[Paclitaxel, nanoparticle albumin-bound (Abraxane)]] 100 mg/m<sup>2</sup> IV once per day on days 1, 8, 15
*[[Pembrolizumab (Keytruda)]] 200 mg IV once on day 1, '''given first'''

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*[[#Pembrolizumab_monotherapy_2|Pembrolizumab maintenance]]

===References===
# '''KEYNOTE-407:''' Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, Hermes B, Çay Şenler F, Csőszi T, Fülöp A, Rodríguez-Cid J, Wilson J, Sugawara S, Kato T, Lee KH, Cheng Y, Novello S, Halmos B, Li X, Lubiniecki GM, Piperdi B, Kowalski DM; KEYNOTE-407 Investigators. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018 Nov 22;379(21):2040-2051. Epub 2018 Sep 25. [https://www.nejm.org/doi/10.1056/NEJMoa1810865 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/30280635 PubMed]

==Carboplatin & Paclitaxel {{#subobject:c5fbdf|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
TC: '''<u>T</u>'''axol (Paclitaxel) & '''<u>C</u>'''arboplatin
<br>CP: '''<u>C</u>'''arbolpatin & '''<u>P</u>'''aclitaxel
===Variant #1, 5/200 {{#subobject:5g4ff1|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/abs/10.1200/jco.2015.33.15_suppl.tps8105 Mok et al. 2015 (KEYNOTE-042)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Pembrolizumab_monotherapy|Pembrolizumab]]
|style="background-color:#d73027"|Inferior OS
|-
|}
''Patients enrolled in this arm of KEYNOTE-042 had squamous histology.''
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 5 IV over 15 to 60 minutes once on day 1, '''given second'''
*[[Paclitaxel (Taxol)]] 200 mg/m<sup>2</sup> IV over 3 hours once on day 1, '''given first'''

'''21-day cycle for 4 to 6 cycles'''

===Variant #2, 6/175 {{#subobject:e3545d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2016.71.7629 Govindan et al. 2017 (CA184-104)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Carboplatin.2C_Paclitaxel.2C_Ipilimumab_2|Carboplatin, Paclitaxel, Ipilimumab]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 6 IV once on day 1
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV once on day 1 

====Supportive medications====
*[[:Category:Steroids|Corticosteroids]] could be used as premedication for [[Paclitaxel (Taxol)]] infusion.

'''21-day cycle for up to 6 cycles'''

===Variant #3, 6/200 {{#subobject:5f5ff1|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/abs/10.1200/jco.2015.33.15_suppl.tps8105 Mok et al. 2015 (KEYNOTE-042)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Pembrolizumab_monotherapy|Pembrolizumab]]
|style="background-color:#d73027"|Inferior OS
|-
|[https://www.nejm.org/doi/10.1056/NEJMoa1810865 Paz-Ares et al. 2018 (KEYNOTE-407)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Carboplatin.2C_Paclitaxel.2C_Pembrolizumab|CP & Pembrolizumab]] x 4, then [[#Pembrolizumab_monotherapy_2|Pembrolizumab maint.]]
|style="background-color:#d73027"|Inferior OS
|-
|}
''Patients enrolled in this arm of KEYNOTE-042 had squamous histology.''
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 6 IV over 15 to 60 minutes once on day 1, '''given second'''
*[[Paclitaxel (Taxol)]] 200 mg/m<sup>2</sup> IV over 3 hours once on day 1, '''given first'''

'''21-day cycle for 4 cycles (KEYNOTE-407) or up to 6 cycles (KEYNOTE-042)'''

===References===
# '''CA184-104:''' Govindan R, Szczesna A, Ahn MJ, Schneider CP, Gonzalez Mella PF, Barlesi F, Han B, Ganea DE, Von Pawel J, Vladimirov V, Fadeeva N, Lee KH, Kurata T, Zhang L, Tamura T, Postmus PE, Jassem J, O'Byrne K, Kopit J, Li M, Tschaika M, Reck M. Phase III trial of ipilimumab combined with paclitaxel and carboplatin in advanced squamous non-small-cell lung cancer. J Clin Oncol. 2017 Oct 20;35(30):3449-3457. Epub 2017 Aug 30. [http://ascopubs.org/doi/full/10.1200/JCO.2016.71.7629 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28854067 PubMed]
# '''Abstract:''' Tony Mok, Yi-Long Wu, Patricia A, Watson, Jin Zhang, Reshma A. Rangwala, and Gilberto Lopes. Phase 3 KEYNOTE-042 trial of pembrolizumab (MK-3475) versus platinum doublet chemotherapy in treatment-naive patients (pts) with PD-L1–positive advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology 2015 33:15_suppl, TPS8105-TPS8105 [http://ascopubs.org/doi/abs/10.1200/jco.2015.33.15_suppl.tps8105 link to abstract]
# '''KEYNOTE-407:''' Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, Hermes B, Çay Şenler F, Csőszi T, Fülöp A, Rodríguez-Cid J, Wilson J, Sugawara S, Kato T, Lee KH, Cheng Y, Novello S, Halmos B, Li X, Lubiniecki GM, Piperdi B, Kowalski DM; KEYNOTE-407 Investigators. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018 Nov 22;379(21):2040-2051. Epub 2018 Sep 25. [https://www.nejm.org/doi/10.1056/NEJMoa1810865 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/30280635 PubMed]

==Carboplatin, Paclitaxel, Ipilimumab {{#subobject:e8ba81|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:f70cfc|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2016.71.7629 Govindan et al. 2017 (CA184-104)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Carboplatin_.26_Paclitaxel_6|Carboplatin & Paclitaxel]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''Note: this is the "phased" approach to this regimen.''
====Chemoimmunotherapy====
*[[Carboplatin (Paraplatin)]] AUC 6 IV once on day 1
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV once on day 1 
*[[Ipilimumab (Yervoy)]] as follows:
**Cycles 3 to 6: 10 mg/kg IV once on day 1

====Supportive medications====
*[[:Category:Steroids|Corticosteroids]] could be used as premedication for [[Paclitaxel (Taxol)]] infusion or for toxicity management.

'''21-day cycle for up to 6 cycles''' 
====Subsequent treatment====
*[[#Ipilimumab_monotherapy|Maintenance ipilimumab]]

===References===
# '''CA184-104:''' Govindan R, Szczesna A, Ahn MJ, Schneider CP, Gonzalez Mella PF, Barlesi F, Han B, Ganea DE, Von Pawel J, Vladimirov V, Fadeeva N, Lee KH, Kurata T, Zhang L, Tamura T, Postmus PE, Jassem J, O'Byrne K, Kopit J, Li M, Tschaika M, Reck M. Phase III trial of ipilimumab combined with paclitaxel and carboplatin in advanced squamous non-small-cell lung cancer. J Clin Oncol. 2017 Oct 20;35(30):3449-3457. Epub 2017 Aug 30. [http://ascopubs.org/doi/full/10.1200/JCO.2016.71.7629 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28854067 PubMed]

==Carboplatin, Paclitaxel, Pembrolizumab {{#subobject:1dc8a3|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:46a0f7|Variant=1}}===
{| class="wikitable" style="color:white; background-color:#404040"
|<small>'''FDA-recommended dose'''</small>
|-
|}
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/10.1056/NEJMoa1810865 Paz-Ares et al. 2018 (KEYNOTE-407)]
|style="background-color:#1a9851"|Phase III (E)
|[[Complex_multipart_regimens#KEYNOTE-407|See link]]
| style="background-color:#1a9850" |[[Complex_multipart_regimens#KEYNOTE-407|See link]]
|-
|}
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 6 IV once on day 1
*[[Paclitaxel (Taxol)]] 200 mg/m<sup>2</sup> IV once on day 1
*[[Pembrolizumab (Keytruda)]] 200 mg IV once on day 1, '''given first'''

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*[[#Pembrolizumab_monotherapy_2|Pembrolizumab maintenance]]

===References===
# '''KEYNOTE-407:''' Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, Hermes B, Çay Şenler F, Csőszi T, Fülöp A, Rodríguez-Cid J, Wilson J, Sugawara S, Kato T, Lee KH, Cheng Y, Novello S, Halmos B, Li X, Lubiniecki GM, Piperdi B, Kowalski DM; KEYNOTE-407 Investigators. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018 Nov 22;379(21):2040-2051. Epub 2018 Sep 25. [https://www.nejm.org/doi/10.1056/NEJMoa1810865 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/30280635 PubMed]

==Cisplatin & Docetaxel {{#subobject:58dfce|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
DC: '''<u>D</u>'''ocetaxel & '''<u>C</u>'''isplatin
===Regimen {{#subobject:8ddb3b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00305-8/fulltext Shukuya et al. 2015 (WJOG5208L)]
|style="background-color:#1a9851"|Phase III (C)
|Docetaxel & Nedaplatin
| style="background-color:#fc8d59" |Seems to have inferior OS
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 80 mg/m<sup>2</sup> IV once on day 1
*[[Docetaxel (Taxotere)]] 60 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 4 to 6 cycles'''

===References===
# '''WJOG5208L:''' Shukuya T, Yamanaka T, Seto T, Daga H, Goto K, Saka H, Sugawara S, Takahashi T, Yokota S, Kaneda H, Kawaguchi T, Nagase S, Oguri T, Iwamoto Y, Nishimura T, Hattori Y, Nakagawa K, Nakanishi Y, Yamamoto N; West Japan Oncology Group. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial. Lancet Oncol. 2015 Dec;16(16):1630-8. Epub 2015 Oct 28. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00305-8/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26522337 PubMed]

==Cisplatin & Gemcitabine {{#subobject:fb3ee0|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
GC: '''<u>G</u>'''emcitabine & '''<u>C</u>'''isplatin
<br>GP: '''<u>G</u>'''emcitabine & '''<u>P</u>'''latinol (Cisplatin)
===Regimen {{#subobject:0e126e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00021-2/fulltext Thatcher et al. 2015 (SQUIRE)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Cisplatin.2C_Gemcitabine.2C_Necitumumab|Cisplatin, Gemcitabine, Necitumumab]]
|style="background-color:#fc8d59"|Seems to have inferior OS
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV over 30 minutes once on day 1
*[[Gemcitabine (Gemzar)]] 1250 mg/m<sup>2</sup> IV over 2 hours once per day on days 1 & 8

'''21-day cycle for up to 6 cycles'''

===References===
# '''SQUIRE:''' Thatcher N, Hirsch FR, Luft AV, Szczesna A, Ciuleanu TE, Dediu M, Ramlau R, Galiulin RK, Bálint B, Losonczy G, Kazarnowicz A, Park K, Schumann C, Reck M, Depenbrock H, Nanda S, Kruljac-Letunic A, Kurek R, Paz-Ares L, Socinski MA; SQUIRE Investigators. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2015 Jul;16(7):763-74. Epub 2015 Jun 1. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00021-2/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26045340 PubMed]
## '''Dataset:''' [https://www.projectdatasphere.org/projectdatasphere/html/content/272 Project Data Sphere]

==Cisplatin, Gemcitabine, Necitumumab {{#subobject:PYR3|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:PYV3|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00021-2/fulltext Thatcher et al. 2015 (SQUIRE)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Cisplatin_.26_Gemcitabine_5|Cisplatin & Gemcitabine]]
|style="background-color:#91cf60"|Seems to have superior OS
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV over 2 hours once on day 1
*[[Gemcitabine (Gemzar)]] 1250 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1 & 8
*[[Necitumumab (Portrazza)]] 800 mg IV over at least 50 minutes once per day on days 1 & 8

====Supportive medications==== 
*Antiemetic premedications for gemcitabine and cisplatin "according to local practice."
*"Pre-emptive treatment for skin toxicity was allowed only after the first cycle."

'''21-day cycle for 6 cycles'''
====Subsequent treatment====
*[[#Necitumumab_monotherapy|Necitumumab maintenance]]

===References===
# '''SQUIRE:''' Thatcher N, Hirsch FR, Luft AV, Szczesna A, Ciuleanu TE, Dediu M, Ramlau R, Galiulin RK, Bálint B, Losonczy G, Kazarnowicz A, Park K, Schumann C, Reck M, Depenbrock H, Nanda S, Kruljac-Letunic A, Kurek R, Paz-Ares L, Socinski MA; SQUIRE Investigators. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2015 Jul;16(7):763-74. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00021-2/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26045340 PubMed]
## '''Dataset:''' [https://www.projectdatasphere.org/projectdatasphere/html/content/272 Project Data Sphere]

=Advanced or metastatic disease, first-line, elderly or poor performance status=
==Best supportive care==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jnci.oxfordjournals.org/content/91/1/66.long Gridelli et al. 1999 (ELVIS)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Vinorelbine_monotherapy|Vinorelbine]]
|style="background-color:#fc8d59"|Seems to have inferior OS
|-
|[https://journals.sagepub.com/doi/abs/10.1177/030089169908500306 De Marinis et al. 1999]
|style="background-color:#1a9851"|Phase III (C)
|1. Lonidamine<br> 2. Lonidamine & Vindesine<br> 3. Vindesine
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''No active antineoplastic treatment.''
===References===
# '''ELVIS:''' Gridelli C, Perrone F, Gallo C; The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst. 1999 Jan 6;91(1):66-72. [http://jnci.oxfordjournals.org/content/91/1/66.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/9890172 PubMed]
# De Marinis F, Rinaldi M, Ardizzoni A, Bruzzi P, Pennucci MC, Portalone L, D'Aprile M, Ripanti P, Romano F, Belli M, Altavilla G, Migliorino MR, Rosso R, Salvati F; Italian Lung Cancer Task Force. The role of vindesine and lonidamine in the treatment of elderly patients with advanced non-small cell lung cancer: a phase III randomized FONICAP trial. Tumori. 1999 May-Jun;85(3):177-82. [https://journals.sagepub.com/doi/abs/10.1177/030089169908500306 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/10426128 PubMed]

==Carboplatin & Gemcitabine {{#subobject:2f045e|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CG: '''<u>C</u>'''arboplatin & '''<u>G</u>'''emcitabine
===Regimen {{#subobject:c4b462|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 20%"|Study
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 20%"|Comparator
!style="width: 20%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
!style="width: 20%"|[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[https://academic.oup.com/annonc/article/22/7/1520/187339 Biesma et al. 2011 (NVALT-3)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Carboplatin_.26_Paclitaxel_7|CP]]
| style="background-color:#ffffbf" |Seems not superior
| style="background-color:#ffffbf" |Similar QoL
|-
|}
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 5 IV once on day 1
*[[Gemcitabine (Gemzar)]] 1250 mg/m<sup>2</sup> IV once per day on days 1 & 8

'''21-day cycle for up to 4 cycles'''
===References===
# '''NVALT-3:''' Biesma B, Wymenga AN, Vincent A, Dalesio O, Smit HJ, Stigt JA, Smit EF, van Felius CL, van Putten JW, Slaets JP, Groen HJ; Dutch Chest Physician Study Group. Quality of life, geriatric assessment and survival in elderly patients with non-small-cell lung cancer treated with carboplatin-gemcitabine or carboplatin-paclitaxel: NVALT-3 a phase III study. Ann Oncol. 2011 Jul;22(7):1520-7. Epub 2011 Jan 20. [https://academic.oup.com/annonc/article/22/7/1520/187339 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21252061 PubMed]

==Carboplatin & Paclitaxel {{#subobject:050d96|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
TC: '''<u>T</u>'''axol (Paclitaxel) & '''<u>C</u>'''arboplatin
<br>CP: '''<u>C</u>'''arboplatin & '''<u>P</u>'''aclitaxel
===Variant #1, 5/175 {{#subobject:5dd7ea|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 20%"|Study
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 20%"|Comparator
!style="width: 20%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
!style="width: 20%"|[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[https://academic.oup.com/annonc/article/22/7/1520/187339 Biesma et al. 2011 (NVALT-3)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Carboplatin_.26_Gemcitabine_2|CG]]
| style="background-color:#ffffbf" |Seems not superior
| style="background-color:#ffffbf" |Similar QoL
|-
|}
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 5 IV once on day 1
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for up to 4 cycles'''

===Variant #2, 6/90 {{#subobject:bd42df|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2811%2960780-0/fulltext Quoix et al. 2011 (IFCT-0501)]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. [[#Gemcitabine_monotherapy|Gemcitabine]]
|style="background-color:#1a9850"|Superior OS
|-
|2. [[#Vinorelbine_monotherapy|Vinorelbine]]
|style="background-color:#1a9850"|Superior OS
|-
|}
''Study involved only patients 70 to 89 years old''
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 6 IV once on day 1
*[[Paclitaxel (Taxol)]] 90 mg/m<sup>2</sup> IV once per day on days 1, 8, 15

====Supportive medications====
*Growth factor support was not recommended as primary prophylaxis during cycle 1, but could be used if the patient develops grade 3-4 neutropenia

'''28-day cycle for up to 4 cycles'''

===Variant #3, 6/200 {{#subobject:7ba15a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/26/6/863.full Lilenbaum et al. 2008]
|style="background-color:#1a9851"|Phase III (C)
|Erlotinib
|style="background-color:#91cf60"|Seems to have superior OS
|-
|}
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 6 IV over 15 to 60 minutes once on day 1, '''given second'''
*[[Paclitaxel (Taxol)]] 200 mg/m<sup>2</sup> IV over 3 hours once on day 1, '''given first'''

'''21-day cycle for up to 4 cycles'''

===Variant #4, 6/225 {{#subobject:e1af15|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.jto.org/article/S1556-0864(15)31485-4/fulltext Langer et al. 2008]
|style="background-color:#1a9851"|Phase III (C)
|Carboplatin & PPX
|style="background-color:#91cf60"|Seems to have superior OS
|-
|}
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 6 IV once on day 1
*[[Paclitaxel (Taxol)]] 225 mg/m<sup>2</sup> IV once on day 1

'''21-day cycles'''

===References===
# Lilenbaum R, Axelrod R, Thomas S, Dowlati A, Seigel L, Albert D, Witt K, Botkin D. Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2. J Clin Oncol. 2008 Feb 20;26(6):863-9. [http://jco.ascopubs.org/content/26/6/863.full link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18281658 PubMed]
# Langer CJ, O'Byrne KJ, Socinski MA, Mikhailov SM, Leśniewski-Kmak K, Smakal M, Ciuleanu TE, Orlov SV, Dediu M, Heigener D, Eisenfeld AJ, Sandalic L, Oldham FB, Singer JW, Ross HJ. Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer. J Thorac Oncol. 2008 Jun;3(6):623-30. [https://www.jto.org/article/S1556-0864(15)31485-4/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18520802 PubMed]
# '''NVALT-3:''' Biesma B, Wymenga AN, Vincent A, Dalesio O, Smit HJ, Stigt JA, Smit EF, van Felius CL, van Putten JW, Slaets JP, Groen HJ; Dutch Chest Physician Study Group. Quality of life, geriatric assessment and survival in elderly patients with non-small-cell lung cancer treated with carboplatin-gemcitabine or carboplatin-paclitaxel: NVALT-3 a phase III study. Ann Oncol. 2011 Jul;22(7):1520-7. Epub 2011 Jan 20. [https://academic.oup.com/annonc/article/22/7/1520/187339 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21252061 PubMed]
# '''IFCT-0501:''' Quoix E, Zalcman G, Oster JP, Westeel V, Pichon E, Lavolé A, Dauba J, Debieuvre D, Souquet PJ, Bigay-Game L, Dansin E, Poudenx M, Molinier O, Vaylet F, Moro-Sibilot D, Herman D, Bennouna J, Tredaniel J, Ducoloné A, Lebitasy MP, Baudrin L, Laporte S, Milleron B; Intergroupe Francophone de Cancérologie Thoracique. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet. 2011 Sep 17;378(9796):1079-88. Epub 2011 Aug 8. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2811%2960780-0/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21831418 PubMed]

==Carboplatin & Pemetrexed {{#subobject:fc1ec6|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Example orders===
*[[Example orders for Carboplatin (Paraplatin) and Pemetrexed (Alimta) in non-small cell lung cancer]]

===Regimen {{#subobject:b1cc1a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/31/23/2849.long Zukin et al. 2013 (INCA-Lung001)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Pemetrexed_monotherapy|Pemetrexed]]
|style="background-color:#1a9850"|Superior OS
|-
|}
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 5 IV over 15 to 60 minutes once on day 1, '''given second'''
*[[Pemetrexed (Alimta)]] 500 mg/m<sup>2</sup> IV over 10 minutes once on day 1, '''given first'''

====Supportive medications====
*(Ardizzoni et al. 2012 contained more details):
*[[Dexamethasone (Decadron)]] 4 mg or [[steroid conversions|equivalent corticosteroid]] PO twice per day on the day before, the day of, and day after each dose of [[Pemetrexed (Alimta)]]
*Folic acid 350 to 600 mcg PO once per day, starting 1 to 2 weeks before the first dose of [[Pemetrexed (Alimta)]], to be taken throughout pemetrexed therapy.
*[[Cyanocobalamin (Vitamin B12)]] 1000 mcg IM once every 9 weeks, first dose 1 to 2 weeks before the first dose of [[Pemetrexed (Alimta)]], to be given throughout pemetrexed therapy

'''21-day cycle for up to 4 cycles'''

===References===
<!-- Presented at the 48th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 1-5, 2012. -->
# '''INCA-Lung001:''' Zukin M, Barrios CH, Rodrigues Pereira J, De Albuquerque Ribeiro R, de Mendonça Beato CA, do Nascimento YN, Murad A, Franke FA, Precivale M, de Lima Araujo LH, Da Rocha Baldotto CS, Vieira FM, Small IA, Ferreira CG, Lilenbaum RC. Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2. J Clin Oncol. 2013 Aug 10;31(23):2849-53. Epub 2013 Jun 17. [http://jco.ascopubs.org/content/31/23/2849.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23775961 PubMed]

==Carboplatin, Pemetrexed, Bevacizumab {{#subobject:03239b|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:8a4c4f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.30986 Spigel et al. 2018]
|style="background-color:#1a9851"|Randomized Phase II (E)
|1. [[#Pemetrexed_monotherapy|Pemetrexed]]<br> 2. [[#Pemetrexed_.26_Bevacizumab|Pemetrexed & Bevacizumab]]
|PFS: 4.8 mo
|-
|}
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 5 IV once on day 1
*[[Pemetrexed (Alimta)]] 500 mg/m<sup>2</sup> IV once on day 1
*[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1

====Supportive medications====
*Premedications, folic acid, and vitamin supplementation per standard guidelines
*Antiemetics per standard guidelines

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*[[#Pemetrexed_.26_Bevacizumab_2|Pemetrexed & Bevacizumab maintenance]]

===References===
# Spigel DR, Hainsworth JD, Joseph MJ, Shipley DL, Hagan MK, Thompson DS, Burris HA 3rd, Greco FA. Randomized phase 2 trial of pemetrexed, pemetrexed/bevacizumab, and pemetrexed/carboplatin/bevacizumab in patients with stage IIIB/IV non-small cell lung cancer and an Eastern Cooperative Oncology Group performance status of 2. Cancer. 2018 May 1;124(9):1982-1991. Epub 2018 Feb 16. [https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.30986 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29451696 PubMed]

==Docetaxel monotherapy {{#subobject:17ba7f|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Example orders===
*[[Example orders for Docetaxel (Taxotere) in non-small cell lung cancer]]
===Variant #1, 25 mg/m<sup>2</sup>, 3 out of 4 weeks {{#subobject:22a876|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://academic.oup.com/jjco/article/45/1/88/889067 Tsukada et al. 2014 (JCOG0207)]
|style="background-color:#1a9851"|Phase III (C)
|Cisplatin & Docetaxel
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 25 mg/m<sup>2</sup> IV once per day on days 1, 8, 15

'''28-day cycles'''

===Variant #2, 36 mg/m<sup>2</sup>, 3 out of 4 weeks {{#subobject:110876|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://onlinelibrary.wiley.com/doi/abs/10.1002/cncr.23019 Hainsworth et al. 2007]
|style="background-color:#1a9851"|Phase III (C)
|[[Non-small_cell_lung_cancer_-_historical#Docetaxel_.26_Gemcitabine|Docetaxel & Gemcitabine]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 36 mg/m<sup>2</sup> IV once per day on days 1, 8, 15

'''28-day cycles'''

===Variant #3, 38 mg/m<sup>2</sup>, 2 out of 3 weeks {{#subobject:75b593|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.clinical-lung-cancer.com/article/S1525-7304(11)00016-7/fulltext Karampeazis et al. 2011]
|style="background-color:#1a9851"|Phase III (E)
|[[#Vinorelbine_monotherapy|Vinorelbine]]
| style="background-color:#d9ef8b" |Might have superior OS
|-
|}
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 38 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1 & 8

'''21-day cycle for up to 6 cycles'''

===Variant #4, 60 mg/m<sup>2</sup> q3wk {{#subobject:afca35|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/10.1200/JCO.2006.06.1044 Kudoh et al. 2006 (WJTOG 9904)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Vinorelbine_monotherapy|Vinorelbine]]
|style="background-color:#ffffbf"|Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2014.55.8627 Abe et al. 2015 (JCOG0803/WJOG4307L)]
|style="background-color:#1a9851"|Phase III (C)
|Cisplatin & Docetaxel
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''This is the PMDA-approved dose.''
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 60 mg/m<sup>2</sup> IV over 60 minutes once on day 1

'''21-day cycle for up to 4 cycles (WJTOG 9904) or indefinitely'''
===References===
# '''WJTOG 9904:''' Kudoh S, Takeda K, Nakagawa K, Takada M, Katakami N, Matsui K, Shinkai T, Sawa T, Goto I, Semba H, Seto T, Ando M, Satoh T, Yoshimura N, Negoro S, Fukuoka M. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol. 2006 Aug 1;24(22):3657-63. [http://ascopubs.org/doi/10.1200/JCO.2006.06.1044 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16877734 PubMed]
# Hainsworth JD, Spigel DR, Farley C, Shipley DL, Bearden JD, Gandhi J, Houston GA, Greco FA. Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer: a randomized phase 3 trial of the Minnie Pearl Cancer Research Network. Cancer. 2007 Nov 1;110(9):2027-34. [https://onlinelibrary.wiley.com/doi/abs/10.1002/cncr.23019 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17823908 PubMed]
# Karampeazis A, Vamvakas L, Agelidou A, Kentepozidis N, Chainis K, Chandrinos V, Vardakis N, Pallis AG, Christophyllakis C, Georgoulias V. Docetaxel vs vinorelbine in elderly patients with advanced non--small-cell lung cancer: a Hellenic Oncology Research Group randomized phase III study. Clin Lung Cancer. 2011 May;12(3):155-60. Epub 2011 Apr 27. [https://www.clinical-lung-cancer.com/article/S1525-7304(11)00016-7/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21663857 PubMed]
# '''JCOG0207:''' Tsukada H, Yokoyama A, Goto K, Shinkai T, Harada M, Ando M, Shibata T, Ohe Y, Tamura T, Saijo N; Lung Cancer Study Group of the Japan Clinical Oncology Group (JCOG). Randomized controlled trial comparing docetaxel-cisplatin combination with weekly docetaxel alone in elderly patients with advanced non-small-cell lung cancer: Japan Clinical Oncology Group (JCOG) 0207. Jpn J Clin Oncol. 2015 Jan;45(1):88-95. Epub 2014 Nov 6. [https://academic.oup.com/jjco/article/45/1/88/889067 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25378648 PubMed]
# '''JCOG0803/WJOG4307L:''' Abe T, Takeda K, Ohe Y, Kudoh S, Ichinose Y, Okamoto H, Yamamoto N, Yoshioka H, Minato K, Sawa T, Iwamoto Y, Saka H, Mizusawa J, Shibata T, Nakamura S, Ando M, Yokoyama A, Nakagawa K, Saijo N, Tamura T. Randomized phase III trial comparing weekly docetaxel plus cisplatin versus docetaxel monotherapy every 3 weeks in elderly patients with advanced non-small-cell lung cancer: the intergroup trial JCOG0803/WJOG4307L. J Clin Oncol. 2015 Feb 20;33(6):575-81. Epub 2015 Jan 12. [http://ascopubs.org/doi/full/10.1200/JCO.2014.55.8627 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25584004 PubMed]

==Gemcitabine monotherapy {{#subobject:21a88f|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 1000 mg/m<sup>2</sup>, 3 out of 4 weeks {{#subobject:137c9f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.jto.org/article/S1556-0864(15)33345-1/fulltext O'Brien et al. 2008]
|style="background-color:#1a9851"|Phase III (C)
|Paclitaxel Poliglumex
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Gemcitabine (Gemzar)]] 1000 mg/m<sup>2</sup> IV once per day on days 1, 8, 15

'''28-day cycle for up to 6 cycles'''

===Variant #2, 1150 mg/m<sup>2</sup>, 2 out of 3 weeks {{#subobject:340c10|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2811%2960780-0/fulltext Quoix et al. 2011 (IFCT-0501)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Carboplatin_.26_Paclitaxel_7|Carboplatin & Paclitaxel]]
|style="background-color:#d73027"|Inferior OS
|-
|}
''Study involved only patients 70 to 89 years old''
====Chemotherapy====
*[[Gemcitabine (Gemzar)]] 1150 mg/m<sup>2</sup> IV once per day on days 1 & 8 

====Supportive medications====
*Growth factor support was not recommended as primary prophylaxis during cycle 1, but could be used if the patient develops grade 3 to 4 neutropenia

'''21-day cycle for up to 5 cycles'''

===Variant #3, 1200 mg/m<sup>2</sup>, 2 out of 3 weeks {{#subobject:b8de5d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[http://jnci.oxfordjournals.org/content/95/5/362.long Gridelli et al. 2003 (MILES)]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. [[#Gemcitabine_.26_Vinorelbine_2|Gemcitabine & Vinorelbine]]
|style="background-color:#ffffbf"|Seems not superior
|-
|2. [[#Vinorelbine_monotherapy|Vinorelbine]]
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2793001/ Reynolds et al. 2009 (USO-03012)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Carboplatin_.26_Gemcitabine_2|Carboplatin & Gemcitabine]]
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.lungcancerjournal.info/article/S0169-5002(13)00155-4/fulltext Morabito et al. 2013 (CAPPA-2)]
|style="background-color:#1a9851"|Phase III (C)
|Cisplatin & Gemcitabine
| style="background-color:#fc8d59" |Seems to have inferior OS
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2017.76.8390 Gridelli et al. 2018 (MILES-3/MILES-4)]
|style="background-color:#1a9851"|Phase III (C)
|Cisplatin & Gemcitabine
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''MILES studies involved only patients at least 70 years old. CAPPA-2 allowed patients aged 18-70 with ECOG PS = 2.''
====Chemotherapy====
*[[Gemcitabine (Gemzar)]] 1200 mg/m<sup>2</sup> IV once per day on days 1 & 8 

====Supportive medications====
*"[[:Category:Emesis_prevention|Antiemetic]] agents and other supportive treatments were provided at the discretion of the treating physician."

'''21-day cycle for 4 to 6 cycles'''

===References===
# '''MILES:''' Gridelli C, Perrone F, Gallo C, Cigolari S, Rossi A, Piantedosi F, Barbera S, Ferraù F, Piazza E, Rosetti F, Clerici M, Bertetto O, Robbiati SF, Frontini L, Sacco C, Castiglione F, Favaretto A, Novello S, Migliorino MR, Gasparini G, Galetta D, Iaffaioli RV, Gebbia V; MILES Investigators. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst. 2003 Mar 5;95(5):362-72. [http://jnci.oxfordjournals.org/content/95/5/362.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12618501 PubMed]
# '''SICOG 9909:''' Comella P, Frasci G, Carnicelli P, Massidda B, Buzzi F, Filippelli G, Maiorino L, Guida M, Panza N, Mancarella S, Cioffi R. Gemcitabine with either paclitaxel or vinorelbine vs paclitaxel or gemcitabine alone for elderly or unfit advanced non-small-cell lung cancer patients. Br J Cancer. 2004 Aug 2;91(3):489-97. [https://www.nature.com/articles/6602011 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409832/ link to PMC article]  '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15266334 PubMed]
# O'Brien ME, Socinski MA, Popovich AY, Bondarenko IN, Tomova A, Bilynsky BT, Hotko YS, Ganul VL, Kostinsky IY, Eisenfeld AJ, Sandalic L, Oldham FB, Bandstra B, Sandler AB, Singer JW. Randomized phase III trial comparing single-agent paclitaxel Poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer. J Thorac Oncol. 2008 Jul;3(7):728-34. [https://www.jto.org/article/S1556-0864(15)33345-1/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18594318 PubMed]
# '''USO-03012:''' Reynolds C, Obasaju C, Schell MJ, Li X, Zheng Z, Boulware D, Caton JR, Demarco LC, O'Rourke MA, Shaw Wright G, Boehm KA, Asmar L, Bromund J, Peng G, Monberg MJ, Bepler G. Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J Clin Oncol. 2009 Dec 1;27(34):5808-15. Epub 2009 Nov 2. [http://ascopubs.org/doi/full/10.1200/JCO.2009.21.9766 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2793001/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19884554 PubMed]
# '''IFCT-0501:''' Quoix E, Zalcman G, Oster JP, Westeel V, Pichon E, Lavolé A, Dauba J, Debieuvre D, Souquet PJ, Bigay-Game L, Dansin E, Poudenx M, Molinier O, Vaylet F, Moro-Sibilot D, Herman D, Bennouna J, Tredaniel J, Ducoloné A, Lebitasy MP, Baudrin L, Laporte S, Milleron B; Intergroupe Francophone de Cancérologie Thoracique. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet. 2011 Sep 17;378(9796):1079-88. Epub 2011 Aug 8. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2811%2960780-0/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21831418 PubMed]
# '''CAPPA-2:''' Morabito A, Gebbia V, Di Maio M, Cinieri S, Viganò MG, Bianco R, Barbera S, Cavanna L, De Marinis F, Montesarchio V, Costanzo R, Sandomenico C, Montanino A, Mancuso G, Russo P, Nacci A, Giordano P, Daniele G, Piccirillo MC, Rocco G, Gridelli C, Gallo C, Perrone F. Randomized phase III trial of gemcitabine and cisplatin vs gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2: the CAPPA-2 study. Lung Cancer. 2013 Jul;81(1):77-83. Epub 2013 May 1. [https://www.lungcancerjournal.info/article/S0169-5002(13)00155-4/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23643177 PubMed]
# '''MILES-3/MILES-4:''' Gridelli C, Morabito A, Cavanna L, Luciani A, Maione P, Bonanno L, Filipazzi V, Leo S, Cinieri S, Ciardiello F, Burgio MA, Bilancia D, Cortinovis D, Rosetti F, Bianco R, Gebbia V, Artioli F, Bordonaro R, Fregoni V, Mencoboni M, Nelli F, Riccardi F, di Isernia G, Costanzo R, Rocco G, Daniele G, Signoriello S, Piccirillo MC, Gallo C, Perrone F. Cisplatin-based first-line treatment of elderly patients with advanced non-small-cell lung cancer: joint analysis of MILES-3 and MILES-4 phase III trials. J Clin Oncol. 2018 Sep 1;36(25):2585-2592. Epub 2018 Jul 20. [http://ascopubs.org/doi/full/10.1200/JCO.2017.76.8390 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/30028656 PubMed]

==Gemcitabine & Paclitaxel {{#subobject:fa1732|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
GT: '''<u>G</u>'''emcitabine & '''<u>T</u>'''axol (Paclitaxel)
===Regimen {{#subobject:a80095|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409832/ Comella et al. 2004 (SICOG 9909)]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. [[#Gemcitabine_monotherapy|Gemcitabine]]<br> 2. [[Non-small_cell_lung_cancer_-_historical#Paclitaxel_monotherapy|Paclitaxel]]
| style="background-color:#91cf60" |Seems to have superior OS
|-
|3. [[#Gemcitabine_.26_Vinorelbine_2|GV]]
|style="background-color:#d3d3d3"|Not reported
|-
|}
====Chemotherapy====
*[[Gemcitabine (Gemzar)]] 1000 mg/m<sup>2</sup> IV once per day on days 1 & 8 
*[[Paclitaxel (Taxol)]] 80 mg/m<sup>2</sup> IV once per day on days 1 & 8 

'''21-day cycle for up to 6 cycles'''

===References===
# '''SICOG 9909:''' Comella P, Frasci G, Carnicelli P, Massidda B, Buzzi F, Filippelli G, Maiorino L, Guida M, Panza N, Mancarella S, Cioffi R. Gemcitabine with either paclitaxel or vinorelbine vs paclitaxel or gemcitabine alone for elderly or unfit advanced non-small-cell lung cancer patients. Br J Cancer. 2004 Aug 2;91(3):489-97. [https://www.nature.com/articles/6602011 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409832/ link to PMC article]  '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15266334 PubMed]

==Gemcitabine & Vinorelbine {{#subobject:0e1f07|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
GV: '''<u>G</u>'''emcitabine & '''<u>V</u>'''inorelbine
<br>VG: '''<u>V</u>'''inorelbine & '''<u>G</u>'''emcitabine
===Variant #1, 1000/25 {{#subobject:4d6b82|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[http://jnci.oxfordjournals.org/content/95/5/362.long Gridelli et al. 2003 (MILES)]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. [[#Gemcitabine_monotherapy|Gemcitabine]]
|style="background-color:#ffffbf"|Seems not superior
|-
|2. [[#Vinorelbine_monotherapy|Vinorelbine]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''This study involved only patients at least 70 years old''
====Chemotherapy====
*[[Gemcitabine (Gemzar)]] 1000 mg/m<sup>2</sup> IV once per day on days 1 & 8 
*[[Vinorelbine (Navelbine)]] 25 mg/m<sup>2</sup> IV once per day on days 1 & 8 

====Supportive medications====
*"[[:Category:Emesis_prevention|Antiemetic]] agents and other supportive treatments were provided at the discretion of the treating physician."

'''21-day cycle for up to 6 cycles'''

===Variant #2, 1200/30 {{#subobject:07e5b2|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2000.18.13.2529 Frasci et al. 2000]
|style="background-color:#1a9851"|Phase III (E)
|[[#Vinorelbine_monotherapy|Vinorelbine]]
| style="background-color:#1a9850" |Superior OS
|-
|}
''This study involved only patients at least 70 years old''
====Chemotherapy====
*[[Gemcitabine (Gemzar)]] 1200 mg/m<sup>2</sup> IV once per day on days 1 & 8 
*[[Vinorelbine (Navelbine)]] 30 mg/m<sup>2</sup> IV once per day on days 1 & 8 

'''21-day cycle for up to 6 cycles'''

===References===
# Frasci G, Lorusso V, Panza N, Comella P, Nicolella G, Bianco A, De Cataldis G, Iannelli A, Bilancia D, Belli M, Massidda B, Piantedosi F, Comella G, De Lena M. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol. 2000 Jul;18(13):2529-36. [http://ascopubs.org/doi/full/10.1200/JCO.2000.18.13.2529 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10893283 PubMed]
# '''MILES:''' Gridelli C, Perrone F, Gallo C, Cigolari S, Rossi A, Piantedosi F, Barbera S, Ferraù F, Piazza E, Rosetti F, Clerici M, Bertetto O, Robbiati SF, Frontini L, Sacco C, Castiglione F, Favaretto A, Novello S, Migliorino MR, Gasparini G, Galetta D, Iaffaioli RV, Gebbia V; MILES Investigators. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst. 2003 Mar 5;95(5):362-72. [http://jnci.oxfordjournals.org/content/95/5/362.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12618501 PubMed]
# '''SICOG 9909:''' Comella P, Frasci G, Carnicelli P, Massidda B, Buzzi F, Filippelli G, Maiorino L, Guida M, Panza N, Mancarella S, Cioffi R. Gemcitabine with either paclitaxel or vinorelbine vs paclitaxel or gemcitabine alone for elderly or unfit advanced non-small-cell lung cancer patients. Br J Cancer. 2004 Aug 2;91(3):489-97. [https://www.nature.com/articles/6602011 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409832/ link to PMC article]  '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15266334 PubMed]

==Pemetrexed monotherapy {{#subobject:615e55|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Example orders===
*[[Example orders for Pemetrexed (Alimta) in non-small cell lung cancer]]

===Regimen {{#subobject:7f11b0|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/31/23/2849.long Zukin et al. 2013 (INCA-Lung001)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Carboplatin_.26_Pemetrexed_3|Carboplatin & Pemetrexed]]
|style="background-color:#d73027"|Inferior OS
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2017.76.8390 Gridelli et al. 2018 (MILES-4)]
|style="background-color:#1a9851"|Phase III (C)
|1. Cisplatin & Gemcitabine<br> 2. Cisplatin & Pemetrexed
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Chemotherapy====
*[[Pemetrexed (Alimta)]] 500 mg/m<sup>2</sup> IV over 10 minutes once on day 1

'''21-day cycle for up to 4 cycles (INCA-Lung001) or 6 cycles (MILES-4)'''

===References===
<!-- Presented at the 48th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 1-5, 2012. -->
# '''INCA-Lung001:''' Zukin M, Barrios CH, Rodrigues Pereira J, De Albuquerque Ribeiro R, de Mendonça Beato CA, do Nascimento YN, Murad A, Franke FA, Precivale M, de Lima Araujo LH, Da Rocha Baldotto CS, Vieira FM, Small IA, Ferreira CG, Lilenbaum RC. Randomized phase III Trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2. J Clin Oncol. 2013 Aug 10;31(23):2849-53. Epub 2013 Jun 17. [http://jco.ascopubs.org/content/31/23/2849.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23775961 PubMed]
# Spigel DR, Hainsworth JD, Joseph MJ, Shipley DL, Hagan MK, Thompson DS, Burris HA 3rd, Greco FA. Randomized phase 2 trial of pemetrexed, pemetrexed/bevacizumab, and pemetrexed/carboplatin/bevacizumab in patients with stage IIIB/IV non-small cell lung cancer and an Eastern Cooperative Oncology Group performance status of 2. Cancer. 2018 May 1;124(9):1982-1991. Epub 2018 Feb 16. [https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.30986 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29451696 PubMed]
# '''MILES-4:''' Gridelli C, Morabito A, Cavanna L, Luciani A, Maione P, Bonanno L, Filipazzi V, Leo S, Cinieri S, Ciardiello F, Burgio MA, Bilancia D, Cortinovis D, Rosetti F, Bianco R, Gebbia V, Artioli F, Bordonaro R, Fregoni V, Mencoboni M, Nelli F, Riccardi F, di Isernia G, Costanzo R, Rocco G, Daniele G, Signoriello S, Piccirillo MC, Gallo C, Perrone F. Cisplatin-based first-line treatment of elderly patients with advanced non-small-cell lung cancer: joint analysis of MILES-3 and MILES-4 phase III trials. J Clin Oncol. 2018 Sep 1;36(25):2585-2592. Epub 2018 Jul 20. [http://ascopubs.org/doi/full/10.1200/JCO.2017.76.8390 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/30028656 PubMed]

==Pemetrexed & Bevacizumab {{#subobject:3c119a|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:e31aed|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.30986 Spigel et al. 2018]
|style="background-color:#1a9851"|Randomized Phase II (E)
|1. [[#Pemetrexed_monotherapy|Pemetrexed]]<br> 2. [[#Carboplatin.2C_Pemetrexed.2C_Bevacizumab_2|Carboplatin, Pemetrexed, Bevacizumab]]
|PFS: 4.0 mo
|-
|}
====Chemotherapy====
*[[Pemetrexed (Alimta)]] 500 mg/m<sup>2</sup> IV once on day 1
*[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1

====Supportive medications====
*Premedications, folic acid, and vitamin supplementation per standard guidelines
*Antiemetics per standard guidelines

'''21-day cycles'''

===References===
# Spigel DR, Hainsworth JD, Joseph MJ, Shipley DL, Hagan MK, Thompson DS, Burris HA 3rd, Greco FA. Randomized phase 2 trial of pemetrexed, pemetrexed/bevacizumab, and pemetrexed/carboplatin/bevacizumab in patients with stage IIIB/IV non-small cell lung cancer and an Eastern Cooperative Oncology Group performance status of 2. Cancer. 2018 May 1;124(9):1982-1991. Epub 2018 Feb 16. [https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.30986 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29451696 PubMed]

==Placebo==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488187/ Lee et al. 2012 (TOPICAL)]
|style="background-color:#1a9851"|Phase III (C)
|Erlotinib
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''No active antineoplastic treatment. Placed here because one or more randomized clinical trials included a placebo arm in this disease context.''

===References===
# '''TOPICAL:''' Lee SM, Khan I, Upadhyay S, Lewanski C, Falk S, Skailes G, Marshall E, Woll PJ, Hatton M, Lal R, Jones R, Toy E, Chao D, Middleton G, Bulley S, Ngai Y, Rudd R, Hackshaw A, Boshoff C. First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2012 Nov;13(11):1161-70. Epub 2012 Oct 16. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70412-6/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488187/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23078958 PubMed]

==Vinorelbine monotherapy {{#subobject:aa0ce0|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 25 mg/m<sup>2</sup> {{#subobject:5beb7a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/10.1200/JCO.2006.06.1044 Kudoh et al. 2006 (WJTOG 9904)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Docetaxel_monotherapy|Docetaxel]]
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.clinical-lung-cancer.com/article/S1525-7304(11)00016-7/fulltext Karampeazis et al. 2011]
|style="background-color:#1a9851"|Phase III (E)
|[[#Docetaxel_monotherapy|Docetaxel]]
| style="background-color:#fee08b" |Might have inferior OS
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2811%2960780-0/fulltext Quoix et al. 2011 (IFCT-0501)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Carboplatin_.26_Paclitaxel_7|Carboplatin & Paclitaxel]]
|style="background-color:#d73027"|Inferior OS
|-
|}
''IFCT-0501 involved only patients 70 to 89 years old''
====Chemotherapy====
*[[Vinorelbine (Navelbine)]] 25 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1 & 8 

====Supportive medications====
*Growth factor support was not recommended as primary prophylaxis during cycle 1, but could be used if the patient develops grade 3 to 4 neutropenia

'''21-day cycle for up to 4 cycles (WJTOG 9904), 5 cycles (IFCT-0501), or 6 cycles (Karampeazis et al. 2011)'''

===Variant #2, 30 mg/m<sup>2</sup> {{#subobject:408bee|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jnci.oxfordjournals.org/content/91/1/66.long Gridelli et al. 1999 (ELVIS)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Best_supportive_care|Best supportive care]]
|style="background-color:#91cf60"|Seems to have superior OS
|-
|rowspan=2|[http://jnci.oxfordjournals.org/content/95/5/362.long Gridelli et al. 2003 (MILES)]
|rowspan=2 style="background-color:#1a9851"|Phase III (C)
|1. [[#Gemcitabine_monotherapy|Gemcitabine]]
|style="background-color:#ffffbf"|Seems not superior
|-
|2. [[#Gemcitabine_.26_Vinorelbine|Gemcitabine & Vinorelbine]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''Study involved only patients at least 70 years old''
====Chemotherapy====
*[[Vinorelbine (Navelbine)]] 30 mg/m<sup>2</sup> IV once per day on days 1 & 8 

====Supportive medications====
*(varies depending on reference):
*Elderly Lung Cancer Vinorelbine Italian Study Group, 1999: [[Metoclopramide (Reglan)]] 20 mg IV bolus prior to [[Vinorelbine (Navelbine)]]
*Gridelli et al. 2003: "[[:Category:Emesis_prevention|Antiemetic]] agents and other supportive treatments were provided at the discretion of the treating physician."

'''21-day cycle for up to 6 cycles'''

===References===
# '''ELVIS:''' Gridelli C, Perrone F, Gallo C; The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst. 1999 Jan 6;91(1):66-72. [http://jnci.oxfordjournals.org/content/91/1/66.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/9890172 PubMed]
# '''MILES:''' Gridelli C, Perrone F, Gallo C, Cigolari S, Rossi A, Piantedosi F, Barbera S, Ferraù F, Piazza E, Rosetti F, Clerici M, Bertetto O, Robbiati SF, Frontini L, Sacco C, Castiglione F, Favaretto A, Novello S, Migliorino MR, Gasparini G, Galetta D, Iaffaioli RV, Gebbia V; MILES Investigators. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst. 2003 Mar 5;95(5):362-72. [http://jnci.oxfordjournals.org/content/95/5/362.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12618501 PubMed]
# '''WJTOG 9904:''' Kudoh S, Takeda K, Nakagawa K, Takada M, Katakami N, Matsui K, Shinkai T, Sawa T, Goto I, Semba H, Seto T, Ando M, Satoh T, Yoshimura N, Negoro S, Fukuoka M. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol. 2006 Aug 1;24(22):3657-63. [http://ascopubs.org/doi/10.1200/JCO.2006.06.1044 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16877734 PubMed]
# Karampeazis A, Vamvakas L, Agelidou A, Kentepozidis N, Chainis K, Chandrinos V, Vardakis N, Pallis AG, Christophyllakis C, Georgoulias V. Docetaxel vs vinorelbine in elderly patients with advanced non--small-cell lung cancer: a Hellenic Oncology Research Group randomized phase III study. Clin Lung Cancer. 2011 May;12(3):155-60. Epub 2011 Apr 27. [https://www.clinical-lung-cancer.com/article/S1525-7304(11)00016-7/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21663857 PubMed]
# '''IFCT-0501:''' Quoix E, Zalcman G, Oster JP, Westeel V, Pichon E, Lavolé A, Dauba J, Debieuvre D, Souquet PJ, Bigay-Game L, Dansin E, Poudenx M, Molinier O, Vaylet F, Moro-Sibilot D, Herman D, Bennouna J, Tredaniel J, Ducoloné A, Lebitasy MP, Baudrin L, Laporte S, Milleron B; Intergroupe Francophone de Cancérologie Thoracique. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet. 2011 Sep 17;378(9796):1079-88. Epub 2011 Aug 8. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2811%2960780-0/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21831418 PubMed]

=Maintenance after first-line therapy=

==Atezolizumab & Bevacizumab {{#subobject:ef3aef|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:c2b52e|Variant=1}}===
{| class="wikitable" style="color:white; background-color:#404040"
|<small>'''FDA-recommended dose'''</small>
|-
|}
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1716948 Socinski et al. 2018 (IMpower150)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|}
''Note: this is the FDA-recommended dose for atezolizumab.''
====Preceding treatment====
*[[#ABCP|ABCP]] x 4 or [[#ABCP|ABCP]] x 6
====Chemotherapy====
*[[Atezolizumab (Tecentriq)]] 1200 mg IV over 60 minutes once on day 1
*[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1

'''21-day cycles'''
===References===
# '''IMpower150:''' Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, Finley G, Kelsch C, Lee A, Coleman S, Deng Y, Shen Y, Kowanetz M, Lopez-Chavez A, Sandler A, Reck M; IMpower150 Study Group. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018 Jun 14;378(24):2288-2301. Epub 2018 Jun 4. [https://www.nejm.org/doi/full/10.1056/NEJMoa1716948 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29863955 PubMed]

==Bevacizumab monotherapy {{#subobject:75f589|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 7.5 mg/kg {{#subobject:799728|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2007.14.5466 Reck et al. 2009 (AVAil)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[http://jco.ascopubs.org/content/31/24/3004.long Barlesi et al. 2013 (AVAPERL)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Bevacizumab_.26_Pemetrexed|Bevacizumab & Pemetrexed maintenance]]
|style="background-color:#d73027"|Inferior PFS
|-
|}
====Preceding treatment====
*AVAil: [[#Cisplatin.2C_Gemcitabine.2C_Bevacizumab|Cisplatin, Gemcitabine, Bevacizumab]] x 6
*AVAPERL: [[#Cisplatin.2C_Pemetrexed.2C_Bevacizumab|Cisplatin, Pemetrexed, Bevacizumab]] x 4
====Chemotherapy====
*[[Bevacizumab (Avastin)]] 7.5 mg/kg IV once on day 1

'''21-day cycles'''

===Variant #2, 15 mg/kg {{#subobject:e01dd1|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 20%"|Study
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 20%"|Comparator
!style="width: 20%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
!style="width: 20%"|[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa061884 Sandler et al. 2006 (ECOG E4599)]
|style="background-color:#1a9851"|Phase III (E)
|[[Complex_multipart_regimens#ECOG_E4599|See link]]
| style="background-color:#1a9850" |[[Complex_multipart_regimens#ECOG_E4599|See link]]
| style="background-color:#d3d3d3" |
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2007.14.5466 Reck et al. 2009 (AVAil)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2012.47.3983 Johnson et al. 2013 (ATLAS-NSCLC)]
|style="background-color:#1a9851"|Phase III (C)
|Erlotinib & Bevacizumab maintenance
|style="background-color:#d73027"|Inferior PFS (*)
| style="background-color:#1a9850" |Less toxic
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881367/ Patel et al. 2013 (PointBreak)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881367/ Zinner et al. 2015 (PRONOUNCE)]
|style="background-color:#1a9851"|Phase III (C)
|[[Complex_multipart_regimens#PRONOUNCE|See link]]
|style="background-color:#ffffbf"|[[Complex_multipart_regimens#PRONOUNCE|See link]]
| style="background-color:#d3d3d3" |
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1716948 Socinski et al. 2018 (IMpower150)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|}
''Note that while this arm was inferior in ATLAS, the authors note that, due to toxicity, the "two-drug maintenance regimen will not lead to a new postchemotherapy standard of care." Also, this trial should not be confused with the ones with the same name in breast cancer and in renal cell carcinoma.''
====Preceding treatment====
*ECOG E4599: [[#Carboplatin.2C_Paclitaxel.2C_Bevacizumab_2|PacCBev]] x 6
*AVAil: [[#Cisplatin.2C_Gemcitabine.2C_Bevacizumab|Cisplatin, Gemcitabine, Bevacizumab]] x 6
*ATLAS: Carboplatin, Docetaxel, Bevacizumab x 4 or Carboplatin, Gemcitabine, Bevacizumab x 4 or [[#Carboplatin.2C_Paclitaxel.2C_Bevacizumab|PacCBev]] x 4 or Cisplatin, Docetaxel, Bevacizumab x 4 or [[#Cisplatin.2C_Gemcitabine.2C_Bevacizumab|Cisplatin, Gemcitabine, Bevacizumab]] x 4 or Cisplatin, Vinorelbine, Bevacizumab x 4
*PointBreak and PRONOUNCE: [[#Carboplatin.2C_Paclitaxel.2C_Bevacizumab_2|PacCBev]] x 4
*IMpower150: [[#Carboplatin.2C_Paclitaxel.2C_Bevacizumab_2|BCP]] x 4 or [[#Carboplatin.2C_Paclitaxel.2C_Bevacizumab_2|BCP]] x 6
====Chemotherapy====
*[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1

'''21-day cycles'''

===References===
# '''ECOG E4599:''' Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006 Dec 14;355(24):2542-50. [https://www.nejm.org/doi/full/10.1056/NEJMoa061884 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17167137 PubMed]
## '''Subgroup analysis:''' Ramalingam SS, Dahlberg SE, Langer CJ, Gray R, Belani CP, Brahmer JR, Sandler AB, Schiller JH, Johnson DH; Eastern Cooperative Oncology Group. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol. 2008 Jan 1;26(1):60-5. [http://jco.ascopubs.org/content/26/1/60.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18165641 PubMed]
# '''AVAil:''' Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N, Manegold C. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol. 2009 Mar 10;27(8):1227-34. Epub 2009 Feb 2. Erratum in: J Clin Oncol. 2009 May 10;27(14):2415. [http://ascopubs.org/doi/full/10.1200/JCO.2007.14.5466 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19188680 PubMed]
## '''Update:''' Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N, Manegold C; BO17704 Study Group. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol. 2010 Sep;21(9):1804-9. Epub 2010 Feb 11. [https://academic.oup.com/annonc/article/21/9/1804/145254 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2924992/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/20150572 PubMed]
# '''AVAPERL:''' Barlesi F, Scherpereel A, Rittmeyer A, Pazzola A, Ferrer Tur N, Kim JH, Ahn MJ, Aerts JG, Gorbunova V, Vikström A, Wong EK, Perez-Moreno P, Mitchell L, Groen HJ. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). J Clin Oncol. 2013 Aug 20;31(24):3004-11. Epub 2013 Jul 8. [http://jco.ascopubs.org/content/31/24/3004.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23835708 PubMed]
## '''Update:''' Barlesi F, Scherpereel A, Gorbunova V, Gervais R, Vikström A, Chouaid C, Chella A, Kim JH, Ahn MJ, Reck M, Pazzola A, Kim HT, Aerts JG, Morando C, Loundou A, Groen HJ, Rittmeyer A. Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial. Ann Oncol. 2014 May;25(5):1044-52. Epub 2014 Feb 27. [https://academic.oup.com/annonc/article/25/5/1044/156906 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/24585722 PubMed]
# '''ATLAS:''' Johnson BE, Kabbinavar F, Fehrenbacher L, Hainsworth J, Kasubhai S, Kressel B, Lin CY, Marsland T, Patel T, Polikoff J, Rubin M, White L, Yang JC, Bowden C, Miller V. ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol. 2013 Nov 1;31(31):3926-34. Epub 2013 Oct 7. [http://ascopubs.org/doi/full/10.1200/JCO.2012.47.3983 link to original article] '''contains verified protocol in supplement''' [https://www.ncbi.nlm.nih.gov/pubmed/24101054 PubMed]
<!-- Presented in part at the Chicago Multidisciplinary Symposium in Thoracic Oncology, Chicago, IL, September 6-8, 2012, and at the American Society of Clinical Oncology's Quality Care Symposium, San Diego, CA, November 30-December 1, 2012. -->
# '''PointBreak:''' Patel JD, Socinski MA, Garon EB, Reynolds CH, Spigel DR, Olsen MR, Hermann RC, Jotte RM, Beck T, Richards DA, Guba SC, Liu J, Frimodt-Moller B, John WJ, Obasaju CK, Pennella EJ, Bonomi P, Govindan R. PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013 Dec 1;31(34):4349-57. [http://jco.ascopubs.org/content/31/34/4349.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881367/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24145346 PubMed]
## '''Dataset:''' [https://www.projectdatasphere.org/projectdatasphere/html/content/141 Project Data Sphere]
# '''PRONOUNCE:''' Zinner RG, Obasaju CK, Spigel DR, Weaver RW, Beck JT, Waterhouse DM, Modiano MR, Hrinczenko B, Nikolinakos PG, Liu J, Koustenis AG, Winfree KB, Melemed SA, Guba SC, Ortuzar WI, Desaiah D, Treat JA, Govindan R, Ross HJ. PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer. J Thorac Oncol. 2015 Jan;10(1):134-42. [http://www.jto.org/article/S1556-0864(15)30782-6/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4276572/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25371077 PubMed]
# '''IMpower150:''' Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, Finley G, Kelsch C, Lee A, Coleman S, Deng Y, Shen Y, Kowanetz M, Lopez-Chavez A, Sandler A, Reck M; IMpower150 Study Group. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018 Jun 14;378(24):2288-2301. Epub 2018 Jun 4. [https://www.nejm.org/doi/full/10.1056/NEJMoa1716948 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29863955 PubMed]

==Gemcitabine monotherapy {{#subobject:5d1f99|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:ce1f77|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.lungcancerjournal.info/article/S0169-5002(06)00060-2/fulltext Brodowicz et al. 2006]
|style="background-color:#1a9851"|Phase III (E)
|[[#Observation_3|Observation]]
|style="background-color:#1a9850"|Superior TTP
|-
|rowspan=2|[http://ascopubs.org/doi/full/10.1200/JCO.2011.39.9782 Pérol et al. 2012]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. [[Non-small_cell_lung_cancer_-_historical#Erlotinib_monotherapy|Erlotinib]]
|style="background-color:#d3d3d3"|Not reported
|-
|2. [[#Observation_3|Observation]]
|style="background-color:#1a9850"|Superior PFS
|-
|}
====Preceding treatment====
*[[#Cisplatin_.26_Gemcitabine_3|Cisplatin & Gemcitabine]] x 4
====Chemotherapy====
*[[Gemcitabine (Gemzar)]] 1250 mg/m<sup>2</sup> IV once per day on days 1 & 8 

'''21-day cycles'''

===References===
# Brodowicz T, Krzakowski M, Zwitter M, Tzekova V, Ramlau R, Ghilezan N, Ciuleanu T, Cucevic B, Gyurkovits K, Ulsperger E, Jassem J, Grgic M, Saip P, Szilasi M, Wiltschke C, Wagnerova M, Oskina N, Soldatenkova V, Zielinski C, Wenczl M; Central European Cooperative Oncology Group CECOG. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer. 2006 May;52(2):155-63. Epub 2006 Mar 29. [https://www.lungcancerjournal.info/article/S0169-5002(06)00060-2/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16569462 PubMed]
# Pérol M, Chouaid C, Pérol D, Barlési F, Gervais R, Westeel V, Crequit J, Léna H, Vergnenègre A, Zalcman G, Monnet I, Le Caer H, Fournel P, Falchero L, Poudenx M, Vaylet F, Ségura-Ferlay C, Devouassoux-Shisheboran M, Taron M, Milleron B. Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2012 Oct 1;30(28):3516-24. Epub 2012 Sep 4. [http://ascopubs.org/doi/full/10.1200/JCO.2011.39.9782 link to original article]'''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22949150 PubMed]

==Ipilimumab monotherapy {{#subobject:b19c3f|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:b4472a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/30/17/2046.long Lynch et al. 2012]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2016.71.7629 Govindan et al. 2017 (CA184-104)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|}
====Preceding treatment====
*[[#Carboplatin.2C_Paclitaxel.2C_Ipilimumab|Carboplatin, Paclitaxel, Ipilimumab]] x 6
====Immunotherapy====
*[[Ipilimumab (Yervoy)]] 10 mg/kg IV once on day 1

'''12-week cycles'''

===References===
<!-- Presented in part at The Chicago Multidisciplinary Symposium in Thoracic Oncology, Chicago, IL, December 9-11, 2010, and the 14th World Congress on Lung Cancer, Amsterdam, the Netherlands, July 3-7, 2011. -->
# Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, Sebastian M, Neal J, Lu H, Cuillerot JM, Reck M. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol. 2012 Jun 10;30(17):2046-54. Epub 2012 Apr 30. [http://jco.ascopubs.org/content/30/17/2046.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22547592 PubMed]
# '''CA184-104:''' Govindan R, Szczesna A, Ahn MJ, Schneider CP, Gonzalez Mella PF, Barlesi F, Han B, Ganea DE, Von Pawel J, Vladimirov V, Fadeeva N, Lee KH, Kurata T, Zhang L, Tamura T, Postmus PE, Jassem J, O'Byrne K, Kopit J, Li M, Tschaika M, Reck M. Phase III trial of ipilimumab combined with paclitaxel and carboplatin in advanced squamous non-small-cell lung cancer. J Clin Oncol. 2017 Oct 20;35(30):3449-3457. Epub 2017 Aug 30. [http://ascopubs.org/doi/full/10.1200/JCO.2016.71.7629 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28854067 PubMed]

==Necitumumab monotherapy {{#subobject:027384|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:6b4607|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00021-2/fulltext Thatcher et al. 2015 (SQUIRE)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|}
''Patients had stage IV squamous non-small-cell lung cancer.''
====Preceding treatment====
*[[#Cisplatin.2C_Gemcitabine.2C_Necitumumab|Cisplatin, Gemcitabine, Necitumumab]] x 6
====Chemotherapy====
*[[Necitumumab (Portrazza)]] 800 mg IV over at least 50 minutes once per day on days 1 & 8

'''21-day cycles'''

===References===
# '''SQUIRE:''' Thatcher N, Hirsch FR, Luft AV, Szczesna A, Ciuleanu TE, Dediu M, Ramlau R, Galiulin RK, Bálint B, Losonczy G, Kazarnowicz A, Park K, Schumann C, Reck M, Depenbrock H, Nanda S, Kruljac-Letunic A, Kurek R, Paz-Ares L, Socinski MA; SQUIRE Investigators. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2015 Jul;16(7):763-74. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00021-2/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26045340 PubMed]
## '''Dataset:''' [https://www.projectdatasphere.org/projectdatasphere/html/content/272 Project Data Sphere]

==Observation==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[http://ascopubs.org/doi/full/10.1200/JCO.2011.39.9782 Pérol et al. 2012]
|rowspan=2 style="background-color:#1a9851"|Phase III (C)
|1. [[Non-small_cell_lung_cancer_-_historical#Erlotinib_monotherapy|Erlotinib]]
|style="background-color:#d73027"|Inferior PFS
|-
|2. [[#Gemcitabine_monotherapy_2|Gemcitabine]]
|style="background-color:#d73027"|Inferior PFS
|-
|}
''No further treatment after first-line therapy.''
====Preceding treatment====
*[[#Cisplatin_.26_Gemcitabine_3|Cisplatin & Gemcitabine]] x 4

===References===
# Pérol M, Chouaid C, Pérol D, Barlési F, Gervais R, Westeel V, Crequit J, Léna H, Vergnenègre A, Zalcman G, Monnet I, Le Caer H, Fournel P, Falchero L, Poudenx M, Vaylet F, Ségura-Ferlay C, Devouassoux-Shisheboran M, Taron M, Milleron B. Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2012 Oct 1;30(28):3516-24. Epub 2012 Sep 4. [http://ascopubs.org/doi/full/10.1200/JCO.2011.39.9782 link to original article]'''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22949150 PubMed]

==Pembrolizumab monotherapy {{#subobject:5aa59d|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:3af038|Variant=1}}===
{| class="wikitable" style="color:white; background-color:#404040"
|<small>'''FDA-recommended dose'''</small>
|-
|}
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/10.1056/NEJMoa1810865 Paz-Ares et al. 2018 (KEYNOTE-407)]
|style="background-color:#1a9851"|Phase III (E)
|[[Complex_multipart_regimens#KEYNOTE-407|See link]]
| style="background-color:#1a9850" |[[Complex_multipart_regimens#KEYNOTE-407|See link]]
|-
|}
====Preceding treatment====
*[[#Carboplatin.2C_nab-Paclitaxel.2C_Pembrolizumab|Carboplatin, nab-Paclitaxel, Pembrolizumab]] x 4 or [[#Carboplatin.2C_Paclitaxel.2C_Pembrolizumab|Carboplatin, Paclitaxel, Pembrolizumab]] x 4
====Chemotherapy====
*[[Pembrolizumab (Keytruda)]] 200 mg IV once on day 1

'''21-day cycle for up to 35 cycles (including induction)'''

===References===
# '''KEYNOTE-407:''' Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, Hermes B, Çay Şenler F, Csőszi T, Fülöp A, Rodríguez-Cid J, Wilson J, Sugawara S, Kato T, Lee KH, Cheng Y, Novello S, Halmos B, Li X, Lubiniecki GM, Piperdi B, Kowalski DM; KEYNOTE-407 Investigators. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018 Nov 22;379(21):2040-2051. Epub 2018 Sep 25. [https://www.nejm.org/doi/10.1056/NEJMoa1810865 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/30280635 PubMed]

==Pemetrexed monotherapy {{#subobject:ed7aa9|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Example orders===
*[[Example orders for Pemetrexed (Alimta) in non-small cell lung cancer]]

===Regimen {{#subobject:2b465b|Variant=1}}===
{| class="wikitable" style="color:white; background-color:#404040"
|<small>'''FDA-recommended dose'''</small>
|-
|}
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)61497-5/fulltext Ciuleanu et al. 2009 (JMEN)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Placebo_4|Placebo]]
| style="background-color:#91cf60" |Seems to have superior OS
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70063-3/fulltext Paz-Ares et al. 2012 (PARAMOUNT)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Placebo_4|Placebo]]
|style="background-color:#1a9850"|Superior PFS
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881367/ Zinner et al. 2015 (PRONOUNCE)]
|style="background-color:#1a9851"|Phase III (E)
|[[Complex_multipart_regimens#PRONOUNCE|See link]]
|style="background-color:#ffffbf"|[[Complex_multipart_regimens#PRONOUNCE|See link]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1606774 Reck et al. 2016 (KEYNOTE-024)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30498-3/fulltext Langer et al. 2016 (KEYNOTE-021)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[http://ascopubs.org/doi/abs/10.1200/jco.2015.33.15_suppl.tps8105 Mok et al. 2015 (KEYNOTE-042)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[https://academic.oup.com/annonc/article/28/10/2443/4091563 Shi et al. 2017 (CONVINCE)]
|style="background-color:#1a9851"|Phase III (C)
|[[Complex_multipart_regimens#CONVINCE|See link]]
|[[Complex_multipart_regimens#CONVINCE|See link]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1801005 Gandhi et al. 2018 (KEYNOTE-189)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|}
====Preceding treatment====
*JMEN: Platinum-based chemotherapy x 4
*PARAMOUNT: [[#Cisplatin_.26_Pemetrexed_2 |Cisplatin & Pemetrexed]] x 4; maintenance therapy started 21 to 42 days after cycle 4 day 1 of induction chemotherapy
*PRONOUNCE & KEYNOTE-021 (control arm): [[#Carboplatin_.26_Pemetrexed_2|Carboplatin & Pemetrexed]] x 4
*KEYNOTE-024: [[#Carboplatin_.26_Paclitaxel_4|Carboplatin & Paclitaxel]] or [[#Carboplatin_.26_Pemetrexed|Carboplatin & Pemetrexed]] or [[#Cisplatin_.26_Pemetrexed_2 |Cisplatin & Pemetrexed]]
*KEYNOTE-042: [[#Carboplatin_.26_Pemetrexed_2|Carboplatin & Pemetrexed]] x 6
*CONVINCE: [[#Cisplatin_.26_Pemetrexed_2 |Cisplatin & Pemetrexed]] x 4
*KEYNOTE-189 (control arm): [[#Carboplatin_.26_Pemetrexed_2|Carboplatin & Pemetrexed]] x 4 or [[#Cisplatin_.26_Pemetrexed_2 |Cisplatin & Pemetrexed]] x 4
*KEYNOTE-021 & KEYNOTE-189 (experimental arm): [[#Pemetrexed_.26_Pembrolizumab|Pemetrexed & Pembrolizumab maintenance]] x 2 y
====Chemotherapy====
*[[Pemetrexed (Alimta)]] 500 mg/m<sup>2</sup> IV over 10 minutes once on day 1

====Supportive medications====
*Folic acid
*[[Cyanocobalamin (Vitamin B12)]]
*[[Dexamethasone (Decadron)]]
*"Investigators followed current American Society of Clinical Oncology (ASCO) and European Society for Medical Oncology (ESMO) guidelines for use of colony-stimulating factors and erythropoiesis-stimulating agents."

'''21-day cycles'''

===References===
# '''JMEN:''' Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, Wu YL, Bover I, Begbie S, Tzekova V, Cucevic B, Rodrigues Pereira J, Yang SH, Madhavan J, Sugarman KP, Peterson P, John WJ, Krejcy K, Belani CP. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet. 2009 Oct 24;374(9699):1432-40. Epub 2009 Sep 18. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)61497-5/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19767093 PubMed]
# '''PARAMOUNT:''' Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, Corral J, Melemed S, John W, Chouaki N, Zimmermann AH, Visseren-Grul C, Gridelli C. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol. 2012 Mar;13(3):247-55. Epub 2012 Feb 16. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70063-3/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22341744 PubMed]
## '''HRQoL analaysis:''' Gridelli C, de Marinis F, Pujol JL, Reck M, Ramlau R, Parente B, Pieters T, Middleton G, Corral J, Winfree K, Melemed S, Zimmermann A, John W, Beyrer J, Chouaki N, Visseren-Grul C, Paz-Ares LG. Safety, resource use, and quality of life in paramount: a phase III study of maintenance pemetrexed versus placebo after induction pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Thorac Oncol. 2012 Nov;7(11):1713-21. [https://www.jto.org/article/S1556-0864(15)33143-9/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23059776 PubMed]
## '''Update:''' Paz-Ares LG, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, Corral J, Melemed S, John W, Chouaki N, Zimmermann AH, Visseren-Grul C, Gridelli C. PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013 Aug 10;31(23):2895-902. Epub 2013 Jul 8. [http://ascopubs.org/doi/full/10.1200/JCO.2012.47.1102 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23835707 PubMed]
# '''PRONOUNCE:''' Zinner RG, Obasaju CK, Spigel DR, Weaver RW, Beck JT, Waterhouse DM, Modiano MR, Hrinczenko B, Nikolinakos PG, Liu J, Koustenis AG, Winfree KB, Melemed SA, Guba SC, Ortuzar WI, Desaiah D, Treat JA, Govindan R, Ross HJ. PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer. J Thorac Oncol. 2015 Jan;10(1):134-42. [http://www.jto.org/article/S1556-0864(15)30782-6/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4276572/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25371077 PubMed]
# '''KEYNOTE-024:''' Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Leiby MA, Lubiniecki GM, Shentu Y, Rangwala R, Brahmer JR; KEYNOTE-024 Investigators. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016 Nov 10;375(19):1823-1833. Epub 2016 Oct 8. [https://www.nejm.org/doi/full/10.1056/NEJMoa1606774 link to original article] [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1606774/suppl_file/nejmoa1606774_appendix.pdf link to supplementary appendix] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27718847 PubMed]
## '''HRQoL analysis:''' Brahmer JR, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Zhang J, Lubiniecki GM, Deitz AC, Rangwala R, Reck M. Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. Lancet Oncol. 2017 Dec;18(12):1600-1609. Epub 2017 Nov 9. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30690-3/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/29129441 PubMed]
# '''KEYNOTE-021:''' Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Jalal SI, Panwalkar A, Yang JC, Gubens M, Sequist LV, Awad MM, Fiore J, Ge Y, Raftopoulos H, Gandhi L; KEYNOTE-021 investigators. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016 Nov;17(11):1497-1508. Epub 2016 Oct 10. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30498-3/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27745820 PubMed]
# '''Abstract:''' Tony Mok, Yi-Long Wu, Patricia A, Watson, Jin Zhang, Reshma A. Rangwala, and Gilberto Lopes. Phase 3 KEYNOTE-042 trial of pembrolizumab (MK-3475) versus platinum doublet chemotherapy in treatment-naive patients (pts) with PD-L1–positive advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology 2015 33:15_suppl, TPS8105-TPS8105 [http://ascopubs.org/doi/abs/10.1200/jco.2015.33.15_suppl.tps8105 link to abstract]
# '''CONVINCE:''' Shi YK, Wang L, Han BH, Li W, Yu P, Liu YP, Ding CM, Song X, Ma ZY, Ren XL, Feng JF, Zhang HL, Chen GY, Han XH, Wu N, Yao C, Song Y, Zhang SC, Song W, Liu XQ, Zhao SJ, Lin YC, Ye XQ, Li K, Shu YQ, Ding LM, Tan FL, Sun Y. First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study. Ann Oncol. 2017 Oct 1;28(10):2443-2450. [https://academic.oup.com/annonc/article/28/10/2443/4091563 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28945850 PubMed]
# '''KEYNOTE-189:''' Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, Cheng SY, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Hui R, Garon EB, Boyer M, Rubio-Viqueira B, Novello S, Kurata T, Gray JE, Vida J, Wei Z, Yang J, Raftopoulos H, Pietanza MC, Garassino MC; KEYNOTE-189 Investigators. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018 May 31;378(22):2078-2092. Epub 2018 Apr 16. [https://www.nejm.org/doi/full/10.1056/NEJMoa1801005 link to original article] [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1801005/suppl_file/nejmoa1801005_protocol.pdf link to protocol] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29658856 PubMed]

==Pemetrexed & Bevacizumab {{#subobject:db5671|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 500/7.5 {{#subobject:670eab|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/31/24/3004.long Barlesi et al. 2013 (AVAPERL)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Bevacizumab_monotherapy|Bevacizumab maintenance]]
|style="background-color:#1a9850"|Superior PFS
|-
|}
====Preceding treatment====
*[[#Cisplatin.2C_Pemetrexed.2C_Bevacizumab|Cisplatin, Pemetrexed, Bevacizumab]] x 4
====Chemotherapy====
*[[Pemetrexed (Alimta)]] 500 mg/m<sup>2</sup> IV over 10 minutes once on day 1
*[[Bevacizumab (Avastin)]] 7.5 mg/kg IV once on day 1

====Supportive medications====
*[[Cyanocobalamin (Vitamin B12)]] 1000 mcg IM every 3 cycles (i.e. every 9 weeks), given throughout therapy
*Folic acid 350 to 1000 mcg PO once per day, given throughout therapy
*[[Dexamethasone (Decadron)]] 4 mg PO twice per day on days -1, 1, 2 of each cycle

'''21-day cycles'''

===Variant #2, 500/15 {{#subobject:14cbc9|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881367/ Patel et al. 2013 (PointBreak)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|[https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.30986 Spigel et al. 2018]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|}
====Preceding treatment====
*PointBreak: [[#Carboplatin.2C_Pemetrexed.2C_Bevacizumab|PemCBev (AUC 6)]] x 4
*Spigel et al. 2018: [[#Carboplatin.2C_Pemetrexed.2C_Bevacizumab_2|PemCBev (AUC 5)]] x 4

====Chemotherapy====
*[[Pemetrexed (Alimta)]] 500 mg/m<sup>2</sup> IV once on day 1
*[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1

====Supportive medications====
*Premedications, folic acid, and vitamin supplementation per pemetrexed label
*Erythropoietic agents or granulocyte colony-stimulating factors allowed per ASCO & NCCN guidelines

'''21-day cycles'''

===References===
# '''AVAPERL:''' Barlesi F, Scherpereel A, Rittmeyer A, Pazzola A, Ferrer Tur N, Kim JH, Ahn MJ, Aerts JG, Gorbunova V, Vikström A, Wong EK, Perez-Moreno P, Mitchell L, Groen HJ. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). J Clin Oncol. 2013 Aug 20;31(24):3004-11. Epub 2013 Jul 8. [http://jco.ascopubs.org/content/31/24/3004.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23835708 PubMed]
## '''Update:''' Barlesi F, Scherpereel A, Gorbunova V, Gervais R, Vikström A, Chouaid C, Chella A, Kim JH, Ahn MJ, Reck M, Pazzola A, Kim HT, Aerts JG, Morando C, Loundou A, Groen HJ, Rittmeyer A. Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial. Ann Oncol. 2014 May;25(5):1044-52. Epub 2014 Feb 27. [https://academic.oup.com/annonc/article/25/5/1044/156906 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/24585722 PubMed]
<!-- Presented in part at the Chicago Multidisciplinary Symposium in Thoracic Oncology, Chicago, IL, September 6-8, 2012, and at the American Society of Clinical Oncology's Quality Care Symposium, San Diego, CA, November 30-December 1, 2012. -->
# '''PointBreak:''' Patel JD, Socinski MA, Garon EB, Reynolds CH, Spigel DR, Olsen MR, Hermann RC, Jotte RM, Beck T, Richards DA, Guba SC, Liu J, Frimodt-Moller B, John WJ, Obasaju CK, Pennella EJ, Bonomi P, Govindan R. PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013 Dec 1;31(34):4349-57. [http://jco.ascopubs.org/content/31/34/4349.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881367/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24145346 PubMed]
## '''Dataset:''' [https://www.projectdatasphere.org/projectdatasphere/html/content/141 Project Data Sphere]
# Spigel DR, Hainsworth JD, Joseph MJ, Shipley DL, Hagan MK, Thompson DS, Burris HA 3rd, Greco FA. Randomized phase 2 trial of pemetrexed, pemetrexed/bevacizumab, and pemetrexed/carboplatin/bevacizumab in patients with stage IIIB/IV non-small cell lung cancer and an Eastern Cooperative Oncology Group performance status of 2. Cancer. 2018 May 1;124(9):1982-1991. Epub 2018 Feb 16. [https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.30986 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29451696 PubMed]

==Pemetrexed & Pembrolizumab {{#subobject:4f9073|Regimen=1}}==
{{#subobject:0365c3|Variant=1}}
{{:Pembrolizumab & Pemetrexed maintenance therapy for advanced or metastatic non-small cell lung cancer}}

==Placebo==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.lungcancerjournal.info/article/S0169-5002(07)00607-1/fulltext Johnson et al. 2008 (NCCTG 97-24-51)]
|style="background-color:#1a9851"|Phase III (C)
|CAI
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)61497-5/fulltext Ciuleanu et al. 2009 (JMEN)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Pemetrexed_monotherapy_2|Pemetrexed]]
| style="background-color:#fc8d59" |Seems to have inferior OS
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2009.21.9733 Lee et al. 2009]
|style="background-color:#1a9851"|Phase III (C)
|Thalidomide
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(10)70112-1/fulltext Cappuzzo et al. 2010 (SATURN)]
|style="background-color:#1a9851"|Phase III (C)
|[[Non-small_cell_lung_cancer_-_historical#Erlotinib_monotherapy|Erlotinib]]
|style="background-color:#d73027"|Inferior PFS
|-
|[https://www.ejcancer.com/article/S0959-8049(11)00249-8/fulltext Koch et al. 2011 (CYCLUS)]
|style="background-color:#1a9851"|Phase III (C)
|Celecoxib
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.ejcancer.com/article/S0959-8049(11)00473-4/fulltext Gaafar et al. 2011 (EORTC 08021)]
|style="background-color:#1a9851"|Phase III (C)
|Gefitinib
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70063-3/fulltext Paz-Ares et al. 2012 (PARAMOUNT)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Pemetrexed_monotherapy_2|Pemetrexed]]
|style="background-color:#d73027"|Inferior PFS
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70117-1/fulltext Zhang et al. 2012 (INFORM)]
|style="background-color:#1a9851"|Phase III (C)
|Gefitinib
|style="background-color:#d73027"|Inferior PFS
|-
|[https://www.ejcancer.com/article/S0959-8049(15)00388-3/fulltext O'Brien et al. 2015 (EORTC 08092)]
|style="background-color:#1a9851"|Phase III (C)
|Pazopanib
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.ejcancer.com/article/S0959-8049(15)00741-8/fulltext Giaccone et al. 2015]
|style="background-color:#1a9851"|Phase III (C)
|Belagenpumatucel-L
|style="background-color:#ffffbf"|Seems not superior
|-
|[http://www.lungcancerjournal.info/article/S0169-5002(16)30504-9/fulltext Cicènas et al. 2016 (IUNO)]
|style="background-color:#1a9851"|Phase III (C)
|[[Complex_multipart_regimens#IUNO|See link]]
|[[Complex_multipart_regimens#IUNO|See link]]
|-
|[http://www.jto.org/article/S1556-0864(17)30089-8/fulltext Baggstrom et al. 2017 (CALGB 30607)]
|style="background-color:#1a9851"|Phase III (C)
|Sunitinib
|style="background-color:#d73027"|Inferior PFS
|-
|}
''No further antineoplastic treatment after first-line therapy. Note: while '''SATURN''' was technically a positive study for erlotinib, the median PFS gain was 1.2 weeks.''
====Preceding treatment====
*JMEN, SATURN, EORTC 08021, INFORM, IUNO: 4 cycles of platinum-doublet therapy
*Lee et al. 2009: [[#Carboplatin_.26_Gemcitabine|Carboplatin & Gemcitabine]] x 4
*PARAMOUNT: [[#Cisplatin_.26_Pemetrexed_2 |Cisplatin & Pemetrexed]] x 4
*Giaccone et al. 2015: Platinum-based chemotherapy
====Subsequent treatment====
*IUNO: [[Non-small_cell_lung_cancer_-_historical#Erlotinib_monotherapy_2|Erlotinib]], after PD or intolerance
===References===
# '''NCCTG 97-24-51:''' Johnson EA, Marks RS, Mandrekar SJ, Hillman SL, Hauge MD, Bauman MD, Wos EJ, Moore DF, Kugler JW, Windschitl HE, Graham DL, Bernath AM Jr, Fitch TR, Soori GS, Jett JR, Adjei AA, Perez EA. Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51). Lung Cancer. 2008 May;60(2):200-7. Epub 2007 Nov 28. [https://www.lungcancerjournal.info/article/S0169-5002(07)00607-1/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/18045731 PubMed]
# '''JMEN:''' Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, Wu YL, Bover I, Begbie S, Tzekova V, Cucevic B, Rodrigues Pereira J, Yang SH, Madhavan J, Sugarman KP, Peterson P, John WJ, Krejcy K, Belani CP. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet. 2009 Oct 24;374(9699):1432-40. Epub 2009 Sep 18. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)61497-5/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19767093 PubMed]
# Lee SM, Rudd R, Woll PJ, Ottensmeier C, Gilligan D, Price A, Spiro S, Gower N, Jitlal M, Hackshaw A. Randomized double-blind placebo-controlled trial of thalidomide in combination with gemcitabine and carboplatin in advanced non-small-cell lung cancer. J Clin Oncol. 2009 Nov 1;27(31):5248-54. Epub 2009 Sep 21. [http://ascopubs.org/doi/full/10.1200/JCO.2009.21.9733 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/19770378 PubMed]
# '''SATURN:''' Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczésna A, Juhász E, Esteban E, Molinier O, Brugger W, Melezínek I, Klingelschmitt G, Klughammer B, Giaccone G; SATURN investigators. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2010 Jun;11(6):521-9. Epub 2010 May 20. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(10)70112-1/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20493771 PubMed]
# '''CYCLUS:''' Koch A, Bergman B, Holmberg E, Sederholm C, Ek L, Kosieradzki J, Lamberg K, Thaning L, Ydreborg SO, Sörenson S; Swedish Lung Cancer Study Group. Effect of celecoxib on survival in patients with advanced non-small cell lung cancer: a double blind randomised clinical phase III trial (CYCLUS study) by the Swedish Lung Cancer Study Group. Eur J Cancer. 2011 Jul;47(10):1546-55. Epub 2011 May 10. [https://www.ejcancer.com/article/S0959-8049(11)00249-8/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/21565487 PubMed]
# '''EORTC 08021:''' Gaafar RM, Surmont VF, Scagliotti GV, Van Klaveren RJ, Papamichael D, Welch JJ, Hasan B, Torri V, van Meerbeeck JP; EORTC Lung Cancer Group and the Italian Lung Cancer Project. A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03). Eur J Cancer. 2011 Oct;47(15):2331-40. Epub 2011 Jul 28. [https://www.ejcancer.com/article/S0959-8049(11)00473-4/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/21802939 PubMed]
# '''PARAMOUNT:''' Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, Corral J, Melemed S, John W, Chouaki N, Zimmermann AH, Visseren-Grul C, Gridelli C. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol. 2012 Mar;13(3):247-55. Epub 2012 Feb 16. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70063-3/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22341744 PubMed]
## '''HRQoL analaysis:''' Gridelli C, de Marinis F, Pujol JL, Reck M, Ramlau R, Parente B, Pieters T, Middleton G, Corral J, Winfree K, Melemed S, Zimmermann A, John W, Beyrer J, Chouaki N, Visseren-Grul C, Paz-Ares LG. Safety, resource use, and quality of life in paramount: a phase III study of maintenance pemetrexed versus placebo after induction pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Thorac Oncol. 2012 Nov;7(11):1713-21. [https://www.jto.org/article/S1556-0864(15)33143-9/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23059776 PubMed]
## '''Update:''' Paz-Ares LG, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, Corral J, Melemed S, John W, Chouaki N, Zimmermann AH, Visseren-Grul C, Gridelli C. PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013 Aug 10;31(23):2895-902. Epub 2013 Jul 8. [http://ascopubs.org/doi/full/10.1200/JCO.2012.47.1102 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23835707 PubMed]
# '''INFORM:''' Zhang L, Ma S, Song X, Han B, Cheng Y, Huang C, Yang S, Liu X, Liu Y, Lu S, Wang J, Zhang S, Zhou C, Zhang X, Hayashi N, Wang M; INFORM investigators. Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial. Lancet Oncol. 2012 May;13(5):466-75. Epub 2012 Apr 17. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70117-1/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22512843 PubMed]
# '''EORTC 08092:''' O'Brien ME, Gaafar R, Hasan B, Menis J, Cufer T, Popat S, Woll PJ, Surmont V, Georgoulias V, Montes A, Blackhall F, Hennig I, Schmid-Bindert G, Baas P; EORTC-LCG. Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy: a double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064). Eur J Cancer. 2015 Aug;51(12):1511-28. Epub 2015 Jun 11. [https://www.ejcancer.com/article/S0959-8049(15)00388-3/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26074395 PubMed]
# Giaccone G, Bazhenova LA, Nemunaitis J, Tan M, Juhász E, Ramlau R, van den Heuvel MM, Lal R, Kloecker GH, Eaton KD, Chu Q, Dunlop DJ, Jain M, Garon EB, Davis CS, Carrier E, Moses SC, Shawler DL, Fakhrai H. A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer. Eur J Cancer. 2015 Nov;51(16):2321-9. Epub 2015 Aug 14. [https://www.ejcancer.com/article/S0959-8049(15)00741-8/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26283035 PubMed]
# '''IUNO:''' Cicènas S, Geater SL, Petrov P, Hotko Y, Hooper G, Xia F, Mudie N, Wu YL. Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum-based chemotherapy (IUNO study). Lung Cancer. 2016 Dec;102:30-37. Epub 2016 Oct 20. [http://www.lungcancerjournal.info/article/S0169-5002(16)30504-9/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27987585 PubMed]
# '''CALGB 30607:''' Baggstrom MQ, Socinski MA, Wang XF, Gu L, Stinchcombe TE, Edelman MJ, Baker S Jr, Feliciano J, Novotny P, Hahn O, Crawford JA, Vokes EE. Maintenance sunitinib following initial platinum-based combination chemotherapy in advanced-stage IIIB/IV non-small cell lung cancer: a randomized, double-blind, placebo-controlled phase III study-CALGB 30607 (Alliance). J Thorac Oncol. 2017 May;12(5):843-849. Epub 2017 Feb 1. [http://www.jto.org/article/S1556-0864(17)30089-8/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28161554 PubMed]

=Advanced or metastatic disease, subsequent lines of therapy=
==Afatinib monotherapy {{#subobject:1bf6db|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 30 mg/day {{#subobject:f69d3b|Variant=1}}===
{| class="wikitable" style="color:white; background-color:#404040"
|<small>'''FDA-recommended dose'''</small>
|-
|}
''This is the FDA-recommended dose for patients with "severe renal impairment".''
====Chemotherapy====
*[[Afatinib (Gilotrif)]] 30 mg PO once per day

'''Continued indefinitely'''

===Variant #2, 40 mg/day {{#subobject:130d4a|Variant=1}}===
{| class="wikitable" style="color:white; background-color:#404040"
|<small>'''FDA-recommended dose'''</small>
|-
|}
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00006-6/fulltext Soria et al. 2015 (LUX-Lung 8)]
|style="background-color:#1a9851"|Phase III (E)
|[[Non-small_cell_lung_cancer_-_historical#Erlotinib_monotherapy_2|Erlotinib]]
|style="background-color:#1a9850"|Superior OS
|-
|}
====Chemotherapy====
*[[Afatinib (Gilotrif)]] 40 mg PO once per day, given 1 hour before eating food

'''Continued indefinitely'''

===Variant #3, 50 mg/day {{#subobject:f109f9|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70087-6/fulltext Miller et al. 2012 (LUX-Lung 1)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Placebo_3|Placebo]]
|style="background-color:#1a9850"|Superior PFS
|-
|[http://jco.ascopubs.org/content/31/27/3335.long Katakami et al. 2013 (LUX-Lung 4)]
|style="background-color:#91cf61"|Phase II
|style="background-color:#d3d3d3"|
| style="background-color:#6e016b; color:white |ORR: 8% (95% CI: 3-18)
|-
|}
''In '''LUX-Lung 4''', 72.6% of patients were EGFR mutation positive. This was third or fourth line therapy for participants, who had progressed while receiving erlotinib and/or gefitinib and had received one or two previous lines of chemotherapy, including at least one platinum-based regimen.'' 
====Chemotherapy====
*[[Afatinib (Gilotrif)]] 50 mg PO once per day, given 1 hour before eating food

'''Continued indefinitely'''

===References===
# '''LUX-Lung 1:''' Miller VA, Hirsh V, Cadranel J, Chen YM, Park K, Kim SW, Zhou C, Su WC, Wang M, Sun Y, Heo DS, Crino L, Tan EH, Chao TY, Shahidi M, Cong XJ, Lorence RM, Yang JC. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol. 2012 May;13(5):528-38. Epub 2012 Mar 26. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70087-6/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22452896 PubMed]
## '''HRQoL analysis:''' Hirsh V, Cadranel J, Cong XJ, Fairclough D, Finnern HW, Lorence RM, Miller VA, Palmer M, Yang JC. Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1). J Thorac Oncol. 2013 Feb;8(2):229-37. [https://www.jto.org/article/S1556-0864(15)32746-5/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23328549 PubMed] 
# '''LUX-Lung 4:''' Katakami N, Atagi S, Goto K, Hida T, Horai T, Inoue A, Ichinose Y, Koboyashi K, Takeda K, Kiura K, Nishio K, Seki Y, Ebisawa R, Shahidi M, Yamamoto N. LUX-Lung 4: A phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. J Clin Oncol. 2013 Sep 20;31(27):3335-41. Epub 2013 Jul 1. [http://jco.ascopubs.org/content/31/27/3335.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23816963 PubMed]
# '''LUX-Lung 8:''' Soria JC, Felip E, Cobo M, Lu S, Syrigos K, Lee KH, Göker E, Georgoulias V, Li W, Isla D, Guclu SZ, Morabito A, Min YJ, Ardizzoni A, Gadgeel SM, Wang B, Chand VK, Goss GD; LUX-Lung 8 Investigators. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2015 Aug;16(8):897-907. Epub 2015 Jul 5. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00006-6/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26156651 PubMed]

==Afatinib & Paclitaxel {{#subobject:3d0a87|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:0cb697|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4769992/ Schuler et al. 2015 (LUX-Lung 5)]
|style="background-color:#1a9851"|Phase III (E)
|Single-agent chemotherapy
|style="background-color:#1a9850"|Superior PFS
|-
|}
====Chemotherapy====
*[[Afatinib (Gilotrif)]]
*[[Paclitaxel (Taxol)]]
===References===
# '''LUX-Lung 5:''' Schuler M, Yang JC, Park K, Kim JH, Bennouna J, Chen YM, Chouaid C, De Marinis F, Feng JF, Grossi F, Kim DW, Liu X, Lu S, Strausz J, Vinnyk Y, Wiewrodt R, Zhou C, Wang B, Chand VK, Planchard D; LUX-Lung 5 Investigators. Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. Ann Oncol. 2016 Mar;27(3):417-23. Epub 2015 Dec 8. [https://academic.oup.com/annonc/article/27/3/417/2196326 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4769992/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26646759 PubMed]

==Amrubicin monotherapy {{#subobject:d1a9ba|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:f264a4|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://academic.oup.com/annonc/article/28/2/285/2676905 Yoshioka et al. 2017]
|style="background-color:#1a9851"|Phase III (E)
|[[#Docetaxel_monotherapy_2|Docetaxel]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Chemotherapy====
*[[Amrubicin (Calsed)]] 35 mg/m<sup>2</sup> IV over 5 minutes once per day on days 1 to 3

'''21-day cycles'''

===References===
# Yoshioka H, Katakami N, Okamoto H, Iwamoto Y, Seto T, Takahashi T, Sunaga N, Kudoh S, Chikamori K, Harada M, Tanaka H, Saito H, Saka H, Takeda K, Nogami N, Masuda N, Harada T, Kitagawa H, Horio H, Yamanaka T, Fukuoka M, Yamamoto N, Nakagawa K. A randomized, open-label, phase III trial comparing amrubicin versus docetaxel in patients with previously treated non-small-cell lung cancer. Ann Oncol. 2017 Feb 1;28(2):285-291. [https://academic.oup.com/annonc/article/28/2/285/2676905 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28426104 PubMed]

==Atezolizumab monotherapy {{#subobject:412fc4|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:9f357f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)00587-0/fulltext Fehrenbacher et al. 2016 (POPLAR)]
|style="background-color:#1a9851"|Randomized Phase II (E)
|[[#Docetaxel_monotherapy_2|Docetaxel]]
|style="background-color:#91cf60"|Seems to have superior OS
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)32517-X/fulltext Rittmeyer et al. 2017 (OAK)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Docetaxel_monotherapy_2|Docetaxel]]
|style="background-color:#1a9850"|Superior OS
|-
|}
====Immunotherapy====
*[[Atezolizumab (Tecentriq)]] 1200 mg IV once on day 1

'''21-day cycles'''

===References===
# '''POPLAR:''' Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, Park K, Smith D, Artal-Cortes A, Lewanski C, Braiteh F, Waterkamp D, He P, Zou W, Chen DS, Yi J, Sandler A, Rittmeyer A; POPLAR Study Group. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016 Apr 30;387(10030):1837-46. Epub 2016 Mar 9. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)00587-0/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26970723 PubMed]
# '''OAK:''' Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC, Cortinovis DL, Leach J, Polikoff J, Barrios C, Kabbinavar F, Frontera OA, De Marinis F, Turna H, Lee JS, Ballinger M, Kowanetz M, He P, Chen DS, Sandler A, Gandara DR; OAK Study Group. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017 Jan 21;389(10066):255-265. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)32517-X/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27979383 PubMed]

==Cabozantinib monotherapy {{#subobject:47f237|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:1276ee|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30561-7/fulltext Neal et al. 2016 (ECOG-ACRIN 1512)]
|rowspan=2 style="background-color:#1a9851"|Randomized Phase II (E)
|1. [[#Cabozantinib_.26_Erlotinib|Cabozantinib & Erlotinib]]
|style="background-color:#d3d3d3"|Not reported
|-
|2. [[Non-small_cell_lung_cancer_-_historical#Erlotinib_monotherapy_2|Erlotinib]]
|style="background-color:#1a9850"|Superior PFS
|-
|}
====Chemotherapy====
*[[Cabozantinib (Cometriq)]] 60 mg PO once per day

'''Continued indefinitely'''

===References===
# '''ECOG-ACRIN 1512:''' Neal JW, Dahlberg SE, Wakelee HA, Aisner SC, Bowden M, Huang Y, Carbone DP, Gerstner GJ, Lerner RE, Rubin JL, Owonikoko TK, Stella PJ, Steen PD, Khalid AA, Ramalingam SS; ECOG-ACRIN 1512 Investigators. Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. Lancet Oncol. 2016 Dec;17(12):1661-1671. Epub 2016 Nov 4. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30561-7/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5154681/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27825638 PubMed]

==Cabozantinib & Erlotinib {{#subobject:d9d1c0|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:238161|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30561-7/fulltext Neal et al. 2016 (ECOG-ACRIN 1512)]
|rowspan=2 style="background-color:#1a9851"|Randomized Phase II (E)
|1. [[#Cabozantinib_monotherapy|Cabozantinib]]
|style="background-color:#d3d3d3"|Not reported
|-
|2. [[Non-small_cell_lung_cancer_-_historical#Erlotinib_monotherapy_2|Erlotinib]]
|style="background-color:#1a9850"|Superior PFS
|-
|}
====Chemotherapy====
*[[Cabozantinib (Cometriq)]] 40 mg PO once per day
*[[Erlotinib (Tarceva)]] 150 mg PO once per day

'''Continued indefinitely'''

===References===
# '''ECOG-ACRIN 1512:''' Neal JW, Dahlberg SE, Wakelee HA, Aisner SC, Bowden M, Huang Y, Carbone DP, Gerstner GJ, Lerner RE, Rubin JL, Owonikoko TK, Stella PJ, Steen PD, Khalid AA, Ramalingam SS; ECOG-ACRIN 1512 Investigators. Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. Lancet Oncol. 2016 Dec;17(12):1661-1671. Epub 2016 Nov 4. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30561-7/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5154681/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27825638 PubMed]

==Carboplatin & Pemetrexed {{#subobject:60fd1d|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Example orders===
*[[Example orders for Carboplatin (Paraplatin) and Pemetrexed (Alimta) in non-small cell lung cancer]]

===Regimen {{#subobject:95c37d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/30/36/4501.long Ardizzoni et al. 2012 (GOIRC 02-2006)]
|style="background-color:#1a9851"|Randomized Phase II (E)
|[[#Pemetrexed_monotherapy_3|Pemetrexed]]
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1612674 Mok et al. 2016 (AURA3)]
|style="background-color:#1a9851"|Phase III (C)
|[[Non-small_cell_lung_cancer,_EGFR-mutated#Osimertinib_monotherapy|Osimertinib]]
|style="background-color:#d73027"|Inferior PFS
|-
|}
''Patients enrolled in '''AURA3''' had locally advanced or metastatic NSCLC with progression after first-line EGFR TKI therapy, and were required to have presence of an EGFR p.T790M mutation.''
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 5 IV over 15 to 60 minutes once on day 1, '''given second'''
*[[Pemetrexed (Alimta)]] 500 mg/m<sup>2</sup> IV over 10 minutes once on day 1, '''given first'''

====Supportive medications====
*(Ardizzoni et al. 2012 contained more details):
*[[Dexamethasone (Decadron)]] 4 mg or [[steroid conversions|equivalent corticosteroid]] PO twice per day on the day before, the day of, and day after each dose of pemetrexed
*Folic acid 350 to 600 mcg PO once per day, starting 1 to 2 weeks before the first dose of pemetrexed, to be taken throughout pemetrexed therapy.
*[[Cyanocobalamin (Vitamin B12)]] 1000 mcg IM once every 9 weeks, first dose 1 to 2 weeks before the first dose of pemetrexed, to be given throughout pemetrexed therapy

'''21-day cycle for 4 to 6 cycles, or until progressive disease, unacceptable toxicity, or patient refusal'''
====Subsequent treatment====
*AURA3: Optional [[#Pemetrexed_monotherapy_2|pemetrexed maintenance]]

===References===
<!-- Presented at the 47th Annual Meeting of the American Society of Clinical Oncology, Chicago, June 3-7, 2011; 14th World Conference on Lung Cancer, Amsterdam, the Netherlands, July 3-7, 2011; and 13th National Congress of Medical Oncology, Bologna, Italy, November 5-7, 2011. -->
# '''GOIRC 02-2006:''' Ardizzoni A, Tiseo M, Boni L, Vincent AD, Passalacqua R, Buti S, Amoroso D, Camerini A, Labianca R, Genestreti G, Boni C, Ciuffreda L, Di Costanzo F, de Marinis F, Crinò L, Santo A, Pazzola A, Barbieri F, Zilembo N, Colantonio I, Tibaldi C, Mattioli R, Cafferata MA, Camisa R, Smit EF. Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non-small-cell lung cancer: results of the GOIRC 02-2006 randomized phase II study and pooled analysis with the NVALT7 trial. J Clin Oncol. 2012 Dec 20;30(36):4501-7. Epub 2012 Oct 29. [http://jco.ascopubs.org/content/30/36/4501.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23109689 PubMed]
# '''AURA3:''' Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS, Lee CK, Sebastian M, Templeton A, Mann H, Marotti M, Ghiorghiu S, Papadimitrakopoulou VA; AURA3 Investigators. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017 Feb 16;376(7):629-640. Epub 2016 Dec 6. [https://www.nejm.org/doi/full/10.1056/NEJMoa1612674 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27959700 PubMed]

==Cisplatin & Pemetrexed {{#subobject:26b03e|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:7dcf71|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00121-7/fulltext Soria et al. 2015 (IMPRESS)]
|style="background-color:#1a9851"|Phase III (C)
|Cisplatin, Pemetrexed, Gefitinib
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1612674 Mok et al. 2016 (AURA3)]
|style="background-color:#1a9851"|Phase III (C)
|[[Non-small_cell_lung_cancer,_EGFR-mutated#Osimertinib_monotherapy|Osimertinib]]
|style="background-color:#d73027"|Inferior PFS
|-
|}
''Patients enrolled in '''IMPRESS''' were EGFR mutation positive and had progression after first-line gefitinib. Patients enrolled in '''AURA3''' had locally advanced or metastatic NSCLC with progression after first-line EGFR TKI therapy, and were required to have presence of an EGFR p.T790M mutation.''
====Chemotherapy====
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV once on day 1
*[[Pemetrexed (Alimta)]] 500 mg/m<sup>2</sup> IV once on day 1

====Supportive medications====
*(as described in Scagliotti et al. 2008):
*[[Cyanocobalamin (Vitamin B12)]] 1000 mcg IM every 9 weeks, first dose prior to [[Pemetrexed (Alimta)]]
*Folic acid 1 mg PO once per day
*In Sequist et al. 2013: Patients "received folic acid, vitamin B12, and dexamethasone, as per package recommendations for [[Pemetrexed (Alimta)]]."

'''21-day cycle for 4 to 6 cycles'''
====Subsequent treatment====
*AURA3: Patients without disease progression could optionally proceed to [[#Pemetrexed_monotherapy_2|pemetrexed maintenance]] after 4 cycles

===References===
# '''IMPRESS:''' Soria JC, Wu YL, Nakagawa K, Kim SW, Yang JJ, Ahn MJ, Wang J, Yang JC, Lu Y, Atagi S, Ponce S, Lee DH, Liu Y, Yoh K, Zhou JY, Shi X, Webster A, Jiang H, Mok TS. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncol. 2015 Aug;16(8):990-8. Epub 2015 Jul 6. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00121-7/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26159065 PubMed]
## '''Update:''' Mok TSK, Kim SW, Wu YL, Nakagawa K, Yang JJ, Ahn MJ, Wang J, Yang JC, Lu Y, Atagi S, Ponce S, Shi X, Rukazenkov Y, Haddad V, Thress KS, Soria JC. Gefitinib plus chemotherapy versus chemotherapy in epidermal growth factor receptor mutation-positive non-small-cell lung cancer resistant to first-line gefitinib (IMPRESS): overall survival and biomarker analyses. J Clin Oncol. 2017 Dec 20;35(36):4027-4034. Epub 2017 Oct 2. [http://ascopubs.org/doi/full/10.1200/JCO.2017.73.9250 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28968167 PubMed]
# '''AURA3:''' Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS, Lee CK, Sebastian M, Templeton A, Mann H, Marotti M, Ghiorghiu S, Papadimitrakopoulou VA; AURA3 Investigators. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017 Feb 16;376(7):629-640. Epub 2016 Dec 6. [https://www.nejm.org/doi/full/10.1056/NEJMoa1612674 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27959700 PubMed]

==Docetaxel monotherapy {{#subobject:fd1716|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Example orders===
*[[Example orders for Docetaxel (Taxotere) in non-small cell lung cancer]]

===Variant #1, 35 mg/m<sup>2</sup>, 3 out of 4 weeks {{#subobject:5b296|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2005.02.3739 Schuette et al. 2005]
|style="background-color:#1a9851"|Phase III (E)
|Docetaxel 75 mg/m<sup>2</sup>, every 3 wks
| style="background-color:#d9ef8b" |Might have superior OS
|-
|rowspan=2|[http://journal.chestnet.org/article/S0012-3692(15)38821-8/fulltext Chen et al. 2006]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. Docetaxel 40 mg/m<sup>2</sup>, 2 out of 3 wks
|style="background-color:#ffffbf"|Seems not superior
|-
|2. Docetaxel 75 mg/m<sup>2</sup>, every 3 wks
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70310-3/fulltext Garassino et al. 2013 (TAILOR-NSCLC)]
|style="background-color:#1a9851"|Phase III (C)
|[[Non-small_cell_lung_cancer_-_historical#Erlotinib_monotherapy_2|Erlotinib]]
|style="background-color:#91cf60"|Seems to have superior OS
|-
|}
''Note that there is another trial named TAILOR in colorectal cancer, so this one has been dubbed TAILOR-NSCLC.''
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 35 mg/m<sup>2</sup> IV once per day on days 1, 8, 15

====Supportive medications====
*[[Dexamethasone (Decadron)]] 8 mg PO once 12 hours before docetaxel, 10 mg IV once 30 minutes before docetaxel, and 8 mg PO 12 hours after docetaxel

'''28-day cycles'''

===Variant #2, 50 mg/m<sup>2</sup> q2wk, limited duration {{#subobject:4cf20a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2994826/ Pallis et al. 2010]
|style="background-color:#1a9851"|Phase III (C)
|Carboplatin & Docetaxel
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''These patients had previously been treated with a platinum-free regimen.''
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 50 mg/m<sup>2</sup> IV once per day on days 1 & 15

'''28-day cycle for up to 6 cycles'''

===Variant #3, 60 mg/m<sup>2</sup> q3wk, limited duration {{#subobject:b90b5e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3225192/ Herbst et al. 2010 (ZODIAC)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Docetaxel_.26_Vandetanib|Docetaxel & Vandetanib]]
|style="background-color:#d73027"|Inferior PFS
|-
|}
''This is the PMDA-approved dose. While statistically inferior, the median PFS difference was only 0.8 months.''
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 60 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for up to 6 cycles'''

===Variant #4, 60 mg/m<sup>2</sup> q3wk, indefinite {{#subobject:3a67f3|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2007.15.0185 Maruyama et al. 2008 (V-15-32)]
|style="background-color:#1a9851"|Phase III (C)
|Gefitinib
|style="background-color:#ffffbf"|Inconclusive whether non-inferior
|-
|[https://academic.oup.com/annonc/article/20/5/835/150097 Takeda et al. 2009 (JCOG 0104)]
|style="background-color:#1a9851"|Phase III (C)
|Docetaxel & Gemcitabine
|style="background-color:#ffffbf"|Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2013.52.4694 Kawaguchi et al. 2014 (DELTA)]
|style="background-color:#1a9851"|Phase III (C)
|[[Non-small_cell_lung_cancer_-_historical#Erlotinib_monotherapy_2|Erlotinib]]
| style="background-color:#d9ef8b" |Might have superior PFS
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2960845-X/fulltext Garon et al. 2014 (REVEL)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Docetaxel_.26_Ramucirumab|Docetaxel & Ramucirumab]]
|style="background-color:#fc8d59"|Seems to have inferior OS
|-
|[https://academic.oup.com/annonc/article/28/2/285/2676905 Yoshioka et al. 2017]
|style="background-color:#1a9851"|Phase III (C)
|[[#Amrubicin_monotherapy|Amrubicin]]
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834128/ Nokihara et al. 2017]
|style="background-color:#1a9851"|Phase III (C)
|[[#S-1_monotherapy|S-1]]
|style="background-color:#eeee01"|Non-inferior OS
|-
|}
''This is the PMDA-approved dose, the dose used for East Asian patients in REVEL, and the dose used in Japanese patients in Nokihara et al. 2017.''
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 60 mg/m<sup>2</sup> IV over at least 60 minutes once on day 1

'''21-day cycles'''

===Variant #5, 75 mg/m<sup>2</sup> q3wk, limited duration {{#subobject:500ace|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3225192/ Herbst et al. 2010 (ZODIAC)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Docetaxel_.26_Vandetanib|Docetaxel & Vandetanib]]
|style="background-color:#d73027"|Inferior PFS
|-
|}
''While statistically inferior, the median PFS difference was only 0.8 months.''
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for up to 6 cycles'''

===Variant #6, 75 mg/m<sup>2</sup> q3wk, indefinite {{#subobject:b495b6|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2000.18.10.2095 Shepherd et al. 2000]
|style="background-color:#1a9851"|Phase III (E)
|Best supportive care
| style="background-color:#91cf60" |Seems to have superior OS
|-
|rowspan=2|[http://ascopubs.org/doi/full/10.1200/JCO.2000.18.12.2354 Fossella et al. 2000 (TAX 320)]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. Docetaxel 100 mg/m<sup>2</sup>
|style="background-color:#ffffbf"|Seems not superior
|-
|2. Ifosfamide<br> 3. [[#Vinorelbine_monotherapy_2|Vinorelbine]]
|style="background-color:#ffffbf"|Seems not superior
|-
|[http://jco.ascopubs.org/content/22/9/1589.full Hanna et al. 2004 (JMEI)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Pemetrexed_monotherapy_3|Pemetrexed]]
|style="background-color:#ffffbf"|Inconclusive whether non-inferior
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409790/ Gridelli et al. 2004 (DISTAL 01)]
|style="background-color:#1a9851"|Phase III (C)
|Docetaxel 33.3 mg/m<sup>2</sup>, 6 out of 8 wks
|style="background-color:#ffffbf"|Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2005.02.3739 Schuette et al. 2005]
|style="background-color:#1a9851"|Phase III (C)
|Docetaxel 35 mg/m<sup>2</sup>, 3 out of 4 wks
| style="background-color:#fee08b" |Might have inferior OS
|-
|[https://academic.oup.com/annonc/article/17/3/467/146360 Camps et al. 2005]
|style="background-color:#1a9851"|Phase III (C)
|Docetaxel 36 mg/m<sup>2</sup>, 6 out of 8 wks
|style="background-color:#ffffbf"|Seems not superior
|-
|rowspan=2|[http://journal.chestnet.org/article/S0012-3692(15)38821-8/fulltext Chen et al. 2006]
|rowspan=2 style="background-color:#1a9851"|Phase III (C)
|1. Docetaxel 35 mg/m<sup>2</sup>, 3 out of 4 wks
|style="background-color:#ffffbf"|Seems not superior
|-
|2. Docetaxel 40 mg/m<sup>2</sup>, 2 out of 3 wks
|style="background-color:#ffffbf"|Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2005.03.6491 Ramlau et al. 2006]
|style="background-color:#1a9851"|Phase III (C)
|Topotecan
| style="background-color:#d9ef8b" |Might have superior OS
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2391114/ Paz-Ares et al. 2008]
|style="background-color:#1a9851"|Phase III (C)
|Paclitaxel poliglumex
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(08)61758-4/fulltext Kim et al. 2008 (INTEREST)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Gefitinib_monotherapy_2|Gefitinib]]
|style="background-color:#eeee01"|Seems non-inferior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2008.17.1405 Fidias et al. 2008]
|style="background-color:#1a9851"|Phase III (C)
|Docetaxel consolidation
|style="background-color:#fee08b"|Might have inferior OS
|-
|[http://clincancerres.aacrjournals.org/content/16/4/1307.long Lee et al. 2010 (ISTANA)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Gefitinib_monotherapy_2|Gefitinib]]
| style="background-color:#fc8d59" |Seems to have inferior PFS
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2009.23.4146 Krzakowski et al. 2010]
|style="background-color:#1a9851"|Phase III (C)
|Vinflunine
| style="background-color:#eeee01" |Non-inferior PFS
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2012.42.6932 Ramlau et al. 2012 (EFC10261)]
|style="background-color:#1a9851"|Phase III (C)
|Docetaxel & ziv-Aflibercept
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1214886 Shaw et al. 2013 (PROFILE 1007)]
|style="background-color:#1a9851"|Phase III (C)
|[[Non-small_cell_lung_cancer,_ALK-positive#Crizotinib_monotherapy|Crizotinib]]
|style="background-color:#d73027"|Inferior PFS
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70310-3/fulltext Garassino et al. 2013 (TAILOR-NSCLC)]
|style="background-color:#1a9851"|Phase III (C)
|[[Non-small_cell_lung_cancer_-_historical#Erlotinib_monotherapy_2|Erlotinib]]
|style="background-color:#91cf60"|Seems to have superior OS
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70586-2/fulltext Reck et al. 2014 (LUME-Lung 1)]
|style="background-color:#1a9851"|Phase III (C)
|Docetaxel & Nintedanib
|style="background-color:#d73027"|Inferior PFS
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2960845-X/fulltext Garon et al. 2014 (REVEL)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Docetaxel_.26_Ramucirumab|Docetaxel & Ramucirumab]]
|style="background-color:#fc8d59"|Seems to have inferior OS
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4855243/ Blumenschein et al. 2015]
|style="background-color:#1a9851"|Randomized Phase II (C)
|Trametinib
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4681400/ Brahmer et al. 2015 (CheckMate 017)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Nivolumab_monotherapy_2|Nivolumab]]
|style="background-color:#d73027"|Inferior OS
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1507643 Borghaei et al. 2015 (CheckMate 057)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Nivolumab_monotherapy_2|Nivolumab]]
|style="background-color:#d73027"|Inferior OS
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01281-7/fulltext Herbst et al. 2015 (KEYNOTE-010)]
|style="background-color:#1a9851"|Phase II/III (C)
|[[#Pembrolizumab_monotherapy_3|Pembrolizumab]]
|style="background-color:#d73027"|Inferior OS
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)00587-0/fulltext Fehrenbacher et al. 2016 (POPLAR)]
|style="background-color:#1a9851"|Randomized Phase II (C)
|[[#Atezolizumab_monotherapy|Atezolizumab]]
|style="background-color:#fc8d59"|Seems to have inferior OS
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)32517-X/fulltext Rittmeyer et al. 2016 (OAK)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Atezolizumab_monotherapy|Atezolizumab]]
|style="background-color:#d73027"|Inferior OS
|-
|[http://jamanetwork.com/journals/jama/article-abstract/2625317 Jänne et al. 2017 (SELECT-1)]
|style="background-color:#1a9851"|Phase III (C)
|Docetaxel & Selumetinib
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30339-X/fulltext Shaw et al. 2017 (ASCEND-5)]
|style="background-color:#1a9851"|Phase III (C)
|[[Non-small_cell_lung_cancer,_ALK-positive#Ceritinib_monotherapy|Ceritinib]]
|style="background-color:#d73027"|Inferior PFS
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834051/ Katakami et al. 2017 (E7389-G000-302)]
| style="background-color:#1a9851" |Phase III (C)
|Eribulin
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834128/ Nokihara et al. 2017]
|style="background-color:#1a9851"|Phase III (C)
|[[#S-1_monotherapy|S-1]]
|style="background-color:#eeee01"|Non-inferior OS
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30673-9/fulltext Barlesi et al. 2018 (JAVELIN Lung 200)]
| style="background-color:#1a9851" |Phase III (C)
|Avelumab
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Patients in Blumenschein et al. 2015 and SELECT-1 had KRAS-mutated NSCLC. Patients in ASCEND-5 had ALK-rearranged NSCLC progressed after crizotinib. Note that there is another trial named TAILOR in colorectal cancer, so this one has been dubbed TAILOR-NSCLC.''
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV over 60 minutes once on day 1

====Supportive medications====
*Per JMEI: [[Dexamethasone (Decadron)]] 8 mg PO twice per day the day before, the day of, and the day after docetaxel
*Per Chem et al. 2006: [[Dexamethasone (Decadron)]] 8 mg PO once 12 hours before docetaxel, 10 mg IV once 30 minutes before docetaxel, and 8 mg PO 12 hours after docetaxel

'''21-day cycles'''

===Variant #7, 100 mg/m<sup>2</sup> q3wk {{#subobject:465aa0|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://ascopubs.org/doi/abs/10.1200/JCO.1995.13.3.645 Fossella et al. 1995]
| style="background-color:#91cf61" |Phase II
|-
|}
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV once on day 1

'''21-day cycles'''
===References===
# Fossella FV, Lee JS, Shin DM, Calayag M, Huber M, Perez-Soler R, Murphy WK, Lippman S, Benner S, Glisson B, Chasen M, Hong WK, Raber M. Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. J Clin Oncol. 1995 Mar;13(3):645-51. [http://ascopubs.org/doi/abs/10.1200/JCO.1995.13.3.645 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/7884425 PubMed]
# Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, Levitan N, Gressot L, Vincent M, Burkes R, Coughlin S, Kim Y, Berille J. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000 May;18(10):2095-103. [http://ascopubs.org/doi/full/10.1200/JCO.2000.18.10.2095 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10811675 PubMed]
# '''TAX 320:''' Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kalman L, Miller V, Lee JS, Moore M, Gandara D, Karp D, Vokes E, Kris M, Kim Y, Gamza F, Hammershaimb L; The TAX 320 Non-Small Cell Lung Cancer Study Group. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol. 2000 Jun;18(12):2354-62. Erratum in: J Clin Oncol. 2004 Jan 1;22(1):209. [http://ascopubs.org/doi/full/10.1200/JCO.2000.18.12.2354 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10856094 PubMed]
# '''JMEI:''' Hanna N, Shepherd FA, Fossella FV, Rodrigues Pereira J, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar M, Manegold C, Paul S, Paoletti P, Einhorn L, Bunn PA Jr. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004 May 1;22(9):1589-97. [http://jco.ascopubs.org/content/22/9/1589.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15117980 PubMed]
# '''DISTAL 01:''' Gridelli C, Gallo C, Di Maio M, Barletta E, Illiano A, Maione P, Salvagni S, Piantedosi FV, Palazzolo G, Caffo O, Ceribelli A, Falcone A, Mazzanti P, Brancaccio L, Capuano MA, Isa L, Barbera S, Perrone F. A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer: the DISTAL 01 study. Br J Cancer. 2004 Dec 13;91(12):1996-2004. [https://www.nature.com/articles/6602241 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409790/ link to PMC article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15558071 PubMed]
# Schuette W, Nagel S, Blankenburg T, Lautenschlaeger C, Hans K, Schmidt EW, Dittrich I, Schweisfurth H, von Weikersthal LF, Raghavachar A, Reissig A, Serke M. Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel. J Clin Oncol. 2005 Nov 20;23(33):8389-95. [http://ascopubs.org/doi/full/10.1200/JCO.2005.02.3739 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16293869 PubMed]
# Camps C, Massuti B, Jiménez A, Maestu I, Gómez RG, Isla D, González JL, Almenar D, Blasco A, Rosell R, Carrato A, Viñolas N, Batista N, Girón CG, Galán A, López M, Blanco R, Provencio M, Diz P, Felip E; Spanish Lung Cancer Group. Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial. Ann Oncol. 2006 Mar;17(3):467-72. Epub 2005 Dec 21. [https://academic.oup.com/annonc/article/17/3/467/146360 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16371411 PubMed]
# Chen YM, Shih JF, Perng RP, Tsai CM, Whang-Peng J. A randomized trial of different docetaxel schedules in non-small cell lung cancer patients who failed previous platinum-based chemotherapy. Chest. 2006 Apr;129(4):1031-8. [http://journal.chestnet.org/article/S0012-3692(15)38821-8/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16608954 PubMed]
# Ramlau R, Gervais R, Krzakowski M, von Pawel J, Kaukel E, Abratt RP, Dharan B, Grotzinger KM, Ross G, Dane G, Shepherd FA. Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer. J Clin Oncol. 2006 Jun 20;24(18):2800-7. Epub 2006 May 8. [http://ascopubs.org/doi/full/10.1200/JCO.2005.03.6491 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16682727 PubMed]
# Paz-Ares L, Ross H, O'Brien M, Riviere A, Gatzemeier U, Von Pawel J, Kaukel E, Freitag L, Digel W, Bischoff H, García-Campelo R, Iannotti N, Reiterer P, Bover I, Prendiville J, Eisenfeld AJ, Oldham FB, Bandstra B, Singer JW, Bonomi P. Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer. Br J Cancer. 2008 May 20;98(10):1608-13. Epub 2008 May 13. [https://www.nature.com/articles/6604372 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2391114/ link to PMC article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18475293 PubMed]
# '''V-15-32:''' Maruyama R, Nishiwaki Y, Tamura T, Yamamoto N, Tsuboi M, Nakagawa K, Shinkai T, Negoro S, Imamura F, Eguchi K, Takeda K, Inoue A, Tomii K, Harada M, Masuda N, Jiang H, Itoh Y, Ichinose Y, Saijo N, Fukuoka M. Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol. 2008 Sep 10;26(26):4244-52. [http://ascopubs.org/doi/full/10.1200/JCO.2007.15.0185 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18779611 PubMed]
## '''HRQoL analysis:''' Sekine I, Ichinose Y, Nishiwaki Y, Yamamoto N, Tsuboi M, Nakagawa K, Shinkai T, Negoro S, Imamura F, Eguchi K, Takeda K, Itoh Y, Tamura T, Saijo N, Fukuoka M. Quality of life and disease-related symptoms in previously treated Japanese patients with non-small-cell lung cancer: results of a randomized phase III study (V-15-32) of gefitinib versus docetaxel. Ann Oncol. 2009 Sep;20(9):1483-8. Epub 2009 Mar 12. [https://academic.oup.com/annonc/article/20/9/1483/217917 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/19282468 PubMed]
# '''INTEREST:''' Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, Li LY, Watkins CL, Sellers MV, Lowe ES, Sun Y, Liao ML, Osterlind K, Reck M, Armour AA, Shepherd FA, Lippman SM, Douillard JY. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet. 2008 Nov 22;372(9652):1809-18. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(08)61758-4/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19027483 PubMed]
## '''Dataset:''' [https://www.projectdatasphere.org/projectdatasphere/html/content/151 Project Data Sphere]
# Fidias PM, Dakhil SR, Lyss AP, Loesch DM, Waterhouse DM, Bromund JL, Chen R, Hristova-Kazmierski M, Treat J, Obasaju CK, Marciniak M, Gill J, Schiller JH. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol. 2009 Feb 1;27(4):591-8. Epub 2008 Dec 15. [http://ascopubs.org/doi/full/10.1200/JCO.2008.17.1405 link to original article]'''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19075278 PubMed]
# '''JCOG 0104:''' Takeda K, Negoro S, Tamura T, Nishiwaki Y, Kudoh S, Yokota S, Matsui K, Semba H, Nakagawa K, Takada Y, Ando M, Shibata T, Saijo N. Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG0104). Ann Oncol. 2009 May;20(5):835-41. Epub 2009 Jan 22. [https://academic.oup.com/annonc/article/20/5/835/150097 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19164456 PubMed]
# '''ISTANA:''' Lee DH, Park K, Kim JH, Lee JS, Shin SW, Kang JH, Ahn MJ, Ahn JS, Suh C, Kim SW. Randomized phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. Clin Cancer Res. 2010 Feb 15;16(4):1307-14. Epub 2010 Feb 9. [http://clincancerres.aacrjournals.org/content/16/4/1307.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20145166 PubMed]
# Krzakowski M, Ramlau R, Jassem J, Szczesna A, Zatloukal P, Von Pawel J, Sun X, Bennouna J, Santoro A, Biesma B, Delgado FM, Salhi Y, Vaissiere N, Hansen O, Tan EH, Quoix E, Garrido P, Douillard JY. Phase III trial comparing vinflunine with docetaxel in second-line advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy. J Clin Oncol. 2010 May 1;28(13):2167-73. Epub 2010 Mar 29. [http://ascopubs.org/doi/full/10.1200/JCO.2009.23.4146 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20351334 PubMed]
# '''ZODIAC:''' Herbst RS, Sun Y, Eberhardt WE, Germonpré P, Saijo N, Zhou C, Wang J, Li L, Kabbinavar F, Ichinose Y, Qin S, Zhang L, Biesma B, Heymach JV, Langmuir P, Kennedy SJ, Tada H, Johnson BE. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol. 2010 Jul;11(7):619-26. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(10)70132-7/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3225192/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20570559 PubMed]
## '''Dataset:''' [https://www.projectdatasphere.org/projectdatasphere/html/content/163 Project Data Sphere]
# Pallis AG, Agelaki S, Agelidou A, Varthalitis I, Syrigos K, Kentepozidis N, Pavlakou G, Kotsakis A, Kontopodis E, Georgoulias V. A randomized phase III study of the docetaxel/carboplatin combination versus docetaxel single-agent as second line treatment for patients with advanced/metastatic non-small cell lung cancer. BMC Cancer. 2010 Nov 19;10:633. [https://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-10-633 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2994826/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21092076 PubMed]
<!-- Presented in part at the 14th World Conference on Lung Cancer, Amsterdam, the Netherlands, July 3-7, 2011. -->
# '''EFC10261:''' Ramlau R, Gorbunova V, Ciuleanu TE, Novello S, Ozguroglu M, Goksel T, Baldotto C, Bennouna J, Shepherd FA, Le-Guennec S, Rey A, Miller V, Thatcher N, Scagliotti G. Aflibercept and docetaxel versus docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial. J Clin Oncol. 2012 Oct 10;30(29):3640-7. Epub 2012 Sep 10. [http://ascopubs.org/doi/full/10.1200/JCO.2012.42.6932 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22965962 PubMed]
## '''Dataset:''' [https://www.projectdatasphere.org/projectdatasphere/html/content/133 Project Data Sphere]
# '''PROFILE 1007:''' Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, Wu YL, Thomas M, O'Byrne KJ, Moro-Sibilot D, Camidge DR, Mok T, Hirsh V, Riely GJ, Iyer S, Tassell V, Polli A, Wilner KD, Jänne PA. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013 Jun 20;368(25):2385-94. Epub 2013 Jun 1. [https://www.nejm.org/doi/full/10.1056/NEJMoa1214886 link to original article] [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1214886/suppl_file/nejmoa1214886_appendix.pdf link to supplementary appendix] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23724913 PubMed]
## '''Pooled subgroup analysis:''' Nishio M, Kim DW, Wu YL, Nakagawa K, Solomon BJ, Shaw AT, Hashigaki S, Ohki E, Usari T, Paolini J, Polli A, Wilner KD, Mok T. Crizotinib versus chemotherapy in Asian patients with ALK-positive advanced non-small cell lung cancer. Cancer Res Treat. 2018 Jul;50(3):691-700. Epub 2017 Jul 6. [https://www.e-crt.org/journal/view.php?doi=10.4143/crt.2017.280 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6056984/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/28701030 PubMed]
# '''TAILOR-NSCLC:''' Garassino MC, Martelli O, Broggini M, Farina G, Veronese S, Rulli E, Bianchi F, Bettini A, Longo F, Moscetti L, Tomirotti M, Marabese M, Ganzinelli M, Lauricella C, Labianca R, Floriani I, Giaccone G, Torri V, Scanni A, Marsoni S; TAILOR trialists. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol. 2013 Sep;14(10):981-8. Epub 2013 Jul 22. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70310-3/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23883922 PubMed]
# '''LUME-Lung 1:''' Reck M, Kaiser R, Mellemgaard A, Douillard JY, Orlov S, Krzakowski M, von Pawel J, Gottfried M, Bondarenko I, Liao M, Gann CN, Barrueco J, Gaschler-Markefski B, Novello S; LUME-Lung 1 Study Group. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 2014 Feb;15(2):143-55. 2. Epub 2014 Jan 9. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70586-2/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/24411639 PubMed]
# '''DELTA:''' Kawaguchi T, Ando M, Asami K, Okano Y, Fukuda M, Nakagawa H, Ibata H, Kozuki T, Endo T, Tamura A, Kamimura M, Sakamoto K, Yoshimi M, Soejima Y, Tomizawa Y, Isa S, Takada M, Saka H, Kubo A. Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA). J Clin Oncol. 2014 Jun 20;32(18):1902-8. Epub 2014 May 19. [http://ascopubs.org/doi/full/10.1200/JCO.2013.52.4694 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24841974 PubMed]
# '''REVEL:''' Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, Park K, Gorbunova V, Kowalyszyn RD, Pikiel J, Czyzewicz G, Orlov SV, Lewanski CR, Thomas M, Bidoli P, Dakhil S, Gans S, Kim JH, Grigorescu A, Karaseva N, Reck M, Cappuzzo F, Alexandris E, Sashegyi A, Yurasov S, Pérol M. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014 Aug 23;384(9944):665-73. Epub 2014 Jun 2.[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2960845-X/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24933332 PubMed]
# Blumenschein GR Jr, Smit EF, Planchard D, Kim DW, Cadranel J, De Pas T, Dunphy F, Udud K, Ahn MJ, Hanna NH, Kim JH, Mazieres J, Kim SW, Baas P, Rappold E, Redhu S, Puski A, Wu FS, Jänne PA. A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC). Ann Oncol. 2015 May;26(5):894-901. Epub 2015 Feb 26. [https://academic.oup.com/annonc/article/26/5/894/218509 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4855243/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25722381 PubMed]
# '''CheckMate 017:''' Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, Arén Frontera O, Havel L, Steins M, Garassino MC, Aerts JG, Domine M, Paz-Ares L, Reck M, Baudelet C, Harbison CT, Lestini B, Spigel DR. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015 Jul 9;373(2):123-35. Epub 2015 May 31. [https://www.nejm.org/doi/full/10.1056/NEJMoa1504627 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4681400/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26028407 PubMed]
## '''Pooled update:''' Horn L, Spigel DR, Vokes EE, Holgado E, Ready N, Steins M, Poddubskaya E, Borghaei H, Felip E, Paz-Ares L, Pluzanski A, Reckamp KL, Burgio MA, Kohlhäeufl M, Waterhouse D, Barlesi F, Antonia S, Arrieta O, Fayette J, Crinò L, Rizvi N, Reck M, Hellmann MD, Geese WJ, Li A, Blackwood-Chirchir A, Healey D, Brahmer J, Eberhardt WEE. Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057). J Clin Oncol. 2017 Dec 10;35(35):3924-3933. Epub 2017 Oct 12. [http://ascopubs.org/doi/full/10.1200/JCO.2017.74.3062 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/29023213 PubMed]
# '''CheckMate 057:''' Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhäufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crinò L, Blumenschein GR Jr, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015 Oct 22;373(17):1627-39. Epub 2015 Sep 27. [https://www.nejm.org/doi/full/10.1056/NEJMoa1507643 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26412456 PubMed]
## '''Pooled update:''' Horn L, Spigel DR, Vokes EE, Holgado E, Ready N, Steins M, Poddubskaya E, Borghaei H, Felip E, Paz-Ares L, Pluzanski A, Reckamp KL, Burgio MA, Kohlhäeufl M, Waterhouse D, Barlesi F, Antonia S, Arrieta O, Fayette J, Crinò L, Rizvi N, Reck M, Hellmann MD, Geese WJ, Li A, Blackwood-Chirchir A, Healey D, Brahmer J, Eberhardt WEE. Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057). J Clin Oncol. 2017 Dec 10;35(35):3924-3933. Epub 2017 Oct 12. [http://ascopubs.org/doi/full/10.1200/JCO.2017.74.3062 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/29023213 PubMed]
# '''KEYNOTE-010:''' Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, de Castro G Jr, Garrido M, Lubiniecki GM, Shentu Y, Im E, Dolled-Filhart M, Garon EB. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016 Apr 9;387(10027):1540-50. Epub 2015 Dec 19. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01281-7/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26712084 PubMed]
# '''POPLAR:''' Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, Park K, Smith D, Artal-Cortes A, Lewanski C, Braiteh F, Waterkamp D, He P, Zou W, Chen DS, Yi J, Sandler A, Rittmeyer A; POPLAR Study Group. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016 Apr 30;387(10030):1837-46. Epub 2016 Mar 9. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)00587-0/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26970723 PubMed]
# '''OAK:''' Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC, Cortinovis DL, Leach J, Polikoff J, Barrios C, Kabbinavar F, Frontera OA, De Marinis F, Turna H, Lee JS, Ballinger M, Kowanetz M, He P, Chen DS, Sandler A, Gandara DR; OAK Study Group. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017 Jan 21;389(10066):255-265. Epub 2016 Dec 13. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)32517-X/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27979383 PubMed]
# Yoshioka H, Katakami N, Okamoto H, Iwamoto Y, Seto T, Takahashi T, Sunaga N, Kudoh S, Chikamori K, Harada M, Tanaka H, Saito H, Saka H, Takeda K, Nogami N, Masuda N, Harada T, Kitagawa H, Horio H, Yamanaka T, Fukuoka M, Yamamoto N, Nakagawa K. A randomized, open-label, phase III trial comparing amrubicin versus docetaxel in patients with previously treated non-small-cell lung cancer. Ann Oncol. 2017 Feb 1;28(2):285-291. [https://academic.oup.com/annonc/article/28/2/285/2676905 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28426104 PubMed]
# '''SELECT-1:''' Jänne PA, van den Heuvel MM, Barlesi F, Cobo M, Mazieres J, Crinò L, Orlov S, Blackhall F, Wolf J, Garrido P, Poltoratskiy A, Mariani G, Ghiorghiu D, Kilgour E, Smith P, Kohlmann A, Carlile DJ, Lawrence D, Bowen K, Vansteenkiste J. Selumetinib plus docetaxel compared with docetaxel alone and progression-free survival in patients with KRAS-mutant advanced non-small cell lung cancer: The SELECT-1 randomized clinical trial. JAMA. 2017 May 9;317(18):1844-1853. [http://jamanetwork.com/journals/jama/article-abstract/2625317 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28492898 PubMed]
# '''ASCEND-5:''' Shaw AT, Kim TM, Crinò L, Gridelli C, Kiura K, Liu G, Novello S, Bearz A, Gautschi O, Mok T, Nishio M, Scagliotti G, Spigel DR, Deudon S, Zheng C, Pantano S, Urban P, Massacesi C, Viraswami-Appanna K, Felip E. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2017 Jul;18(7):874-886. Epub 2017 Jun 9. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30339-X/fulltext link to original article]'''contains protocol'''[https://www.ncbi.nlm.nih.gov/pubmed/28602779 PubMed]
# '''E7389-G000-302:''' Katakami N, Felip E, Spigel DR, Kim JH, Olivo M, Guo M, Nokihara H, Yang JC, Iannotti N, Satouchi M, Barlesi F. A randomized, open-label, multicenter, phase 3 study to compare the efficacy and safety of eribulin to treatment of physician's choice in patients with advanced non-small cell lung cancer. Ann Oncol. 2017 Sep 1;28(9):2241-2247. [https://academic.oup.com/annonc/article/28/9/2241/3979219 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834051/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28911085 PubMed]
# Nokihara H, Lu S, Mok TSK, Nakagawa K, Yamamoto N, Shi YK, Zhang L, Soo RA, Yang JC, Sugawara S, Nishio M, Takahashi T, Goto K, Chang J, Maemondo M, Ichinose Y, Cheng Y, Lim WT, Morita S, Tamura T. Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer). Ann Oncol. 2017 Nov 1;28(11):2698-2706. [https://academic.oup.com/annonc/article/28/11/2698/4282669 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834128/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29045553 PubMed]
# '''JAVELIN Lung 200:''' Barlesi F, Vansteenkiste J, Spigel D, Ishii H, Garassino M, de Marinis F, Özgüroğlu M, Szczesna A, Polychronis A, Uslu R, Krzakowski M, Lee JS, Calabrò L, Arén Frontera O, Ellers-Lenz B, Bajars M, Ruisi M, Park K. Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study. Lancet Oncol. 2018 Nov;19(11):1468-79. Epub 2018 Sep 21. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30673-9/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/30262187 PubMed]

==Docetaxel & Ramucirumab {{#subobject:7b9570|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 60 mg/m<sup>2</sup> docetaxel {{#subobject:07d626|Variant=1}}===
{| class="wikitable" style="color:white; background-color:#404040"
|<small>'''FDA-recommended dose'''</small>
|-
|}
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2960845-X/fulltext Garon et al. 2014 (REVEL)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Docetaxel_monotherapy_2|Docetaxel]]
|style="background-color:#91cf60"|Seems to have superior OS
|-
|}
''Note: This is the PMDA-approved dose and the dose recommended for East Asians. The FDA only provides recommendations for ramucirumab dosing.''
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 60 mg/m<sup>2</sup> IV once on day 1
*[[Ramucirumab (Cyramza)]] 10 mg/kg IV once on day 1

====Supportive medications====
*Colony-stimulating factors and erythroid-stimulating factor use per investigator discretion.

'''21-day cycles'''

===Variant #2, 75 mg/m<sup>2</sup> docetaxel {{#subobject:b3ec19|Variant=1}}===
{| class="wikitable" style="color:white; background-color:#404040"
|<small>'''FDA-recommended dose'''</small>
|-
|}
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2960845-X/fulltext Garon et al. 2014 (REVEL)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Docetaxel_monotherapy_2|Docetaxel]]
|style="background-color:#91cf60"|Seems to have superior OS
|-
|}
''Note: The FDA only provides recommendations for ramucirumab dosing.''
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV once on day 1
*[[Ramucirumab (Cyramza)]] 10 mg/kg IV once on day 1

====Supportive medications====
*Colony-stimulating factors and erythroid-stimulating factor use per investigator discretion.

'''21-day cycles'''

===References===
# '''REVEL:''' Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, Park K, Gorbunova V, Kowalyszyn RD, Pikiel J, Czyzewicz G, Orlov SV, Lewanski CR, Thomas M, Bidoli P, Dakhil S, Gans S, Kim JH, Grigorescu A, Karaseva N, Reck M, Cappuzzo F, Alexandris E, Sashegyi A, Yurasov S, Pérol M. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014 Aug 23;384(9944):665-73. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2960845-X/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24933332 PubMed]

==Docetaxel & Vandetanib {{#subobject:827eac|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 60 mg/m<sup>2</sup> docetaxel {{#subobject:c0b4c2|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3225192/ Herbst et al. 2010 (ZODIAC)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Docetaxel_monotherapy_2|Docetaxel]]
|style="background-color:#1a9850"|Superior PFS
|-
|}
''This is the PMDA-approved dose of docetaxel. While statistically superior, the median PFS difference was only 0.8 months. Vandetanib is continued until disease progression, unacceptable toxicity, or withdrawal of consent.''
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 60 mg/m<sup>2</sup> IV once on day 1
*[[Vandetanib (Caprelsa)]] 100 mg PO once per day

'''21-day cycle for up to 6 cycles (*)'''

===Variant #2, 75 mg/m<sup>2</sup> docetaxel {{#subobject:10fe1c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3225192/ Herbst et al. 2010 (ZODIAC)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Docetaxel_monotherapy_2|Docetaxel]]
|style="background-color:#1a9850"|Superior PFS
|-
|}
''While statistically superior, the median PFS difference was only 0.8 months. Vandetanib is continued until disease progression, unacceptable toxicity, or withdrawal of consent.''
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV once on day 1
*[[Vandetanib (Caprelsa)]] 100 mg PO once per day

'''21-day cycle for up to 6 cycles (see note)'''

===References===
# Herbst RS, Sun Y, Eberhardt WE, Germonpré P, Saijo N, Zhou C, Wang J, Li L, Kabbinavar F, Ichinose Y, Qin S, Zhang L, Biesma B, Heymach JV, Langmuir P, Kennedy SJ, Tada H, Johnson BE. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol. 2010 Jul;11(7):619-26. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(10)70132-7/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3225192/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20570559 PubMed]

==Gefitinib monotherapy {{#subobject:ebbf2d|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:1b028f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jama.jamanetwork.com/article.aspx?articleid=197532 Kris et al. 2003 (IDEAL2)]
|style="background-color:#1a9851"|Randomized Phase II (E)
|Gefitinib 500 mg/day
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(05)67625-8/fulltext Thatcher et al. 2005 (ISEL)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Placebo_4|Placebo]]
| style="background-color:#d9ef8b" |Might have superior OS
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(08)61758-4/fulltext Kim et al. 2008 (INTEREST)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Docetaxel_monotherapy_2|Docetaxel]]
|style="background-color:#eeee01"|Seems non-inferior
|-
|[http://clincancerres.aacrjournals.org/content/16/4/1307.long Lee et al. 2010 (ISTANA)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Docetaxel_monotherapy_2|Docetaxel]]
| style="background-color:#91cf60" |Seems to have superior PFS
|-
|[http://clincancerres.aacrjournals.org/content/17/6/1553.long Han et al. 2011]
|style="background-color:#1a9851"|Randomized Phase II (C)
|Gefitinib & Simvastatin
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.27630 Sun et al. 2012 (KCSG-LU08-01)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Pemetrexed_monotherapy_3|Pemetrexed]]
| style="background-color:#1a9850" |Superior PFS
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70355-3/fulltext Shi et al. 2013 (ICOGEN)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Icotinib_monotherapy|Icotinib]]
|style="background-color:#eeee01"|Seems non-inferior
|-
|[http://jco.ascopubs.org/content/34/27/3248.full Urata et al. 2016 (WJOG 5108L)]
|style="background-color:#1a9851"|Phase III (C)
|[[Non-small_cell_lung_cancer_-_historical#Erlotinib_monotherapy_2|Erlotinib]]
|style="background-color:#ffffbf"|Inconclusive whether non-inferior
|-
|}
====Chemotherapy====
*[[Gefitinib (Iressa)]] 250 mg PO once per day

'''Continued indefinitely'''

===References===
# '''IDEAL2:''' Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ, Kay AC. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003 Oct 22;290(16):2149-58. [http://jama.jamanetwork.com/article.aspx?articleid=197532 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/14570950 PubMed]
# '''ISEL:''' Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, Thongprasert S, Tan EH, Pemberton K, Archer V, Carroll K. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005 Oct 29-Nov 4;366(9496):1527-37. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(05)67625-8/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16257339 PubMed]
# '''INTEREST:''' Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, Li LY, Watkins CL, Sellers MV, Lowe ES, Sun Y, Liao ML, Osterlind K, Reck M, Armour AA, Shepherd FA, Lippman SM, Douillard JY. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet. 2008 Nov 22;372(9652):1809-18. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(08)61758-4/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19027483 PubMed]
## '''Dataset:''' [https://www.projectdatasphere.org/projectdatasphere/html/content/151 Project Data Sphere]
# '''ISTANA:''' Lee DH, Park K, Kim JH, Lee JS, Shin SW, Kang JH, Ahn MJ, Ahn JS, Suh C, Kim SW. Randomized phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. Clin Cancer Res. 2010 Feb 15;16(4):1307-14. Epub 2010 Feb 9. [http://clincancerres.aacrjournals.org/content/16/4/1307.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20145166 PubMed]
# Han JY, Lee SH, Yoo NJ, Hyung LS, Moon YJ, Yun T, Kim HT, Lee JS. A randomized phase II study of gefitinib plus simvastatin versus gefitinib alone in previously treated patients with advanced non-small cell lung cancer. Clin Cancer Res. 2011 Mar 15;17(6):1553-60. [http://clincancerres.aacrjournals.org/content/17/6/1553.long link to orinigal article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21411446 PubMed]
# '''KCSG-LU08-01:''' Sun JM, Lee KH, Kim SW, Lee DH, Min YJ, Yun HJ, Kim HK, Song HS, Kim YH, Kim BS, Hwang IG, Lee K, Jo SJ, Lee JW, Ahn JS, Park K, Ahn MJ; Korean Cancer Study Group. Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial. Cancer. 2012 Dec 15;118(24):6234-42. Epub 2012 Jun 6. [https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.27630 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22674612 PubMed]
# '''ICOGEN:''' Shi Y, Zhang L, Liu X, Zhou C, Zhang L, Zhang S, Wang D, Li Q, Qin S, Hu C, Zhang Y, Chen J, Cheng Y, Feng J, Zhang H, Song Y, Wu YL, Xu N, Zhou J, Luo R, Bai C, Jin Y, Liu W, Wei Z, Tan F, Wang Y, Ding L, Dai H, Jiao S, Wang J, Liang L, Zhang W, Sun Y. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. Lancet Oncol. 2013 Sep;14(10):953-61. Epub 2013 Aug 13. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70355-3/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23948351 PubMed]
# '''WJOG 5108L:''' Urata Y, Katakami N, Morita S, Kaji R, Yoshioka H, Seto T, Satouchi M, Iwamoto Y, Kanehara M, Fujimoto D, Ikeda N, Murakami H, Daga H, Oguri T, Goto I, Imamura F, Sugawara S, Saka H, Nogami N, Negoro S, Nakagawa K, Nakanishi Y. Randomized phase III study comparing gefitinib with erlotinib in patients with previously treated advanced lung adenocarcinoma: WJOG 5108L. J Clin Oncol. 2016 Sep 20;34(27):3248-57. Epub 2016 Mar 28. [http://jco.ascopubs.org/content/34/27/3248.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27022112 PubMed]

==Gemcitabine monotherapy {{#subobject:63e7a9|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 1000 mg/m<sup>2</sup> {{#subobject:dda826|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.1999.17.7.2081 Crinò et al. 1999]
| style="background-color:#91cf61" |Phase II
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834051/ Katakami et al. 2017 (E7389-G000-302)]
| style="background-color:#1a9851" |Phase III (C)
|Eribulin
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm.''
====Chemotherapy====
*[[Gemcitabine (Gemzar)]] 1000 mg/m<sup>2</sup> IV once per day on days 1, 8, 15 

'''28-day cycles'''

===Variant #2, 1250 mg/m<sup>2</sup> {{#subobject:7f2a5c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834051/ Katakami et al. 2017 (E7389-G000-302)]
| style="background-color:#1a9851" |Phase III (C)
|Eribulin
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm.''
====Chemotherapy====
*[[Gemcitabine (Gemzar)]] 1250 mg/m<sup>2</sup> IV once per day on days 1 & 8 

'''21-day cycles'''

===References===
# Crinò L, Mosconi AM, Scagliotti G, Selvaggi G, Novello S, Rinaldi M, Della Giulia M, Gridelli C, Rossi A, Calandri C, De Marinis F, Noseda M, Tonato M. Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: a phase II trial. J Clin Oncol. 1999 Jul;17(7):2081-5. [http://ascopubs.org/doi/full/10.1200/JCO.1999.17.7.2081 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10561261 PubMed]
# '''E7389-G000-302:''' Katakami N, Felip E, Spigel DR, Kim JH, Olivo M, Guo M, Nokihara H, Yang JC, Iannotti N, Satouchi M, Barlesi F. A randomized, open-label, multicenter, phase 3 study to compare the efficacy and safety of eribulin to treatment of physician's choice in patients with advanced non-small cell lung cancer. Ann Oncol. 2017 Sep 1;28(9):2241-2247. [https://academic.oup.com/annonc/article/28/9/2241/3979219 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834051/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28911085 PubMed]

==Icotinib monotherapy {{#subobject:9720a1|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:d7253b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70355-3/fulltext Shi et al. 2013 (ICOGEN)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Gefitinib_monotherapy_2|Gefitinib]]
|style="background-color:#eeee01"|Seems non-inferior
|-
|}
''Note: this drug is only approved in China.''
====Chemotherapy====
*[[Icotinib (Conmana)]] 125 mg PO TID

'''Continued indefinitely'''

===References===
# '''ICOGEN:''' Shi Y, Zhang L, Liu X, Zhou C, Zhang L, Zhang S, Wang D, Li Q, Qin S, Hu C, Zhang Y, Chen J, Cheng Y, Feng J, Zhang H, Song Y, Wu YL, Xu N, Zhou J, Luo R, Bai C, Jin Y, Liu W, Wei Z, Tan F, Wang Y, Ding L, Dai H, Jiao S, Wang J, Liang L, Zhang W, Sun Y. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. Lancet Oncol. 2013 Sep;14(10):953-61. Epub 2013 Aug 13. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70355-3/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23948351 PubMed]

==Nivolumab monotherapy {{#subobject:7e5a40|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:f73cfc|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!Study
![[Levels_of_Evidence#Evidence|Evidence]]
!Comparator
![[Levels_of_Evidence#Efficacy|Efficacy]]
!ORR
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2815%2970054-9/fulltext Rizvi et al. 2015 (CheckMate 063)]
|style="background-color:#91cf61"|Phase II
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|14% (95% CI 9 - 22)
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4681400/ Brahmer et al. 2015 (CheckMate 017)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Docetaxel_monotherapy_2|Docetaxel]]
|style="background-color:#1a9850"|Superior OS
|20% (95% CI 14 - 28)
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1507643 Borghaei et al. 2015 (CheckMate 057)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Docetaxel_monotherapy_2|Docetaxel]]
|style="background-color:#1a9850"|Superior OS
|19% (95% CI 15 - 24)
|-
|}
''Patients in '''CheckMate 017''' had squamous histology. Patients in '''CheckMate 057''' had non-squamous histology.''
====Immunotherapy====
*[[Nivolumab (Opdivo)]] 3 mg/kg IV once on day 1
**Notably, on 9/13/16 the [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm520871.htm FDA recommended] that dosing for this indication be changed to 240 mg with the same schedule based on updated pharmacokinetic data.

'''14-day cycles'''

===References===
# '''CheckMate 063:''' Rizvi NA, Mazières J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, Horn L, Lena H, Minenza E, Mennecier B, Otterson GA, Campos LT, Gandara DR, Levy BP, Nair SG, Zalcman G, Wolf J, Souquet PJ, Baldini E, Cappuzzo F, Chouaid C, Dowlati A, Sanborn R, Lopez-Chavez A, Grohe C, Huber RM, Harbison CT, Baudelet C, Lestini BJ, Ramalingam SS. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015 Feb 19. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2815%2970054-9/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25704439 PubMed]
# '''CheckMate 017:''' Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, Arén Frontera O, Havel L, Steins M, Garassino MC, Aerts JG, Domine M, Paz-Ares L, Reck M, Baudelet C, Harbison CT, Lestini B, Spigel DR. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015 Jul 9;373(2):123-35. Epub 2015 May 31. [https://www.nejm.org/doi/full/10.1056/NEJMoa1504627 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4681400/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26028407 PubMed]
# '''CheckMate 057:''' Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhäufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crinò L, Blumenschein GR Jr, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015 Oct 22;373(17):1627-39. Epub 2015 Sep 27. [https://www.nejm.org/doi/full/10.1056/NEJMoa1507643 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26412456 PubMed]

==Pembrolizumab monotherapy {{#subobject:068cc1|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:d2e0eb|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!Study
![[Levels_of_Evidence#Evidence|Evidence]]
!Comparator
![[Levels_of_Evidence#Efficacy|Efficacy]]
!ORR
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1501824 Garon et al. 2015 (KEYNOTE-001)]
| style="background-color:#91cf61" |Phase 1, >20 pts in dosing cohort
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01281-7/fulltext Herbst et al. 2015 (KEYNOTE-010)]
|style="background-color:#1a9851"|Phase II/III (E)
|[[#Docetaxel_monotherapy_2|Docetaxel]]
|style="background-color:#1a9850"|Superior OS
|2 mg/kg: 18% (95% CI 14 - 23)<br> 10 mg/kg: 19% (95% CI 15 - 23)
|-
|}
''Note: patients had previously received chemotherapy.''
====Immunotherapy====
*[[Pembrolizumab (Keytruda)]] 2 mg/kg or 10 mg/kg IV once on day 1

'''21-day cycles'''

===References===
# '''Phase 1:''' Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J, Lunceford JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, Gandhi L; KEYNOTE-001 Investigators. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015 May 21;372(21):2018-28. Epub 2015 Apr 19. [https://www.nejm.org/doi/full/10.1056/NEJMoa1501824 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25891174 PubMed]
# '''KEYNOTE-010:''' Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, de Castro G Jr, Garrido M, Lubiniecki GM, Shentu Y, Im E, Dolled-Filhart M, Garon EB. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016 Apr 9;387(10027):1540-50. Epub 2015 Dec 19. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01281-7/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26712084 PubMed]

==Pemetrexed monotherapy {{#subobject:24ad9b|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Example orders===
*[[Example orders for Pemetrexed (Alimta) in non-small cell lung cancer]]

===Regimen {{#subobject:4e0d06|Variant=1}}===
{| class="wikitable" style="color:white; background-color:#404040"
|<small>'''FDA-recommended dose'''</small>
|-
|}
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/22/9/1589.full Hanna et al. 2004 (JMEI)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Docetaxel_monotherapy_2|Docetaxel]]
|style="background-color:#ffffbf"|Inconclusive whether non-inferior
|-
|[https://academic.oup.com/annonc/article/19/5/939/168250 Cullen et al. 2008]
|style="background-color:#1a9851"|Phase III (C)
|High-dose pemetrexed
|style="background-color:#ffffbf"|Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2010.29.5717 de Boer et al. 2011 (ZEAL)]
|style="background-color:#1a9851"|Phase III (C)
|Pemetrexed & Vandetanib
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.27630 Sun et al. 2012 (KCSG-LU08-01)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Gefitinib_monotherapy_2|Gefitinib]]
| style="background-color:#d73027" |Inferior PFS
|-
|[http://jco.ascopubs.org/content/30/36/4501.long Ardizzoni et al. 2012 (GOIRC 02-2006)]
|style="background-color:#1a9851"|Randomized Phase II (C)
|[[#Carboplatin_.26_Pemetrexed_4|Carboplatin & Pemetrexed]]
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.28132 Karampeazis et al. 2013]
|style="background-color:#1a9851"|Phase III (E)
|[[Non-small_cell_lung_cancer_-_historical#Erlotinib_monotherapy_2|Erlotinib]]
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1214886 Shaw et al. 2013 (PROFILE 1007)]
|style="background-color:#1a9851"|Phase III (C)
|[[Non-small_cell_lung_cancer,_ALK-positive#Crizotinib_monotherapy|Crizotinib]]
|style="background-color:#d73027"|Inferior PFS
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70473-X/fulltext Kim et al. 2013]
|style="background-color:#1a9851"|Phase III (C)
|Pemetrexed & Cetuximab
|style="background-color:#ffffbf"|Seems not superior
|-
|[http://www.lungcancerjournal.info/article/S0169-5002(16)30510-4/fulltext Hanna et al. 2016 (LUME-Lung 2)]
|style="background-color:#1a9851"|Phase III (C)
|Nintedanib & Pemetrexed
|style="background-color:#fc8d59"|Seems to have inferior PFS
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30339-X/fulltext Shaw et al. 2017 (ASCEND-5)]
|style="background-color:#1a9851"|Phase III (C)
|[[Non-small_cell_lung_cancer,_ALK-positive#Ceritinib_monotherapy|Ceritinib]]
|style="background-color:#d73027"|Inferior PFS
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834051/ Katakami et al. 2017 (E7389-G000-302)]
| style="background-color:#1a9851" |Phase III (C)
|Eribulin
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Note: Kim et al. 2013 also evaluated docetaxel versus docetaxel & cetuximab, but did not report the efficacy of this comparison; see paper for details. Patients in '''ASCEND-5''' had ALK-rearranged NSCLC that had progressed on crizotinib.''
====Chemotherapy====
*[[Pemetrexed (Alimta)]] 500 mg/m<sup>2</sup> IV over 10 minutes once on day 1

====Supportive medications====
*(per Ardizzoni et al. 2012):
*[[Dexamethasone (Decadron)]] 4 mg or [[steroid conversions|equivalent corticosteroid]] PO twice per day on the day before, the day of, and day after each dose of pemetrexed
*Folic acid 350 to 600 mcg PO once per day, starting 1 to 2 weeks before the first dose of pemetrexed, to be taken throughout pemetrexed therapy.
**JMEI used folic acid 1 mg PO once per day
*[[Cyanocobalamin (Vitamin B12)]] 1000 mcg IM once every 9 weeks, first dose 1 to 2 weeks before the first dose of pemetrexed, to be given throughout pemetrexed therapy

'''21-day cycles''' 

''GOIRC 02-2006 treated patients for up to 4 cycles or until progressive disease, unacceptable toxicity, or patient refusal.''

===References===
# '''JMEI:''' Hanna N, Shepherd FA, Fossella FV, Rodrigues Pereira J, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar M, Manegold C, Paul S, Paoletti P, Einhorn L, Bunn PA Jr. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004 May 1;22(9):1589-97. [http://jco.ascopubs.org/content/22/9/1589.full link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15117980 PubMed]
# Cullen MH, Zatloukal P, Sörenson S, Novello S, Fischer JR, Joy AA, Zereu M, Peterson P, Visseren-Grul CM, Iscoe N. A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer. Ann Oncol. 2008 May;19(5):939-45. Epub 2008 Feb 17. [https://academic.oup.com/annonc/article/19/5/939/168250 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18283036 PubMed]
<!-- Presented as a poster discussion at the 45th Annual Meeting of the American Society of Clinical Oncology, May 29-June 2, 2009, Orlando, FL, and as an oral presentation at the 13th World Congress on Lung Cancer, July 31-August 4, 2009, San Francisco, CA, and at the European Cancer Organisation 15/34th European Society for Medical Oncology Congress, September 20-24, 2009, Berlin, Germany. -->
# '''ZEAL:''' de Boer RH, Arrieta Ó, Yang CH, Gottfried M, Chan V, Raats J, de Marinis F, Abratt RP, Wolf J, Blackhall FH, Langmuir P, Milenkova T, Read J, Vansteenkiste JF. Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2011 Mar 10;29(8):1067-74. Epub 2011 Jan 31. [http://ascopubs.org/doi/full/10.1200/JCO.2010.29.5717 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21282537 PubMed]
# '''KCSG-LU08-01:''' Sun JM, Lee KH, Kim SW, Lee DH, Min YJ, Yun HJ, Kim HK, Song HS, Kim YH, Kim BS, Hwang IG, Lee K, Jo SJ, Lee JW, Ahn JS, Park K, Ahn MJ; Korean Cancer Study Group. Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial. Cancer. 2012 Dec 15;118(24):6234-42. Epub 2012 Jun 6. [https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.27630 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22674612 PubMed]
<!-- Presented at the 47th Annual Meeting of the American Society of Clinical Oncology, Chicago, June 3-7, 2011; 14th World Conference on Lung Cancer, Amsterdam, the Netherlands, July 3-7, 2011; and 13th National Congress of Medical Oncology, Bologna, Italy, November 5-7, 2011. -->
# '''GOIRC 02-2006:''' Ardizzoni A, Tiseo M, Boni L, Vincent AD, Passalacqua R, Buti S, Amoroso D, Camerini A, Labianca R, Genestreti G, Boni C, Ciuffreda L, Di Costanzo F, de Marinis F, Crinò L, Santo A, Pazzola A, Barbieri F, Zilembo N, Colantonio I, Tibaldi C, Mattioli R, Cafferata MA, Camisa R, Smit EF. Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non-small-cell lung cancer: results of the GOIRC 02-2006 randomized phase II study and pooled analysis with the NVALT7 trial. J Clin Oncol. 2012 Dec 20;30(36):4501-7. Epub 2012 Oct 29. [http://jco.ascopubs.org/content/30/36/4501.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23109689 PubMed]
# Karampeazis A, Voutsina A, Souglakos J, Kentepozidis N, Giassas S, Christofillakis C, Kotsakis A, Papakotoulas P, Rapti A, Agelidou M, Agelaki S, Vamvakas L, Samonis G, Mavroudis D, Georgoulias V. Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study. Cancer. 2013 Aug 1;119(15):2754-64. Epub 2013 May 9. [https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.28132 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23661337 PubMed]
# '''PROFILE 1007:''' Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, Wu YL, Thomas M, O'Byrne KJ, Moro-Sibilot D, Camidge DR, Mok T, Hirsh V, Riely GJ, Iyer S, Tassell V, Polli A, Wilner KD, Jänne PA. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013 Jun 20;368(25):2385-94. Epub 2013 Jun 1. [https://www.nejm.org/doi/full/10.1056/NEJMoa1214886 link to original article] [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1214886/suppl_file/nejmoa1214886_appendix.pdf link to supplementary appendix] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23724913 PubMed]
## '''Pooled subgroup analysis:''' Nishio M, Kim DW, Wu YL, Nakagawa K, Solomon BJ, Shaw AT, Hashigaki S, Ohki E, Usari T, Paolini J, Polli A, Wilner KD, Mok T. Crizotinib versus chemotherapy in Asian patients with ALK-positive advanced non-small cell lung cancer. Cancer Res Treat. 2018 Jul;50(3):691-700. Epub 2017 Jul 6. [https://www.e-crt.org/journal/view.php?doi=10.4143/crt.2017.280 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6056984/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/28701030 PubMed]
# Kim ES, Neubauer M, Cohn A, Schwartzberg L, Garbo L, Caton J, Robert F, Reynolds C, Katz T, Chittoor S, Simms L, Saxman S. Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial. Lancet Oncol. 2013 Dec;14(13):1326-36. Epub 2013 Nov 12. Erratum in: Lancet Oncol. 2014 Jan;15(1):e4. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70473-X/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24231627 PubMed]
# '''LUME-Lung 2:''' Hanna NH, Kaiser R, Sullivan RN, Aren OR, Ahn MJ, Tiangco B, Voccia I, Pawel JV, Kovcin V, Agulnik J, Gaschler-Markefski B, Barrueco J, Sikken P, Schloss C, Kim JH; LUME-Lung 2 Study group. Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial. Lung Cancer. 2016 Dec;102:65-73. Epub 2016 Oct 27. [http://www.lungcancerjournal.info/article/S0169-5002(16)30510-4/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27987591 PubMed]
# '''ASCEND-5:''' Shaw AT, Kim TM, Crinò L, Gridelli C, Kiura K, Liu G, Novello S, Bearz A, Gautschi O, Mok T, Nishio M, Scagliotti G, Spigel DR, Deudon S, Zheng C, Pantano S, Urban P, Massacesi C, Viraswami-Appanna K, Felip E. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2017 Jul;18(7):874-886. Epub 2017 Jun 9. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30339-X/fulltext link to original article]'''contains protocol'''[https://www.ncbi.nlm.nih.gov/pubmed/28602779 PubMed]
# '''E7389-G000-302:''' Katakami N, Felip E, Spigel DR, Kim JH, Olivo M, Guo M, Nokihara H, Yang JC, Iannotti N, Satouchi M, Barlesi F. A randomized, open-label, multicenter, phase 3 study to compare the efficacy and safety of eribulin to treatment of physician's choice in patients with advanced non-small cell lung cancer. Ann Oncol. 2017 Sep 1;28(9):2241-2247. [https://academic.oup.com/annonc/article/28/9/2241/3979219 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834051/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28911085 PubMed]

==Placebo==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa050753 Shepherd et al. 2005 (NCIC CTG BR.21)]
|style="background-color:#1a9851"|Phase III (C)
|[[Non-small_cell_lung_cancer_-_historical#Erlotinib_monotherapy_2|Erlotinib]]
|style="background-color:#d73027"|Inferior OS
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(05)67625-8/fulltext Thatcher et al. 2005 (ISEL)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Gefitinib_monotherapy_2|Gefitinib]]
| style="background-color:#fee08b" |Might have inferior OS
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2011.36.1709 Lee et al. 2012 (ZEPHYR)]
|style="background-color:#1a9851"|Phase III (C)
|Vandetanib
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70087-6/fulltext Miller et al. 2012 (LUX-Lung 1)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Afatinib_monotherapy|Afatinib]]
|style="background-color:#d73027"|Inferior PFS
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70472-3/fulltext Ellis et al. 2014 (NCIC CTG BR.26)]
|style="background-color:#1a9851"|Phase III (C)
|Dacomitinib
|style="background-color:#ffffbf"|Seems not superior
|-
|[http://www.jto.org/article/S1556-0864(15)35098-X/fulltext Paz-Ares et al. 2015 (MISSION)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Sorafenib_monotherapy|Sorafenib]]
|style="background-color:#d73027"|Inferior PFS
|-
|}

''No active antineoplastic treatment. Placed here because one or more randomized clinical trials included a placebo arm in this disease context.''

===References===
# '''NCIC CTG BR.21:''' Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabárbara P, Seymour L; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005 Jul 14;353(2):123-32. [https://www.nejm.org/doi/full/10.1056/NEJMoa050753 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16014882 PubMed]
# '''ISEL:''' Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, Thongprasert S, Tan EH, Pemberton K, Archer V, Carroll K. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005 Oct 29-Nov 4;366(9496):1527-37. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(05)67625-8/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16257339 PubMed]
# '''ZEPHYR:''' Lee JS, Hirsh V, Park K, Qin S, Blajman CR, Perng RP, Chen YM, Emerson L, Langmuir P, Manegold C. Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol. 2012 Apr 1;30(10):1114-21. Epub 2012 Feb 27. [http://ascopubs.org/doi/full/10.1200/JCO.2011.36.1709 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22370318 PubMed]
# '''LUX-Lung 1:''' Miller VA, Hirsh V, Cadranel J, Chen YM, Park K, Kim SW, Zhou C, Su WC, Wang M, Sun Y, Heo DS, Crino L, Tan EH, Chao TY, Shahidi M, Cong XJ, Lorence RM, Yang JC. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol. 2012 May;13(5):528-38. Epub 2012 Mar 26. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70087-6/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22452896 PubMed]
## '''HRQoL analysis:''' Hirsh V, Cadranel J, Cong XJ, Fairclough D, Finnern HW, Lorence RM, Miller VA, Palmer M, Yang JC. Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1). J Thorac Oncol. 2013 Feb;8(2):229-37. [https://www.jto.org/article/S1556-0864(15)32746-5/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23328549 PubMed] 
# '''NCIC CTG BR.26:''' Ellis PM, Shepherd FA, Millward M, Perrone F, Seymour L, Liu G, Sun S, Cho BC, Morabito A, Leighl NB, Stockler MR, Lee CW, Wierzbicki R, Cohen V, Blais N, Sangha RS, Favaretto AG, Kang JH, Tsao MS, Wilson CF, Goldberg Z, Ding K, Goss GD, Bradbury PA; NCIC CTG; Australasian Lung Cancer Trials Group; NCI Naples Clinical Trials Unit. Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial. Lancet Oncol. 2014 Nov;15(12):1379-88. Epub 2014 Oct 15. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70472-3/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25439692 PubMed]
# '''MISSION:''' Paz-Ares L, Hirsh V, Zhang L, de Marinis F, Yang JC, Wakelee HA, Seto T, Wu YL, Novello S, Juhász E, Arén O, Sun Y, Schmelter T, Ong TJ, Peña C, Smit EF, Mok TS. Monotherapy administration of sorafenib in patients with non-small cell lung cancer (MISSION) trial: A phase III, multicenter, placebo-controlled trial of sorafenib in patients with relapsed or refractory predominantly nonsquamous non-small-cell lung cancer after 2 or 3 previous treatment regimens. J Thorac Oncol. 2015 Dec;10(12):1745-53. [http://www.jto.org/article/S1556-0864(15)35098-X/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26743856 PubMed]

==S-1 monotherapy {{#subobject:7702f2|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:48e547|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834128/ Nokihara et al. 2017]
| style="background-color:#1a9851" |Phase III (E)
|[[#Docetaxel_monotherapy_2|Docetaxel]]
| style="background-color:#eeee01" |Non-inferior OS
|-
|}
====Chemotherapy====
*[[Tegafur, gimeracil, oteracil (S-1)]] as follows:
**BSA less than 1.25 m<sup>2</sup>: 40 mg PO twice per day on days 1 to 28
**BSA at least 1.25 m<sup>2</sup> and less than 1.5 m<sup>2</sup>: 50 mg PO twice per day on days 1 to 28
**BSA 1.5 m<sup>2</sup> or more: 60 mg PO twice per day on days 1 to 28

'''42-day cycles'''

===References===
# Nokihara H, Lu S, Mok TSK, Nakagawa K, Yamamoto N, Shi YK, Zhang L, Soo RA, Yang JC, Sugawara S, Nishio M, Takahashi T, Goto K, Chang J, Maemondo M, Ichinose Y, Cheng Y, Lim WT, Morita S, Tamura T. Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer). Ann Oncol. 2017 Nov 1;28(11):2698-2706. [https://academic.oup.com/annonc/article/28/11/2698/4282669 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834128/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/29045553 PubMed]

==Sorafenib monotherapy {{#subobject:6ab28b|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:b0db12|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://www.jto.org/article/S1556-0864(15)35098-X/fulltext Paz-Ares et al. 2015 (MISSION)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Placebo_4|Placebo]]
|style="background-color:#1a9850"|Superior PFS
|-
|}
''Note: although the primary endpoint (OS) was negative overall, the authors note that the subgroup of patients with known EGFR mutations treated with sorafenib had significantly superior survival (p=0.002).''
====Chemotherapy====
*[[Sorafenib (Nexavar)]] 400 mg PO twice per day

'''Continued indefinitely'''

===References===
# '''MISSION:''' Paz-Ares L, Hirsh V, Zhang L, de Marinis F, Yang JC, Wakelee HA, Seto T, Wu YL, Novello S, Juhász E, Arén O, Sun Y, Schmelter T, Ong TJ, Peña C, Smit EF, Mok TS. Monotherapy administration of sorafenib in patients with non-small cell lung cancer (MISSION) trial: A phase III, multicenter, placebo-controlled trial of sorafenib in patients with relapsed or refractory predominantly nonsquamous non-small-cell lung cancer after 2 or 3 previous treatment regimens. J Thorac Oncol. 2015 Dec;10(12):1745-53. [http://www.jto.org/article/S1556-0864(15)35098-X/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26743856 PubMed]

==Vinorelbine monotherapy {{#subobject:f604bd|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:0441ba|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[http://ascopubs.org/doi/full/10.1200/JCO.2000.18.12.2354 Fossella et al. 2000 (TAX 320)]
|rowspan=2 style="background-color:#1a9851"|Phase III (C)
|1. [[#Docetaxel_monotherapy_2|Docetaxel 100 mg/m<sup>2</sup>]]
|style="background-color:#ffffbf"|Seems not superior
|-
|2. [[#Docetaxel_monotherapy_2|Docetaxel 75 mg/m<sup>2</sup>]]
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834051/ Katakami et al. 2017 (E7389-G000-302)]
| style="background-color:#1a9851" |Phase III (C)
|Eribulin
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm.''
====Chemotherapy====
*[[Vinorelbine (Navelbine)]] 30 mg/m<sup>2</sup> IV over 5 to 10 minutes once per week

====Supportive medications====
*Per TAX 320:
*Patients who had either grade 4 neutropenia lasting at least 5 days or both fever and grade 3 or 4 neutropenia could receive [[:Category:Granulocyte colony-stimulating factors|G-CSF]] (dose/schedule/duration not specified)
*[[Metoclopramide (Reglan)]] (dose/schedule/route not specified) used first for nausea
*Nausea despite metoclopramide was treated with a 5-HT3 antagonist such as [[Ondansetron (Zofran)]] or [[Granisetron]] (dose/schedule/route not specified) prn nausea

'''Continued indefinitely'''

===References===
# '''TAX 320:''' Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kalman L, Miller V, Lee JS, Moore M, Gandara D, Karp D, Vokes E, Kris M, Kim Y, Gamza F, Hammershaimb L; The TAX 320 Non-Small Cell Lung Cancer Study Group. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol. 2000 Jun;18(12):2354-62. Erratum in: J Clin Oncol. 2004 Jan 1;22(1):209. [http://ascopubs.org/doi/full/10.1200/JCO.2000.18.12.2354 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10856094 PubMed]
# '''E7389-G000-302:''' Katakami N, Felip E, Spigel DR, Kim JH, Olivo M, Guo M, Nokihara H, Yang JC, Iannotti N, Satouchi M, Barlesi F. A randomized, open-label, multicenter, phase 3 study to compare the efficacy and safety of eribulin to treatment of physician's choice in patients with advanced non-small cell lung cancer. Ann Oncol. 2017 Sep 1;28(9):2241-2247. [https://academic.oup.com/annonc/article/28/9/2241/3979219 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834051/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28911085 PubMed]

=Investigational agents=
''Drugs with some degree of promising activity in clinical trials.''
*[[Sacituzumab govitecan (IMMU-132)]]

[[Category:Non-small cell lung cancer regimens]]
[[Category:Disease-specific pages]]
[[Category:Thoracic cancers]]
